2023 CPT Book

Pathology and Laboratory Guidelines
Services in Pathology and Laboratory ...................................................•.. 595

Separate or Multiple Procedures .......................................................... 595
Unlisted Service or Procedure ............................................................. 595
Special Report ........ . .................................................................. 595
Pathology and Laboratory

The following is a listing of headings and subheadings that appear within the Pathology and Laboratory section of the
CPT code set. The subheadings or subsections denoted with asterisks (*) below have special instructions unique to
that subsection. Where these are indicated, special notes or guidelines will be presented preceding those procedural
terminology listings, referring to that subsection specifically. Note that all code ranges in each subsection are listed as they
appear in the subsection, even if the code numbers are out of numerical sequence and/or repeated in the next subsection.
Organ or Disease-Oriented Panels* (80047-80076) ............................................ 596
Drug Assay* (80305-80377) ................................................................ 598
Presumptive Drug Class Screening* (80305-80307) ......•.........•...................................601
Definitive Drug Testing* (80320-80377) ...•..•.........................•.•........•..............•....602
Definitive Drug Classes Listing* (80320-80373) ........................................................604
Therapeutic Drug Assays* (80143-80299) .................................................... 606
Evocative/Suppression Testing* (80400-80439) ............................................... 609
Pathology Clinical Consultations* (80503-80506) ............................................. 611
Instructions for Selecting a Level of Pathology Clinical Consultation Services* .......................... 611
Medical Decision Making* (80503-80506) .................•............................. •............•.•..... 611
Time* (80503-80506) ...... . ............................................•............... •............•....... 613
Urinalysis* (81000-81099).... . ............................................................. 614
Molecular Pathology* (81170-81479) ........................................................ 614
Tier 1 Molecular Pathology Procedures* (81170-81383) .................•............•.................617
Tier 2 Molecular Pathology Procedures* (81400-81479) ..•.............................................629
Genomic Sequencing Procedures and Other Molecular Multianalyte Assays* (81410-81471) ...... 645
Multianalyte Assays with Algorithmic Analyses* (81490-81599) ............................... 649
Chemistry* (82009-84999) .................................................................. 652
Hematology and Coagulation (85002-85999) ................................................. 664
Immunology (86015-86849) .................................................................667
Tissue Typing (86805-86849) .........................................................................673
Transfusion Medicine (86850-86999) ........................................•............... 674
Microbiology* (87003-87999) .............................................................. 675
Anatomic Pathology (88000-88099) .........................................•............... 684
Postmortem Examination* (88000-88099) .............................................................684
0 0 0 0 0
0 0 0 0 0 0
0
0 0 0
0 0
0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
American Medical Association 571

Cytopathology (88104-88199) ............................................................... 684
Cytogenetic Studies* (88230-88299) ........................................................ 687
Surgical Pathology* (88300-88399) ......................................................... 688
In Vivo (eg, Transcutaneous) Laboratory Procedures (88720-88749) ............................. 693
Other Procedures (89049-89240) ............................................................ 694
Reproductive Medicine Procedures (89250-89398) ........................................... 694
Proprietary Laboratory Analyses* (0001U-0354U) ............................................. 696
0 0 0 0 0
0 0 0 0 0 0 0
0 0
., 0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0 0
0
0
0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
CPT 2023 Molecular Pathology Gene Table
Molecular Patholo
II~,,,
....-,.\ i,,.
I
.·• "'
;n11:•.l -
. ., ..
...
.• al~llt.Jlll l
• l~U
; 1111•~ ... I • I I ~ t I "
ABCA4 ABCA4 ATP-binding cassette. sub-family A (ABCl ). member 4 Stargardt disease, age-related macular degeneration, 81408, 81 434
-~ hereditary retinal disorders
ABCCB ABCC8 ATP-binding cassette, sub-family C(CFTR/MRPI. Familial hyperinsulinism 81 401, 81407
members
ABCOl ABCOl ATP-binding cassette, sub-family 0 (ALO), member 1 Adrenoleukodystrophy 81405
ABL1 ABL1 ABL proto-oncogene 1 non-receptor tyrosine kinase Acquired imatinib resistance 81401
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase Acquired imatinib tyrosine kinase inhibitor resistance 81170
ACADM ACADM Acyl-coa dehydrogenase. C-4 to C- 12 straight chain, Medium chain acyl dehydrogenase deficiency, severe 81400, 81401,
MCAD inherited conditions 81443
ACADS ACADS Acyl-coa dehydrogenase, C-2 to C-3 short chain Short chain acyl·CoA dehydrogenase deficiency 81404. 81 40S
ACADVL ACADVL Acyl-coa dehydrogenase, very long chain Very long chain acyl-coenzyme A dehydrogenase deficiency 81 406
ACE ACE Angiotensin converting enzyme hereditary blood pressure regulation 81400
ACTA2 ACTA2 Actin, alpha 2, smooth muscle, aorta Thoracic aortic aneurysms and aortic dissections, aortic 81 40S, 8141 0
dysfunction or dilation
ACTCl ACTCl Actin, alpha, cardiac muscle 1 Familial hypertrophic cardiomyopathy 81405
ACTN4 ACTN4 Actinin, alpha 4 Focal segmental glomerulosclerosis 81406
ADRB2 ADRB2 Adrenergic beta-2 receptor surface Drug metabolism 81401
AFF2 AFF2 AF4/FMR2 family, member 2 (FMR2J Fragile Xmental retardation 2 (FRAXEJ 81171, 81172
AFG3L2 AFG3L2 AFG3 atpase family gene 3-like 2 (S. Cerevisiae) Spinocerebellar ataxia 81 406
AGL AGL Amylo·alpha-1. 6-glucosidase, 4-alpha· Glycogen storage disease type Ill 81407
glucanotransferase
AGTA1 AGTR1 c Angiotensin II receptor, type 1 Essential hypertension 81 400
AHl1 AHl1 Abelson helper integration site 1 Joubert syndrome 81 407
AIRE AIRE Autoimmune regulator Autoimmune polyendocrinopathy syndrome type 1 81 406
ALDH7A1 ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 Pyridoxine-dependent epilepsy, epilepsy 81406, 81419
ALK ALK Anaplastic lymphoma receptor tyrosine kinase Solid organ neoplasm or hematolymphoid neoplasm 8144S, 81449,
81 455, 81 456
ANG ANG Angiogenin, ribonuclease. rnase A family, 5 Amyotrophic lateral sclerosis 81403
ANK2 ANK2 Ankyrin-2 Cardiac ion channelopathies 81413
ANKA01 ANKRD1 Ankyrin repeat domain 1 Dilated cardiomyopathy 81405
ANOS ANOS Anoctamin 5 Limb-girdle muscular dystrophy 81406
ANOSl ANOS1 Anosmin· 1 Kallmann syndrome 1 81406
APC Adenomatous polyposis coli Familial adenomatosis polyposis (FAP), attenuated FAP. 81201, 81202.
hereditary colon cancer disorders 81203. 8143S
APOB APOB Apolipoprotein B Familial hypercholesterolemia type B 81 401, 81 407
APOE APOE Apolipoprotein E Hyperlipoproteinemia type Ill. cardiovascular disease, 81401
Alzheimer disease
APP APP Amyloid beta (A4) precursor protein Alzheimer disease 81 406
APTX APTX Aprataxin Ataxia with oculomotor apraxia 1 81405
AQP2 AOP2 Aquaporin 2 (collecting duct) Nephrogenic diabetes insipidus 81404
AR AR Androgen receptor Spinal and bulbar muscular rophy, Kennedy disease, X 81173, 81174,
chromosome inactivatiO!l, androgen insensitivity syndrome 81204
ARSA ARSA Ary1sulfatase A Arylsulfatase A deficiency. severe inherited conditions 81405, 81443
ARX ARX Aristaless related homeobox X-linked lissencephaly with ambiguous genitalia, X-linked 81403, 81404.
mental retardation, X-linked intellectual disability (XLIO) 81470, 81471
ASPA Aspartoacylase Canavan disease. Ashkenazi Jewish-associated disorders, 81200, 81412,
severe inherited conditions 81443
0
.
0
0
0
0
0
..,
0
0
0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0 0-
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0
-
Molecular Pathology Gene Table CPT 2023
• r 1:....,
ASPM ASPM Asp (abnormal spindle) homolog. microcephaly Primary microcephaly 81407
associated (Drosophila)
ASSl ASSl Argininosuccinate synthase 1 Citrullinemia type I 81406
ASXll ASXLl Additional sex combs like 1. transcriptional regulator Myelodysplastic syndrome. myeloproliferative neoplasms. 81175. 81176
chronic myelomonocytic leukemia
ATLl ATLl Atlastin gtpase 1 Spastic paraplegia 81406
ATM ATM Ataxia telangiectasia mutated Ataxia telangiectasia 81408
ATNl ATNl Atrophin 1 Dentatorubral-pallidoluysian atrophy 81177
ATP1A2 ATP1A2 Atpase. Na+/K+ transporting, alpha 2 polypeptide Familial hemiplegic migraine 81406
ATP7B ATP7B Atpase. Cu++ transporting, beta polypeptide Wilson disease. severe inherited conditions 81406. 81443
ATRX ATRX Alpha thalassemia/mental retardation syndrome X-linked intellectual disability (XUD) 81470. 81471
X-linked
ATXNl ATXN1 Ataxin 1 Spinocerebellar ataxia 81178
ATXN2 ATXN2 Ataxin2 Spinocerebellar ataxia 81179
ATXN3 ATXN3 Ataxin 3 Spinocerebellar ataxia. Machado-Joseph disease 81180
ATXN7 ATXN7 Ataxin 7 Spinocerebellar ataxia 81181
ATXN80S ATXN80S ATXN8 opposite strand (non-protein coding} Spinocerebellar ataxia 81182
ATXN10 ATXN10 Ataxin 10 Spinocerebellar ataxia 81183
AVPR2 AVPR2 Arginine vasopressin receptor 2 Nephrogenic diabetes insipidus 81404
BBS1 BBS1 Bardet-Biedl syndrome 1 Bardet·Biedl syndrome 81406
BBS2 BBS2 Bardet-Biedl syndrome 2 Bardet-Biedl syndrome 81406
BBS10 BBS10 Bardet·Biedl syndrome 10 Bardet-Biedl syndrome 81404
BCKDHA BCKDHA Branched-chain keto acid dehydrogenase El. alpha Maple syrup urine disease type lA, severe Inherited 81400. 81405,
polypeptide conditions 81443
BCKDHB BCKDHB Branched-chain keto acid dehydrogenase El, beta Maple syrup urine disease, maple syrup urine disease type 81205, 81406,
polypeptide 1B. severe inherited conditions 81443
BCR/ABLl t(9;22) Chronic myelogenous leukemia 81206, 81207,
81208
BCSlL BCS1L BCSl-like (S. Cerevisiae) Leigh syndrome, mitochondrial complex Ill deficiency. 81405, 81440
GRACILE syndrome, mitoctlondrial disorders
BEST1 BEST1 Bestrophin 1 Vitelliform macular dystrophy 81406
BLM Bloom syndrome, recq helicase-like Bloom syndrome, Ashkenazi Jewish-associated disorders. 81209, 81412.
BMPRlA BMPAlA Bone morphogenetic protein receptor. type IA Hereditary colon cancer disorders 81435
BMPA2 BMPR2 Bone morphogenetic protein receptor, type II (serine/ Heritable pulmonary arterial hypertension 81405, 81406
threonine kinase)
BRAF V-raf murine sarcoma vira l oncogene homolog 81 Colon cancer 81210
BAAF BAAF B-Raf proto-oncogene. serine/threonine kinase Noonan syndrome. Noonan spectrum disorders. solid organ 81406, 81442,
neoplasm. hematolymphoid neoplasm or disorder 81445, 81449,
81450. 81451.
81455. 81456
BACA 1 BACA 1. DNA repair associated Hereditary breast and ovarian cancer, hereditary breast 81165.
cancer-related disorders 81166,81215,
81432J1433
BACA2 BACA2, DNA repair associated Hereditary breast and ovarian cancer. hereditary breast 81167. 81216,
cancer-related disorders, inherited bone marrow failure 81217, 81432.
syndromes (IBMFS) 81433, 81441
BACA1 and BACA2 BACA 1. DNA repair associated Hereditary breast and ovarian cancer 81162, 81163,
BACA2. DNA repair associated 81164. 81212
0 0 0
0 0 0 0 0 0
0
0 0 0 0
0 0
0 0 0 0 0 0
0 0 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0 0 0
0 0 0 0
574
BSCL2 Berardinelli-Seip congenital lipodystrophy, hereditary

peripheral neuropathies
BTO Biotinidase Biotinidase deficiency 81404
BTK BTK Bruton agammaglobulinemia tyrosine kinase X-linked agammaglobulinemia. chrome lymphocytic 81406. 81233
leukemia
C100RF2 C10orf2 Chromosome 10 open reading frame 2 Mitochondrial DNA depletion syndrome. mitochondrial 81404. 81440
disorders
C1P190 Chromosome N/A Glial tumors 81402
1p-/ 19q· deletion
analysis
CACNAlA CACNA1A Calcium channel. voltage-dependent. P/Q type, alpha Spinocerebellar ataxia, epilepsy 81184.81185.
1Asubunit 81186. 81419
CACNB2 CACNB2 Calcium channel. voltage-dependent, beta 2 subunit Brugada syndrome 81406
CALR Calreticulin Myeloproliferative disorders 81219
CAPN3 CAPN3 Calpain 3 Limb-girdle muscular dystrophy ILGMD) type 2A. 81406
calpainopathy
CASQ2 CAS02 Calsequestrin 2 lcardiac muscle) Catecholaminergic polymorphic ventricular tachycardia, 81405. 81413
cardiac ion channelopathies
CASA CASA Calcium-sensing receptor Hypocalcemia 81405
CAV3 CAV3 Caveolin 3 CAV3-related distal myopathy, limb-girdle muscular 81404. 81413
dystrophy type 1C. cardiac ion channelopathies
CBF8MYH11 CBFB/MYH11 lnv(16) Acute myeloid leukemia 81401
CBL CBL Cbl proto-oncogene. E3 ubiquitin protein ligase Noonan spectrum disorders 81442
CBS CBS Cystathionine-beta-synthase Homocystinuria. cystathionine beta-synthase deficiency 81401 , 81406
CCND11GH CCND1/IGH 1(11 ;14) Mantle cell lymphoma 81168
CCR5 CCR5 Chemokine C·Cmotif receptor 5 HIV resistance 81400
CD40LG CD40l6 CD40 ligand X-linked hyper lgM syndrome 81404
CDH1 CDH1 Cadherin 1. type 1. E-cadherin (epithelial) Hereditary diffuse gastric cancer. hereditary breast cancer- 81406. 81432.
related disorders. hereditary colon cancer disorders 81435
CDH23 CDH23 Cadherin-related 23 Usher syndrome, type 1. hearing loss 81408. B1430
CDKL5 CDKL5 Cychn-dependent kinase-like 5 Early infantile epileptic encephalopathy, X-linked 81405. 81406.
intellectual disability (XLIDI. epilepsy 81419, 81470.
81471
CDKN2A CDKN2A Cyclin-dependent kinase inhibitor 2A CDKN2A-related cutaneous malignant melanoma, solid 81404. 81445.
organ neoplasm or hematolymphoid neoplasm 81449. 81455,
81456
CEBPA CCAAT/enhancer binding protein (C/EBPI. alpha Acute myeloid leukemia. hematolymphoid neoplasm or 81218. 81450,
disorder. solid organ neoplasm 81451 , 81455,
81456
CEL CEL Carboxyl ester lipase (bile salt-stimulated lipase) Maturity-onset dia of the young !MODY) 81403
CEP290 CEP290 Centrosomal protein 290kda Joubert syndrome 81408
CFHARMS2 CFH/ARMS2 Complement factor H/age-related maculopathy Macular degeneration 81401
susceptibility 2
CFTR Cystic fibrosis transmembrane conductance regulator Cystic f1bros1s, Ashkenaz1Jewish-associated disorders. 81220. 81221.
severe inherited conditions 81222. 81223.
81224. 81412,
81443
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0
0 0 0
0 0 0 0 0 0
0
0 0 0 o. 0
0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

Ch22013 Cytogenomic N/A N/A 81405

constitutional
targeted microarray
anaiysis of
chromosome 22q13
by interrogation of
genomic regions for
copy number and
single nucleotide
polymorphism
variants
CHD2 Chromodomain helicase DNA binding protein 2 Epilepsy 81419
CHD7 CHD7 Chromodomain helicase DNA binding protein 7 CHARGE syndrome 81407
Chimerism N/A Post transplantation specimen (eg, hematopoietic stem 81267, 81268
engraftment cell)
analysis
CHRNA4 CHRNA4 Cholinergic receptor. nicotinic, alpha 4 Nocturnal frontal lobe epilepsy 81405
CHRNB2 CHRNB2 Cholinergic receptor. nicotinic, beta 2 (neuronal) Nocturnal frontal lobe epilepsy 81405
CHROM180 Chromosome 1Bq- Colon cancer 81402
CLCNl CLCNl Chloride channel 1. skeletal muscle Myotonia congenita 81406
CLCNKB CLCNKB Chloride channel, voltage-sensitive Kb Bamer syndrome 3 and 4b 81406
CLRNl CLRN1 Clarin 1 Usher syndrome. type 3, hearing loss 81400, 81404,
81430
CNBP CNBP CCHC-type zinc finger. nucleic acid binding protein Myotonic dystrophy type 2 81187
CNGA1 CNGAl Cyclic nucleotide gated channel alpha 1 Hereditary retinal disorders 81434
CNTNAP2 CNTNAP2 Contactin associated protein-like 2 Pitt-Hopkins-like syndrome 1 81406
COL1A1 COL1A1 Collagen, type I, alpha 1 Osteogenesis 1mpertecta, type I 81408
COL1A1 PDGFB COL1A1 /PDGFB 1(17;221 Dermatofibrosarcoma protuberans 81402
COL1A2 COL1A2 Collagen. type I, alpha 2 Osteogenesis imperfecta, type I 81408
COL3A1 COL3A1 Collagen, type Ill, alpha 1 Aortic dysfunction or dilation 81410, 81411
COL4A1 COL4A1 Collagen, type IV, alpha 1 Brain small-vessel disease with hemorrhage 81408
COL4A3 COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) Alport syndrome 81408
COL4A4 COL4A4 Collagen, type IV, alpha 4 Alport syndrome 81407
COL4A5 COL4A5 Collagen, type IV, alpha 5 Alport syndrome 81407, 81408
COL6A1 COL6A1 Collagen. type VI, alpha 1 Collagen type VI-re.lated disorders 81407
COL6A2 COL6A2 Collagen, type VI. alpha 2 CoUagen type VI-related disorders 81406, 81407
COL6A3 COL6A3 Collagen, type VI, alpha 3 Collagen type VI-related disorders 81407
C002 C002 Coenzyme 02. polyprenyltransferase Mitochondrial disi!tders 81440
COX10 COX10 COX10 homolog, cytochrome c oxidase assembly Mitochondrial respiratory chain complex N deficiency, 81405, 81440
protein mitochondrial disorders
COX15 COX15 COX15 homolog, cytochr~c oxidase assembly Mitochondrial respiratory chain complex IV deficiency 81405
protein
COX6B1 COX6B1 CytochrO!!Je c oxidase subunit vlb polypeptide 1 Mitochondrial respiratory chain complex IV deficiency 81404
CPOX CPOX Copropbrphyrinogen oxidase Hereditary coproporphyria 81405
CPTlA CPTlA Carnitine palmitoyltransferase lA (liver) Cami tine palm1toyltransferase 1A (CPT1 Al deficiency 81406
CPT2 CPT2 Carnitine palmitoyltransferase 2 Carnitine palmitoyltransferase II deficiency 81404
CRB1 CRB1 Crumbs homolog 1 (Drosophila) Leber congenital amaurosis. hereditary retinal disorders 81406. 81434
CREBBP CREBBP CREB binding protein Rubinstein-Taybi syndrome 81406, 81407
0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0
0 " 0
0 0 0
0
0 "0 0
" 0 0
0
0
0 0 0 0 0 0 0 0 0 0
0 0 0
0
00
0
0 0
00 " 0
0 0
0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
576
Molecular Patholog Gene Table, continued

.' . ., ~-; .,. ·;;·-. ,._,__ ----- ~
I· ~~:,;,\~~ '_. •;JI: ;,-::.: M· i·:~:::: 1·~:--:7~
CRX CR Cone-rod homeobox Cone-rod dystrophy 2, Leber congenital amaurosis 81404
CSTB CSTB Cystatin B(stefin Bl Unverricht-Lundborg disease 81188. 81189,
81190
CTNNB1 CTNNBl Catenin (cadherin-associated protein}. beta 1, 88kda Desmoid tumors 81403
CTRC CTRC Chymotrypsin C Hereditary pancreatitis 81405
CYP11B1 CYP11B1 Cytochrome P450. family 11, subfamily B. polypeptide Congenital adrenal hyperplasia 81405
1
CYP17A1 CYP17A1 Cytochrome P450. family 17. subfamily A. polypeptide Congenital adrenal hyperplasia 81405
1
CYP181 CYP181 Cytochrome P450. family 1. subfamily B. polypeptide 1 Primary congenital glaucoma 81404
CYP21A2 CYP21A2 Cytochrome P450. family 21 . subfamily A. polypeptide Congenital adrenal hyperplasia, 21-hydroxylase deficiency, 81402. 81405
2 steroid 21-hydroxylase isoform
CYP2C9 Cytochrome P450. family 2, subfamily C. polypeptide 9 Drug metabolism 81227
CYP2C19 Cytochrome P450, family 2. subfamily C. polypeptide Drug metabolism 81225. 81418
19
CYP206 Cytochrome P450, family 2, subffil111ly D. polypeptide 6 Drug metabolism 81226, 81418
CYP3A4 CYP3A4 Cytochrome P450 family 3 subfamily A member 4 Drug metabolism 81230
CYP3A5 CYP3A5 Cytochrome P450 family 3 subfamily A member 5 Drug metabolism 81231
Cytogenomic NIA NIA 81228. 81229.
(genome-wide) 81349
analysis for
constitutional
chromosomal
abnormalities
Cytogenomic NJA NIA 81277
neoplasia (genome-
wide) microarray
analysis
DAZSRY DAZISRY Deleted in azoospermia and sex determining region Y Male infertility 81403
OST DBT Dihydrolipoamide branched chain transacylase E2 Maple syrup urine disease. type 2 81405. 81406
DCX DCX Ooublecortin X-linked lissencephaly 81405
DEKNUP214 DEKINUP214 t(6;9) Acute myeloid leukemia 81401
DES DES Desmin n Myofibrillar myopathy 81405
DFNB1 DFNB1 NIA Hearing loss 81431
DFNB59 DFNB59 Deafness. autosomal recessive 59 Autosomal recessive nonsyndromic hearing impairment 81405
DGUOK DGUDK Deoxyguanosine kinase Hepatocerebral mitochondrial DNA depletion syndrome. 81405. 81440
mitochondrial disorders
DHCR7 DHCR7 7-dehydrocholesterol reductase Smith-Lemli-Opitz syndrome. severe inherited conditions 81405. 81443
DKCl Oyskerin pseudouridine synthase 1 Inherited bone marrow failure syndromes (IBMFS) 81441
DLAT DLAT Dihydrolipoamide S-acetyltransferase Pyruvate dehydrogenase E2 deficiency 81406
OLD OLD Dihydrolipoamide dehydrogenase Maple syrup urine disease. type Ill 81406
DMD Dystrophin OuchennelBecker muscular dystrophy 81161
DMD DMD Dystrophin OuchennelBecker muscular dystrophy 81408
DMPK DMPK Dystrophia myotonica-protein kinase Myotonic dystrophy, type 1 81234. 81239
ONMT3A DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha Acute myeloid leukemia, hematolympho1d neoplasm or 81403, 81450.
disorder. solid organ neoplasm 81451 , 81455.
81456
OPYD OPYD Dihydropyrimidine dehydrogenase 5-fluorouracil/5-FU and capecitabine drug metabolism 81232
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
~ 0
0
0
0 0
0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

Molecular Patholog ' Gene Table, continued

-
DSC2
DSG2
:\t-:•.•r:r.c.,:.~.~
DSC2
DSG2
..•·
~. ""
•4'. ... •
Desmocollin
Desmoglein 2
'l;Ull;U
I
•
u.~ ... -'
[141111111.
~·
·- ....,,.
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
11
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
.:11;.u
II,
".,.
-
·. / .• 81406
81406, 81439
10, hereditary cardiomyopathy
DSP DSP Desmoplakin Arrhythmogenic right ventricular dysplasia/cardiomyopathy 81406
8
DYSF DYSF Dysferlin, limb-girdle muscular dystrophy 28 Limb-girdle muscu dystrophy 81408
(autosomal recessive}
2APBX1 E2NPBX1 (1;19) Acute lymphocytic leukemia 81401
EFHC1 EFHC1 EF-hand domain IC-terminal} containing 1 Juvenile myoclonic epilepsy 81406
EGFR Epidermal growth factor receptor Non-small cell lung cancer. solid organ neoplasm or 81235, 81445,
' hematolymphoid neoplasm 81449, 81455.
81456
EGR2 EGR2 Early growth response 2 Charcot-Marie-Tooth disease 81404
EIF2B2 EIF2B2 Eukaryotic translation initiation factor 28, subunit 2 Leukoencephalopathy with vanishing white matter 81405
beta, 39kda
... gamma. 58kda
delta, 67kda
EIF2B5 EIF2B5 Eukaryotic translation initiation factor 28. subunit 5 Childhood ataxia with central nervous system 81406
epsilon. 82kda hypomyelination/vanishing white matter
EMO EMO Emerin Emery-Dreifuss muscular dystrophy 81404, 81405
L4 L I I } I Non-small cell lung cancer 81401
ENG ENG Endoglin Hereditary hemorrhagic telangiectasia, type 1 81 05, 1406
EPCAM EPCAM Epithelial cell adhesion molecule Lynch syndrome, hereditary colon cancer disorders 81403. Bl 436
EPM2A EPM2A Epilepsy, progressive myoclonus type 2A. Lafora Progressive myoclonus epilepsy 81404
disease (laforin}
ERBB2 ERBB2 V-Erb·B2 avian erythroblastic leukemia viral oncogene Solid organ neoplasm or hematolymphoid neoplasm 81445. 81449,
homolog2 81455. 81456
ESR1PGR ESRl/PGR Receptor 1/progesterone receptor Breast cancer 81402
ElV6RUNX1 ETV6/RUNX1 1{12;21} Acute lymphocytic leukemia 01
EWSR1ATF1 EWSR1/ATF1 1(12;22} Clear cell sarcoma 81401
EWSRlERG EWSRl/ERG 1{21;22} Ewing sarcoma/peripheral neuroectodermal tumor 81401
EWSR1FLl1 EWSR1/FLl1 1(11;22} Ewing sarcoma/peripheral neuroectodermal tumor 81401
EWSR1WT1 EWSR1/WT1 1{11;22} Desmoplastic small round cell tumor 81401
EYAl EYAl Eyes absent homolog 1 (Drosophila) Branchio-oto-renal (BDR} spectrum disorders 81405, 81406
EYS EYS Eyes shut homolog (Drosophila} Hereditary retinal disorders 81434
EZH2 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 Myelodysplastic syndrome. myeloproliferative neoplasms, 81236, 81237.
subumt diffuse large B-cell lymphoma, solid organ or 81450. 81451
hematolymphoid neoplasm or disorder 81455, 81456
F2 Prothrombin. coagulation factor II Hereditary hypercoagulability 81240
F2 F2 Prothrombtn, coagulation factor II Hereditary hypercoagulability 81400
F5 Coagulation factor V Hereditary hypercoagulability 81241
F5 F5 Coagulation factor V Hereditary hypercoagulability 81400
F7 F7 Coagulation factor VII (serum prothrombin conversion Hereditary hypercoegulability 81400
accelerator)
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
578
1.
Mole.~,~la-~........
r
-
.::.(~Ji ' • • • • I , loUuut •••• t ·-
F8 F8 Coagulation factor VIII Hemophilia A 81403. 81406,

81407
F9 F9 Coagulation factor IX Hemophilia B 81238
F11 Fl 1 Coagulation factor XI Coagulation disorder 81401
F12 F12 Coagulation factor XII (Hageman factor) Angioedema, hereditary, type Ill; factor XII deficiency 81403
F13B F13B Coagulation factor XIII. B polypeptide Hereditary hypercoagulability 81400
FAH FAH Fumarylacetoacetate hydrolase (fumarylacetoacetase) Tyrosinemia, type 1 81406
FAN CA FA complementation group A Inherited bone marrow failure syndromes (IBMFS) 81441
FANCB 'fA complementation group B Inherited bone marrow failure syndromes (IBMFS) 81441
FANCC Fanconi anemia, complementation group C Fanconi anemia, type C. Ashkenazi Jewish-associated 81242, 81412,
disorders. severe inherited conditions. inherited bone 81441. 81443
marrow failure syndromes (IBMFS)
FANCD2 FA complementation group 02 Inherited bone marrow failure syndromes (IBMFS) 81441
FANCE2 FA complementation group E Inherited bone marrow failure syndromes (18MFS) 81441
FAN CF FA complementation group F Inherited bone marrow failure syndromes (IBMFS) 81441
FANCG FA complementation group G Inherited bone marrow failure syndromes (IBMFS) 81441
FANCI FA complementation group I Inherited bone marrow failure syndromes (IBMFS) 81441
FAN CL FA complementation group L Inherited bone marrow failure syndromes (IBMFS) 81441
FASTKD2 FASTKD2 FAST kinase domains 2 Mitochondrial respiratory chain complex IV deficiency 81406
FBNl FBNl Fibrillin 1 Marian syndrome. aortic dysfunction or dilation 81408. 81410
FGB FGB Fibrinogen beta chain Hereditary ischemic heart disease 81400
FGD1 FGDl FYVE. rhogef and PH domain containing 1 X·hnked intellectual disability (XLID) 81470. 81471
FGF23 FGF23 Fibroblast growth factor 23 Hypophosphatemic rickets 81404
FGFAl FGFAl Fibroblast growth factor receptor 1 Pfeiffer syndrome type 1. cramosynostosis. Kallmann 81400. 81405
syndrome
FGFA2 FGFR2 Fibroblast growth factor receptor 2 Craniosynostosis, Apert syndrome, Crouzon syndrome 81404
FGFA3 FGFA3 Fibroblast growth factor receptor 3 Muenke syndrome. achondroplasia. hypochondroplasia. 81400, 81401,
isolated craniosynostosis 81403. 81404
FH FH Fumarate hydratase Fumarate Hydratase Deficiency, Hereditary Leiomyomatosis 81405
with renal cell cancer
FHL1 FHL1 Four and a half LIM domains 1 Emery-Dreifuss muscular dystrophy 81404
FIG4 FIG4 FIG4 homolog, SAC1 lipid phosphatase domain Charcot-Marie·Tooth disease 81406
containing (S. Cerevisiae)
FIPl L1PDGFAA FIPl Ll /PDGFAA Del(4q12) lmatinib·sens1tive chrome eosmophilic leukemia 81401
FKAP FKRP Fukutin related protein Congenital muscular dystrophy type 1C(MDC1 C). limb- 81404
girdle'lnuscular dystrophy (LGMD) type 21
FKTN FKTN Fukutin Fukuyama congenital muscular dystrophy, limb-girdle 81400, 81405
muscular dystrophy (LGMD) type 2M or 2L
FLG FLG Filaggrin lchthyosis vulgaris 81401
FLT3 Fms-related tyrosine kinase 3 Acute myeloid leukemia. hematolymphoid neoplasm or 81245, 81246,
disorder. solid organ neoplasm 81450, 81451,
81455. 81456
FMRl Fragile Xmental retardation 1 Fragile Xmental retardation. X·linked intellectual disability 81243, 81244.
(XUD) 81470. 81471
FOXG1 FOXG1 Forkhead box G1 Aett syndrome 81404
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0
0 0

-"''.'
FOX01PAX3
FOX01PAX7
FOX01/PAX3
FOX01/PAX7
112;13)
1(1;13)
~(.~'fl
IJllll~FA'lr.
Ewing san:oma/peripheral neuroectodermal tumor, alveolar

rhabdomyosarcoma
Ewing sarcoma/peripheral neuroectodermal tumor, alveolar
rhabdomyosarcoma
ii
81401
81401
I'
FSHM01A FSHMOlA acioscapulohumeral muscular dystrophy 1A Facioscapulohumeral muscular dystrophy 404

SJ FTSJl j RNA methyltrans erase h lo ( . oil X-rn ed en al retardatio 81405, 81406
s s u in sarcoma Amyotrophic lateral sclerosis 81406
FUSDDIT3 FUS/DD 3 12;16) Myxoid liposarcoma 81401
FXN FXN Frataxin Friedreich ataxia 81284, 81285.
81286. 81289
G6PC G6PC Glucose-6-phosphatase. catalytic subunit Glycogen storage disease. type la, von Gierlce disease. 81250, 81443
severe inherited conditions
G6PD G6PD Glucose-6-phosphate dehydrogenase Hemolytic anemia. jaundice 81247, 81248,
81249
GAA GM Glucosidase, alpha; acid Glycogen storage disease type II (Pompe disease), severe 81406, 81443
inherited conditions
GABRG2 GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma Generalized epilepsy with febrile seizures, epilep 81405, 81419
2
c c Ga actosylcer id bbe disease 81401, 81406
GALT GALT Galactose-1-phosphate uridylyltransferase Galactosemia, severe inherited conditions 81401. 81406.
81443
GARS GARS Glycyl-trna synthetase Charcot-Marie-Tooth disease 81406
GATAl ATA binding protein 1 Inherited bone marrow failure syndromes (IBMFSI 81441
Ab'ndingp ti 2 I eritedbon a·1 re syn romes (18 SI 1 1
GBA Glucosidase. beta. acid Gaucher disease. Ashkenazi Jewish-associated disorders. 81251, 81412,
GBE1 1.4-alpha-glucan branching enzyme 1 S v re inherited conditions 81443
~
GCDH GCDH Glutaryf-coa dehydrogenase I ~ Jut ricacidemia type 1 81406

GC 1 CHl GT cyclo rol se Auto l ominan do -respons've ystoni 405
GCK GCK Glucokinase (hexokinase 41 Maturity-onset diabetes of the young (MODY) 81406
GDAPl GDAPl Ganglioside-induced differentiation-associated protein Charcot-Marie-Tooth disease 81405
1
GFAP GFAP Glial fibrillary acidic protein Alexander disease 81405
G1 1 h ho o e 1 Growth hormone deficiency 8 404
GHR GHR Growth hormone receptor Laron syndrome 81405
GHRHR GHRHR Growth hormone releasing hormone receptor Growth hormone deficiency 81405
GJBl GJBl Gap junction protein. beta 1 Charcot-Marie-Tooth X-linked. hereditary peripheral 81403. 81448
(, neuropathies
GJB2 Gap junction protein. beta 2, 26kda. connexin 26 Nonsyndromic hearing loss 81252, 81253,
81430, 81431
ap j ncti n n. beta 6. 30kda. connexin 30 Nonsyndromic hearing loss 1
GLA GLA Galactosidase. alpha Fabry disease 81405
GLUDl GLUDl Glutamate dehydrogenase 1 Familial hyperinsulinism 81406
G AQ G Q uanine nucleotid -bi ding protein G(q) subunit alpha Uveal melanoma
0 0 0 0
0 0 0 0 0 0
0 0 0
0
0 0
0 0 0 0 0 0
0 0 . 0 0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
580
Molecular Patholo ~Y Gene Table, continued '

f.!.1i1t . - - i:.... . - - IE1j1
mmAiJ ;_ ' •I
. ""
l lf"lllUlllllll
' I ;nr.:I•~ 1 11 • . . ...,!.a'iL... !.a......
... ~ -
'II..:·,
11 ._.....,.•111r.n•t .11\1 f 1_,,•RtllllJ " r:,m"rr<;IH
- . ~ ~
GNE GNE Glucosamine Inclusion body myopathy 2 (IBM2). Nonaka myopathy 81400, 81406
(UDP-N-acetyl)-2-epimerase/N-acetylmannosamine
kinase
GPlBB GPlBB Glycoprolein lb (platelet), beta polypeptide Bernard·Soulier syndrome type B 81404
GPR98 GPA98 G-protein coupled receptor 98 Hearing loss 81430
GAIN2A Glutamate ionotropic receptor NMDA type subunit 2A Epilepsy 81419
GAN GAN Granulin Frontotemporal dementia 81406
H19 H19 Imprinted maternally expressed transcript (non·protem Beckwith-Wiedemann syndrome 81401
coding)
HADHA HADHA Hydroxyacyl-coa dehydrogenase/3-ketoacyl-coa Long chain acyl-coenzyme A dehydrogenase deficiency 81406
thiolase/enoyl-coa hydratase (trifunctional
protein) alpha subunit
HADHB HADHB Hydroxyacyl-coa dehydrogenase/3-ketoacyl-coa Trifunctional protein deficiency 81406
th1olase/enoyl-coa hydratase illlfunctional
protein), beta subunit
HBA1/HBA2 HBA1/HBA2 Alpha globin 1 and alpha globin 2 Alpha thalassemia, thalassemia, Hb Bart hydrops fetalis 81257, 81258,
syndrome. HbH disease 81259, 81269
HBB HBB Hemoglobin, subunit beta Sickle cell anemia, beta thalassemia. hemoglobinopathy, 81361 , 81362,
severe inherited conditions 81363, 81364,
81443
HEA HEA Human erythrocyte antigen Sickle-cell disease, thalassemia, hemolytic transfusion 81403
{} reactions, hemolytic disease of the fetus or newborn
HEXA Hexosaminidase A (alpha polypeptide) Tay-Sachs disease, Ashkenazi Jewish-associated disorders. 81 255, 81406,
severe inherited conditions 81412, 81443
HFE Hemochromatosis Hereditary hemochromatosis 81256
HLA Human leukocyte antigen genes Pretransplant and drug therapy testing 81370-81383
HLCS HLCS HLCS holocarboxylase synthetase Holocarboxyfase synthetase deficiency 81406
HMBS HMBS Hydroxymethylbilane synthase Acute Intermittent porphyria 81406
HNFlA HNFlA HNFl homeobox A Maturity-onset diabetes of the young (MODY) 81405
HNFlB HNFlB HNFl homeobox B Maturity·onset diabetes of the young !MODY) 81404, 81405
HNF4A HNF4A Hepatocyte nuclear factor 4, alpha Maturity-onset diabetes of the young (MODY) 81406
HPAl Human Platelet lntegrin, beta 3 (platelet glycoprotem iiia). antigen Neonatal alloimmune thrombocytopenia (NAIT), 81105
Antigen 1 C061 (gpiiia) post-transfusion purpura
genotyping (HPA·1).
ITGB3
HPA2 Human Platelet Glycoprotein lb (platelet), alpha polypeptide (gpibal Neonatal alloimmune thrombocytopenia (NAln. post- 81106
Antigen 2 transfusion purpura
genotyping (HPA·2),
GPlBA
HPA3 Human Platelet lntegrin, alpha 2b (platelet glycoprotem iib of 1ib/iiia Neonatal alloimmune thrombocytopenia (NAIT), post- 81107
Antigen 3 complex), antigen CD41 lgpiib) transfusion purpura
genotyping (HPA·3),
ITGA2B
HPA4 Human Platelet lntegrin. beta 3 (platelet glycoprotein iiia). antigen Neona1al alloimmune thrombocytopenia (NAIT), post- 81108
Antigen4 CD61 (gpiiia) transfusion purpura
genotyping IHPA·4),
ITGB3
HPA5 Human Platelet lntegrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 Neonatal alloimmune thrombocytopenia INAIT). post- 81109
Antigen 5 receptor) (gpia) transfusion purpura
genotyping (HPA-5),
JTGA2
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0
0 0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

- ·
Molecular Patholog Gene Table, continued
HPA6
.
Human Platelet
Antigens
.. ~
genotyping (HPA-
6wJ. ITGB3
lntegrin. beta 3 (platelet glycoprotein iiia, antigen
C061 J(gpiiiaJ
•
,..,,
"1"2-
• [11111111 ':Jf•
Neonatal alloimmune thrombocytopenia (NAITJ. post-

transfusion purpura
81110
I'
HPA9 Human Platelet lntegrin, alpha 2b (platelet glycoprotein iib of iib/iiia Neonatal alloimmune thrombocytopenia (NAITJ. post- 81111
Antigen 9 complex. antigen CD41) (gpiib) :ransfusion purpura
genotyping (HPA-
9w}, ITGA2B
HPA15 Human Platelet CD109 molecule Neonatal alloimmune thrombocytopenia (NAln. post- 81112
Antigen 15 transfusion purpura
genotyping (HPA-
15). CD109
HAAS HAAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog Costello syndrome. Noonan spectrum disorders 81403, 81404,
81442
HS03B2 HSD3B2 Hydroxy-delta-5-steroid dehydrogenase. 3 beta- and 3-beta-hydroxysteroid dehydrogenase type II deficiency 81404
steroid delta-isomerase 2
HSD11B2 HSD11B2 Hydroxysteroid (11 ·beta) dehydrogenase 2 ineralocorticoid excess syndrome 81404
HSP81 HSPB1 Heat shock 27kda protein 1 Charcot-Marie·Tooth disease 81404
HTAAl HTAAl Htra serine peptidase 1 acular degeneration 81405
HTT HTT Huntingtin untington disea~ 81271, 81274
HUWEl HUWEl HECT, UBA and WI/VE domain containing 1. E3 X-linked intellectual disability (XLID) 81470, 81471
ubiquitin protein ligase
IDH1 IDH1 lsocitrate dehydrogenase 1 (NADP+). soluble Glioma, hematolymphoid neoplasm or disorder, solid organ 81120. 81450,
neoplasm 81451, 81 455,
81456
IDH2 IDH2 lsoc1trate dehydrogenase 2 (NADP+). mitochondrial Glioma, hematolymphoid neoplasm or disorder, solid organ 81121 , 81450,
neoplasm 81451 , 81455,
81456
IDS OS lduronate 2-sulfatase ucopolysacchridosis, type II 81405
IDUA IDUA lduromdase, alpha-l- Mucopolysaccharidosis type I 81406
IFNL3 IFNL3 Interferon. lambda 3 Drug response 81
IGH@ lmmunoglobulln heavy chain locus Leukemias and lymphomas. B-cell 81261 . 81262,
81263
IGHBCL2 G c 1. ) ollicular lymplJoma 81278, 81401.
IGK@ lmmunoglobulin kappa light chain locus Leukemia and lymphoma, 8-cell 81264
IKBKAP Inhibitor of kappa light polypeptide gene enhancer in Familial dysautonomia. Ashkenazi Jewish-associated 81260, 81412,
B-cells. kinase complex-associated protein disorders. severe inherited conditions 81443
lllAAPL lllAAPL Interleukin 1 receptor accessory protein X-linked intellectual disability (XLID) 81470, 81471
IL2AG IL2AG Interleukin 2 receptor. gamm~ X-linked severe combined immunodeficiency 81405
INF2 INF2 Inverted formin, FH2 and WH2 domain containing Focal segmental glomerulosclerosis 81406
INS INS Insulin Diabetes mellitus 81404
ISPD ISPD lsoprenoid synthase domain containing Muscle-eye-brain disease, Walker-Warburg syndrome 81405
ITPAl ITPA1 Inositol 1.4.5-trisphosphate receptor, type 1 Spinocerebellar ataxia 81408
IVD IVD lsovaleryl-coa dehydrogenase lsovaleric acidemia 81400, 81406
JAG1 JAG1 Jagged 1 Alagille syndrome 81406, 8 407
JAK2 Janus kinase 2 Myeloproliferative disorder. hematolymphoid neoplasm or 81270, 81279,
disorder, solid organ neoplasm 81450, 81451 .
81 455, 81456
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 cl
0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 cl
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 ., 0 0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0
0 0 0 0
582
Molecular Patholo IV Gene Table, continued

~~"'"1J.~;.::.. t;~ -- - - , .~~.~7~~~ r~~~~~;1'.{i·i,. ·
.._
. coo
~.;,
ll ,._, ,........
I•
-
111
·-
•
·~~'ITTTiTIJ
.:••!..10
' . . .... 1,.-; -.. .• ''" .•

I ·-•"'"
•· ll111e 4
1n~llll•
~
1ftUllllll:..l
tlftr.•r:!.:leu•
._.,L.,.•
,-., ·~
1n:...1
~
•·~,,..,0
·.
1i' ·,.>::
: ~
JUP JUP Junction plakoglobin Arrhythmogenic right ventricular dysplasia/cardiomyopathy 81406
11
KCNC3 KCNC3 Potassium voltage-gated channel, Shaw-related Spinocerebellar ataxia 81403
subfamily. member 3
KCNE1 KCNE1 Potassium voltage-gated channel, subfamily E. Cardiac ion channelopathies 81413
member 1
KCNE2 KCNE2 Potassium voltage-gated channel. subfamily E. Cardiac ion channelopathies 81413
member2
KCNH2 KCNH2 Potassium voltage-gated channel. subfamily H(eag- Shon QT syndrome. long QT syndrome. cardiac ion 81406. 81413,
related). member 2 channelopathies 81414
KCNJ1 KCNJ1 Potassium inwardly-rectifying channel. subfamily J. Banter syndrome 81404
member 1
KCNJ2 KCNJ2 Potassium inwardly-rectifying channel, subfamily J. Andersen-Tawil syndrome. cardiac ion channelopathies 81403. 81413
member 2
KCNJ1 0 KCNJ10 Potassium inwardly-rectifying channel. subfamily J. SeSAME syndrome. EAST syndrome. sensorineural hearing 81404
member 10 loss
KCNJ11 KCNJ11 Potassium inwardly-rectifying channel. subfamily J. Familial hyperinsulinism 81403
member 11
KCN01 KCN01 Potassium voltage-gated channel. KOT-like subfamily, Shon QT syndrome. long QT syndrome, cardiac ion 81406, 81413.
member 1 channelopathies 81414
KCN010T1 KCN010T1 _,. KCNOl overlapping transcript 1 (non-protein coding) Beckwith-Wiedemann syndrome 81401
KCN02 KCN02 Potassium voltage-gated channel. KOT-like subfamily, Epileptic encephalopathy, epilepsy 81406, 81419
member2
KOM5C KOM5C lysine (Kl-specific demethylase SC X-linked mental retardation. X-linked intellectual disability 81407. 81470.
(XLIOJ 81471
KIAA0196 KIAA0196 Kiaa0196 Spastic paraplegia 81407
KIA KIR Killer cell immunoglobulin-like receptor Hematopoietic stem cell transplantation 81403
KIT V-k1t Hardy-Zuckerman 4 feline sarcoma viral Gastrointestinal stromal tumor. acute myeloid leukemia. 81272. 81273,
oncogene homolog melanoma, solid organ neoplasm. hematolymphoid 81445, 81449,
neoplasm or disorder 81450, 81451,
81455, 81456
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog Carcinoma. Noonan syndrome 81275, 81276
KRAS KRAS Kirsten rat sarcoma viral oncogene homolog Noonan syndrome. Noonan spectrum disorders. solid organ 81405. 81442.
neoplasm. hematolymphoid neoplasm or disorder 81445, 81449.
81450, 81451,
81455, 81456
llCAM L1CAM l1 cell adhesion molecule MASA syndrome. X-linked hydrocephaly, X-linked 81407, 81470,
intellectual disability (XLIDJ 81471
LAMA2 LAMA2 Laminin, alpha 2 Congenital muscular dystrophy 81408
LAMB2 LAMB2 Laminin. beta 2 (laminin SJ Pierson syndrome 81407
LAMP2 LAMP2 Lysosomal-associated membrane protein 2 Danon disease 81405
LCT LCT Lactase-phl01izm hydrolase lactose intolerance 81400
LDB3 LDB3 LIM domain binding 3 Familial dilated cardiomyopathy, myofibrillar myopathy 81406
LOLA LOLA Low density hpoprotein receptor Familial hypercholesterolemia 81405. 81406
LEPR LEPR Leptin receptor Obesity with hypogonadism 81406
LHCGR LHCGR luteinizing hormone/choriogonadotropin receptor Precocious male pubeny ~406
LINC00518 UNC00518 Long intergenic non-protein coding RNA 518 Melanoma 81401
LITAF UTAF Lipopolysaccharide-induced TNF fact01 Charcot-Marie-Tooth disease 81404
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 . 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0
0 0

-
Molecular.~ath.~~oE~: ~!~le, continued . _-. .

- . . ........ ··"·. ~. ,.j~ .....~.......:; ~
m•:l711..-~
..
LMNA LMNA Lamin A/C Emery-Dreifuss muscular dystrophy (EDMDl. 2. and 3) 81406
limb·girdle muscular dystrophy {LGMD) type 1B. dilated
cardiomyopathy (CMDlA). familial partial lipodystrophy
(FPLD2)
LRP5 LRP5 Low density lipoprotein receptor-related protein 5 steopetrosis 81406
LR LRR 2 Leucin -rich re at kinase 2 Parkinson disease 81401. 81408
MAP2K1 MAP2K1 Mitogen-activated protein kmase 1 Cardiofaciocutaneous syndrome. Noonan spectrum 81406. 81442
disorders
MAP2K2 MAP2K2 M11ogen-activated protein kinase 2 Cardiofaciocutaneous syndrome. Noonan spectrum 81406, 81442
disorders
MAPT MAPT Microtubule-associated protein tau Frontotemporal dementia 81406
MAX MAX MYC·associated factor X Hereditary neuroendocrine tumor disorders 81437
MC4 MC4R Melan c rti rece1tor si 81403
MCCC1 MCCC1 Methylcrotonoyl·coa carboxylase 1 (alpha) 3-methylcrotonyl-CoA carboxylase deficiency 81406
MCCC2 MCCC2 Methylcrotonoyl-coa carboxylase 2 {beta) 3-methylcrotonyl carboxylase deficiency 81406
MCOLNl Mucolipin 1 Mucolipidosis. type IV. Ashkenazi Jewish-associated 81290, 81412.
disorders. severe inherited conditions 81443
MECP2 Methyl cpg binding protein 2 Ren syndrome. X-linked intellectual disability (XLIO). 81302, 81303,
epilepsy 81304. 81419.
81470, 81471
MED12 MED12 Mediator complex subunit 12 FG syndrome type 1, Lujan syndrome, X-linked intellectual 81401. 81470.
disability (XUO) 81471
MEFV MEFV Medrterranean fever Familial Mediterranean fever 81402, 81404
MEG3DLK1 MEG3/0LK1 Maternally expressed 3 (non-protein coding)/delta-like Intrauterine growth retardation 81401
1 homolog (Drosophila)
MEN1 ultiple endocrine neoplasia 1 Multiple endocrine neoplasia type 1. Warmer syndrome 81404, 81405
MET MET Met proto-oncogene Solid organ neoplasm or hematolyrnphoid neoplasm 81445, 81449.
81455, 81456
MFN2 MFN2 Mitofusin2 Charcot·Marie-Tooth disease. hereditary peripheral 81406, 81448
neuropathies
MGMT 0-6-methylguanine·DNA meth I ransferase Glioblast m mul iforme 812 7
MICA MICA MHC class I polypeptide-related sequence A Solid organ transplantation 81403
Microsatellite N/A Hereditary nonpolyposis colorectal cancer, Lynch syndrome 81301
instability analysis
MID1 MIDl i rne 1 X-linked intellectual disability (XLID) 81470. 81471
MLHl Mutl homolog 1, colon cancer. nonpolyposis type 2 Hereditary nonpolyposis colorectal cancer. Lynch syndrome. 81288. 81292,
hereditary breast cancer-related disorders, hereditary colon 81293, 81294.
cancer disorders 81432. 81433.
81435, 81436
MLL MLL N/A Hematolyrnphoid neoplasm or disorder. solid organ 81450, 81451,
neoplasm 81455. 81456
MLLAFFl MLL/AFFl t(4;11) cute lymphoblastic leukemia 81401
MLLMLLT3 MLL/MLLT3 1(9;11) Acute myeloid leukemia 81401
AA e ylm I ni aciduria (cobalamine deficiency) type A MMAA-related methylmalonic acidemia 81 5
MMAB MMAB Methylmalonic aciduria (cobalamine deficiency) type B -related methylmalonic acidemia 81405
MMACHC MMACHC Methylmalonic aciduria (cobalamin'deficiency) cblc Methylmalonic acidemia and homocystinuria 81404
type. with homccystinuria
MPI MPI Mannose phosphate isomerase Congenital disorder of glycosylation 1b 81405
0 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0 •
0
0
0
0
0
0
0
0
0
0
0 0 0
0 0 • 0
0 0
0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0
0
00
0 0
0 0
0
0
0 0
00
0 0
• 0
0
0
0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
..
0 0 0 0 0 0
0 0 0 0
584
Molecular Patholo Gene Table, continued

mg, - lt•1 t••·
... -,
11r.11;.,,ll ',
,, ,_...,,,,I I
-
llTllJ• . ., •
..
MPL
I"'1iT:JI l'
MPL
F.Tiffil ,;
MPL proto-oncogene, thrombopoietin receptor

, 11111111 Ill~•
Myeloproliferative disorder, inherited bone marrow failure

·-. 81338, 81339,
:·,~
syndromes llBMFS) 81441

MPV17 MPV1 7 Mpv17 mitochondrial inner membrane protein Mitochondrial ONA depletion syndrome, mitochondrial 81 404, 81405,
disorders 81440
MPZ MPZ Myelin protein zero Charcot-Marie-Tooth disease, hereditary peripheral 81405, 81448
neuropathies
MSH2 Muts homolog 2. colon cancer, nonpolyposis type 1 Hereditary nonpolyposis colorectal cancer. Lynch syndrome. 81295, 81296.
hereditary breast cancer-related disorders. hereditary colon 81297, 81432,
cancer disorders 81 433. 81435,
81436
MSH6 Muts homolog 6 (E. Coli) Hereditary nonpolyposis colorectal cancer. Lynch syndrome, 81298, 81299,
hereditary breast cancer-related disorders, hereditary colon 81300, 81432,
cancer disorders 81435
MTATP6 MT-'ATP6 Mitochondrially encoded ATPsynthase 6 Neuropathy with ataxia and retinitis pigmentosa (NARP). 81401
Leigh syndrome
THFR 5. 10-methylenetetrahydrofolate reductase Hereditary hypercoagulability 81291
TMl MTMl Myotubularin 1 X-linked centronuclear myopathy 81405, 81406
MTN04N06 MT·N04, MT-N06 M1tochondrially encoded NAOH dehydrogenase 4, Leber hereditary optic neuropathy (LHON) 81401
mitochondrially encoded NAOH dehydrogenase 6
MTN05 MT-NOS Mitochondrially encoded trna leucine 1 (UUA/G). Mitochondrial encephalopathy with lactic acidosis and 81401
mitochondrially encoded NADH dehydrogenase 5 stroke-like episodes (MELAS)
MTRNRl MT-RNRl Mitochondrially encoded 12S RNA Nonsyndromic hearing loss 81401 , 81403,
81430
MTTK MT-TK Mitochondrially encoded trna lysine Myoclonic epilepsy with ragged-red fibers (MERRFJ 81401
MTTLl T-Tll itoc ondriall en oded trna leucine 1 (UUA/G) Diabetes and hearing loss 81401
MTTSl MT-TSl Mitochondrially encoded tma serine 1 Nonsyndromic hearing loss 81403
MTTS1RNR1 MTTSl, MT-RNRl Mitochondrially encoded trna serine 1 (UCN). Nonsyndromic sensorineural deafness (including 81401
mitochondrially encoded 12S RNA aminoglycoside-induced nonsyndromic deafness)
MUT MUT Methylmalonyl coa mutase Methylmalooic acidemia 81406
MUTYH MUTYH Muty homolog (E. Coli) MYH-associated polyposis, hereditary colon cancer 81401, 81406,
disorders 81435
MYBPC3 MYBPC3 Myosin binding protein C, cardiac Familial hypertrophic cardiomyopathy, hereditary 81407, 81 439
cardiomyopathy
MYD88 MYD88 Myeloid differentiation primary response 88 Waldenstrom's macroglobulinemia, lymphoplasmacytic 81305
leukemia
MYH6 MYH6 Myosin, heavy chain 6, cardiac muscle, alpha Familial dilated cardiomyopathy 81407
MYH7 MYH7 Myosin. heavy chain 7, cardiac muscle. beta Familial hypertrophic cardiomyopathy, Laing distal 81407, 81439
myopathy, hereditary cardiomyopathy
MYH11 MYH11 Myosin. heavy chain 11, smooth muscle Thoracic aortic aneurysms and aortic dissections, aortic 81408, 81410,
dysfunction or dilation 81 411
MYL2 MYL2 sin. l"ght chain 2, regul tory, c rdiac, slo Familial h rtrophic car iomyopathy 81405
MYL3 MYL3 Myosin. light chain 3, alkali, ventricular, skeletal, slow Familial hypertrophic cardimnyopathy 81405
MYLK MYLK Myosin light chain kinase Aortic dysfunction or dilation 81410
MY07A MY07A sin VllA Usher syndrome, type 1, hearing loss 81 407, 81430
MY015A MY015A Myosin XVA Hearing loss 81430
MYOT MYOT Myotilin Limb-girdle muscular dystrophy 81405
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
,J 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0
0
0 0 Cl 0 0
0
0 0 0 0 0
0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0 0

•
Molecular Patholo n Gene Table, continued

l~·~-_.,I
.-~I
-
...... ., ..............
In·
-- - - ,.. L::L l .-.i
I•••
11•?..&1.1r.1 • I
- .;1111:...
,~
'Y•I , ..... _ '.c :,.-,_,. :!;1J~ ~~·~_,._, .•

--- -- ~--{ l • ·-111
I
..._............... .......~--
"· I 1
111 11 ::..
0
1UT'lll -I
,
•11·!~"'-\'.~
•/\'~y, t 1 •
·""' .. j --
NOP NOP Norrie disease (pseudogliomal Norrie disease B1403. B1404

NOUFA1 NOUFAl NAOH dehydrogenase (ubiquinone) 1 alpha Leigh syndrome, mitochondrial complex I deficiency B1404
subcomplex. 1. 7.5kda
NOUFAF2 NOUFAF2 NAOH dehydrogenase (ubiquinone) 1 alpha Leigh syndrome. mitochondrial complex I deficiency B1404
subcomplex, assembly factor 2
NOUFS1 NOUFSl NAOH dehydrogenase (ubiquinonel Fe-S protein 1. Leigh syndrome. mitochondrial complex I deficiency 81406
75kda (NAOH-coenzyme Q reductase)
NOUFS4 NOUFS4 NAOH dehydrogenase (ubiquinone) Fe-S protein 4, Leigh syndrome. mitochondrial complex I deficiency B1404
1Bkda (NAOH-coenzyme Q reductasel
NOUFS7 NOUFS7 NADH dehydrogenase (ubiquinonel Fe-S protein 7. Leigh syndrome, mitochondrial complex I deficiency 81405
20kda (NAOH-<:oenzyme Q reductase)
NOUFSB NOUFS8 NAOH dehydrogenase (ubiquinone) Fe-S protein B. Leigh syndrome. mitochondrial complex I deficiency B1405
23kda (NAOH-coenzyme Q reductase)
NOUFV1 NOUFV1 NAOH dehydrogenase (ubiquinone) flavoprotem 1, Leigh syndrome. mitochondrial complex I deficiency 81405
51kda
NEB NEB Nebulin Nemaline myopathy 2 B1400, B140B
NEF{.: NEFL Neurofilament. light polypeptide Charcot-Marie-Tooth disease 81405
NF1 NF1 Neurofibromin 1 Neurofibromatosis. type 1 B1408
NF2 Nf2 Neurofibromin 2 (merfin) Neurofibromatosis, type 2 B1405. B1406
NHLRC1 NHLRCl NHL repeat containing 1 Progressive myoclonus epilepsy B1403
NHP2 NHP2 ribonucleoprotein Inherited bone marrow failure syndromes (IBMFS) B1441
NIPA1 NIPA1 Non-imprinted in Prader-Willi/Angelman syndrome 1 Spastic paraplegia B1404
NLGN3 NLGN3 Neuroligin3 Autism spectrum disorders 81405
NLGN4X NLGN4X Neuroligin 4, X-linked Autism spectrum disorders 81404, 81405
NOD2 NDD2 Nucleotide-binding oligomerization domain containing Crohn's disease. Blau syndrome 81401
2
NOPIO NOPIO ribonucleoprotein Inherited bone marrow failure syndromes (18MFS) 81441
NOS Known familial N/A N/A 81403
variant NOS
NOTCH1 NOTCH1 Notch 1 Aortic valve disease, hematolymphoid neoplasm or 81407. 81450,
disorder or solid organ neoplasm B1451, 81455,
81456
NOTCH3 NOTCH3 Notch3 Cerebral autosomal dominant arteriopathy with subcortical B1406
infarcts and leukoencephalopathy (CAOASIL)
NPCl NPCl Niemann-Pick disease. type Cl Niemann-Pick disease B1406
NPC2 NPC2 Niemann-Pick disease. type C2 (epididxmal secretory Niemann-Pick disease type C2 B1404
protein El)
NPHPl NPHP1 Nephronophthisis 1 (juvenile) Joubert syndrome B1405, 81406
NPHSl NPHSl Nephrosis 1, congenital. Finnish type (nephrinl Congenital Finnish nephrosis B1407
NPHS2 NPHS2 Nephros1s 2. idiopathic, steroid-resistant (podocin) Steroid-resistant nephrotic syndrome B1405
NPMl Nucleophosmin Acute myeloid leukemia. hematolymphoid neoplasm or B1310. B1450.
disorder or solid organ neoplasm 81451. 81455.
B1456
NPMlALK NPM1/ALK t(2;5) Anaplastic large cell lymphoma B1401
NROBl NROBl Nuclear receptor subfamily O. group B. member 1 Congenital adrenal hypoplasia 81404
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog Colorectal carcinoma. Noonan spectrum disorders. solid B1311, 81442,
organ neoplasm, hematolymphoid neoplasm or disorder B1445, B1449,
B1450. 81451,
B1455, B1456
0 0 0 0 0
0 0 0 0 0 0 0
0 0
0
0
" 0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
586
NSOl Nuclear receptor binding SET dornain protein 1 Sotos syndrome 81405, 81406
NTRK Neurotrophic-tropomyosin receptor tyrosine kinase 1, Solid tumors 81194
2, and 3
NTRKl Neurotrophic receptor tyrosine kinase 1 Solid tumors 81191
NTRK2 Neurotrophic receptor tyrosine kinase 2 Solid tumors 81192
NTRK3 Neurotrophic receptor tyrosine kinase 3 Solid tumors 81193
NUDT15 Nudix hydrolase 15 Drug metabolism 81306
OCRL OCRL Oculocerebrorenal syndrome of Lowe X-linked intellectual disability (XUOJ 81 470, 81471
OPA1 OPA1 Optic atrophy 1 Optic atrophy, mitochondrial disorders 81406, 81407,
81440
OPTN OPTN Optineurin Amyotrophic lateral sclerosis 81406
OTC OTC Ornithine carbamoyltransferase Ornithine transcarbamylase defici~ncy 81405
OTOF OTOF Otoferlin Hearing loss 81430
PABPN1 PABPN1 Poly(AJ binding protein. nuclear 1 Oculopharyngeal muscular dystrophy 81312
PAFAH181 PAFAH1B1 Platelet-ai;tivating factor acetylhydrolase 1b. lissencephaly. Miller-Dieker syndrome 81405, 81406
regulatory subunit 1 (45kda)
PAH PAH Phenylalanine hydroxylase Phenylketonuria, severe inherited conditions 81406, 81443
PALB2 PALB2 Partner and localizer of BRCA2 Breast and pancreatic cancer. hereditary breast cancer- 81307' 81308,
related disorders. inherited bone marrow failure syndromes 81 432, 81441
(IBMFS)
PARK2 PARK2 Parkinson protein 2, E3 ubiquitin protein ligase (parkin) Parkinson disease 81405, 81406
PAX2 PAX2 Paired box 2 Renal coloboma syndrome 81406
PAX8PPARG PAX8/PPARG 112:3) lq13;p25) Follicular thyroid carcinoma 81401
PC PC PyruVCl!e carboxylase Pyruvate carboxylase deficiency 81406
PCA3/KLK3 Prostate cancer antigen 3/kallikrein-related peptidase Prostate cancer 81313
3
PCCA PCCA Propionyl coa carboxylase. alpha polypeptide Propionic acidemia. type 1 81405, 81406
PCCB PCCB Propionyl coa carboxylase, beta polypeptide Propionic acidemia 81 406
PCOH15 PCDH15 Protocadherin-related 15 Usher syndrome type 1F, Usher syndrome type 1, hearing 81400. 81406,
loss 81407, 81430
PCDH19 PCDH19 Protocadherin 19 Epileptic encephalopathy, epilepsy 81405, 81419
PCSK9 PCSK9 Proprotein convertase subtilisin/kexin type 9 Familial hypercholesterolemia 81406
PDE6A PDE6A Phosphodiesterase 6A. CGMP-specific. rod, alpha Hereditary retinal disorders 81 434
POE6B POE6B Phosphodiesterase 68. CGMP-specific. rod, beta Hereditary retinal disorders 81434
PDGFRA Platelet-derived growth factor receptor. alpha Gastrointestinal stromal tumor, solid organ neoplasm or 81314, 81445,
polypeptide hematolympho1d neoplasm 81449, 81455.
81456
POGFRB Platelet-derived growth factor receptor, beta Solid organ neoplasm or hematolymphoid neoplasm 81 445, 81 449,
polypeptide 81 455, 81456
POHAl POHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 Lactic acidosis 81 405, 81406
POHB POHB Pyruvate dehydrogenase (lipoamide) beta lactic acidosis 81405
PDHX PDHX Pyruvate dehydrogenase complex, component X Lactic acidosis 81406
POSS2 PDSS2 Decaprenyl diphosphate synthase subunit 2 Mitochondrial disorders 81440
POXl PDXl Pancreatic and duodenal homeobox 1 Matunty-onset diabetes of the young (MODY) 81404
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

Molecular Patholo ~Y Gene Table, continued

r.nmm;;p:. i.r.:· -'"..I'
--
SI •
PGR
PHEX
1111 .
II'"'~---:_;, .ti~.lt.-
1•rn~,:c'l. 0
•~1ilt•"'·•u.,.11r:.J1
PGR
PHEX
.r.
. ''F.JiiT·
I:
_:
-·lrl"~iii'.W~ • ~~~~:::
-_ .!
1
Progesterone receptor
.!!.~
Phosphate regulating endopeptidase homolog,

,..
- • ;.v
- , .,11111111111
I o
- J
t111111:1•
Solid organ or hematolymphoid neoplasm
Hypophosphatemic rickets
:·-~ .r'11l;~~-~~\~ - I•
81445. 81449.
81455. 81456
81406
X-linked
PHOX2B PHOX2B Paired-like homeobox 2b Congenital central hypoventilation syndrome 81403. 81404
PIK3CA PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase. Colorectal cancer, breast cancer. solid organ neoplasm or 81309, 81445,
catalytic subunit alpha hematolymphoid neoplasm 81449. 81455,
81456
PINKl INKl PTEN induced putative kinase 1 Parkinson disease 81405
PKDl PKDl Polycystic kidney disease 1 (autosomal dominant! Polycystic kidney disease 81407
PK02 KD2 Polycystic kidney disease 2 (autosomal dominant! Polycystic kidney disease 81406
PKHDl PKHDl Polycystic kidney and hepatic disease 1 utosomal recessive polycystic kidney disease 1
PKLR PKLR Pyruvate kinase, liver and RBC Pyruvate kinase deficiency 81405
PKP2 PKP2 Plakophilin 2 Arrhythmogenic right ventricular dysplasia/cardiomyopathy 81406, 81439
9. hereditary cardiomyopathy
PlCE1 c1 ospholipase C. epsilon 1 Nephrotic syndrome type 3 81407
PLCG2 Phospholipase Cgamma 2 Chronic lymphocytic leukemia 8132
PLN PlN Phospholamban Dilated cardiomyopathy, hypertrophic cardiomyopathy 81403
PLPl L1 roteolipid rotein 1 Pelizaeus-Merzbacher disease. spastic paraplegia 81404. 81405
PML/RARalpha U15;17) promyelocytic leukemia/retinoic acid receptor Promyelocytic leukemia 81315. 81316
alpha
J
PMP22 Peripheral myelin protein 22 Charcot-Mane-Tooth disease, hereditary neuropathy with 81324. 81325,
liability to pressure palsies 81326
PMS2 Postmeiotic segregation increased 2 (S. Cerevisiae) Hereditary nonpolyposis colorectal cancer. Lynch syndrome 81317, 81318,
81319
PNKD PNKD Paroxysmal nonkinesigenic dyskinesia aroxysmal nonkinesigenic d s inesia 81 06
POLG POLG Polymerase (DNA directed!. gamma Alpers·Huttenlocher syndrome, autosomal dominant 81406. 81419,
progressive external ophthalmoplegia. mitochondrial 81440
disorders, epilepsy
POLG2 POLG2 Polymerase (DNA directed!. gamma 2 itochondrial disorders 81 0
POMGNTl POMGNT1 Protein 0-linked mannose betal.2-N Muscle-eye-brain disease. Walker-Warburg syndrome 81406
acetylglucosaminyltransferase
POMT1 POMT1 Protein-0-mannosyltransferase 1 Limb-girdle muscular dystrophy (LGMD) type 2K, Walker- 81406
Warburg syndrome
POMT2 POMT2 Protein-CJ..mannosyltransferase 2 Limb-girdle muscular dystrophy (LGMDI type 2N. Walker- 81406
Warburg syndrome
POU1F1 POU1F1 POU class 1 homeobox 1 Combined pituitary hormone deficiency 81405
PPOX PPOX Protoporphyrinogen oxidase Variegate porphyria 81406
PPP2 28 PPP2R2B rotem hosphatase 2, regulate subunit . bet Spin erebellar ataxia 81343
POBPl P08P1 Polyglutamine binding protein 1 Renpenning syndrome 81404, 81405
PRAME PRAME Preferentially expressed antigen m melanoma Melanoma 81401
PRKAG2 PRKAG2 Protein kinase, AMP-activated. gamma 2 non-catalytic Familial hypertrophic cardiomyopathy with Wolff- 81406
subunit Parkinson-White syndrome, lethal congenital glycogen
storage disease of heart
PRKCG PRKCG Protein kinase C, gamma: (sodium channel, voltage- Spmocerebellar ataxia; hyperkalem1c periodic paralysis 81406
gated. type IV, alpha subunit!
PRNP PANP Srion protein Genetic prion disease 81404
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0
588
Gene Table, continued
PROP! PROPl PROP paired-like ho bo 1 Combined pituita hormone deficient 81

PRPF31 PRPF31 Pre-MANA processing factor 31 Hereditary retinal disorders 81434
PRPH2 PAP 2 eripherin 2 (retinal degeneration, slow) Retinitis pigmentosa, hereditary retinal disorders 81404, 81434
PRRT2 Praline rich transmembrane p t i
PASSl PASSI Protease. serine, 1 (trypsin 11 Hereditary pancreatitis 81401, 81404
PRX i n Charcot-Marie-Tooth disease 81405
PSEN1 PSEN1 Presenilin 1 Alzhe' er i se 5
PSEN2 PSEN2 Presenilin 2 (Alzheimer disease 41 Alzheimer disease 81406
PTEN Phosphatase and tensin homolog Cowden syndrome, PTEN hamartoma tumor syndrome, 81321 81322,
hereditary breast cancer-related disorders, hereditary colon 81323, 81432,
cancer disorders, solid organ neoplasm or hematolymphoid 81435, 81445,
neoplasm 81449, 81455,
81456
PTPN11 PTPN11 Protein tyrosine phosphatase, non-receptor type 11 Noonan syndrome. LEOPARD syndrome, Noonan spectrum 81406, 81442
disorders
PYG PYG osphorylase, glycogen, muscle Glycogen storage disease type V, McArdle disease 81401 , 81406
7 RAB7A RAB7A, member RAS on ne mil C rcot- ri -li th i
RAD51C RAD51 paralog C Inherited bone marrow failure syndromes (IBMFSI 81441
r
RAFI RAFl V-raf-1 murine leukemia viral oncogene homolog 1 LEOPARD syndrome. Noonan spectrum disorder 81404, 81406.
81442
Al l All tinoic acid induced 1 Smith-Magenis syndrome 81405
RDH12 RDH12 Retinol dehydrogenase 12 I- a s/9· i /11-Cisl red· ti I disorders
REEP! REEP! Receptor accessory protein 1 Spastic paraplegia, hereditary peripheral neuropathies 81405, 81448
RET RET Ret proto-oncogene Multiple endocrine neoplasia, type 2A and familial 81404, 81405,
medullary thyroid carcinoma. Hirschsprung disease. solid 81406, 81445,
organ neoplasm or hematolymphoid neoplasm 81449, 81455,
81456
RHODA RHO, deletion Rh blood group, D antigen Hemolytic disease of the fetus and newborn, Rh maternal/ 81403
analysis fetal compatibility
RHDDAM8 RHO, deletion Rh blood group, D antigen Hemolytic disease of the fetus and newborn, Rh maternal/ 81403
analysis. cell-free fetal compatibility
F fetal DNA in
maternal blood
RHO RHO Rhodopsin etinitis pigmen osa, heredi a retinal isorders 81 ,8 4
Rill RITl Ras-like without CAAX 1 Noonan spectrum disorders 81442
RPI RP etinitis pigmentos 1 Retinitis pigmentosa. hereditary retinal disorders 81404, 81434
RP2 RP2 Retinitis pigmentosa 2 Hereditary retinal disorders
RPE65 RPE65 Retinal pigment epithelium-specific protein 65kda Retinitis pigmentosa, Leber congenital amaurosis, 81406, 81434
hereditary retinal disorders
RPGR RPGR Retinitis pigmentosa gtpase regulator Hereditary retinal disorders 81434
p1 o al proeinL11 Inherited bone marrow failure syndromes (IBMFSI 81441
RPL35A Ribosomal protein 135a nh ri e s 1 1
RPL5 Ribosomal protein LS Inherited bone marrow failure syndromes (IBMFS) 81441
ibo I pro ein SlO Inherited bone marrow failure syndromes (IBMFSI 81441
RPS19 RPS1 9 Ribosomal protein S19 Diamond-Blackfan anemia, inherited bone marrow failure 81405, 81441
syndromes (IBMFSI
RPS24 Ribosomal protein S24 nh rit one rrow f ilu romes(I S 1 1
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0
0 0 0
0
0
0 0 0 0
a
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

-
RPS6KA3
RPS26
RPS6KA3
Ri osomal protein S26
Ribosomal protein SS kinase, 90kda. polypeptide 3
...._.···-:...
Inherited bone marrow failure syndromes (IBMFSl
X-rn ed intellectual disability (XL/Dl
r !nn ·!l1n..-.11l11,.."'t ·~.._...
'· ,,1~
81441
'.
81470. 81471
RPS7 Ribosomal protein S7 Inherited bone marro failure s ndromes (IB FSl 81441
RRM2B RM2B Ribonucleotide reductase M2 B(TP53 inducible) i hondrial DNA depletion. mitochondrial disorders 81405, 81440
RUNXl RUNXl Runt related transcription factor 1 Acute myeloid leukemia, familial platelet disorder with 81334
associated myeloid malignancy
RUNX1RUNX1T1 RUNX1/RUNX1T1 !(8;21) u e myeloid leukemia 81401
RYRl RYRl Ryanodine receptor 1, skeletal alignant hyperthermia 81406. 81408
RYR2 RYR2 Ryanodine receptor 2 (cardiac) Catecholaminergic polymorphic ventricular tachycardia. 81408. 81413
arrhythmogenic right ventricular dysplasia, cardiac ion
channelopathies
SBDS Ribosome maturation factor Inherited bone marro failure s ndromes (IB FSl 81 1
c1 SCNlA Sodium channel. voltage-gated. type 1, alpha subunit Generalized epilepsy with febrile seizures. epilepsy 81407. 81419
SCNlB SCNlB Sodium channel. voltage-gated, type I, beta Brugada syndrome. epilepsy 81404, 81419
SCN2A Sodium voltage-gated channel alpha subunit 2 pil psy 81419
SC SCN4A Sodium channel. voltage-gated. type IV, alpha subunit Hyperkalemic periodic paralysis 81406
SCN8A Sodium voltage-gated channel alpha subunit 8 Epilepsy 81419
SCN5A SCN5A Sodium channel, voltage-gated, type V, alpha subunit Familial dilated cardiomyopathy, cardiac ion 81407. 81413
channelopathies
SCNNlA SCNNlA Sodium channel. nonvoltage-gated 1 alpha Pseudohypoaldost ronism 8
SCNNlB SCNNlB Sodium channel, nonvoltage-gated 1, beta Liddle syndrome, pseudohypoaldosteronism 81406
SCNN1G SCNN1G Sodium channel. nonvoltage-gated 1, gamma Li die syndrome. pseudohypoaldosteronism 81406
SCOl SCOl sea cytochrome oxidase deficient homolog 1 Mitochondrial respiratory chain complex IV deficiency. 81405. 81440
SC02 SC02 SCOCytochrome oxidase deficient homolog 2 (SCOT Ll Mitochondrial respiratory chain complex IV deficiency, 81404, 81440
SDHA SDHA Succinate dehydrogenase complex, subunit A. Leigh syndrome, mitochondrial complex II deficiency 81406
flavoprotein (Fp)
SDHB SDHB Succinate dehydrogenase complex, subunit B. iron Hereditary paraganglioma, hereditary neuroendocrine 81405, 81437,
sulfur tumor disorders 81438
SDHC SDHC Succinate dehydrogenase complex, subunit C. integral Hereditary paraganglioma-pheochromocytoma syndrome, 81404, 81405,
membrane protein. 15kda hereditary neuroendocrine tumor disorders 81437, 81438
SOHO SOHO Succinate dehydrogenase complex. subunit D. integral Hereditary paraganglioma, hereditary neuroendocrine 81404. 81437,
membrane protein tumor disorders 81438
9-Sep 9-Sep Septin 9 Colorectal cancer 81327
Sef1PINA1 Serpin peptidase inhibitor. clade A, alpha-1 Alpha-1-antitrypsin deficiency 81332
antiproteinase. antitrypsin. member 1
SEAPINEl SERPINEl Serpine peptidase inhibitor clade E. member 1, Thrombophilia 81400
plasminogen activator inhibitor -1, PAl-1
SETJ< SETX Senata in xia 81406
SF3B1 Splicing factor [3bl subunit Bl Myelodysplastic syndrome/acute myeloid leukemia 81347
Ill
SGCA SGCA Sarcoglycan, alpha (50kda dystrophin-associated Limb-girdle muscular dystrophy 81405
glycoprotein)
SGCB SGCB Sarcoglycan, beta l43kda dystrophin-associated Limb-girdle muscular dystrophy 81405
glycoprotein)
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 ,o 0 0
0 0
0 0 0 0
0 0 0 0
590
•
cular_~at~~!~11y Ge~~ T~ble, co:;tinued ····· _ ___
-~,M~·~·
..
t 111: t ,~ ... - - -
1 . ., , , . . . .
·n1~ •
~
•
-
.. ., • •
l:.t
,., "'--'-
·•:n•'··-~ ~,. .
.): ·:--
-
•
:)I
-
··~.w~~~·
. :'!,·. -1:~~."'>< -,
-·
.l._•
.......
~.......,,
I , •.. I
~ ~,
•
-.
tltllt ' •
R"' ·
:slie!!\~!=5:1i
• · • •• · •
I 0 '
SGCD SGCO Sarcoglytan, delta 135kda dystrophin-associated Limb-girdle muscular dystrophy 81405
glycoprotein)
SGCE SGCE Sarcoglycan, epsilon Myoclonic dystonia 81405, 81406

SGCG SGCG Sarcoglycan. gamma (35kda dystrophin-associated Limb-girdle muscular dystrophy 81404. 81405
glycoprotein)
SH2D1A SH2D1A SH2 domain containing 1A X-linked lymphoproliferative syndrome 81403, 81404
SH3TC2 SH3TC2 SH3 domain and tetratricopeptide repeats 2 Charcot-Marie-Tooth disease 81406
SHOC2 SHOC2 Soc-2 suppressor of clear homolog Noonan-like syndrome with loose anagen hair, Noonan 81400. 81405,
spectrum disorders 81442
Short Tandem N/A Pre-transplant recipient. donor germline testing, post- 81265. 81266
Repeat ISTR) transplant recipient
SHOX SHOX Short stature homeobox Langer mesomelic dysplasia 81405
Sill Sill Sill homolog, endoplasmic reticulum chaperone IS. Ataxia 81405
Cerevisiae)
SLC2A1 SLC2A1 Solute carrier family 2 (facilitated glucose transporter). Glucose transporter type 1 !GLUT 1) deficiency syndrome. 81405, 81419
member 1 epilepsy
SLC2A10 SLC2A10 Solute carrier family 2 lfacilitated glucose transporter). Aortic dysfunction or dilation 81410
member 10
SLC9A6 SLC9A6 Solute carrier family 9 (sodium/hydrogen exchanger). Christianson syndrome. epilepsy 81406, 81419
members
SLC12A1 SLC12A1 Solute carrier family 12 lsodium/potassium/chloride 8artter syndrome 81407
transporters). member 1
SLC12A3 SLC12A3 Solute carrier family 12 (sodium/chloride transporters). Gitelman syndrome 81407
member3
SLC16A2 SLC16A2 Solute carrier family 16, member 2 (thyroid hormone Specific thyroid hormone cell transporter deficiency, Allan- 81404. 81405.
transporter) Herndon-Dudley syndrome, X-linked intellectual disability 81470, 81471
(XUD)
SLC22A5 SLC22A5 Solute carrier family 22 (organic cation/carnitine Systemic primary carnitine deficiency 81405
transporter), member 5
SLC25A4 SLC25A4 Solute carrier family 25 (mitochondrial carrier; adenine Progressive external ophthalmoplegia. mitochondrial 81404. 81440
nucleotide translocator), member 4 disorders
SLC25A20 SLC25A20 Solute carrier family 25 (carnitine/acylcarnitine Carnitine-acylcarnitine translocase deficiency 81404, 81405
translocase). member 20
SLC26A4 SLC26A4 Solute carrier family 26. member 4 Pendred syndrome, hearing loss 81406. 81430
SLC37A4 SLC37A4 Solute carrier family 37 (glucose-6-phosphate Glycogen storage disease type lb 81406
transporter), member 4
SLC0181 SLC0181 Solute carrier organic anion transporter family, Adverse drug reaction 81328
member 181
SMAD3 SMAD3 SMAD family member 3 Aortic dysfunction or dilation 81410
SMAD4 SMAD4 SMAD family member 4 Hemorrhagic telangiectasia syndrome, juvenile polyposis, 81405. 81406,
hereditary colon cancer disorders 81435, 81436
SMN1 SMN1 Survival of motor neuron 1, telomeric Spinal muscular atrophy 81329. 81336,
81337
SMN1SMN2 SMN1/SMN2 Survival of motor neuron 1. telomeric/survival of motor Spinal muscular atrophy 81329
neuron 2, centromeric
SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal Niemann-Pick disease, type A. Ashkenazi Jewish· 81330, 81412
associated disorders
SNRPN/UBE3A Small nuclear ribonucleoprotein polypeptide N and Prader-Willi syndrome and/or Angelman syndrome 81331
ubiquitin protein ligase E3A
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 00 0 00
.o 0 0 0 0
0
0 0 0
0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0

•
Molecular Patholo1 IY Gene Table, continued
!1i1 . • • ,.,,r' ~-~~- .•.._.. • •• • ·t • I •
. "'. ·""'{~·; . . . . ~~ :~/ !~ .. . '~""' ,, .

SODl ' SOD1 Superoxide dismutase 1, soluble Am atrophic lateral sclerosis 81
-
SOSl SOS1 Son of sevenless homolog 1 Noonan syndrome. gingival fibromatosis. Noonan spectrum 81406, 81442
disorders
SPA ST SPAST Spastin Spastic paraplegia, hereditary peripheral neuropathies 81405, 81406,
81448
SPG11 SPG11 Spastic paraplegia 11 (autosomal recessive) Spastic paraplegia, hereditary peripheral neuropathies 81407, 81448
SPG7 SPG7 Spastic paraplegia 7 (pure and complicated autosomal Spastic paraplegia 81405, 81406
recessive)
SPINKl SP1NK1 Serine peptidase inhibitor, Kazal type 1 Hereditary pancreatitis 81404
SPRED1 SPRED1 Sprouty-related, EVHl domain co~taining 1 Legius syndrome 1405
SPTBN2 SPTBN2 Spectrin. beta. non-erythrocytic 2 Spinocerebellar ataxia 81407
SPTLC1 SPTLC1 Serine palmitoyltransferase, long chain base subunit 1 Hereditary peripheral neuropathies 81448
SRSF2 Serine and arginine-rich splicing factor 2 Myelodysplastic syndrome. acute myeloid leukemi
SRY SRY Sex determining region Y 46. XX testicular disorder of sex development. gonadal 81400
dysgenesis
SS18SSX1 SS18/SSX1 t(x;181 Synovial sarcoma 81 401
SS18SSX2 SS18/SSX2 t(x;181 Synovial sarcoma 81401
STAT3 STAT3 Signal transducer and activator of transcription 3 Autosomal dominant hyper-lgE syndrome 81405
(acute-phase response factor)
STK11 STK11 Serine/threonine kinase 11 Peutz-Jeghers syndrome, hereditary breast cancer-related 81404, 81405,
disorders, hereditary colon cancer disorders 81432. 81433.
81435, 81436
STRC STRC Stereocilin Hearing loss 81431
STXBP1 STX8P1 Syntaxin binding protern 1 Epileptic encephalopathy, epilepsy 406, 81 19
SUCLA2 SUCLA2 Succinate-coa ligase ADP-forming beta subunit Mitochondrial disorders 81440
SUCLGl SUCLGl Succinate-coa ligase alpha subunit Mitochondrial disorders 81440
SURF1 SUAFl Surfeit 1 Mitochondrial respiratory chain complex IV deficiency 1 5
SYNGAPl Synaptic Ras gtpase activating protein 1 Epilepsy 81419
TAC01 TAC01 Translational activator of mitochondrial encoded Mitochondrial respiratory chain complex IV deficiency 81404
Cytochrome c oxidase I
TARDBP TARD BP TAR DNA binding protein Amyotrophic lateral sclerosis 81405
TAZ TAZ Tafazzin Methylglutaconic aciduria type 2. Barth syndrome, 81406, 81 440
TBP TBP TATA box binding protein Spinocerebellar ataxia
T :> TB 5 T-box 5 Holt-Oram syndrome 81405
TCF4 TCF4 Transcription factor 4 Pin-Hopkins syndrome, epilepsy 81405, 81406.
81 419
TEAT Telomerase reverse transcriptase Thyroid carcinoma. glioblastoma mulllforme. inherited 81345. 81441
bone marrow failure syndromes (IBMFSI
TGFBI Transforming growth factor beta-induced Corneal dystrophy 81333
TGFBRl TGFBRl Transforming growth factor, beta receptor 1 Marfan syndrome, aortic dysfunction or dilation 81405, 81410,
81411
TGFBR2 TGFBR2 Transforming growth factor. beta receptor 2 Marfan syndrome, aortic dysfunction or dilation 81405, 81410.
81411
TH TH Tyrosine ydroxylase Segawa syndrome 81406
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0
592
CPT 2023 M9lecular Pathology Gene Table
f"
Molecular Patholo IY Gene Table, continued t
~\- If.;-; · -, .. .,ii - - . . . .~ . ·· ~·'-'· ~
I '._It h;:.u1~t;1111:.1
~ ..·-~·
,..,,.... ,,,,.jlllf•
·~~ill~
~::., ~ 1 "" . ... ;~~,C••tfllol"l·fl._,l_.;j
THAPl THAPl THAP domain containing, apoptosis associated Torsion dystonia 81404
protein 1
THRB THAB Thyroid hormone receptor. beta Thyroid hormone resistance, thyroid hormone beta receptor 81405
deficiency
TINF2 TEAFl interacting nuclear factor 2 Inherited bone marrow failure syndromes llBMFS) 81441
TK2 TK2 Thymidine kinase 2, mitochondrial Mitochondrial ONA depletion syndrome, mitochondrial 81405, 81440
' disorders
TMCl TMC1 Transmembrane channel-like 1 Hearmg loss 81430
TMEM43 TMEM43 Transmembrane protein 43 Arrhythmogenic right ventricular cardiomyopathy 81406
TMEM67 TMEM67 Transmembrane protein 67 Joubert syndrome 81407
TMEM127 TMEM127 Transmembrane protein 127 Hereditary neuroendocrine tumor disorders 81437
-TMPASS3 TMPASS3 Transmembrane protease, serine 3 Hearing loss 81430
TNNC1 TNNC1 Troponin Ctype 1 (slow) Hypertrophic cardiomyopathy or dilated cardiomyopathy 81405
TNNl3 TNNl3 Troponin I, type 3 (cardiac) Familial hypertroph1c cardiomyopathy 81405
TNNT2 TNNT2 Troponin T. type 2 (cardiac) Familial hypertrophic cardiomyopathy 81406
TOAlA TORlA Torsin family 1, member A ltorsin A) Early-onset primary dystonia (OYTl ). torsion dystonia 81400, 81404
TP53 TP53 Tumor protein 53 Li-Fraumeni syndrome, hereditary breast cancer-related 81351 , 81352.
disorders 81353, 81432
TPMl TPMl Tropomyosin 1 (alpha) Fam1hal hypertroph1c cardiomyopathy 81405
TPMT TPMT Thiopurine S·methyltransferase Drug metabolism 81335
TPPl Tnpep!idyl peptidase 1 Epilepsy 81 419
TAB@ T cell antigen receptor. beta Leukemia and lymphoma 81340. 81341
TAO TAO@ T cell antigen receptor, delta Leukemia and lymphoma 81402
TAG@ T cell antigen receptor. gamma Leukemia and lymphoma 81342
TAPC6 TRPC6 Transient receptor potential cation channel. subfamily Focal segmental glomerulosclerosis 81406
C.member6
TSCl TSCl Tuberous sclerosis 1 Tuberous sclerosis. epilepsy 81405, 81406.
81419
TSC2 TSC2 Tuberous sclerosis 2 Tuberous sclerosis, epilepsy 81406, 81407.
81419
TTN TTN litin Hereditary cardiomyopathy 81439
TTPA TTPA Tocopherol (alpha) trdnsfer protein Ataxia 81404
TTA TTA Transthyretin Familial transthyretin amyloidosis 81404
lWISTl lWISTl Twist homolog 1 (Drosophila) Saethre-Chotzen syndrome 81403, 81404
TYMP TYMP Thymidine phosphorylase Mitochondrial ONA depletion syndrom&. mitochondrial 81405, 81440
disorders
TYMS TYMS Thymidylate synthetase 5-fluorouracil/5-FU drug metabolism 81346
TVA TYR Tyrosinase (oculocutaneous albinism IA) Oculocutaneous albinism IA 81404
U2AF1 U2 small nuclear RNA auxiliary factor 1 Myelodysplastic syndrome. acute myeloid leukemia 81357
UBA1 UBAl Ubiquitin-like modifier activating enzyme 1 Spinal muscular atrophy, X-linked 81403
UBE3A Q UBE3A Ubiquitin protei~ ligase E3A Angelman syndrome 81406
UGT1A1 UGT1 A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Drug metabolism. Gilbert syndrome. Crigler-Najjar 81350, 81404
syndrome
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0 0

Molecular Pathology Gene Table
Gene Table, continued
UMOO UMOO Uromodulin Glomerulocystic kidney disease with hyperuricemia and 81406
isosthenuria
UPD Uniparental disomy Upd Russell-Silver syndrome. Prader-Willi/Angelman syndrome 81402
USH1C USH1C Usher syndrome 1Clautostmal recessive. severe} Usher syndrome. type 1. hearing loss 81407. 81430
US lG USHlG Usher syndrome 1Glautosomal recessive) Usher syndrome. type 1. hearing loss 81404, 81430
USH2A USH2A Usher syndrome 2A lautosomal recessive. mild} Usher syndrome. type 2. hearing loss. hereditary retinal 81408. 81430.
disorders 81434
VHL VHL Von H1ppel-Lindau tumor suppressor Von Hippel-lindau familial cancer syndrome. hereditary 81403. 81404.
neuroendocrine tumor disorders 81437. 81438
VKORC1 Vitamin K epoxide reductase complex. subunit 1 Warfarin metabolism 81355
VPS13B VPS13B Vacuolar protein sorting 13 homolog B (yeast} Cohen syndrome 81407. 81408
VWF VWF Von Willebrand factor Von Willebrand disease types 1. 1C. 2A. 2B. 2M. 2N. 3 81401. 81403.
81404, 81405.
81406, 81408
WAS WAS Wiskott Aldrich syndrome leczema-thrombocytopenia) Wiskott-Aldrich syndrome 81406
62 D 62 Dre ea omain 62 rimary autosomal recessive microcephaly 81407
WFS1 WFSl olfram syndrome 1 Hearing loss 81430
WT1 WT1 llms tumor 1 Oenys-Orash syndrome. familial Wilms tumor 81405
ZEB2 ZEB2 Zinc finger E·box binding homeobox 2 Mowat-Wilson syndrome. epilepsy 81404. 81405.
81419
z 41 z incfi er protein4 -linked mental retardation 89 81404
ZRSR2 Zinc finger CCCH·type, RNA binding motif and serine/ Myelodysplastic syndrome. acute myeloid leukemia 81360
arginine rich 2
I.
0 0 0 0 0
0 0 0 0 0 0 0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0 0
0
0
0
•
0 0 0 0 0 0
0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
•0 0 0
0 0 0
0 0 0 0
594
"
Pathology and Laboratory Guidelines
Guidelines to direct general reporting of services are
presented in the Introduction. Some of the 88199 Unlisted cytopathology procedure
commonalities are repeated here for the convenience of 88299 Unlisted cytogenetic study
those referring to this section on Pathology and
88399 Unlisted surgical pathology procedure
Laboratory. Other definitions and items unique to
Pathology and Laboratory are also listed. 88749 Unlisted in vivo (eg, transcutaneous) laboratory service
89240 Unlisted miscellaneous pathology test
Services in Pathology and 89398 Unlisted reproductive medicine laboratory procedure
Laboratory
Services in Pathology and Laboratory are provided by a
Special Report
physician or by technologists under responsible A service that is rarely provided, unusual, variable, or new
supervision of a physician. may require a special report. Pertinent information
should include an adequate definition or description of
the nature, extent, and need for the procedure; and the
Separate or Multiple time, effort, and equipment necessary to provide the
service.
Procedures
It is appropriate to designate multiple procedures that are
rendered on the same date by separate entries.
Unlisted Service or Procedure

A service or ·procedure may be provided that is not listed
in this edition of the CPT codebook. When reporting
such a service, the appropriate "Unlisted Procedure" code
may be used to indicate the service, identifying it by
"Special Report" as discussed below. The "Unlisted
Procedures" and accompanying codes for Pathology and
Laboratory are as follows:
81099 Unlisted urinalysis procedure
81479 Unlisted molecular pathology procedure
81599 Unlisted multianalyte assay with algorithmic analysis
84999 Unlisted chemistry procedure
85999 Unlisted hematology and coagulation procedure
86486 unlisted antigen, each
86849 Unlisted immunology procedure
86999 Unlisted transfusion medicine procedure
87999 Unlisted microbiology procedure
88099 Unlisted necropsy (autopsy) procedure
A== Revised code • == New code Jll> .... ==Contains new or revised text *==Duplicate PIA test ti== Category IPIA
80047-80053 Pathology and Laboratory I Organ or Disease-Oriented Panels CPT 2023
Pathology and Lalloratory

80050 General health panel
Organ or Disease-Oriented This panel must include the following:
Panels Comprehensive metabolic panel (80053)
These panels were developed for coding purposes only Blood count. complete (CBC), automated and automated
and should not be interpreted as clinical parameters. The differential WBC count (85025 or 85027 and 85004)
rests listed with each panel identify the defined OR
components of that panel.
Blood count complete (CBC), automated (85027) and
These panel components are not intended to limit the appropriate manual differential WBC count (85007 or
performance of other tests. If one performs tests in 85009)
addition to chose specifically indicated for a particular
Thyroid stimulating hormone (TSH) (84443)
panel, those tests should be reported separately in @ CPT Changes: An Insider's View 2001. 2004
addition co the panel code.
@ CPT AssistantWinter 92:14, Summer 93:14, Jun 97:10.
Do not report two or more panel codes that include any Nov 97:28. Jan 98:6. Sep 99: 11
of the same constituent tests performed from the same 80051 Electrolyte panel
patient collection. If a group of tests overlaps two or more
This panel must include the following:
panels, report the panel that incorporates the greater
number of tests to fulfill the code definition and report Carbon dioxide (bicarbonate) (82374)
the remaining tests using individual test codes (eg, do not Chloride (82435)
report 80047 in conjunction with 80053).
Potassium (84132)
80047 Basic metabolic panel (Calcium, ionized)
Sodium (84295)
This panel must include the following: @ CPT Assistant Nov 97:28. Jan 98:7, Sep 99:11
Calcium. ionized (82330) 80053 Comprehensive metabolic panel
Carbon dioxide (bicarbonate) (82374) This panel must include the following:
Chloride (82435) Albumin (82040)
Creatinine (82565) Bilirubin, total (82247)
Glucose (82947) Calcium, total (82310)

Carbon dioxide (bicarbonate) (82374)
Potassium (84132)
Chloride (82435)
Sodium (84295)
Creatinine (82565)
Urea Nitrogen (BUN) (84520)
Glucose (82947)
@ CPT Changes: An Insider's View 2008
@ CPT Assistant Apr 08:5. Apr 13:10, Dec 20:3. Jan 21 :12. Phosphatase, alkaline (84075)
May 21:8 Potassium (84132)
80048 Basic metabolic panel (Calcium. total) Protein, total (84155)
This panel must include the following: Sodium (84295)
Calcium. total (82310) Transferase. alanine amino (ALT) (SGPT) (84460)
Carbon dioxide (bicarbonate) (82374) Transferase. aspartate amino (AST) (SGOT) (84450)
Chloride (82435) Urea nitrogen (BUN) (84520)

@ CPT Changes: An Insider's View 2000. 2009
Creatinine (82565) @ CPT Assistant Jan 98:6, Nov 98:23. Sep 99:11. Nov 99:44.
May 00:11. Jan 05:46, Apr 08:5. Apr 10:11, Apr 13:10, May 21:9
Glucose (82947)
Potassium (84132) 0
0 0
0
0 0
0
0
0 0 0 0 0 0
0 0 0 0 0 0
Sodium (84295) 0 0 0
0 0 0
0 0
0 0
0 0
0 0 0
0
0 0
0
Urea nitrogen (BUN) (84520) 0 0 0 0 0 0 0 0 0 0 0 0
0 0
@ CPT Changes: An Insider's View 2000. 2008, 2009 0 0 0

0 0 ° 0
0
0 0 0 0 0 0 0 • 0
0 00 0 00
@ CPT Assistant Jan 98:6. Sep 99:11. Nov 99:44. Jan 00:7. 0 0 0 0 0 0 0 0 0 0
0 0
Aug 05:9 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
596 *= Telemedicine ~=Audio-only +=Add-on code ;N =FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory/ Organ or Disease-Oriented Panels 80055--80076
80055 Obstetric panel 80061 Lipid panel

This panel must include the following: This panel must include the following:
Blood count, complete (CBC), automated and automated Cholesterol, serum, total (82465)
differential WBC count (85025 or 85027 and 85004) Lipoprotein, direct measurement. high density cholesterol
(HDL cholesterol) (83718)
OR
Triglycerides (84478)
Blood count, complete (CBC), automated (85027) and @CPT Assistant Winter 92:14. Summer 93:14, Jun 97:10,
appropriate manual differential WBC count (85007 or Sep 99:11, Mar00:11, Feb 05:9, Sep 17:12
85009)
80069 Renal function panel
Hepatitis B surface antigen (HBsAg) (87340)
Antibody, rubella (86762) Albumin (82040)
Syphilis test. non-treponemal antibody; qualitative (eg, Calcium. total (82310)
VDRL. RPR. ART) (86592)
Carbon dioxide (bicarbonate) (8237 4)
Antibody screen. RBC. each serum technique (86850) Chloride (82435)
Blood typing, ABO (86900) AND Creatinine (82565)
Blood typing, Rh (D) (86901) Glucose (82947)
@ CPT Changes: An Insider's View2004 Phosphorus inorganic (phosphate) (84100)
@CPT Assistant Winter 92:14, Summer 93:14, Jun 97:10, Apr 99:6,
Sep 99:11
Potassium (84132)
Sodium (84295)
(When syphilis screening is performed using a
treponemal antibody approach [86780], do not use 80055. Urea nitrogen (BUN) (84520)
Use the individual codes for the tests performed in the @ CPT Changes: An Insider's View 2000, 2009
obstetric panel) @CPT Assistant Sep 99:11. Nov 99:44
# 80081 Obstetric panel (includes HIV testing) 80074 Acute hepatitis panel
Hepatitis A antibody (HAAb). lgM antibody (86709)
Blood count, complete (CBC). and automated differential
WBC count (85025 or 85027 and 85004) Hepatitis B core antibody (HBcAb), lgM antibody (86705)
OR
Hepatitis Cantibody (86803)
Blood count, complete (CBC), automated (85027) and
appropriate manual differential WBC count (85007 or
@ CPT Assistant Sep 99:11, Nov 99:45
85009)
80076 Hepatic function panel
HIV-1 antigen(s). with HIV-1 and HIV-2 antibodies, single
result (87389) Albumin (82040)
Bilirubin, total (82247)
Antibody, rubella (86762)
Bilirubin. direct (82248)
Syphilis test. non-treponemal antibody; qualitative (eg,
VDRL, RPR. ART) (86592) Phosphatase, alkaline (84075)
ProteiR, total (84155)
Antibody screen. RBC, each serum technique (86850)
Transferase, alanine amino (ALT) (SGPT) (84460)
Blood typing, ABO (86900) AND
Transferase. aspartate amino (AST) (SGOT) (84450)
Blood typing, Rh (D) (86901) @ CPT Changes: An Insider's View 2000
@ CPT Changes: An Insider's View 2016 @ CPT Assistant Winter 92:14, Summer 93:14, Jun 97:10. Jan 98:6,
Apr 99:6, Sep 99:11, Nov 99:45, Jan 00:7, Aug 05:9
(When syphilis screening is performed using a
treponemal antibody approach [86780]. do not use 80081. 80081 Code is out of numerical sequence. See 80053-80069
Use the individual codes for the tests performed in the
Obstetric panel) 0
0
0 0
0
0
0
0 0
0
0
0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 o II
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 00 0 0 0 0 00
0 0 0 0
0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0
A=Revised code •=New code ..,. "4 =Contains new or revised text *=Duplicate PLA test t+=Category IPLA American Medical Association 597
Pathology and Laboratory I Drug Assay CPT 2023
Drug Assay associated metabolites, if performed. A presumptive

test is not required prior to a definitive drug test.
Drug procedures are divided into three subsections: The material for drug class procedures may be any
Therapeutic Drug Assay, Drug Assay, and specimen type unless otherwise specified in the code
Chemistry-with code selection dependent on the descriptor {eg, urine, blood, oral fluid, meconium, hair).
purpose and type of patient results obtained. Therapeutic Procedures can be qualitative (eg, positive/negative or
Drug Assays are performed to monitor clinical response present/absent), semi-quantitative, or quantitative
to a known, prescribed medication. The two major (measured) depending on the purpose of the testing.
categories for drug testing in the Drug Assay subsection Therapeutic drug assay {TOA) procedures are typically
are: quantitative tests and the specimen type is whole blood,
serum, plasma, or cerebrospinal fluid.
1. Presumptive Drug Class procedures are used to
identify possible use or non-use of a drug or drug When the same procedure{s) is performed on more than
class. A presumptive test may be followed by a one specimen type {eg, blood and urine), the appropriate
definitive test in order to specifically identify drugs or code is reported separately for each specimen type using
metabolites. modifier 59.
2. Definitive Drug Class procedures are qualitative or Drugs or classes of drugs may be commonly assayed first
quantitative test to identify possible use or non-use of by a presumptive screening method followed by a
a drug. These test identify specific drugs and definitive drug identification method.
(continued on page 601)
DEFINITIONS AND ACRONYM CONVERSION LISTING

Drug Testing
Definition
Term/Acronym
6-MAM Acronym for the heroin drug metabolite 6-monacetylmorphine
Acid Descriptor for classifying drug/drug metabolite molecules based upon chemical ionization properties. Laboratory
procedures for drug isolation and identification may include acid, base. or neutral groupings.
AM A category of synthetic marijuana drugs discovered by and named after Alexandros Makriyannis at Northeastern University
Analog A structural derivative of a parent chemical compound that often differs from it by a single element
Analyte The substance or chemical constituent that is of interest in an analytical procedure
Base Descriptor for classifying drug/drug metabolite molecules based upon chemical ionization properties. Laboratory
procedures for drug isolation and identification may include acid, base, or neutral groupings.
Card(s) Multiplexed presumptive drug class(es) immunoassay product that is read by visual observation, including instrumented
when performed
Cassette(s) Multiplexed presumptive drug class immunoassay product(s) that is read by visual observation, including instrumented
when performed
CEOIA Acronym for Cloned-Enzyme-Donor-lmmuno-Assay. CEDIA immunoassay is a competitive antibody binding procedure that
utilizes enzyme donor fragment-labeled antigens (drugs) to compete for antigens (drugs) contained in the patient sample.
Recombination of enzyme donor fragment and enzyme acceptor fragment produces a functional enzyme. CEOIA
immunoassay enzyme activity is proportional to concentration of drug(s) detected.
Chromatography An analytical technique used to separate components of a mixture. See thin layer chromatography, gas chromatography.
and high performance chromatography.
Confirmatory Term used to describe definitive identification/quantitation procedures that are secondary to presumptive screening
methods
DART Acronym for Direct-Analysis-in-Real-Time. DART is an atmospheric pressure ionization method for mass spectrometry
analysis
0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 00 0 00 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0
0 0 0
598 *= Telemedicine '4 =Audio-only +=Add-on code ,#'=FDA approval pending #=Resequenced code <S)= Modifier 51 exempt 0 00 =See pxix for details
CPT 2023 Pathology and Laboratory I Drug Assay
Drug Testing Definition

Tenn/Acronym
Definitive Drug A procedure that provides specific identification of individual drugs and drug metabolites
Procedure
DESI Acronym for Desorption-ElectroSpray-lonization. DESI is a combination of electrospray ionization and desorption ionization
methods for mass spectrometry analysis.
Dipstick A multiplexed presumptive drug class immunoassay product that is read by visual observation. including instrumented
when performed
Drug test cup A multiplexed presumptive drug class immunoassay product that is read by visual observation. including instrumented
when performed
EDDP Acronym for the methadone drug metabolite 2-ethylidene-1,5-dimethyl-3.3-diphenylpyrrolidine
EIA Acronym for Enzyme lmmuno-Assay. Enzyme immunoassay is a competitive antibody binding procedure that utilizes
enzyme-labeled antigens (drugs) to compete for antigens (drugs) contained in the patient sample. Enzyme immunoassay
enzyme activity is proportional to concentration of drug(s) detected
ELISA Acronym for Enzyme-Linked lmmunosorbent Assay. ELISA is a competitive binding immunoassay that is designed to
measure antigens (drugs) or antibodies. ELISA immunoassay results are proportional to concentration of drug(s) detected.
EMIT Acronym for Enzyme-Multiplied-Immunoassay-Test. EMIT is a trade name for a type of enzyme immunoassay (EIA).
FPIA Acronym for Fluorescence Polarization lmmuno-Assay. FPIA is a competitive binding immunoassay that utilizes fluorescein-
labeled antigens (drugs) to compete for antigens (drugs) contained in the patient sample. The measure of polarize.d light
emission is inversely proportional to the concentration of drug(s) detected.
Gas chromatography Gas chromatography is a chromatography technique in which patient sample preparations are vaporized into a gas (mobile
phase) which flows through a tubular column (containing a stationary phase) and into a detector. The retention time of a
drug on the column is determined by partitioning characteristics of the drug into the mobile and stationary phases.
Chromatography column detectors may be non-specific (eg. flame ionization) or specific (eg, mass spectrometry). The
combination of column retention time and specific detector response provides a definitive identification of the drug or drug
metabolite.
GC Acronym for gas chromatography
GC-MS Acronym for gas chromatography mass spectrometry
GC-MS/MS Acronym for gas chromatography mass spectrometry/mass spectrometry
High performance liquid High performance liquid chromatography is a chromatography technique in which patient sample preparations are injected
chromatography into a liquid (mobile phase) which flows through a tubular column (containing a stationary phase) and into a detector. The
retention time of a drug on the column is determined by partitioning characteristics of the drug into the mobile and
stationary phases. Chromatography column detectors may be non-specific (eg, ultra-violet spectrophotometry) or specific
(eg. mass spectrometry). The combination of column retention time and specific detector response provides a definitive
identification of the drug or drug metabolite. High performance liquid chromatography is also called high pressure liquid
chromatography.
HPLC Acronym for high performance liquid chromatography
HU A category of synthetic marijuana drugs discovered by and named after Raphael Mechoulam at Hebrew University
IA Acronym for immunoassay
Immunoassay Antigen-antibody binding procedures utilized to detect antigens (eg. drugs and/or drug metabolites) in patient samples.
Immunoassay designs include competitive or non-competitive with various mechanisms for detection.
Isobaric In mass spectrometry. ions with the same mass
0 0 0
0 0 0 0 0
0 0 0 0
0
0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 00 0 0 0 0 00
0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0
.6.=Revised code • = New code .,.. •=Contains 11eworrevised text *=Duplicate PLA test U=Category IPLA American Medical Association 599
Pathology and Laboratory I Drug Assay CPT 2023

Drug Testing
Definition
Term/Acronym
Isomers Compounds that have the same molecular formula but differ in structural formula
JWH A category of synthetic marijuana drugs discovered by and named after John W. Huffman at Clemson University.
KIMS Acronym for kinetic interaction of microparticles in solution. KIMS immunoassay is a competitive antibody binding
procedure that utilizes microparticle-labeled antigens (drugs) to compete for antigens (drugs) contained in the patient
sample. Microparticle immunoassay absorbance increase is inversely proportional to concentration of drug(s) detected.
LC-MS Acronym for liquid chromatography mass spectrometry
LC-MS/MS Acronym for liquid chromatography mass spectrometry/mass spectrometry
LDTD Acronym for laser diode thermal desorption. LDTD is a combination of atmospheric pressure chemical ionization and laser
diode thermal desorption methods for mass spectrometry analysis.
MALDI Acronym for matrix assisted laser desorption/ionization mass spectrometry. MALDI is a soft ionization technique that
reduces molecular fragmentation.
MDA Acronym for the drug 3.4-methylenedioxyamphetamine. MDA is also a drug metabolite of MOMA.
MDEA Acronym for the drug 3.4-methylenedioxy-N-ethylamphetamine
MOMA Acronym for the drug 3.4-methylenedioxy-N-methylamphetamine
MDPV Acronym for the drug methylenedioxypyrovalerone
MS ' Acronym for mass spectrometry. MS is an identification technique that measures the charge-to-mass ratio of charged
particles. There are several types of mass spectrometry instruments, such as magnetic sectoring, time of flight, quadrupole
mass filter, ion traps, and Fourier transformation. Mass spectrometry is used as part of the process to assign definitive
identification of drugs and drug metabolites.
MS/MS Acronym for mass spectrometry/mass spectrometry. MS/MS instruments combine multiple units of mass spectrometry
filters into a single instrument. MS/MS is also called tandem mass spectrometry.
MS-TOF Acronym for mass spectrometry time of flight. Time of flight is a mass spectrometry identification technique that utilizes
ion velocity to determine the mass-to-charge ratio.
Multiplexed Descriptor for a multiple component test device that simultaneously measures multiple analytes (drug classes) in a ~ingle
analysis.
Neutral Descriptor for classifying drug/drug metabolite molecules based upon chemical ionization properties. Laboratory
procedures for drug isolation and identification may include acid, base, or neutral groupings.
ng/~L Unit of measure for weight per volume calculated as nanograms per milliliter. The ng/mL unit of measure is equivalent to
the µ/L unit of measure.
Optical observation Optical observation refers to procedure results that are interpreted visually with or without instrumentation assistance.
Opiate Medicinal category of narcotic alkaloid drugs that are natural products in the opium poppy plant Papaver somniferum. This
immunoassay class of drugs typically includes detection of codeine, dihydrocodeine, hydrocodone, hydromorphone, and
morphine.
Opioids A category of medicinal synthetic or semi-synthetic narcotic alkaloid opioid receptor stimulating drugs including
butorphanol, desomorphine, dextromethorphan. dextrorphan. levorphanol, meperidine. naloxone. naltrexone.
normeperidine, and pentazocine.
Presumptive Drug test results that indicate possible. but not definitive. presence of drugs and/or drug metabolites
OTOF Acronym for quadrupole-time of flight mass spectrometry. OTOF is a hybrid mass spectrometry identification technique that
combines ion velocity with tandem quadrupole mass spectrometry (MS or MS/MS) to determine the mass-to-charge ratio.
0 0 0 0 0 0 0
0 0 0
0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 00 0 00 0
0 0 0 0 0 0
0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0
0 0 0 0
600 *=Telemedicine '4 =Audio-only +=Add-on code ,¥'= FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 0 0 =See pxix for details
I

Drug Testing
Definition
Term/Acronym
RCS A category of synthetic marijuana drugs that are analogs of JHW compounds. See JWH.
RIA Acronym for radio-immuno-assay. Radioimmunoassay is a competitive antibody binding procedure that utilizes radioactive-
labeled antigens (drugs) to compete for antigens (drugs) contained in the patient sample. The measure of radioactivity is
inversely proportional to concentration of drug(s) detected.
Stereoisomers Isomeric molecules that have the same molecular formula and sequence of bonded atoms (constitution), but that differ only
in the three-dimensional orientations of their atoms in space
Substance A substance is a drug that does not have an established therapeutic use as distinguished from other analytes listed in the
Chemistry section (82009-84999).
TOM Acronym for therapeutic drug monitoring
THC Acronym for marijuana active drug ingredient tetrahydrocannabinol
Therapeutic Drug
Analysis of blood (serum, plasma) drug concentration to monitor clinical response to therapy
Monitoring
Time of flight Time of flight is a mass spectrometry technique that utilizes ion velocity to determine the mass-to-charge ratio
TLC Acronym for thin layer chromatography
TOF Acronym for time of flight
µ/L Unit of measure for mass per volume calculated as micrograms per liter. The µ/L unit of measure is equivalent to the
ng/ml unit of measure.
(continued from page 598)

Presumptive methods include, but are not limited to, Presumptive Drug Class Screening
immunoassays (IA, EIA, ELISA, RIA, EMIT, FPIA, etc),
enzymatic methods (alcohol dehydrogenase, etc), Drugs or classes of drugs may be commonly assayed first
chromatographic methods without mass spectrometry by a presumptive screening method followed by a
(TLC, HPLC, GC, etc), or mass spectrometry without definitive drug identification method. The methodology
adequate drug resolution by chromatography (MS-TOF, is considered when coding presumptive procedures. Each
DART, DESI, LDTD, MALO!). LC-MS, LCMS/MS, or code (80305 , 80306, 80307) represents all drugs and
mass spectrometry without adequate drug resolution by drug classes performed by the respective methodology per
chromatography may also be used for presumptive testing date of service. Each code also includes all sample
if the chromatographic phase is not adequate to identify validation procedures performed. Examples of sample
individual drugs and distinguish between structural validation procedures may include, but are not limited to,
isomers or isobaric compounds. All drug class pH, specific gravity, and nitrite. The codes (80305,
immunoassays are considered presumptive, whether 80306, 80307) represent three different method
qualitative, semi-quantitative, or quantitative. Methods categories:
that cannot distinguish between structural isomers (such 1. Code 80305 is used to report procedures in which the
as morphine and hydromorphone or methamphetamine results are read by direct optical observation. The
and phentermine) are also considered presumptive. results are visually read. Examples of these procedures
are dipsticks, cups, cards, and cartridges. Report
Definitive drug identification methods are able to
80305 once, irrespective of the number of direct
identify individual drugs and distinguish between
observation c!rug class procedures performed or results
structural isomers but not necessarily stereoisomers.
on any date of service.
Definitive methods include, but are not limited to, gas
chromatography with mass spectrometry (any type, single
or tandem) and liquid chromatography mass
spectrometry (any type, single or tandem) and excludes 0 0 0 0 0
0 0 0 0 0 0
immunoassays (eg, IA, EIA, ELISA, RIA, EMIT, FPIA), • 0 0
0 0 0 0
0 0
0 0 0 0
0 0 0
and enzymatic methods (eg, alcohol dehydrogenase). 0 0
0
0
0 0 0 0
0
0 0 0 0 0
0 0 0 0 0
For chromatography, each combination of stationary and
mobile phase is to be counted as one procedure.
0
0 0
• 0 0
0
0
0
0
0 0 • 0
0
0
0
0
0
0
0
0
0
0 0
0
0
00
0
0
0 0
0
0
00
0
0
0
0
0
0
0
,. 0
0
00
0 0 0 0 0 0 0
0 0
0 0 0 0
0
•=Revised code • = New code • ~=Contains new or revised text H=Ouplicate PlA test t+=Category IPLA American Medical Association 601
80305-80326 Pathology and Laboratory I Drug Assay CPT 2023
2. Code 80306 is used to report procedures when an Use 80320-80377 to report definitive drug class
instrument is used to assist in determining the result procedures. Definitive testing may be qualitative,
of a direct optical observation methodology. Examples quantitative, or a combination of qualitative and
of these procedures are dipsticks, cards, and cartridges quantitative for the same patient on the same date of
inserted into an instrument that determines the final service.
result of an optical observation methodology. Report
The Definitive Drug Classes Listing provides the drug
80306 once, irrespective of the number of drug class classes, their associated CPT codes, and the drugs
procedures or results on any date of service.
included in each class. Each category of a drug class,
3. Code 80307 is used to report any number of devices including metabolite(s) if performed (except
or procedures by instrumented chemistry analyzers. stereoisomers), is reported once per date of service.
There are many different instrumented methodologies Metabolites not listed in the table may be reported using
available to perform presumptive drug assays. the code for the parent drug. Drug class metabolite(s) is
Examples include immunoassay (eg, EIA, ELISA, not reported separately unless the metabolite(s) is listed as
EMIT, FPIA, IA, KIMS, RIA), chromatography (eg, a separate category in Definitive Drug Classes Listing
GC, HPLC), and mass spectrometry, either with or (eg, heroin metabolite).
without chromatography (eg, DART, DESI, GC-MS,
Drug classes may contain one or more codes based on the
GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI,
number of analytes. For example, an analysis in which
TOF). Some of these methodologies may be used for
five or more amphetamines and/or amphetamine
definitive drug testing also, but, for the purpose of
metabolites would be reported with 80326. The code is
presumptive drug testing, the presumptive method is
based on the number of reported analytes and not the
insufficient to provide definitive drug identification.
capacity of the analysis.
Report 80307 once, irrespective of the number of
drug class procedures or results on any date of service. Definitive drug procedures that are not specified in
80320-80373 should be reported using the unlisted
# 80305 Drug testjs). presumptive. any number of drug classes,
definitive procedure codes 80375, 80376, 80377, unless
any number of devices or procedures; capable of being
read by direct optical observation only leg, utilizing the specific analyte is listed in the Therapeutic Drug
immunoassay [eg. dipsticks. cups. cards. or cartridges]). Assays(80143-80203) or Chemistry (82009-84830)
includes sample validation when performed. per date of sections.
service See the Definitive Drug Classes Listing table for a
0 CPT Changes: An Insider's View2017, 2018 listing of the more common analytes within each drug
0 CPTAssistantMar17:6. Jul 18:15 class.
# 80306 read by instrument assisted direct optical observation # 80320 Alcohols
leg. utilizing immunoassay [eg, dipsticks, cups, cards. 0 CPT Changes: An Insider's View 2015
or cartridges]). includes sample validation when 0 CPT Assistant Apr 15:3
performed, per date of service
0 CPT Changes: An Insider's View 2017. 2018 (For alcohol [ethanol] by immunoassay and enzymatic
0 CPTAssistantMar 17:6
methods. use 82077)
# 80307 by instrument chemistry analyzers (eg, utilizing # 80321 Alcohol biomarkers; 1 or 2

immunoassay [eg, EIA. ELISA. EMIT, FPIA, IA. KIMS. 0 CPT Changes: An Insider's View2015
RIA]). chromatography leg, GC. HPLC). and mass # 80322 3 or more
spectrometry either with or without chromatography, 0 CPT Changes: An Insider's View 2015
(eg, DART, DESI. GC-MS. GC-MS/MS. LC-MS, LC-MS/
MS. LDTD. MALDI, TOF) includes sample validation # 80323 Alkaloids. not otherwise specified
when performed. per date of service 0 CPT Changes: An Insider's View 2015
0 CPT Changes: An Insider's View 2017, 2018 # 80324 Amphetamines; 1 or 2
O cPT AssistantMar 17:6 0 CPT Changes: An Insider's View 2015
# 80325 3 or 4
Definitive Drug Testing 0 CPT Changes: An Insider's View 2015
Definitive drug identification methods are able to
# 80326 5 or more
identify individual drugs and distinguish between
structural isomers but not necessarily stereoisomers.
0 CPT Changes: An Insider's View 2015
Definitive methods include, but are not limited to, gas 0

0 0 0 0
0
0
0
0 0 0 0 0
0 0 0 0
chromatography with mass spectrometry (any type, single 0
0 0
0 0
0 0
0 0 0
0 0 0 0 0 0 0 0 0
or tandem) and liquid chromatography mass 0 0 0
0 0 0 0 0 0 0 0 0
0
spectrometry {any type, single or tandem) and exclude 0
0
0
0
immunoassays (eg, IA, EIA, ELISA, RIA, EMIT, FPIA)

0 0 0
0 0
0 0 0 0 0
0 0 ° 0 0
00 0 00 0 0
0 0 0 0 0 0 0
and enzymatic methods (eg, alcohol dehydrogenase). 0
0
0 0
0
0
0
0 0 0 0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0
602 *= Telemedicine '4 =Audio-only +=Add-on code .K =FDA approval pending #=Resequenced code \S) =Modifier 51 exempt =~=See p xix for details
CPT 2023
Pathology and Laboratory I Drug Assay 80327-80363
# 80327 Anabolic steroids; 1 or 2
# 80344 7 or more
0 CPT Assistant Apr 15:5
# 80345 Barbiturates
# 80328 3 or more
0 CPT Assistant Apr 15:5 # 80346 Benzodiazepines; 1-12

(For dihydrotestosterone analysis for endogenous
hormone levels or therapeutic monitoring, use 82642) # 80347 13 or more

# 80329 Analgesics, non-opioid; 1 or 2 0 CPT Changes: An Insider's View 2015
0 CPT Changes: An Insider's View2015 # 80348 Buprenorphine

0 CPT Assistant Jan 21 :8 0 CPT Changes: An Insider's View 2015
# 80330 3-5 # 80349 Cannabinoids, natural
0 CPTChanges: An Insider's View2015 0 CPT Changes: An Insider's View2015
0 CPT Assistant Jan 21 :8 # 80350 Cannabinoids, synthetic; 1-3
# 80331 6 or more 0 CPT Changes: An Insider's View 2015
0 CPTChanges: An Insider's View2015 # 80351 4-6
0 CPT Assistant Jan 21 :8
0 CPT Changes: An Insider's View2015
(For acetaminophen by immunoassay or enzymatic # 80352 7 or more
methods, use 80143)
(For salicylate by immunoassay or enzymatic methods, # 80353 Cocaine
use 80179)
# 80332 Antidepressants, serotonergic class; 1 or 2 # 80354 Fentanyl
# 80333 3-5
# R0355 Gabapentin, non-blood
# 80334 6 or more 0 CPT Assistant Apr 15:3
(For therapeutic drug assay, use 80171)
# 80335 Antidepressants, tricyclic and other cyclicals; 1 or 2 # 80356 Heroin metabolite
0
# 80336
CPT Changes: An Insider's View 2015
o-CPT Changes: An Insider's View 2015
3-5
# 80357 Ketamine and norketamine
0 CPT Changes_· An Insider's View 2015
# 80337 6 or more
# 80358 Methadone
# 80338 Antidepressants, not otherwise specified # 80359 Methylenedioxyamphetamines (MDA. MDEA, MOMA)
# 80339 Antiepileptics, not otherwise specified; 1-3
# 80360 Methylphenidate
# 80340 4-6
!I 80361 Opiates, 1 or more
# 80341 7 or more
# 80362 Opioids and opiate analogs; 1 or 2
(To report definitive drug testing for antihistamines, see # 80363 3 or 4
80375,80376,80377)
(To report therapeutic drug assay for carbamazepine, see
80156,80157,80161)
0 0 0
0 0
# 80342 Antipsychotics, not otherwise specified; 1-3 0
0
0
0
0
0 0
0
0 0
0 0
0
0 0 0 0
0
0 0
0
0 0 0
0
0
0 0
0
0
0 0 0
0
0
0 0
0 0 0
# 80343 4-6 0 0
0 0 0
0
0
0
0
0 0 0
0
0
0
0 0 0 0 0 0 0
0 00
0 0
0 00
0 0
0 0
0 0 0 0 0
0 0 0 0 0 00
0 0 0 0 0
0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0
A=Revised code • = New code ~ <Ill =Contains new or revised text *=Duplicate PLA test ti =Category IPLA
80364-80377 Pathology and Laboratory I Drug Assay CPT 2023
# 80364 5 or more # 80376 4-6

0 CPT Changes: An Insider's View2015 0 CPT Changes: An Insider's View2015
# 80365 Oxycodone
0 CPT Changes: An Insider's View 2015 # 80377 7 or more

# 83992 Phencyclidine (PCP)

(To report definitive drug testing for antihistamines, see

(Phenobarbital, use 80345)
80375,80376,803771
# 80366 Pregabalin
For Example:
To report amphetamine and methamphetamine using any
# 80367 Propoxyphene ,
number of definitive procedures, report 80324 once per
facility per date of service.
# 80368 Sedative hypnotics (non-benzodiazepines)
To report codeine, hydrocodone, hydromorphone,
morphine using any number of definitive procedures,
# 80369 Skeletal muscle relaxants; 1 or 2 report 80361 once per facility per date of service.
To report codeine, hydrocodone, hydromorphone,
# 80370 3 or more morphine, oxycodone, oxymorphone, naloxone,
0 CPT Changes: An Insider's View2015 naltrexone performed using any number of definitive
procedures report 80361X1, 80362 X l, and 80365 X 1
# 80371 Stimulants, synthetic
per facility per date of service.
To report benzoylecgonine, cocaine, carboxy-THC,
# 80372 Tapentadol
meperidine, normeperidine using any number of
definitive procedures, report 80349 X l, 80353 X l, and
# 80373 Tramadol 80362 X I per facility per date of service.
0 CPT Changes.· An Insider's View 2015
# 80374 Stereoisomer (enantiomer) analysis, single drug class Definitive Drug Classes Listing
0 CPT Changes: An Insider's View 2015 Drugs and metabolites included in each definitive drug
(Use 80374 in conjunction with an index drug analysis, class are listed in the Definitive Drug Classes Listing
when performed) table. This is not a comprehensive list. FDA classification
of drugs not listed should be used where possible within
# 80375 Drug(sl or substance(sl, definitive, qualitative or the defined drug classes. Any metabolites that are not
quantitative, not otherwise specified; 1-3 listed should be categorized with the parent drug. Drugs
and metabolites not listed may be reported using codes
from the Therapeutic Drug Assay (80143-80299) or
Chemistry (82009-84999) sections.
DEFINITIVE DRUG CLASSES LISTING
Codes Classes Drugs

80320 Alcohol(sl Acetone, ethanol. ethchlorvynol, ethylene glycol, isopropanol. isopropyl alcohol, methanol
Ethanol conjugates (ethyl glucuronide [ETGJ, ethyl sulfate [ETS]. fatty acid ethyl esters,
80321-80322 Alcohol Biomarkers
phosphatidylethanol)
80323 Alkaloids, not otherwise 7-Hydroxymitragynine, atropine, cotinine, lysergic acid diethylamide (LSDI. mescaline,
specified mitragynine, nicotine, psilocin, psilocybin, scopolamine
80324-80326 Amphetamines Amphetamine, ephedrine, lisdexamphetamine, methamphetamine, phentermine,
phenylpropanolamine, pseudoephedrine
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0 0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0
604 *= Telemedicine '4 =Audio-only + = Add-on code ~ = FDA approval pending #=Resequenced code IS>= Modifier 51 exempt 000 =See p xix for details
Codes Classes Drugs
80327-80328 Anabolic steroids 1-Androstenediol, 1-androstenedione, 1-testosterone, 4-hydroxy-testosterone, 6-oxo,

19-norandrostenedione, androstenedione, androstanolone, bolandiol. bolasterone.
boldenone, boldione, calusterone, clostebol, danazol. dehydrochlormethyltestosterone,
dihydrotestosterone, drostanolone, epiandrosterone, epitestosterone, fluoxymesterone.
furazabol, mestanolone, mesterolone, methandienone, methandriol, methenolone,
methydienolone, methyl-1-testosterone, methylnortestosterone. methyltestosterone,
mibolerone, nandrolone, norbolethone, norclostebol, norethandrolone, norethindrone.
oxabolone, oxandrolone, oxymesterone, oxymetholone. stanozolol, stenbolone. tibolone.
trenbolone, zeranol
80329-80331 Analgesics. non-opioid Acetaminophen. diclofenac ibuprofen, ketoprofen, naproxen, oxaprozin, salicylate
80332-80334 Antidepressants, serotonergic Citalopram, duloxetine. escitalopram. fluoxetine, fluvoxamine. paroxetine, sertraline
class
80335-80337 Antidepressants, Tricyclic and Amitriptyline, amoxapine, clomipramine. demexiptiline, desipramine. doxepin, imipramine.
other cyclicals maprotiline. mirtazpine, nortriptyline. protriptyline
80338 Antidepressants. not Bupropion, desyenlafaxine, isocarboxazid, nefazodone. phenelzine, selegiline.
otherwise specified tranylcypromine, trazodone. venlafaxine
80339-80341 Antiepileptics not otherwise Carbamazepine. clobazam, diamethadione, ethosuximide, ezogabine, lamotrigine.
specified levetiracetam, methsuximide. oxcarbazepine, phenytoin, primidone. rufinamide, tiagabine,
topiramate, trimethadione. valproic acid, zonisamide
80342-80344 Antipsychotics not otherwise Aripiprazole. chlorpromazine, clozapine. fluphenazine, haloperidol, loxapine, mesoridazine,
specified molindone. olanzapine. paliperidone, perphenazine, phenothiazine, pimozide,
prochlorperazine. quetiapine, risperidone, trifluoperazine, thiothixene, thoridazine.
ziprasidone
80345 Barbiturates Amobarbital, aprobarbital, butalbital. cyclobarbital, mephobarbital, pentobarbital.
phenobarbital, secobarbital. talbutal, thiopental
80346,80347 Benzodiazepines Alprazolam. chlordiazepoxide, clonazepam, clorazepate, diazepam. estazolam,
flunitrazepam, flurazepam, halazepam, lorazepam. midazo1am, nitrazepam. nordazepam,
oxazepam, prazepam. quazepam, ternazepam
80348 Buprenorphine Buprenorphine
80349 Cannabinoids. natural Marijuana, dronabinol carboxy-THC
80350-80352 Cannabinoids, synthetic CP-47.497. CP497 C8-homolog, JWH-018 and AM678. JWH-073, JWH-019, JWH-200,
JWH-210. JWH-250, JWH-081, JWH-122, HWH-398, AM-2201, AM-694, SR-19 and
RCS-4, SR-18 and RCS-8. JWH-203, UR-144, XLR-11, MAM-2201, AKB-48
80353 Cocaine Benzoylecgonine, cocaethylene, cocaine, ecgonine methyl ester, norcocaine
80354 Fentanyls Acetylfentanyl. alfentanil, fentanyl, remifentanil, sufentanil
80355 Gabapentin, non-blood Gabapentin
80356 Heroin metabolite 6-acetylmorphine. acetylcodeine, diacetylmorphine
80368 Hypnotics. sedative (non- See Sedative Hypnotics
benzodiazepines)
80357 Ketamine and Norketamine Ketamine, norketamine
0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
0 0
0
0
0 0 0
0 0
0
0
0
• 0
0 0
0 0 0 0 0 0 0
o. 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 . 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0
.&=Revised code •=New code ~ <1111 =Contains new or revised text *=Duplicate PLA test U=Category IPLA American Medical Association 605
80143--80162 Pathology and Laboratory I Therapeutic Drug Assays CPT 2023
Codes Classes Drugs

80358 Methadone Methadone and EDDP
80359 Methylenedioxyamphetamines MDA, MDEA. MOMA
80360 Methyl phenidate Methylphenidate, ritalinic acid
80357 Norketamine See Ketamine
80368 Non-Benzodiazepines See Hypnotics, sedative
80361 Opiates Codeine, dihydrocodeine. hydrocodone, hydromorphone, morphine
80362-80364 Opioids and opiate analogs Butorphanol, desomorphine. dextromethorphan. dextrorphan, levorphanol. meperidine,
naloxone. naltrexone, normeperidine. pentazocine
80365 Oxycodone Oxycodone. oxymorphone
83992 Phencyclidine Phencyclidine
80366 Pregabalin Pregabalin
80367 Propoxyphene Norpropoxyphene, propoxyphene
80368 Sedative Hypnotics (non- Eszopiclone, zaleplon, zolpidem
benzodiazepines)
80369, 80370 Skeletal muscle relaxants Baclofen. carisoprodol , cyclobenzaprine, meprobamate. metaxalone, methocarbamol,
orphenadrine, tizanidide
80371 Stimulants, synthetic 2C-B, 2C-E, 2C-I, 2C-H, 3TFMPP, 4-methylethcathinone, alpha-PVP. benzylpiperazine,
bromodragonfly, cathinone, m-CPP. MDPBP. MDPPP. MDPV, mephedrone. methcathinone,
methylone, phenethylamines. salvinorin, tryptamines
80372 Tapentadol Tapentadol
80373 Tramadol Tramadol
80156 Carbamazepine; total

Therapeutic Drug Assays 0 C?T Changes: An Insider's View 2001
Therapeutic drug assays are performed to monitor levels 0 CPTAssistantDct10:7, Mar 11:10, Jan 21 :8
of a known, prescribed, or over-the-counter medication. 80157 free
The material for examination is whole blood, serum, 0 CPT Changes: An Insider's View2001
plasma, or cerebrospinal fluid. Examination is 0 CPT AssistantOct 10:7. Mar 11 :10, Jan 21:8
quantitative. Coding is by parent drug; measured # 80161 -10.11-epoxide
metabolites of the drug are included in the code, if 0 CPT Changes: An Insider's View 2021
performed. 0 CPT Assistant Jan 21 :8
80143 Acetaminophen 80158 Cyclosporine
0 CPT Changes: An Insider's View2021 0 CPTAssistantOct10:7. Mar 11:10
80159 Clozapine
(For definitive drug testing for acetaminophen. see 0 CPT Changes: An Insider's View 2014
80329,80330, 80331)
80161 Code is out of numerical sequence. See 80156-80159
80145 Adalimumab
80162 Digoxin; total
80150 Arnikacin 0 CPT Assistant Oct 10:7. Mar 11 :10, Apr 15:3
0 CPT Assistant Aug 05:9, Oct 10:7, Dec 10:7, Mar 11 :10, Apr 15:3
0 0 0 0 0
0 0 0 0 0 0
80151 Amiodarone 0 0
0
0
0
0
0 0
0
0
0
0 •
0
0 0
0
0 0 0
0
0 0
0 0 0 0 q •

0
0
0
0
0 0 0
0
0 0
0
0
0 0
0
0
0 0
80155 Caffeine
0 0 0 0 0 0 0 0 0 0
0 0 ° 0 0 0
0 00 00 0 0
0 0 0 0 0 0 0
0 0 0
0
0
0
0 0 0 0 0 0
0
0
0
0 0 0
0
0
0 0 0
0 0 0
0
606 *= Telemedicine i4 =Audio-only +=Add-on code ~=FDA approval pending #=Resequenced code \Sl= Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory I Therapeutic Drug Assays 80163-80199
80163 free # 80204 Methotrexate

0 CPT Changes: An Insider's View 2015 0 CPT Changes: An Insider's View2021
0 CPT Assistant Apr 15:3 0 CPT Assistant Jan 21 :8
80164 Code is out of numerical sequence. See 80200-80203 80180 Mycophenolate (mycophenolic acid)

80183 Oxcarbazepine
80168 Ethosuximide
@ CPT Assistant Oct 10:7. Mar 11 :10
80184 Phenobarbital
80169 Everolimus
0 CPT Assistant Oct 10:7, Mar 11:10
Felbamate
80185 Phenytoin; total
# 80167
@ CPT Changes: An Insider's View2021
0 CPT AssistantOct 10:7. Mar 11:10
0 CPT Assistant Jan 21 :8 80186 free

0 CPTAssistantOct10:7. Mar 11:10
# 80181 Flecainide
0 CPT Changes: An Insider's View 2021 80187 Posaconazole
0 CPT Assistant Jan 21 :8 0 CPT Changes: An Insider's View 2020
# 80171 Gabapentin. whole blood, serum. or plasma 80188 Primidone

@ CPTChanges: An Insider's View2015, 2014 0 CPT Assistant Oct 10:7. Mar 11: 10
80170 Gentamicin
80190 Procainamide;
@ CPT Assistant Oct 10:7, Mar 11 :10
80192 with metabolites (eg, n-acetyl procainamide)
80173 Haloperidol 0 CPT AssistantOct 10:7. Mar 11 :10
@ CPT Assistant Oct 10:7. Mar 11 :10
00194 Ouinidine
# 80220 Hydroxychloroquine
# 80210 Rutinamide
# 80230 lnfliximab
# 80189 ltraconazole
# 80179 Salicylate
# 80235 Lacosamide
(For definitive drug testing for salicylate, see 80329.
80330, 80331)
80175 Lamotrigine
80195 Sirolimus
80176 Code is out of numerical sequence. See 80170-80183 0 CPT Assistant Mar 06:6. Oct 10:7. Mar 11 :10
# 80193 Letlunomide 80197 Tacrolimus

0 CPT Changes: An Insider's View 2021 0 CPT Assistant Oct 10:7. Mar 11 :10
80198 Theophylline
80177 Levetiracetam 0 CPT Assistant Oct 10:7. Mar 11 :10
80199 Tiagabine
# 80176 Lidocaine 0 CPT Changes: An Insider's View 2014
0 CPT AssistantOct 10:7, Mar 11 :10
0 0 0 0
0 0 0 0 0 0 0
80178 Lithium 6 0 0
0
0
0 0 0
0
0
0
0 0
0 0 0 0 0
0 CPTAssistantOct10:7, Mar 11 :10 0 0 0
0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
80179 Code is out of numerical sequence. See 80192-80197 0 0 0
0
0 0
0
0 0 0
0
0 0
0
0 0 0
0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0 D
0 0 0 0 0 D 0 0 0 0
D 0 0 0 0 0 0 0
0 0
0 0 0 0 c
A=Revisedaxle •=New code Ill> ~ = Contains new or revised text *=Duplicate PlA test t+=Category I PLA American Medical Association 607
80200-80299 Pathology and Laboratory I Therapeutic Drug Assays CPT 2023
80200 Tobramycin 80327 Code is out of numerical sequence. See Definitive Drug
0 CPT Assistant Oct 10:7, Mar 11:10 Testing subsection
80201 Topiramate 80328 Code is out of numerical sequence. See Definitive Drug
0 CPT Assistant Nov 97:28, Oct 10:7. Mar 11:10 Testing subsection
# 80164 Valproic acid (dipropylacetic acid); total 80329 Code is out of numerical sequence. See Definitive Drug
0 CPT Changes: An Insider's View2015 · Testing subsection
0 CPT Assistant Oct 10:7, Mar 11:10. Apr 15:3
80330 Code is out of numerical sequence. See Definitive Drug
# 80165 free Testing subsection
0 CPT Changes: An Insider's View 2015 80331 Code is out of numerical sequence. See Definitive Drug
0 CPT Assistant Apr 15:3 Testing subsection
80202 Vancomycin 80332 Code is out of numerical sequence. See Definitive Drug
0 CPTAssistantOct10:7. Mar 11:10. Apr 15:3 Testing subsection
# 80280 Vedolizumab 80333 Code is out of numerical sequence. See Definitive Drug
0 CPT Changes: An Insider's View 2020 Testing subsection
# 80285 Voriconazole 80334 Code is out of numerical sequence. See Definitive Drug
0 CPT Changes: An Insider's View2020 Testing subsection
80203 Zonisamide 80335 Code is out of numerical sequence. See Definitive Drug
0 CPT Changes: An Insider's View 2014 Testing subsection
80204 Code is out of numerical sequence. See 80170-80183 80336 Code is out of numerical sequence. See Definitive Drug
Testing subsection
80337 .Code is out of numerical sequence. See Definitive Drug
Testing subsection
80235 Code is out of numerical sequence. See 80170-80183 Testing subsection
80280 Code is out of numerical sequence. See 80201-80299 80339 Code is out of numerical sequence. See Definitive Drug
Testing subsection
80299 Ouantitation of therapeutic drug, not elsewhere specified
Testing subsection
0 CPT Assistant Mar 00:3, Oct 04:14, Aug 05:9. Oct 10:7. Dec 10:3, 80341 Code is out of numerical sequence. See Definitive Drug
Mar 11:10, Apr 15:3 Testing subsection
80305 Code is out of numerical sequence. See Presumptive 80342 Code is out of numerical sequence. See Definitive Drug
Drug Class Screening subsection Testing subsection
80320 Code is out of numerical sequence. See Definitive Drug 80345 Code is out of numerical sequence. See Definitive Drug
Testing subsection Testing subsection
il0323 Code is out of numerical sequence. See Definitive Drug 80348 Code is out of numerical sequence. See Definitive Drug
80324 Code is out of numerical sequence. See Definitive Drug 0
0
0 0 0
0
0 0
0
0
0
0 0
Testing subsection 0 0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0
0 0 0
0
0
0 0 0
0
0 0 0 0
Testing subsection 0 0 0
0 0
0
0 0 0
0
0 0
0
0 0
0 0
00 0 00 0 0
80326 Code is out of numerical sequence. See Detinitive Drug 0
0 0 0 0
0
0 0 0
0
0
0 0 0 0
0
0
0 0
0 0
0
0
0
0
0
0 0 0 0
0
608 *= Telemedicine ~ =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code 19 =Modifier 51 exempt 0 0 0 = See pxix for details
CPT 2023 Pathology and Laboratory I Evocative/Suppression Testing 80400----80408

Testing subsection Evocative/Suppression Testing
80354 Code is out of numerical sequence. See Definitive Drug The following test panels involve the administration of
Testing subsection evocative or suppressive agents and the baseline and
80355 Code is out of numerical sequence. See Definitive Drug subsequent measurement of their effects on chemical
Testing subsection constituents. These codes are to be used for the reporting
of the laboratory component of the overall testing
80356 Code is out of numerical sequence. See Definitive Drug protocol. For the administration of the evocative or
Testing subsection suppressive agents, see Hydration, Therapeutic,
80357 Code is out of numerical sequence. See Definitive Drug Prophylactic, Diagnostic Injections and Infusions, and
Testing subsection Chemotherapy and Other Highly Complex Drug or
Highly Complex Biologic Agent Administration
80358 Code is out of numerical sequence. See Definitive Drug (eg,96365,96366,96367,96368,96372,96374,
Testing subsection 96375, 96376). In the code descriptors where reference is
80359 Code is out of numerical sequence. See Definitive Drug made to a particular analyte (eg, Cortisol: 82533 x 2) the
Testing subsection "x 2" refers to the number of times the test for that
particular analyte is performed.
Testing subsection 80400 ACTH stimulation panel; for adrenal insufficiency
80361 Code is out of numerical sequence. See Definitive Drug This panel must include the following:
Testing subsection Cortisol (82533 x 2)
80362 Code is out of numerical sequence. See Definitive Drug 0 CPT Assistant Summer 94:1, Fall 94:10, Aug 05:9
Testing subsection 80402 for 21 hydroxylase deficiency

80363 Code is out of numerical sequence. See Definitive Drug This panel must include the following:
Testing subsection Cortisol (82533 x 2)
80364 Code is out of numerical sequence. See Definitive Drug 17 hydroxyprogesterone (83498 x 2)
Testing subsection 0 CPT Assistant Summer 94:1, Fall 94:10
80365 Code is out of numerical sequence. See Definitive Drug 80406 for 3 beta-hydroxydehydrogenase deficiency
Testing subsection
Cortisol (82533 x 2)
Testing subsection
17 hydroxypregnenolone (84143 x 2)
Testing subsection
0 CPT AssistantSummer94:1, Fall 94:10
80408 Aldosterone suppression evaluation panel (eg, saline

80368 Code is out of numerical sequence. See Definitive Drug infusion)
Testing subsection
Testing subsection Aldosterone (82088 x 2)
80370 Code is out of numerical sequence. See Definitive Drug Renin (84244 x 2)
Testing subsection 0 CPT Assistant Summer 94:1, Fall 94:10
0 0
80371 Code is out of numerical sequence. See Definitive Drug 0 0 0 0
0 0 0 0
0
0 0 0 0 0 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0 0
0 0 0 0 0
80372 Code is out of numerical sequence. See Definitive Drug 0 • 0
0 0 0
0
0
0
0
0
0 0 0
0
0
0
0
Testing subsection 0 0 0
0 0
0 0 0 0
0 0
0 0 0 0 0
00 0 00 0 00
0 0 0
0
0
0 0 0 0
0
0 0 0 0 0 0 0 0 0
0 0 0
Testing subsection 0
0 0
0
0
0
0 0
0
0
0 0
.&=Revised code •=New code .,. <Ill =Contains new or revised text *=Duplicate PlA test t~=Category I PlA American Medical Association 609
80410--80434 Pathology and Laboratory I Evocative/Suppression Testing CPT 2023
80410 Calcitonin stimulation panel (eg, calcium, pentagastrin) 80422 Glucagon tolerance panel; for insulinoma
Calcitonin (82308 x 3) Glucose (82947 x 3)
0 CPT Assistant Summer 94:1. Fall 94:11
Insulin (83525 x 3)
80412 Corticotropic releasing hormone (CRH) stimulation panel 0 CPT Assistant Summer 94:1. Fall 94:13
This panel must include the following: 80424 for pheochromocytoma
Cortisol (82533 x 6) This panel must include the following:
Adrenocorticotropic hormone (ACTH) (82024 x 6) Catecholamines. fractionated (82384 x 2)
@ CPT Assistant Summer 94:1, Fall 94:11 0 CPT Assistant Summer 94:1, Fall 94:14
80414 Chorionic gonadotropin stimulation panel; testosterone 80426 Gonadotropin releasing hormone stimulation panel
response
Follicle stimulating hormone (FSH) (83001 x 4)
Testosterone (84403 x 2 on 3 pooled blood samples)
Luteinizing hormone (LH) (83002 x 4)
@ CPTAssistantSummer94:1, Fall 94:11
0 CPT AssistantSummer94:1. Fall 94:14
80428 Growth hormone stimulation panel (eg, arginine infusion.
80415 estradiol response
I-dopa administration)
Estradiol. total (82670 x 2 on 3 pooled blood samples)
Human growth hormone (HGH) (83003 x 41
@ CPT Changes: An Insider's View2009, 2021
0 CPT Assistant Summer 94:1. Fall 94:11 0 CPT Assistant Summer 94:1, Fall 94:14
80430 Growth hormone suppression panel (glucose
80416 Renal vein renin stimulation panel (eg, captopril)
administration)
Renin (84244 x 6)
Glucose (82947 x 3)
0 CPT Assistant Summer 94:1
Human growth hormone (HGH) (83003 x 41
80417 Peripheral vein renin stimulation panel (eg, captopril)
0 CPT Assistant Summer 94:1, Fall 94:14
80432 Insulin-induced C-peptide suppression panel
Renin (84244 x 2)
80418 Combined rapid anterior pituitary evaluation panel Insulin (83525)
C-peptide (84681 x 51
Adrenocorticotropic hormone (ACTH) (82024 x 4) Glucose (82947 x 5)
Luteinizing hormone (LHI (83002 x 4) 0 CPT AssistantSummer94:1, Fall 94:15
Follicle stimulating hormone (FSH) (83001 x 4) 80434 Insulin tolerance panel; for ACTH insufficiency
Prolactin (84146 x 4) This panel must include the following:
Human growth hormone (HGH) (83003 x 4) Cortisol (82533 x 5)
Cortisol (82533 x 4) Glucose (82947 x 5)
Thyroid stimulating hormone (TSH) (84443 x 4)
0 CPT Assistant Summer 94:1, Fall 94:15
0 CPT Assistant Summer 94:1. Fall 94:13

80420 Oexamethasone suppression panel, 48 hour
Free cortisol, urine (82530 x 2) 0 0 0 0
0 0 0 0 0 0 0
0
Cortisol (82533 x 2) 0
0
0
0
0
0 0
0
0
0
0
0
0 0 0 0
0 0 0 0 0 0 0
Volume measurement for timed collection (81050 x 2) 0
0 0 0 0 0
0 0 0 0 0 0 0
0 CPT Assistant Fall 94:13 0 0 0 0 0 0
0
0
0 0 0 0 0 0
0 00 0 00
(For single dose dexamethasone, use 82533) 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0
0
610 *=Telemedicine '4=Audio-only +=Add-oncode ~=FDAapprovalpending #=Resequenced code &=Modifier51 exempt @@@=Seepxixfordetails
CPT2023 Pathology and Laboratory I Pathology Clinical Consultations 80435--80439
80435 for growth hormone deficiency The pathology clinical consultation services (80503,
This panel must include the following: 80504, 80505, 80506) may be reported when the
following criteria have been met:
Glucose (82947 x 5)
• The pathologist renders a pathology clinical
Human growth hormone (HGH) (83003 x 5) consultation at the request of a physician or other
~ CPT Assistant Summer 94:1, Fall 94:15, Oct 21:14 qualified health care professional at the same or another
institution.
80436 Metyrapone panel
• The pathology clinical consultation request is related to
This panel must include the following: pathology and laboratory findings or other relevant
Cortisol (82533 x 2) clinical or diagnostic information (eg, radiology
findings or operative/procedural notes) that require
11 deoxycortisol (82634 x 2)
additional medical interpretive judgment.
~ CPT AssistantSummer94:1. Fall 94:16
A pathologist may also render a pathology clinical
80438 Thyrotropin releasing hormone (TRH) stimulation panel; 1
consultation when mandated by federal or state
hour
regulation (eg, Clinical Laboratory Improvement
This panel must include the following: Amendments [CUA]) .
Thyroid stimulating hormone (TSH) (84443 x 3)
~ CPT AssistantSummer94:1. Fall 94:16 Instructions for Selecting a Level of
80439 2 hour Pathology Clinical Consultation
This panel must include the following: Services
Thyroid stimulating hormone (TSH) (84443 x 4) Selection of the appropriate level of pathology clinical
~ CPT Assistant Summer 94:1. Fall 94:16
consultation services may be based on either the total
time for pathology clinical consultation services
performed on the date of consultation or the level of
Pathology .Clinical medical decision making as defined for each service.
Consultations Medical Decision Making

Physician review of pathology and laboratory findings is See Medical Decision Making table on page 612.
frequently performed in the course of providing care to
patients. Review of pathology and laboratory test results
occurs in conjunction with the provision of an evaluation
and management (E/M) service. Considered part of the
non-face-to-face time activities associated with the overall
E/M service, reviewing pathology and laboratory results is
not a separately reportable service. Communicating
results to the patient, family, or caregiver of independent
interpretation of results (not separately reported) may
constitute an E/M service.
l Pathology clinical consultation services codes (80503,
80504, 80505, 80506) describe physician pathology
clinical consultation services provided at the request of
another physician or other qualified health care
professional at the same or another facility or institution.
A pathology clinical consultation is a service, including a
written report, rendered by the pathologist in response to
a request (eg, written request, electronic request, phone
request, or face-co-face request) from a physician or other
qualified health care professional that is related to clinical
assessment, evaluation of pathology and laboratory 0 0 0 0 0
findings, or other relevant clinical or diagnostic 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
information that requires additional medical interpretive 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0 0
judgment. Reporting pathology and laboratory findings 0
0 0 0 0
0
0
0 0 0 0
0
0
0
0 0 0 0
or other relevant clinical or diagnostic information 0 0
0 0
0 0 0 0 0
0 0
0 0 0
without medical interpretive judgment is not considered 0

00
0
0 0
00
0
0 0
00
0 0 0 0 0 0
a pathology clinical consultation. 0 0
0 0
0 0
0
0 0
0 0
0 0
0
0 0
0 0
0 0 0 0
A=Revised code · • = New code .,. ~=Contains new or revised text ~Duplicate PLA test t+=Category I PLA American Medical Association 611
Pathology and Laboratory I Pathology Clinical Consultations CPT 2023
Elements of Medical Decision Making
Amount and/or Complexity of Data to Be

Level of MOM Reviewed and Analyzed
(Based on 2 out Number and *Each unique test, order, or document Risk of Complications and/or
of 3 Elements Complexity of contributes to the combination of 2 or Morbidity or Mortality of Patient
Code of MOM) Problems Addressed combination of 3 in Category 1 below. Management
80503 Low Low Limited Low risk of morbidity from
• 1 to 2 laboratory or (Must meet the requirements of at least 1of the 2 additional diagnostic testing or
pathology findings; categories) treatment
or Category 1: Tests and documents
•2 or more self-limited •Any combination of 2 from the following:
problems •Review of prior note(s) from each unique
source*;
•Review of the result(s) of each unique test*;
•Ordering or recommending additional or
follow-up testing*
or
Category 2: Assessment requiring an
independent historian(s)
(For the categories of independent interpretation of
tests and discussion of management or test
interpretation, see moderate or high)
80504 Moderate Moderate Moderate Moderate risk of morbidity from
• 3 to 4 laboratory or (Must meet the requirements of at least 1out of 3 additional diagnostic testing or
pathology findings; categories) treatment
or Category 1: Tests, documents, or independent Examples only:
• 1 or more chronic hislorian(s) Prescription drug management
illnesses with •Any combination of 3 from the following: •Decision regarding minor surgetY
exacerbation, •Review of prior note(s) from each unique with identified patient or procedure
progression, or side source*; risk factors
effects of treatment; •Review of the result(s) of each unique test*; •Decision regarding elective major
or •Ordering or recommending additional or surgery without identified patient or
• 2 or more stable follow-up testing*; procedure risk factors
chronic illnesses; •Assessment requiring an independent •Diagnosis or treatment significantly
or historian(s) limited by social determinants of
• 1 undiagnosed new or health
problem with Category 2: Independent interpretation of
uncertain prognosis; tests
or •Independent interpretation of a test performed by
• 1 acute illness with another physician/other qualified health care
systemic symptoms professional (not separately reported);
or
Category 3: Discussion of management or test
interpretation
•Discussion of management or test interpretation
with external physician/other qualified health
care professional/appropriate source (not
separately reported)
0 0 0 0 0
0 0 0 0 0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
• 0
0
0
0 0
0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0
0 0 0 0 Al 0 0 0 0
0 0 0 0
00 0 00 0
0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0
0
612 *= Telemedicine '4 =Audio-only +=Add-on code ~ = FDA approval pending #=Resequenced code ~=Modifier 51 exempt O O O =See pxix for details
CPT 2023 Pathology and Laboratory I Pathology Clinical Consultations
Elements of Medical Decision Making
Amount and/or Complexity of Data to Be

Level of MOM Reviewed and Analyzed
(Based on 2 out Number and *Each unique test, order, or document Risk of Complications and/or
of 3 Elements Complexity of contributes to the combination of 2 or Morbidity or Mortality of Patient
Code of MOM) Problems Addressed combination of 3 in Category 1 below. Management
80505 H,igh High Extensive High risk of morbidity from
• 5 or more laboratory (Must meet the requirements of at least 2 out of 3 additional diagnostic testing or
or pathology categories) treatment
findings; Category 1: Tests, documents, or independent Examples only:
or historian(s) •Drug therapy requiring intensive
• 1 or more chronic •Any combination of 3 from the following: monitoring for toxicity
illnesses with •Review of prior note(s) from each unique •Decision regarding elective major
severe exacerbation, source*; surgery with identified patient or
progression, or side •Review of the result(s) of each unique test*; procedure risk factors
effects of treatment; •Ordering or recommending additional or •Decision regarding emergency major
or follow-up testing*; surgery
• 1 acute or chronic •Assessment requiring an independent •Decision regarding hospitalization
illness or injury that historian(s)
poses a threat to life or
or bodily function Category 2: Independent interpretation of
tests
•Independent interpretation of a test performed by
another physician/other qualified health care
professional (not separately reported);
or
•Category 3: Discussion of management or
test interpretation
Discussion of management or test interpretation
with external physician/other qualified health
care professional/appropriate source (not
separately reported)
Time • Review of all relevant past and current laboratory,

pathology, and clinical findings
Time alone may be used to select the appropriate code
level for the pathology clinical consultation services codes • Arriving at a tentative conclusion/differential diagnosis
(ie, 80503, 80504, 80505). When time is used to select • Comparing against previous study reports, including
the appropriate level for pathology clinical consultation radiographic reports, images as applicable, and results
codes, time is defined by the service descriptions. When of other clinical testing
prolonged service time occurs, add-on code 80506 may
• Ordering or recommending additional or follow-up
be reported. The appropriate time should be documented
testing
in the medical record when it is used as the basis for code
selection. • Referring and communicating with other health care
professionals (not separately reported)
Total time on the date ofthe consultation (pathology
clinical consultation services): For coding purposes, • Counseling and educating the clinician or other
time for these services is the total time on the date of the qualified health care professional
consultation. It includes 'time personally spent by the • Documenting the clinical consultation report in the
consultant on the day of the consultation (includes time electronic or other health record
in activities that require the consultant and does not
(80500, 80502 have been deleted. To report a clinical
include time in activities normally performed by clinical
pathology consultation, limited or comprehensive, see
staff).
80503,80504,80505,80506)
Consultant time includes the following activities, when 0
0
0
0
0
0
0
performed: 0 0
0
0
0
0
0
0
0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
• Review of available medical history, including 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
presenting complaint, signs and symptoms, personal 0 0 0 0 0
0
0 0 0 0 0
0
0 0 0
0 0 0 0
and family history 0
00 0 0
00 0 0
00
0 0 0 0 0 0
0 0
• Review of test results 0
0 0
0
0
0
0 0
0
0 0
0
0
0
0
0
0
0 0
0 0 0 0
A= Revised code • = New code .. •=Contains new or revised text *=Duplicate PLA test ti= Category IPLA American Medical Association 613
80503---a1099 Pathology and Laboratory I Molecular Pathology CPT 2023
80503 Pathology clinical consultation; for a clinical problem, 81005 Urinalysis; qualitative or semiquantitative. except
with limited review of patient's history and medical immunoassays
records and straightforward medical decision making 0 CPT Assistant Winter 90:4, Winter 91 :10. Fall 93:25
When using time for code selection, 5-20 minutes of total (For non-immunoassay reagent strip urinalysis, see
time is spent on the date Of the consultation. 81000, 81002)
(For immunoassay. qualitative or semiquantitative. use
0 CPT Assistant Feb 22:3, Mar 22:13
83518)
""(For consultations involving the examination and
(For microalbumin, see 82043, 82044)
evaluation of the patient, see evaluation and
management services)<llll 81007 bacteriuria screen, except by culture or dipstick
80504 for a moderately complex clinical problem. with
review of patient's history and medical records and (For culture, see 87086-87088)
moderate level of medical decision making
(For dipstick. use 81000 or 81002)
When using time for code selection. 21-40 minutes of
81015 microscopic only
total time is spent on-the date of the consultation.
0 CPTAssistantNov17:11
0 CPT Assistant Feb 22:3, Mar 22:13 (For sperm evaluation for retrograde ejaculation. use
89331)
80505 for a highly complex clinical problem. with
comprehensive review of patient's history and 81020 2 or 3 glass test
medical records and high level of medical decision 0 CPT Assistant Winter 90:4. Winter 91 :10
making
81025 Urine pregnancy test, by visual color comparison methods
When using time for code selection, 41-60 minutes of 0 CPT Assistant Mar 98:3
total time is spent on the date of the consultation.
81050 Volume measurement for timed collection. each
0 CPT Assistant Feb 22:3, Mar 22:13 81099 Unlisted urinalysis procedure
0 CPT Assistant Aug 05:9
+ 80506 prolonged service, each additional 30 minutes (List
separately in addition to code for primary procedure)
0 CPT Assistant Feb 22:3, Mar 22:13 Molecular Pathology
(Use 80506 in conjunction with 8050~) Molecular pathology procedures are medical laboratory
procedures involving the analyses of nucleic acid (ie,
(Do not report 80503, 80504, 80505, 80506 in conjunction
DNA, RNA) to detect variants in genes that may be
with 88321 , 88323, 88325)
indicative of germline (eg, constitutional disorders) or
(Prolonged pathology clinical consultation service of less somatic (eg, neoplasia) conditions, or to test for
than 15 additional minutes is not reported separately) histocompatibility antigens (eg, HLA). Code selection is
""(For consultations involving the examination and typically based on the specific gene(s) that is being
evaluation of the patient. see evaluation and analyzed. Genes are described using Human Genome
management services)<llll Organization (HUGO) approved gene names and are
italicized in the code descriptors. Gene names were taken
from tables of the HUGO Gene Nomenclature
Urinalysis Committee (HGNC) at the time the CPT codes were
developed. For the most part, Human Genome Variation
For specific analyses, see appropriate section. Society (HGVS) recommendations were followed for the
names of specific molecular variants. The familiar name is
81000 Urinalysis. by dip stick or tablet reagent for bilirubin.
glucose, hemoglobin, ketones, leukocytes, nitrite, pH,
used for some variants because defined criteria were not
protein. specific gravity, urobilinogen, any number of in place when the variant was first described or because
these constituents; non-automated, with microscopy HGVS recommendations were changed over time (eg,
0 CPT Assistant Winter 90:4, Winter 91 :10. Fall 93:25. Aug 05:9. intronic variants, processed proteins). When the gene
Jul 18:15 name is represented by an abbreviation, the abbreviation
81001 automated. with microscopy 0
0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0
0 0 0 0
81002 non-automated, without microscopy 0
0 0
0
0 0 0 0
0 0
0
0
0 0 0
0
0 CPT Assistant Mar 98:3. Apr 07:1 0
0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
81003 automated, without microscopy

0 0 0 0 0
0 0
0
0
00
0 0
0 0
0 0
0
• 00
0 CPT Assistant Apr 07:1 0
0
00
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0 0 0
0 0 0 0 0
0 0 0 0
0
614 *
= Telemedicine '4 =Audio-only +=Add-on code .K' =FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 0 00 =See p xix for details
CPT 2023 Pathology ~nd Laboratory I Molecular Pathology
,
is listed first, followed by the full gene name italicized in Testing for additional uncommon variants may provide
parentheses (eg, "F5 [coagulation Factor VJ'), except for additional limited value in assessment of a patient. Often
the HIA series of codes. Proteins or diseases commonly there are professional society recommendations or
associated with the genes are listed as examples in the guidelines for which variants are most appropriate to test
code descriptors. The examples do not represent all (eg, American College of Medical Genetics/American
conditions in which testing of the gene may be indicated. College of Obstetrics and Gynecology guidelines for
variants used in population screening for cystic fibrosis).
Codes that describe tests to assess for the presence of gene
variants (see definitions) use common gene variant Constitutional: synonymous with germline, often used
names. Typically, all of the listed variants would be tested. in reference to the genetic code that is present at birth.
However, these lists are not exclusive. If other variants are Copy number variants (CNVs): structural changes in the
also tested in the analysis, they would be included in the genome composed oflarge deletions or duplications.
procedure and not reported separately. Full gene CNVs can be found in the germline, but can also occur
sequencing should not be reported using codes that assess in somatic cells. See also Duplication/Deletion (Dup/
for the presence of gene variants unless specifically stated Del).
in the code descriptor.
Cytogenomic: chromosome analysis using molecular
The molecular pathology codes include all analytical
techniques.
services performed in the test (eg, cell lysis, nucleic acid
stabilization, extraction, digestion, ampl!fication, and DNA methykztion: the process of adding methyl groups
detection). Any procedures required prior to cell lysis (eg, to a DNA sequence, specifically adenine and cytosine
microdissection, codes 88380 and 88381) should be nucleotides, thereby affecting transcription of that
reported separately. sequence. DNA hyper-methylation in a gene promoter
typically represses gene transcription. DNA methylation
The results of the procedure may require interpretation serves as a regulatory mechanism in numerous scenarios
by a physician or other qualified health care professional. including development, chromosome inactivation, and
When only the interpretation and report are performed,
carcinogenesis.
modifier 26 may be appended to the specific molecular
pathology code. DNA methykztion analysis: analytical protocols are
designed to evaluate the degree of DNA methylation
All analyses are qualitative unless otherwise noted.
related to specific disease processes. This analysis has
For microbial identification, see 87149-87153 and various applications, qualitative or quantitative, and
87471-87801, and 87900-87904. For in situ could be gene specific or encompass global degrees of
hybridization analyses, see 88271-88275 and 88365- methylation. All assays employ specific maneuvers (eg,
88368. chemical, enzymatic) that allow for distinguishable
evaluation of methylated and non-methylated sequences.
Molecular pathology procedures that are not specified in
81161, 81200-81383 should be reported using either the Duplication/Dektion (Dup/Del): terms that are usually
appropriate Tier 2 code (81400-81408) or the unlisted used together with the "/" to refer to molecular testing,
molecular pathology procedure code, 81479. which assesses the dosage of a particular genomic region.
The region tested is typically of modest to substantial
Definitions
size-from several dozen to several million or more
For purposes of CPT reporting, the following definitions nucleotides. Normal gene dosage is two copies per cell,
apply: except for the sex chromosomes (X and Y). Thus, zero or
Abnormal all.ek: an alternative form of a gene that one copy represents a deletion, and three (or more) copies
contains a disease-related variation from the normal represent a duplication.
sequence. Dynamic mutation: polynucleotide (eg, trinucleotide)
Breakpoint: the region at which a chromosome breaks repeats that are in or associated with genes that can
during a translocation (defined elsewhere). These regions undergo disease-producing increases or decreases in the
are often consistent for a given translocation. numbers of repeats within tissues and across generations.
Codon: a discrete unit of three nucleotides of a DNA or F.xome: DNA sequences within the human genome that
mRNA sequence that encodes a specific amino acid code for proteins (coding regions).
within, or signals the termination of, a polypeptide.
Common variants: variants (as defined elsewhere) that
0 0 0 0 0
are associated with compromised gene function and are 0 0 0 0
0
0
0 0 0
0
0
0
0 0 0 0 0
interrogated in a single round of laboratory testing (in a 0 0
0
0 0
0
0 0
0
0 0
0
0
0
0
0 0 0 0 0 0 0
single, typically multiplex, assay format or using more 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
than one assay to encompass all variants to be tested). 0 0 0 0 0
0
0 0 0 0 0
0
0 0 6
0 0 0 0
These variants typically fit the definition of a "mutation," 00 0 0
00 0 0
00
0 0 0
0 0 0 0 0 0
and are usually the predominant ones causing disease. 0 0
0 0 0 0 0
0 0 0 0 0
0 0
0 0 0
0 0
0 0 0 0 0
0 0 0 0 0
A=Revised code • = New code .. ...i =Contains new or revised text H=Duplicate PLA test ti =Category IPLA American Medical Association 615
Pathology and Laboratory I Molecular Pathology CPT 2023
.Exon: typically, one of multiple nucleic acid sequences Mitochondrial DNA (mtDNA): DNA located in the
used to encode information for a gene product mitochondria, which are cytoplasmic organelles involved
(polypeptide or protein). Exons are separated from each with energy production. MtDNA contains 37 genes
other by non-protein-coding sequences known as introns. coding for oxidative phosphorylation enzymes, transfer
Exons at the respective ends of a gene also contain nucleic RNAs (tRNAs) and ribosomal RNAs (rRNAs).
acid sequence that does not code for the gene's protein
Mutations: typically are variants associated with altered
product. gene function that lead to functional deficits or disease
Gene: a nucleic acid sequence that typically contains (pathogenic).
information for coding a protein as well as for the
Mutation scanning: a technique (eg, single strand
regulated expression of that protein. Human genes
conformation polymorphism, temperature gradient gel
usually contain multiple protein coding regions (exons)
electrophoresis, etc.) typically employed on multiple PCR
separated by non-protein coding regions (introns) . See
amplicons to indicate the presence of DNA sequence
also exon, intron, and polypeptide.
variants by differences in physical properties compared to
Gene expression: the sequence of events that results in normal. Variants are then further characterized by DNA
the production and assembly of a protein product sequence analysis only in amplicons which demonstrate
corresponding to the information encoded in a specific differences.
gene. The process begins with the transcription of gene
Nuclear DNA: DNA located in the nucleus of a cell,
sequences to produce an mRNA intermediary, which is
generally packaged in chromosomes.
subsequently translated to produce a specific protein
product. Polymorphisms: typically are variants that do not
compromise gene function or produce disease (benign).
Genome: the total (nuclear) human genetic content.
Polypeptide: a sequence of amino acids covalently linked
Heteroplasmy: the copy number of a variant within a in a specified order. Polypeptides alone or in combination
cell; it is expressed as a percent. It reflects the varied
with other polypeptide subunits are the building blocks
distribution and dosage of mutant mitochondria in
of proteins.
tissues and organs (mitotic segregation).
Promoter: a region of DNA associated with a gene (on
Intron: a nucleic acid sequence found between exons in the same strand) which regulates gene expression.
human genes. An intron contains essential sequences for
Promoter regions can affect gene transcription through
its proper removal (by a process known as splicing) to join
the binding of specific transcription factors.
exons together and thus facilitate production of a
functional protein from a gene. An intron is sometimes Short tandem repeat (STR}: a region of DNA where a
referred to as an intervening sequence (IVS). pattern of two or more nucleotides are repeated. The
number of repeating segments can be used as genetic
Inversion: a defect in a chromosome in which a segment
markers for human identity testing.
breaks and reinserts in the same place but in the opposite
orientation. Single-nucleotide polymorphism (SNP): a DNA
sequence variation existing at a significant frequency in
Loss ofheterozygosity (LOH, allelic imbalance): an the population, in which a single nucleotide (A, T, C, or
event that can occur in dividing cells that are
G) differs between individuals and/or within an
heterozygous for one or more alleles, in which a daughter
individual's paired chromosomes.
cell becomes hemizygous or homozygous for the allele(s)
through mitotic recombination, deletion, or other Somatic: synonymous with acquired, referring to genetic
chromosomal event. code alterations that develop after birth (eg, occurring in
neoplastic cells).
Low-pass sequencing: a method of genome sequencing
intended for cytogenomic analysis of chromosomal Translocation: an abnormality resulting from the
abnormalities, such as that performed for trait mapping breakage of a chromosome and the relocation of a portion
or copy number variation, typically performed to an of that chromosome's DNA sequence to the same or
average depth of sequencing ranging from 0.1 to 5X. another chromosome. Most common translocations
involve a reciprocal exchange of DNA sequences between
Microarray: surface(s) on which multiple specific nucleic two differently numbered (ie, non-homologous)
acid sequences are attached in a known arrangement.
chromosomes, with or without a clinically significant loss
Sometimes referred to as a "gene chip." Examples of uses
of DNA.
of microarrays include evaluation of a patient specimen
0 0 0 0
for gains or losses of DNA sequences (copy number 0
0 0 0
0 0 0 0
0 0 0 0 0 0
0 0
variants, CNVs), identification of the presence of specific 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0 0
0 0 0 0 0
nucleotide sequence variants (also known as single 0 0 0
0 0 0 0 0 0 0
nucleotide polymorphisms, SNPs), mRNA expression 0 0 0
0
0 0
0
0 0 0
0
0 0
0 0 0 0
levels, or DNA sequence analysis.
0 o• 0 0 0
0
0
0
00
0 0 0
0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
616 *= Telemedicine ~ = AudiO-{)nly +=Add-on code j( =FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 00 O=See pxix for details
CPT 2023 Pathology and Laboratory /"Molecular Pathology 81170--81174
6
Uniparental disomy (UPD): abnormal inheritance of 81161 Code is out of numerical sequence. See 81228-81235
both members of a chromosome pair from one parent, 81162 Code is out of numerical sequence. See 81182-81216
with absence of the other parent's chromosome for the
pair. 81163 Code is out of numerical sequence. See 81182-81216
Variant: a nucleotide sequence difference from the 81164 Code is out of numerical sequence. See 81182-81216
"normal" (predominant) sequence for a given region. 81165 Code.is out of numerical sequence. See 81182-81216
Variants are typically of two types: substitutions of one
nucleotide for another, and deletions or insertions of 81166 Code is out of numerical sequence. See 81182-81216
nucleotides. Occasionally, variants reflect several 81167 Code is out of numerical sequence. See 81215-81220
nucleotide sequence changes in reasonably close
proximity on the same chromosomal strand of DNA (a
haplotype). These nucleotide sequence variants often 81170 ABL 1(ABL proto-oncogene 1, non-receptor tyrosine
result in amino acid changes in the protein made by the kinase) (eg, acquired imatinib tyrosine kinase inhibitor
gene. The term variant does not itself carry a functional resistance}, gene analysis, variants in the kinase domain
implication for those protein changes. 0 CPT Changes: An Insider's View2016
Variants in introns are typically described in one of two

ways. The altered nucleotide(s) within a defined 81171 AFF2 (AF4/FMR2 family, member 2 [FMR2])(eg, fragile X
intervening sequence (eg, IVS3-2A>G) of a gene is listed mental retardation 2 [FRAXE]) gene analysis; evaluation
with a"+" or"-" sign, which indicates the position to detect abnormal (eg, expanded) alleles
relative to the first or last nucleotide of the intron. Or, the 0 CPT Changes.· An Insider's View 2019
variant position is indicated relative to the last nucleotide 81172 characterization of alleles (eg, expanded size and
of the preceding exon or first nucleotide of the following methylation status)
exon (eg, c.171+1 G>A c.172-1 G> T are single nucleotide 0 CPT Changes: An Insider's View Wl 9
changes at the first and last nucleotide of a given intron
for a specific gene). 81173 Code is out of numerical sequence. See 81171-81176
The majority of the variants described here are listed by 81174 Code is out of numerical sequence. See 81171-81176
the amino acid change using the single letter amino acid # 81201 APC (adenomatous polyposis coli)(eg, familial
code for the original amino acid followed by the adenomatosis polyposis [FAP]. attenuated FAP) gene
numerical position in the protein product and the amino analysis; full gene sequence
acid substitution, eg, for ASPA E285A, Glutamic acid (E) 0 CPT Changes: An Insider's View 2013
at position 285 is replaced with an alanine (A). A few of 0 CPT Assistant May 12:4, Sep 13:3, Aug 16:10, Nov 18:9
the variants are described by the DNA change using the
# 81202 known familial variants
numerical position followed by the original nucleotide, a
greater than sign (>) and the new nucleotide, eg,
MTHFR. 677C>T.
0 CPT Assistant May 12:4. Sep 13:3, Aug 16:10, Nov 18:9
# 81203 duplication/deletion variants

A known familial variant is a specific mutation that has
previously been identified within a patient's family. 0 CPT Changes: An Insider's View2013
0 CPT Assistant May 12:4, Sep 13:3, Aug 16:10, Nov 18:9
Tier 1 Molecular Pathology # 81204 AR (androgen receptor)(eg , spinal and bulbar muscular
atrophy, Kennedy disease. X chromosome inactivation)
Procedures gene analysis; characterization of alleles (eg, expanded
The following codes represent gene-specific and genomic size or methylation status)
procedures: 0 CPT Changes: An Insider's View 2019

0 CPT Assistan~Nov 18:9
# 81173 full gene sequence

# 81174 known familial variant
81108 Code is out of numerical sequence. See 81255-81270 0 CPT Changes: An Insider's View 2019

81110 Code is out of numerical sequence. See 81255-81270 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
81111 Code is out of numerical sequence. See 81255-81270 0 0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0 0 0 0 0
81112 Code is out of numerical sequence. See 81255-81270 0
0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0
0 0
0 0
0
0 0
0 0
0 0
0
0 0
0 0
0 0 0 0 0
A=Revised code • = New code "' • = Contains new or revised text *=Duplicate PlA test t~ =Category I PLA American Medical Association 617
81200-81210 Pathology and Laboratory I Molecular Pathology CPT 2023
# 81200 ASPA (aspartoacylase)(eg, Canavan disease) gene 81191 Code is out of numerical sequence. See 81310-81314
analysis, common variants (eg. E285A, Y231X)
0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9 81193 Code is out of numerical sequence. See 81310-81314
81175 ASXL 1(additional sex combs like 1, transcriptional 81194 Code is out of numerical sequence. See 81310-81314
regulator)(eg, myelodysplastic syndrome,
myeloproliferative neoplasms, chronic myelomonocytic
leukemia). gene analysis; full gene sequence 81201 Code is out of numerical sequence. See 81171-81176
81176 targeted sequence analysis (eg, exon 12) 81203 Code is out of numerical sequence. See 81171-81176
81177 ATN1(atrophin1)(eg, dentatorubral-pallidoluysian
atrophy) gene analysis. evaluation to detect abnormal 81205 Code is out of numerical sequence. See 81182-81216
(eg, expanded) alleles 81206 Code is out of numerical sequence. See 81182-81216
81178 ATXN1(ataxin1)(eg, spinocerebellar ataxia) gene
analysis. evaluation to detect abnormal (eg, expanded) 81208 Code is out of numerical sequence. See 81182-81216
alleles 81209 Code is out of numerical sequence. See 81182-81216
0 CPT Assistant Sep 19:7 81210 Code is out of numerical sequence. See 81182-81216
81179 ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene # 81205 BCKDHB (branched-chain keto acid dehydrogenase E1,
analysis. evaluation to detect abnormal (eg, expanded) beta polypeptide) (eg, maple syrup urine disease) gene
alleles analysis. common variants (eg, R183P. G278S, E422X)
0 CPT Assistant Sep 19:7 0 CPT AssistantMay 12:4, Aug 16:10. Nov 18:9
81180 ATXN3 (ataxin 3) (eg, spinocerebellar ataxia. Machado- # 81206 BCR!ABL 1(t (9.22)) (eg, chronic myelogenous leukemia)
Joseph disease) gene analysis, evaluation to detect translocation analysis; major breakpoint. qualitative or
abnormal (eg, expanded) alleles quantitative
0 CPT Changes: An Insider's View 2019 0 CPT Changes: An Insider's View 2012
0 CPT Assistant Sep 19:7 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
81181 ATXN7 (ataxin 7)(eg, spinocerebellar ataxia) gene # 81207 minor breakpoint, qualitative or quantitative
analysis, evaluation to detect abnormal (eg, expanded) 0 CPT Changes: An Insider's View 2012
alleles 0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9
0 CPT Changes: An Insider's View 2019 # 81208 other breakpoint, qualitative or quantitative
0 CPT Assistant Sep 19:7 0 CPT Changes: An Insider's View 2012
81182 ATXNBOS (ATXNB opposite strand [non-protein coding]) 0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9
(eg, spinocerebellar ataxia) gene analysis. evaluation to # 81209 BLM (Bloom syndrome. RecO helicase-like) (eg, Bloom
detect abnormal (eg, expanded) alleles syndrome) gene analysis, 2281 del6ins7 variant
81183 ATXN10 (ataxin 70)(eg, spinocerebellar ataxia) gene # 81210 BRAF (8-Raf proto-oncogene, serine/threonine kinase)
analysis. evaluation to detect abnormal (eg, expanded) (eg, colon cancer, melanoma). gene analysis, V600
alleles variant(s)
0 CPT Changes: An Insider's View 2019 0 CPT Changes: An Insider's View 2012, 2016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 •
0 0
0 0 0 0
0 0 0 0 0
0
0 0
0
0
0 0
0
0 0
0
0
0 0
0
•
0 0 0 0 0 0 0 0 0
0 0
0
0 0 0 0 0
0
0 0 0 0
DO 00
0 0 0
0
0
0
0 0 0
0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0 0
618 *
= Telemedicine ~ =Audio-only +=Add-on code )t' = FDA approval pending #=Resequenced code & =Modifier 51 exempt 000 =See p xix for details
CPT 2023 Pathology and Laboratory I Molecular Pathology 81162--81218
# 81162 BRCA 1{BRCA 1, DNA rep?ir associated), BRCA2 {BRCA2, 81216 BRCA2 {BRCA2, DNA repair associated) (eg, hereditary "
DNA repair associated)(eg, hereditary breast and ovarian breast and ovarian cancer) gene analysis; full sequence
cancer) gene analysis; full sequence analysis and full analysis
duplication/deletion analysis (ie. detection of large gene 0 CPT Changes: An Insider's View 2012, 2019
rearrangements) 0 CPT Assistant May 12:4. Aug 16: 10, Nov 18:9, May 19:5
0 CPT Changes: An Insider's View 2016, 2019
# 81167 full duplication/deletion analysis {ie, detection of
0 CPT Assistant Aug 16: 10, May 19:5
large gene rearrangements)
(Do not report 81162 in conjunction with 81163, 81164. 0 CPT Changes: An Insider's View2019
81165.81166.81167,81215,81216,81217,81432) 0 CPT Assistant May 19:5
# 81163 full sequence analysis 81217 known familial variant

0 CPT Changes: An Insider's View 2019 0 CPT Changes: An Insider's View2012. 2019
0 CPT AssistantMay 19:5 0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9. May 19:5
# 81164 full duplication/deletion analysis (ie. detection of (Do not report 81216 in conjunction with 81162. 81163,
large gene rearrangements) 81432)
(Do not report 81167 in conjunction with 81162. 81164,
0 CPT Assistant May 19:5
81217)
(To report BRCA 1, BRCA2full sequence analysis and full
duplication/deletion analysis on the same date of
81167)
service, use 81162)
# 81233 BTK (Bruton's tyrosine kinase)(eg, chronic lymphocytic
(For analysis of common duplication/deletion variant(s) in
leukemia) gene analysis. common variants (eg, C481 S.
BRCAT [ie, exon 13 del 3.835kb. exon 13 dup 6kb, exon
C481 R. C481 F)
14-20 del 26kb. exon 22 del 510bp, exon 8-9 del 7.1kb].
use 81479)
0 CPT Assistant Nov 18:9
(Do not report 81163 in conjunction with 81162, 81164,
# 81184 CACNA TA {calcium voltage-gated channel subunit alpha1
81165.81216,81432)
AJ(eg, spinocerebellar ataxia) gene analysis; evaluation
(Do not report 81164 in conjunction with 81162, 81163, to detect abnormal (eg, expanded) alleles
81166,81167,81217) 0 CPT Changes: An Insider's View 2019
81212 185delAG. 5385insC. 617 4delT variants # 81185 full gene sequence
0 CPT Changes.· An Insider's View 2012. 2019 0 CPT Changes: An Insider's View 2019
0 CPT AssistantMay 12:4, Aug 16:10. Nov 18:9. May 19:5
# 81165 BRCA 1{BRCA1, DNA repair associated)(eg, hereditary 0 CPT Changes: An Insider's View 2019
breast and ovarian cancer) gene analysis; full sequence
analysis # 81219 CALR {calreticulin)(eg, myeloproliferative disorders).
gene analysis, common variants in exon 9
0 CPT Assistant Aug 16:10. Nov 18:9
# 81166 full duplication/deletion analysis (ie, detection of
large gene rearrangements) # 81168 CCNDT/IGH {t(71;14)) (eg. mantle cell lymphoma)
translocation analysis. major breakpoint, qualitative and
quantitative. if performed
81215 known familial variant
81218 CEBPA {CCAAT/enhancer binding protein [C/EBPL alpha)
0 CPTChanges: An Insider's View2012. 2019
(eg, acute myeloid leukemia), gene analysis, full gene
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9, May 19:5
sequence
(For analysis of common duplication/deletion variant(s) in 0 CPT Changes: An Insider's View 2016
BRCA 1[ie, exon 13 del 3.835kb, exon 13 dup 6kb. exon 0 CPT Assistant Aug 16:10
14-20 del 26kb. exon 22 del 510bp, exon 8-9 del 7.1kb].
use 81479)
(Do not report 81165 in conjunction with 81162. 81163.
81432)
0 0 0 0 0
0 0 0 0 0 0 0
(Do not report 81166 in conjunction with 81162. 81164) 0 0
0
0
0 0 0 0
0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
0 00 0 0 0 0 00 0 0 0 0 00
0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 D 0 0 0
0 0 0 0 0 0
& = Revised code •=Newcode ..,. ~ = Contains new or revised text H=Duplicate PlA test U=Category I PlA American Medical Association 619
8122o--81229 Pathology and Laboratory I Molecular Pathology CPT2023
81220 CFTR (cystic fibrosis transmembrane conductance # 81188 CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene
regulator) (eg, cystic fibrosis) gene analysis; common analysis; evaluation to detect abnormal (eg, expanded)
variants (eg, ACMG/ACOG guidelines) alleles
0 CPT Changes: An Insider's View2012 0 CPT Changes: An Insider's View 2019
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
(When lntron 8 poly-T analysis is performed in 0 CPT Changes: An Insider's View 2019
conjunction with 81220 in a R117H positive patient, do
# 81190 known familial variant(s)
not report 81224)
81221 known familial variants
# 81227 CYP2C9 (cytochrome P450, family 2, subfamily C,
polypeptide 9)(eg, drug metabolism), gene analysis.
common variants (eg. *2. *3, *5, *61
81222 duplication/deletion variants 0 CPT Changes: An Insider's View 2012
0 CPT Changes: An Insider's View 2012 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9
81225 CYP2C7 9 (cytochrome P450, family 2, subfamily C.
81223 full gene sequence polypeptide 79)(eg, drug metabolism). gene analysis,
0 CPT Changes: An Insider's View2012 common variants (eg. *2, *3, * 4, *8, *171
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 0 CPT Changes: An Insider's View 2012
0CPTAssistantMay12:4, Aug 16:10, Nov 18:9
81224 intron 8 poly-T analysis (eg, male infertility)
0 CPTChanges: An Insider's View2012 81226 CYP2D6 (cytochrome P450, family 2, subfamily D,
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 polypeptide 6)(eg, drug metabolism). gene analysis,
common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17.
# 81267 Chimerism (engraftment) analysis, post transplantation *19, *29, *35, *41, *1XN. *2XN. *4XNl
specimen (eg, hematopoietic stem cell), includes
comparison to previously performed baseline analyses;
without cell selection
0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9
0 CPT Changes: An Insider's View 2012 81227 Code is out of numerical sequence. See 81223-81226
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 # 81230 CYP3A4 (cytochrome P450 family 3 subfamily A member
# 81268 with cell selection (eg, CD3, CD33). each cell type 4)(eg, drug metabolism). gene analysis, common
0 CPT Changes: An Insider's View2012 variant(s) (eg, *2. *22)
(If comparative STR analysis of recipient [using buccal
swab or other germline tissue sample) arid donor are # 81231 CYP3A5 (cytochrome P450 family 3 subfamily A member
performed after hematopoietic stem cell transplantation. 5)(eg, drug metabolism). gene analysis, common variants
report 81265. 81266 in conjunction with 81267. 81268 for (eg, *2, *3, *4. *5. *6. *7)
chimerism testing) 0 CPT Changes: An Insider's View 2018
# 81187 CNBP (CCHC-type zinc finger nucleic acid binding protein)

(eg, myotonic dystrophy type 2) gene analysis, evaluation 81228 Cytogenomic (genome-~idel analysis for constitutional
to detect abnormal (eg, expanded) alleles chromosomal abnormalities; interrogation of genomic
0 CPT Changes: An Insider's View2019 regions for copy number variants, comparative genomic
hybridization [CGH) microarray analysis
# 81265 Comparative analysis using Short Tandem Repeat (STR)
markers; patient and comparative specimen (eg, pre-
0 CPT Changes: An Insider's View2012, 2022
@CPT Assistant May 12:4, Sep 13:4, 6. Aug 16:10. Nov 18:9
transplant recipient and donor germline testing, post-
transplant non-hematopoietic recipient germline [eg, (Do not report 81228 in conjunction with 81229. 81349)
buccal swab or other germline tissue sample) and donor
81229 interrogation of genomic regions for copy number and
testing, twin zygosity testing, or maternal cell
single nucleotide polymorphism (SNP) variants,
contamination of fetal cells)
comparative genomic hybridization (CGHl microarray
0 CPTChanges: An Insider's View2012
analysis
@ CPT Changes: An Insider's View2012. 2022
#+ 81266 each additional specimen (eg, additional cord blood 0 CPT Assistant May 12:4. Sep 13:4, Aug 16:10. Nov 18:9
donor. additional fetal samples from different
0
cultures, or additional zygosity in multiple.birth 0
o'
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
pregnancies) (List separately in addition to code for 0
0
0
0
0 0
0
0
0
0
0
0
0 0 0
0 0 0
primary procedure) 0 0 0 0 0
0
0 0 0 0 0 0
0 CPT Changes: An Insider's View 2012 0 0 0
0
0 0
0 0
0
0 0 0
0
0 0
0 0
0
I o
0 CPT AssistantMay 12:4, Aug 16:10. Nov 18:9
0
00
0
0 0
00
0
0 0
0 0 0 0 0 0
0 0 0 0 0
(Use 81266 in conjunction with 81265) 0 0 0 0 0
0
0
0
. 0
0
0
0
0
0
0
0
620 *
= Telemedicine ,. =Audio-only +=Add-on code ~=FDA approval pending #=Resequenced code \Si= Modifier 51 exempt ~~~ =See p xix for details
CPT 2023 Pathology and Laboratory I Molecular Pathology 81349-81242
(Do not report 81229 in conjunction with 81228, 81349) 81232 DPYD (dihydropyrimidine dehydrogenase) (eg,
(Do not report 88271 when performing cytogenomic 5-fluorouracil/5-FU and capecitabine drug metabolism),
[genome-wide] analysis for constitutional chromosomal gene analysis, common variant(s) (eg, *2A, *4, *5, *6)
abnormalities) 0 CPT Changes: An Insider's View2018
(For genomic sequencing procedures or other molecular
multianalyte assays for copy number analysis using 81233 Code is out of numerical sequence. See 81215-81220
circulating cell-free fetal DNA in maternal blood, see 81234 Code is out of numerical sequence. See 81228-81235
81420,81422,81479)
81235 EGFR (epidermal growth factor receptor) (eg, non-small
# 81349 interrogation of genomic regions for copy number and cell lung cancer) gene analysis, common variants (eg,
loss-of-heterozygosity variants, low-pass sequencing exon 19 LREA deletion, L858R, T790M, G719A, G719S,
analysis L861Q)
(When performing cytogenomic [genome-wide] analysis 0 CPT Assistant Sep 13:3, Aug 16:10. Nov 18:9
for constitutional chromosomal abnormalities that is not 81236 EZH2 (enhancer of zeste 2 polycomb repressive complex
genome-wide [ie, regionally targeted]. report the specific 2 subunit)(eg, myelodysplastic syndrome.
code for the targeted analysis if available [eg, 81405]. or
myeloproliferative neoplasms) gene analysis, full gene
the unlisted molecular pathology code [81479]) sequence
(Do not report 81349 in conjunction with 81228, 81229) 0 CPT Changes: An Insider's View 2019
(Do not report 81349 when analysis for chromosomal

0 CPT Assistant Nov 18:9, Jul 19:3
abnormalities is performed by sequence analysis 81237 EZH2 (enhancer of zeste 2 polycomb repressive complex
included in 81425, 81426) 2 subunit)(eg, diffuse large B-cell lymphoma) gene
analysis. common variant(s) (eg, codon 646)
(Do not report analyte-specific molecular pathology
procedures separately in conjunction with 81228, 81229,
81349, when the specific analytes are included as part of

the cytogenomic [genome-wide] analysis for 81238 Code is out of numerical sequence. See 81240-81248
constitutional chromosomal abnormalities)
# 81277 Cytogenomic neoplasia (genome-wide) microarray
81240 F2 (prothrombin. coagulation factor II) (eg, hereditary
analysis, interrogation of genomic regions for copy
hypercoagulability) gene analysis, 20210G>A variant
number and loss-of-heterozygosity variants for
chromosomal abnormalities 0 CPT Changes: An Insider's View 2012
0 CPT Changes: An Insider's View 2020 0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9
0 CPT Assistant Feb 20:10 81241 F5 (coagulation factor VJ (eg, hereditary
hypercoagulability) gene analysis, Leiden variant
procedures separately when the specific analytes are 0 CPT Changes: An Insider's View2012
included as part of the cytogenomic microarray analysis 0 CPT AssistantMay 12:4, Aug 16:10, Nov 18:9
for neoplasia) # 81238 F9 (coagulation factor IX) (eg, hemophilia B), full gene
(Do not report 88271 when performing cytogenomic sequence
microarray analysis) 0 CPT Changes: An Insider's View 2018
81242 FANCC (Fanconi anemia, complementation group CJ (eg,
81231 Code is out of numerical sequence. See 81225-81229 Fanconi anemia, type C) gene analysis, common variant
# 81161 DMD (dystrophin) (eg, Duchenne/Becker muscular (eg, IVS4+4A>T)
dystrophy) deletion analysis, and duplication analysis, if 0 CPT Changes: An Insider's View 2012
performed 0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9
0 CPT Assistant Aug 16:10, Nov 18:9
# 81234 DMPK (DM1 protein kinase)(eg, myotonic dystrophy type

1) gene analysis; evaluation to detect abnormal
(expanded) alleles
0 CPT Changes: An Insider's View 2019 0
0
0
0
0
0
0
0 0
0
0 0
0
0 0
0
0 CPT Assistant Nov 18:9 0

0 0
0
0
0
0 0
0
0
0
0
0
0
0
0 0
0
0
0
0 0 0 0 0 0
0
# 81239 characterization of alleles (eg, expanded size) 0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0
0 CPT Changes: An Insider's View2019 0 0 0
0 0
0 0 0 0 0
0 0 • 0
0
0 0 0
0 CPT Assistant Nov 18:9 0

00
0 0 0
0
0
0
00
0 0 0
0
0
0
00
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0
0 0 0
.&=Revised code •=New code ..,.. <1111 =Contains new or revised text H=Duplicate PLA test t+=Category I PLA American Medical Association 621
8124!>---81363 Pathology and Laboratory I Molecular Pathology CPT 2023
# 81245 FLT3 (fros-related tyrosine kinase 3) (eg, acute myeloid 81251 GBA (glucosidase. beta, acid)(eg, Gaucher disease) gene
leukemia). gene analysis; internal tandem duplication analysis. common variants (eg, N370S, 84GG, L444P.
(ITD) variants (ie, exons 14, 15) JVS2+1G>A)
0 CPT Changes: An Insider's View 2012, 2015 0 CPT Changes: An Insider's View 2012
0 CPT Assistant May 12:4, Jan 15:3. Aug 16:10. Nov 18:9 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
# 81246 tyrosine kinase domain (TKO) variants (eg, 0835. 1836) 81252 GJB2 (gap junction protein, beta 2, 26k0a, connexin 26)
0 CPT Changes: An Insider's View 2015 (eg. nonsyndromic hearing loss) gene analysis; full gene
0 CPT Assistant Jan 15:3, Aug 16:10, Nov 18:9 sequence
81243 FMRI (fragile X mental retardation 1) (eg, fragile X
mental retardation) gene analysis; evaluation to detect

0 CPT Assistant Sep 13:3. Aug 16:10, Nov 18:9
abnormal (eg, expanded) alleles 81253 known familial variants

0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9 0 CPT AssistantSep 13:3. Aug 16:10, Nov 18:9
(For evaluation to detect and characterize abnormal 81254 GJB6 (gap junction protein, beta 6, 30k0a, connexin 30)
alleles. see 81243, 81244) (eg. nonsyndromic hearing loss) gene analysis, common
variants (eg, 309kb [del(GJBS-013S1830)] and 232kb
(For evaluation to detect and characterize abnormal
[del(GJB6-D13S1854)])
alleles using a single assay [eg, PCR]. use 81243)
81244 characterization of alleles (eg, expanded size and 0 CPT AssistantSep 13:3. Aug 16:10, Nov 18:9
promoter methylation status)
# 81257 HBA 1/HBA2 (alpha globin 1and alpha globin 2)(eg,
0 CPT Changes: An Insider's View2012. 2019
alpha thalassemia, Hb Bart hydrops fetalis syndrome,
0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9. Jul 19:3
HbH disease), gene analysis; common deletions or
81245 Code is out of numerical sequence. See 81240-81248 variant (eg, Southeast Asian, Thai, Filipino,
Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant
Spring)
# 81284 FXN (frataxin)(eg, Friedreich ataxia) gene analysis; 0 CPT Changes: An Insider's View2012, 2018
evaluation to detect abnormal (expanded) alleles 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
# 81285 characterization of alleles (eg, expanded size) 0 CPT AssistantNov 18:9
# 81286 full gene sequence 0 CPT Assistant Nov 18:9
# 81269 duplication/deletion variants
# 81289 known familial variant(s) 0 CPT Assistani Nov 18:9
# 81361 HBB (hemoglobin, subunit beta)(eg, sickle cell anemia,
beta thalassemia, hemoglobinopathy); common variant(s)
# 81250 G6PC (glucose-6-phosphatase, catalytic subunit) (eg, (eg, HbS, HbC, HbE)
Glycogen storage disease, type 1a. von Gierke disease) 0 CPT Changes: An Insider's View 2018
gene analysis, common variants (eg, R83C, Q347X) 0 CPT Assistant Nov 18:9
# 81362 known familial variant(s)
81247 G6PD (glucose-6-phosphate dehydrogenase) (eg, 0 CPT Assistant Nov 18:9
hemolytic anemia. jaundice), gene analysis; common
variant(s) (eg, A. A-)
# 81363 duplication/deletion variant(s)

0 CPT AssistantSep 18:14. Nov 18:9
81248 known familial variant(s)

0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0
0 0
0 0 0 0
81249 full gene sequence 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0

0
0
0
0 0 0
0
0
0
0
0 0 0
0
0 CPT Assistant Nov 18:9 0 0 0

0 0
0 0
0
0 0 0
0 0
0 0
0
0
00 0 00 0
0 0 0
0
0 0 0 0
0
0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0
0
622 *
= Telemedicine ~ = Audio-<Jnly +=Add-on code )f' =FDA approval pending #=Resequenced code <S>= Modifier 51 exempt O O O =See p xix for details
CPT 2023 Pathology and Laboratory/ Molecular Pathology 81364-81278
# 81364 full gene sequence # 81110 Human Platelet Antigen 6 genotyping (HPA-6w), /TGB3
0 CPT Changes: An Insider's View 2018 (integrin. beta 3 [platelet glycoprotein Illa, antigen CD61]
@ CPT AssistantSep 18:14. Nov 18:9 [GPll/a])(eg, neonatal alloimmune thrombocytopenia
81255 HEXA (hexosaminidase A [alpha polypeptide]) (eg, [NAIT). post-transfusion purpura), gene analysis, common
variant. HPA-6a/b (R489Q)
Tay-Sachs disease) gene analysis, common variants
(eg, 1278insTATC, 1421+1G>C, G269S) 0 CPT Changes: An Insider's View 2018
:> CPT Changes: An Insider's View 2012 # 81111 Human Platelet Antigen 9 genotyping (HPA-9w}, ITGA28
@ CPT Assistant May 12:4, Aug 16:10, Nov 18:9 (integrin. alpha 2b [platelet glycoprotein /lb of /lb/Illa
complex, antigen CD41] [GP/lb]) (eg, neonatal alloimmune
81256 HFE (hemochromatosis)(eg, hereditary hemochromatosis)
thrombocytopenia [NAIT). post-transfusion purpura), gene
gene analysis, common variants (eg, C282Y, H630)
@ CPT AssistantMay 12:4, Aug 16:10, Nov 18:9
=
analysis, common variant, HPA-9a/b (V837M)
CPT Changes: An Insider's View 2018
# 81112 Human Platelet Antigen 15 genotyping (HPA-15), CD109

(CD109 molecule)(eg, neonatal alloimmune
81258 Code is out of numerical sequence. See 81253-81256 thrombocytopenia [NAIT]. post-transfusion purpura). gene
analysis, common variant, HPA-15a/b (S682Y)
# 81271 HTT (huntingtin)(eg, Huntington disease) gene analysis;
# 81120 /OHi (isocitrate dehydrogenase 1[NADP+J soluble) (eg,
evaluation to detect abnormal (eg. expanded) alleles
glioma). common variants (eg. R132H, R132C)
@ CPT Assistant Nov 18:9
# 81121 IDH2 (isocitrate dehydrogenase 2 [NADP+J mitochondrial)
# 81274 characterization of alleles (eg, expanded size)
(eg, glioma), common variants (eg, Ri40W, R172M)
# 81283 IFNL3 (interferon, lambda 3) (eg, drug response), gene
# 81105 Human Platelet Antigen 1genotyping (HPA-1 ). ITGB3
ar·alysis. rs12979860 variant
(integrin, beta 3 [platelet glycoprotein 11/aJ antigen CD61
[GP/Ila]) (eg, neonatal alloimmune thrombocytopenia
[NAID, post-transfusion purpura), gene analysis, common

variant, HPA-1 a/b (L33P) # 81261 IGH@(lmmunoglobulin heavy chain locus) (eg, leukemias
0 CPT Changes: An Insider's View 2018 and lymphomas. 8-cell), gene rearrangement analysis to
detect abnormal clonal population(s); amplified
# 81106 Human Platelet Antigen 2 genotyping (HPA-2), GPIBA
methodology (eg, polymerase chain reaction)
(glycoprotein lb [platelet] alpha polypeptide [GPlba])(eg,
neonatal alloimmune thrombocytopenia [NAID, post-
transfusion purpura), gene analysis, common variant. 0 CPT Assistant May 12:4, Sep 13:7. Aug 16:10. Nov 18:9
HPA-2a/b (T145M) # 81262 direct probe methodology (eg, Southern blot)
# 81107 Human Platelet Antigen 3 genotyping (HPA-3), ITGA28 0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9
(integrin. alpha 2b [platelet glycoprotein /lb of /lb/Illa # 81263 IGH@ (lmmunoglobulin heavy chain locus) (eg, leukemia
complex], antigen CD41 [GPl/b])(eg. neonatal alloimmune and lymphoma, 8-cell), variable region somatic mutation
thrombocytopenia [NAIT). post-transfusion purpura). gene analysis
analysis, common variant, HPA-3a/b (1843S) 0 CPTChanges: An Insider's View2012
0 CPT Changes: An Insider's View2018 0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9
# 81108 Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 # 81278 IGH@/BCL2 (t(14;18))(eg, follicular lymphoma)
(integrin. beta 3 [platelet glycoprotein II/al antigen CD61 translocation analysis. major breakpoint region (M8R)
[GPll/a])(eg, neonatal alloimmune thrombocytopenia and minor cluster region (mer) breakpoints. qualitative or
[NAIT). post-transfusion purpura), gene analysis. common quantitative
variant, HPA-4a/b (R1430) 0 CPT Changes: An Insider's View 2021
0 CPT Changes: An Insider's View 2018 0 CPT Assistant Aug 21:10
# 81109 Human Platelet Antigen 5 genotyping (HPA-5), ITGA2
(integrin. alpha 2 [CD498, alpha 2 subunit of VLA-2
receptor] [GPla])(eg, neonatal alloimmune 0 0 0 0 0
0 0 0
thrombocytopenia [NAIT). post-transfusion purpura), gene 0 0 0
0
0
0
0
0
0
0 0
0 0 0 0
analysis. common variant (eg, HPA-5a/b [K505E]) 0 0 0 0 0 0 0
0 0
0 0 0
0 0
0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 0 0
0
l>o o 0
0 0 0 0 0 0 0 0
0 0 ° 0 0 0 0
0 00 0 0 0 0 00
0 0 0 0 0 0 00
0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
&.=Revised code •=New code .,.. <Ill = Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 623
81264-81292 Pathology and Laboratory/ Molecular Pathology CPT 2023
# 81264 /GK@ {lmmunoglobulin kappa light chain locus) (eg, 81276 additional variant(s) (eg, codon 61, codon 146)
leukemia and lymphoma, 8-celll. gene rearrangement 0 CPT Changes: An Insider's View2016
analysis, evaluation to detect abnormal clonal 0 CPT Assistant Aug 16:10, Nov 18:9
population(s)
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 81278 Code is out of numerical sequence. See 81255-81260
(For immunoglobulin lambda gene /IGL@Jrearrangement 81279 Code is out of numerical sequence. See 81260-81273
or immunoglobulin kappa deleting element, [IGKDELJ
analysis, use 81479)
81260 IKBKAP {inhibitor of kappa light polypeptide gene
enhancer in 8-ce/ls, kinase complex-associated protein) 81285 Code is out of numerical sequence. See 81243-81248
(eg, familial dysautonomia) gene analysis, common
variants (eg, 2507+6T>C, R696Pl
81261 Code is out of numerical sequence. See 81255-81270 81289 Code is out of numerical sequence. See 81243-81248
81262 Code is out of numerical sequence. See 81255-81270 81290 MCOLN1 (mucolipin 1)(eg, Mucolipidosis, type IV) gene
81263 Code is out of numerical sequence. See 81255-81270 analysis, common variants (eg, IVS3-2A>G. del6.4kb)

0 CPT AssistantMay 12:4, Aug 16:10, Nov 18:9
# 81302 MECP2 (methyl CpG binding protein 2)(eg, Rett
81266 Code is out of numerical sequence. See 81223-81226 syndrome) gene analysis; full sequence analysis
81270 JAK2 (Janus kinase 2)(eg, myeloproliferative disorder) 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
gene analysis. p.Val617Phe (V617F) variant # 81304 duplication/deletion variants
0 CPT Changes.· An Insider's View2012 0 CPT Changes: An Insider's View2012
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
# 81279 JAK2 {Janus kinase 2J(eg, myeloproliferative disorder) # 81287 MGMT (0-6-methylguanine-DNA methyltransferase) (eg,
targeted sequence analysis (eg, exons 12 and 13) glioblastoma multiformel promoter methylation analysis
0 CPT Changes: An Insider's View 2021 0 CPT Changes: An Insider's View2014, 2019
0 CPT Assistant Aug 21: 10 0 CPTAssistantAug16;10, Nov 18:9, Oec 18:10, Jul 19:3
81271 Code is out of numerical sequence. See 81255-81270 # 81301 Microsatellite instability analysis (eg, hereditary non-
81272 KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral polyposis colorectal cancer, Lynch syndrome) of markers
oncogene homolog) (eg, gastrointestinal stromal tumor for mismatch repair deficiency (eg, BAT25, BAT26),
[GIST). acute myeloid leukemia, melanoma), gene includes comparison of neoplastic and normal tissue, if
analysis, targeted sequence analysis (eg, exons 8, 11, 13, performed
17, 18) 0 CPT Changes: An Insider's View2012
0 CPT Changes: An Insider's View 2016 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
0 CPTAssistantAug16:10, Nov 18:9 # 81292 MLH1 {mutl homolog 1, colon cancer, nonpolyposis type
2) (eg, hereditary non-polyposis colorectal cancer. Lynch
81273 KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog)(eg, mastocytosisl. gene analysis, syndrome) gene analysis; full sequence analysis
0816 variant(s) 0 CPT Changes: An Insider's View 2012
0 CPT Changes: An Insider's View 2016 0 CPT Assistant May 12:4, Jan 15:3, Aug 16:10, Nov 18:9
0 CPT Assistant Aug 16:10, Nov 18:9

0 0 0 0 0
0 0 0 0 0 0
81275 KRAS {Kirsten rat sarcoma viral oncogene homolog)(eg, 0 0 0
0 0 0 0
0
0 0 0 0
0 0
carcinoma) gene analysis; variants in exon 2 (eg, codons 0
0 0
0
0
0 0 0 0
0
0
0 0 0
12 and 13) 0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0 CPTChanges: An Insider's View2012, 2016 0 0 0
0 0
0 0
0
0 0 0 0 0
0 0 0 •
0 CPT Assistant May 12:4, Sep 13:6, Aug 16:10, Nov 18:9 0
00
0 0 0
0
0
0
00
0 0 0
0
0
0
0
0 0 0 0 0 0 0 0 0
0 0
..
0 0 0 0 0
0 0
0 0 0 0
0
624 *=Telemedicine '4=Audio-only +=Add-on code ~=FDAapproval pending #=Resequenced code <Sl=Modifier51 exempt @~~ =Seepxixfordetails
# 81288 promoter methylation analysis # 81291 MTHFR (5, 10-methy/enetetrahydrofolate reductase)(eg,

O CPT Changes: An Insider's View 2015 hereditary hypercoagulability) gene analysis. common
O CPTAssistantJan 15:3, Aug 16:10, Nov 18:9 variants (eg, 677T, 1298C)
known familial variants
# 81293 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9 81305 MYD88 (myeloid differentiation primary response 88) (eg,
Waldenstrom's macroglobulinemia, lymphoplasmacytic
# 81294 duplication/deletion variants leukemia) gene analysis. p.Leu265Pro (L265P) variant
0 CPTAssistantMay12:4, Aug 16:10. Nov 18:9
0 CPT Assistant Nov 18:9. Jul 19:3
# 81338 MPL (MPL proto-oncogene, thrombopoietin receptor)(eg, 81306 Code is out of numerical sequence. See 81310-81316
myeloproliferative disorder) gene analysis; common
variants (eg, W515A, W515K, W515L, W515R) 81307 Code is out of numerical sequence. See 81310-81316
0 CPT Assistant Aug 21 :10
# 81339 sequence analysis, exon 10
0 CPT Changes: An Insider's View2021 81310 NPM1 (nucleophosmin)(eg, acute myeloid leukemia)
0 CPT Assistant Aug 21:10 gene analysis, exon 12 variants
# 81295 MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9
1) (eg. hereditary non-polyposis colorectal cancer. Lynch
syndrome) gene analysis; full sequence analysis 81311 NAAS (neuroblastoma RAS viral [v-ras] oncogene
0 CPT Changes: An Insider's View 2012 homolog) (eg, colorectal carcinoma), gene analysis,
0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9 variants in exon 2 (eg, codons 12and13) and exon 3 (eg,
codon 61)
81291 Code is out of numerical sequence. See 81299-81310 0 CPT Changes: An Insider's View2016
81292 Code is out of numerical sequence. See 81276-81297 0 CPT Assistant Aug 16:10
81294 Code is out of numerical sequence. See 81276-81297 # 81191 NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid
tumors) translocation analysis
81296 known familial variants # 81192 NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid
0 CPT Changes: An Insider's View 2012 tumors) translocation analysis
0 CPT Assistant May 12:3, Aug 16:10, Nov 18:9 0 CPT Changes: An Insider's View2021
81297 duplication/deletion variants # 81193 NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid
0 CPT Changes: An Insider's View2012 tumors) translocation analysis
81298 MSH6 (mutS homolog 6 [E. coli])(eg, hereditary non- # 81194 NTRK (neurotrophic receptor tyrosine kinase 1, 2, and 3)
polyposis colorectal cancer, Lynch syndrome) gene (eg, solid tumors) translocation analysis
analysis; full sequence analysis 0 CPT Changes: An Insider's View 2021, 2022
0 CPT Assistant May .12:4, Aug 16:10, Nov 18:9 (For translocation analysis NTRK1,NTRK2, and NTRK3
using a single assay, use 81194)
81299 known familial variants
# 81306 NUDT15 (nudix hydrolase 15)(eg, drug metabolism) gene
analysis. common variant(s) (eg, *2, *3, *4, *5, *6)
81300 duplication/deletion variants 0 CPT Assistant Nov 18:9, Jul 19:3

0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0 0
0 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
.
0
0
0
0
0
0
0
0
0
0
00 0 00 0 00
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
~=Revised aide • == New code ... • =Contains new or revised text H =Duplicate PLA test ti= Category I PLA American Medical Association 625
81312--81327 Pathology and Laboratory/ Molecular Pathology CPT 2023
# 81312 PABPN1 (poly/A] binding protein nuclear 1) (eg, # 81326 known familial variant
oculopharyngeal muscular dystrophy) gene analysis. 0 CPT Changes: An Insider's View 2013
evaluation to detect abnormal (eg, expanded) alleles 0 CPT Assistant Sep 13:3. Aug 16:10, Nov 18:9
81317 PMS2 (postmeiotic segregation increased 2
# 81307 PALB2 (partner and localizer of BRCA2) (eg, breast and [S. cerevisiae]) (eg. hereditary non-polyposis colorectal
pancreatic cancer) gene analysis; full gene sequence cancer. Lynch syndrome) gene analysis; full sequence
0 CPT Changes: An Insider's View2020 analysis
0 CPT Assistant Mar 20:13 0 CPT Changes: An Insider's View 2012

0 CPT AssistantMay 12:4. Aug 16:10. Nov 18:9
0 CPT Changes: An Insider's View2020 81318 known familial variants

0 CPT Assistant Mar 20:13 0 CPT Changes: An Insider's View 2012
81313 PCA3/KLK3 (prostate cancer antigen 3 [non-protein

coding]/kal/ikrein-related peptidase 3 [prostate specific 81319 duplication/deletion variants

antigen]) ratio (eg, prostate cancer) 0 CPT Changes: An Insider's View2012
0 CPT Changes: An Insider's View 2015 0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9
0 CPT Assistant Jan 15:3, Aug 16: 10
81314 PDGFRA (platelet-derived growth factor receptor. alpha
# 81343 PPP2R28 (protein phosphatase 2 regulatory subunit
polypeptide)(eg, gastrointestinal stromal tumor [GIST]),
Bbeta) (eg, spinocerebellar ataxia) gene analysis,
gene analysis. targeted sequence analysis (eg, exons 12.
evaluation to detect abnormal (eg, expanded) alleles
18)

81321 PTEN (phosphatase and tensin homolog) (eg, Cowden

# 81309 PIK3CA (phosphatidylinositol-4. 5-biphosphate 3-kinase,
syndrome. PTENhamartoma tumor syndrome) gene
catalytic subunit alpha) (eg, colorectal and breast cancer)
analysis; full sequence analysis
gene analysis. targeted sequence analysis (eg, exons 7,
9, 20)

0 CPT Assistant Sep 13:3. Aug 16:10. Nov 18:9
0 CPT Assistant Apr 20:11 81322 known familial variant

# 81320 PLCG2 (phospholipase Cgamma 2) (eg, chronic
lymphocytic leukemia) gene analysis. common variants 0 CPT AssistantSep 13:3, Aug 16:10. Nov 18:9
(eg, R665W. S707F. L845F) 81323 duplication/deletion variant
0 CPT Changes: An Insider's View2019 0 CPTChanges: An Insider's View2013
0 CPT Assistant Jul 19:3 0 CPT Assistant Sep 13:3, Aug 16:10, Nov 18:9
81315 PML!RARalpha, (t(15;17)), (promyelocytic leukemia/ 81324 Code is out of numerical sequence. See 81310-81318
retinoic acid receptor alpha) (eg, promyelocytic leukemia)
translocation analysis; common breakpoints (eg, intron 3 81325 Code is out of numerical sequence. See 81310-81318
and intron 6), qualitative or quantitative 81326 Code is out of numerical sequence. See 81310-81318
# 81334 RUNX1 (runt related transcription factor 1J(eg, acute
0 CPT Assistant May 12:4, Aug 16:10
myeloid leukemia. familial platelet disorder with
81316 single breakpoint (eg, intron 3, intron 6 or exon 6). associated myeloid malignancy) gene analysis, targeted
qualitative or quantitative sequence analysis (eg, exons 3-8)
0 CPT Changes: An Insider's View 2012 0 CPTChanges: An Insider's View2018
0 CPTAssistantMay12:4. Aug 16:10 0 CPT Assistant Nov 18:9
(For intron 3 and intron 6 [including exon 6 if performed] 81327 SEPT9 (Septin9) (eg, colorectal cancer) promoter
analysis, use 81315) methylation analysis
(If both intron 6 and exon 6 are analyzed, without intron
0 CPTChanges: An Insider's View2017. 2019
3, use one unit of 81316) 0 CPT Assistant Nov 18:9. Jul 19:3
# 81324 PMP22 (peripheral myelin protein 22){eg, Charcot-Marie-

Tooth, hereditary neuropathy with liability to pressure
0 0 0 0 0
palsies) gene analysis; duplication/deletion analysis 0
0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
0 0
0 0
0 0 0
0
0
0 0
0 0
0 0 0
0
0
0 CPT AssistantSep 13:3, Aug 16:10. Nov 18:9 0

0
0
0
0 0
0 0 0 0 0 0 0 0 0
0 0
# 81325 full sequence analysis 0 0 0
0 0 ° 0 0 0 0
0 0 ° 0 0
0 CPT Changes: An Insider's View 2013 0 00

0 0 0 0 0 0 00
0 0 0 0 0 0 0
0 CPT Assistant Sep 13:3, Aug 16:10, May 18:6, Nov 18:9 0 0 0
0
0
0
0 0 0
0
0 0 0
0
0
0
0 0 0
0
0 0
0
626 *
= Telemedicine '4 = Audi<>-only +=Add-on code )(=FDA approval pending #=Resequenced code l9 =Modifier 51 exempt ~00 =See p xix for details
CPT2023 Pathology and Laboratory I Molecular Pathology 81332-81342
# 81332 SERPINA 1(serpin peptidase inhibitor, clade A alpha-1 #81345 TERT (telomerase reverse transcriptase) (eg, thyroid
antiproteinase, antitrypsin, member 1}(eg, alpha-1- carcinoma, glioblastoma multiforme) gene analysis,
antitrypsin deficiency). gene analysis, common variants targeted sequence analysis (eg, promoter region) ·
(eg, *S and *Z) 0 CPT Changes: An Insider's View 2019
@ CPTChanges: An Insider's View2012 0 CPT Assistant Nov 18:9. Jul 19:3
@ CPT Assistant May 12:4, Aug 16:10, Nov 18:9
81333 TGFBI (transforming growth factor beta-induced) (eg.
# 81347 SF381 (splicing factor [3b] subunit 81 J(eg, corneal dystrophy) gene analysis, common variants (eg,
myelodysplastic syndrome/acute myeloid leukemia) gene R124H,R124C, R124L,R555W,R555Q)
analysis, common variants (eg, A672T. E622D. L833F, 0 CPT Changes: An Insider's View 2019
R625C, R625L) 0 CPT Assistant Nov .18:9. Jul 19:3
0 CPT Assistant Jun 21 :9 #
# 81351 TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene
81328 SLC0181 (solute carrier organic anion transporter family,
analysis; full gene sequence
member 181}(eg, adverse drug reaction). gene analysis,
common variant(s) (eg, *5)
0 CPT Changes: An Insider's View 2018 # 81352 targeted sequence analysis (eg. 4 oncology)
0 CPT Assistant Nov 18:9 0 CPT Changes: An Insider's View2021
81329 SMN1 (survival of motor neuron 1, telomeric} (eg, spinal # 81353 known familial variant
muscular atrophy) gene analysis; dosage/deletion 0 CPT Changes: An Insider's View2021
analysis (eg, carrier testing), includes SMN2 (survival of
motor neuron 2, centromeric) analysis. if performed
81335 TPMT (thiopurine S-methyltransferase) (eg, drug
metabolism). gene analysis, common variants (eg. *2. *3)
0 CPT Assistant Nov 18:9. Jul 19:3 81337 Code is out of numerical sequence. See 81318-81335
# 81337 known familial sequence variant(s) 81338 Code is out of numerical sequence. See 81276-81297
0 CPT AssistantNov 18:9, Jul 19:3
81340 TRB@ (T cell antigen receptor, beta} (eg, leukemia and
81330 SMPD1 (sphingomyelin phosphodiesterase 1, acid lymphoma). gene rearrangement analysis to detect
lysosomal}(eg, Niemann-Pick disease. Type A) gene abnormal clonal population(s); using amplification
analysis, common variants (eg, R496L. L302P. fsP330) methodology (eg, polymerase chain reaction)
0
0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9

0 CPTAssistantMay12:4, Aug 16:10, Nov 18:9
81331 SNRPN!UBE3A (small nuclear ribonucleoprotein 81341 using direct probe methodology (eg, Southern blot)
polypeptide N and ubiquitin protein ligase E3AJ (eg,
Prader-Willi syndrome and/or Angelman syndrome).
methylation analysis
0 CPT Changes: An Insider's View 2012 81342 TRG@ (T cell antigen receptor, gamma) (eg, leukemia and
0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9 lymphoma). gene rearrangement analysis. evaluation to
detect abnormal clonal population(s)
# 81348 SRSF2 (serine and arginine-rich splicing factor 2) (eg, 0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9
myelodysplastic syndrome, acute myeloid leukemia) gene
(For T cell antigen alpha {TRA@]gene rearrangement
analysis. common variants (eg, P95H, P95L)
0 CPT Assistant Jun 21 :9 (For T cell antigen delta [TRD@]gene rearrangement
# 81344 TBP (TATA box binding protein} (eg, spinocerebellar
ataxia) gene analysis, evaluation to detect abnormal (eg, 81343 Code is out of numerical sequence. See 81318-81335
expanded) alleles
0 CPT Changes: An Insider's View2019 0
0
0 0
0
0
0
0
0 0
0
0
0
0
0 CPT AssistantNov 18:9

•
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0 0
0
0
0
0 0 0 0 0 0 0 0
0
0
0
0
0
0
0 0
0
•
0
0
0
0
0
0
0
0
0
0
• 0
0
0
0
0
0
0
0
0
00
0
0 0
0 0 00
0
• 0
0
0
00
0 0 0 0 0 0
0 0
0
0 0
0
0
0
0
0 • 0
0
0 0
0
0
0
0
0
0
0 • 0 0
A=Revised code • = New code .,. •=Contains new or revised text H=Duplicate PIA test ti =Category IPIA American Medical Association 627
8134&-81373 Pathology and Laboratory I Molecular Pathology CPT 2023
81344 Code is out of numerical sequence. See 81318-81335 -B, -C, -DRBl, and -DQBl for kidney transplantation).
81345 Code is out of numerical sequence. See 81318-81335 Each HLA gene typically has multiple variant alleles or
allele groups that can be identified by typing. For HLA
81346 TYMS (thymidylate synthetaseJ(eg. 5-fluorouracil/5-FU result reporting, a low resolution HLA type is denoted by
drug metabolism). gene analysis. common variant(s) (eg, a two digit HLA name {eg, A*02) and intermediate
tandem repeat variant) resolution typing by a string of alleles or an NMDP
0 CPT Changes: An Insider's View2018 {National Marrow Donor Program) code {eg,
0 CPT Assistant Nov 18:9 B*l4:01/07N/08/12/14, B*39CKGN). Both low and
81347 Code is out of numerical sequence. See 81327-81329 intermediate resolutions are considered low resolution for
code assignment. High resolution typing resolves the
common well defined (CWD) alleles and is usually
81349 Code is out of numerical sequence. See 81228-81235 denoted by at least 4 digits {eg, A*02:02, *03:01:01:01,
A*26:01:01G, and C*03:04P), however, high resolution
# 81357 U2AF1 (U2 small nuclear RNA auxiliary factor 1J(eg.
myelodysplastic syndrome, acute myeloid leukemia) gene
typing may include some ambiguities for rare alleles,
analysis. common variants (eg, S34F. S34Y, 0157R, which may be reported as a string of alleles or an NMDP
0157P) code.
0 CPT Changes: An Insider's View 2021 If additional testing is required to resolve ambiguous
0 CPT Assistant Jun 21 :9 allele combinations for high resolution typing, this is
81350 UGT1A 1(UDP glucuronosyltransferase 1 family. included in the base HLA typing codes below. The gene
polypeptideA1J(eg, drug metabolism, hereditary names have been italicized similar to the other molecular
unconjugated hyperbilirubinemia [Gilbert syndrome]) pathology codes.
gene analysis, common variants (eg, *28, *36, *37) (For HLA antigen typing by non-molecular pathology
0 CPT Changes: An Insider's View2012. 2020 techniques. see 86812, 86813. 86816. 86817, 86821)
0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9. Apr 20:9
81370 HLA Class I and II typing, low resolution (eg. antigen
81351 Code is out of numerical sequence. See 81330-81340 equivalents); HLA-A. -8, -C. -DR81/3/ 4/ 5. and -0081
81371 HLA-A. -8. and -DR81 (eg, verification typing)
81355 VKORC1 (vitamin Kepoxide reductase complex. subunit 0 CPT Changes: An Insider's View2012. 2014
1J(eg, warfarin metabolism). gene analysis. common 0 CPT Assistant May 12:4. Aug 16:10. Nov 18:9
variant(s) (eg, -1639G>A. c.173+ 1OOOC>T)
0 CPT Changes: An Insider's View 2012, 2016 (When HLA typing includes a determination of the
0 CPT Assistant May 12:4. A~g 16:10, Nov 18:9 presence or absence of the DRB3/4/5 genes, that service
is included in the typing and is not separately reported)
81372 HLA Class I typing, low resolution (eg, antigen
81360 ZRSR2 (zinc finger CCCH-type. RNA binding motif and equivalents); complete fie, HLA-A. -8, and -CJ
serine/arginine-rich 2J (eg, myelodysplastic syndrome, 0 CPT Changes: An Insider's View2012
acute myeloid leukemia) gene analysis, common 0 CPT Assistant May 12:4, Aug 16:10. Nov 18:9
variant(s) (eg, E65fs. E122fs. R448fs)
0 CPT Changes: An Insider's View2021 (When performing both Class I and II low resolution HLA
0 CPT Assistant Jun 21 :9 typing for HLA-A.-8,-C, -DR81/3/4/5, and -0081, use
81370)
81373 one locus (eg. HLA-A. -8, or -CJ. each
81363 Code is out of numerical sequence. See 81253-81256 0 CPT Assistant May 12:4, Jun 12:16, Aug 16:10, Nov 18:9
81364 Code is out of numerical sequence. See 81253-81256 (When performing a complete Class I [HLA-A.-8, and-CJ
low resolution HLA typing. use 81372)
Human leukocyte antigen (HLA) typing is performed to
assess compatibility of recipients and potential donors as (When the presence or absence of a single antigen
a part of solid organ and hematopoietic stem cell equivalent is reported using low resolution testing. use
pretransplant testing. HLA testing is also performed to 81374)
identify HLA alleles and allele groups {antigen 0 0 0 0
0 0 0 0 0 0
0 0
equivalents) associated with specific diseases and 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
individualized responses to drug therapy {eg, HLA-B*27 0 0 0 0 0 0 0 0 0 0
and ankylosing spondylitis and HLA-B*57:01 and 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0
abacavir hypersensitivity), as well as other clinical uses. 0 0 0 0 0 0 0 0 0
0 0 ° 0 0
00 0 00
One or more HLA genes may be tested in specific clinical 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0
situations {eg, HLA-DQBl for narcolepsy and HLA-A, 0 0 0 0 0 0 0 0 0
. 0 0
0
0 . 0 0 0
0
628 *
= Te!emedicine '4 = Audio-only + = Add-on code ,¥=FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory I Molecular Pathology 81374--81400
81374 one antigen equivalent (eg, 8*27), each 81382 HLA Class II typing, high resolution (ie, alleles or allele
0 CPT Changes: An Insider's View 2012 groups!; one locus (eg, HLA-DR81, -DR83/4/5, -0081,
~ CPT Assistant May 12:4. Jun 12:16, Aug 16:10, Nov 18:9 -DOA 1, -DP81, or -DPA 1), each
(When testing for presence or absence of more than 2
antigen equivalents at a locus. use 81373 for each locus

0 CPT Assistant May 12:4, Jun 12:16, Nov 18:9
tested) (When only the presence or absence of a single allele or

allele group is reported using high resolution testing, use
81375 HLA Class II typing, low resolution (eg, antigen
81383)
equivalents); HLA-DR81/3/4/5 and -D081
0 CPT Changes: An Insider's View 2012 (When high resolution typing of any or all of the
0 CPT Assistant May 12:4. Aug 16:10, Nov 18:9 DRB3/4/5 genes is performed, treat as one locus)
(When performing both Class I and II low resolution HLA 81383 one allele or allele group (eg, HLA-D081 *06:02P),
typing for HLA-A,-8,-C, -DR87/3/4/5,and-D081, use each
81370) 0 CPT Changes: An Insider's View 2012
81376 one locus {eg, HLA-DR81, -DR83/4/5, -D081, -DOA 1,

0 CPT Assistant May 12:4, Jun 12:16, Nov 18:9
-DP81. or -DPA 1), each (When testing for the presence or absence of more than
0 CPT Changes: An Insider's View2012, 2014 2 alleles or allele groups at a locus, use 81382 for each
0 CPT Assistant May 12:4, Jun 12:16. Aug 16:10. Nov 18:9 locus)
(When low resolution typing is performed for HLA-
DR81/3/4/5and-0081, use 81375)
Tier 2 Molecular Pathology
(When HLA typing includes a determination of the
Procedures
presence or absence of the DR83/4/5 genes, that service The following molecular pathology procedure (Tier 2)
is included in the typing and is not separately reported. codes are used to report procedures not listed in the Tier
When low or intermediate resolution typing of any or all 1 molecular pathology codes (81161, 81200-81383).
of the DR83/4/5 genes is performed, treat as one locus) They represent medically useful procedures that are
81377 one antigen equivalent, each generally performed in lower volumes than Tier 1
procedures (eg, the incidence of the disease being tested is
0 CPT Assistant May 12:4, Jun 12:16. Aug 16:10, Nov 18:9
rare). They are arranged by level of technical resources
and interpretive work by the physician or other qualified
(When testing for presence or absence of more than 2 health care professional. The individual analyses listed
antigen equivalents at a locus, use 81376 for each locus) under each code (ie, level of procedure) utilize the
81378 HLA Class I and II typing, high resolution (ie, alleles or definitions and coding principles as described in the
allele groups). HlA-A, -8, -C, and -DR81 introduction preceding the Tier 1 molecular pathology
0 CPT Changes: An Insider's View2012 codes. The parenthetical examples of methodologies
0 CPT AssistantMay 12:4. Jun 12:16, Aug 16:10. Nov 18:9 presented near the beginning of each code provide general
guidelines used to group procedures for a given level and
81379 HLA Class I typing, high resolution (ie, alleles or allele
are not all-inclusive.
groups); complete (ie, HLA-A, -8, and -CJ
0 CPT Changes: An Insider's View2012 Use the appropriate molecular pathology procedure level
0 CPT Assistant May 12:4, Aug 16:10, Nov 18:9 code that includes the specific analyte listed after the code
descriptor. If the analyte tested is not listed under one of
81380 one locus (eg, HLA-A, -8, or -C), each
the Tier 2 codes or is not represented by a Tier 1 code, use
the unlisted molecular pathology procedure code, 81479.
0 CPT Assistant May 12:4. Jun 12:16. Aug 16:10, Nov 18:9
See the Introduction section of the CPT code set for a
(When a complete Class I high resolution typing for HLA- complete list of the dates of release and implementation.
A,-8, and-Cis performed, use 81379)
81400 Molecular pathology procedure, Level 1 (eg, identification
(When the presence or absence of a single allele or allele of single germline variant [eg, SNP] by techniques such
group is reported using high resolution testing, use as restriction enzyme digestion or melt curve analysis)
81381)
ACADM {acyl-CoA dehydrogenase, C-4 to C-12 straight
81381 one allele or allele group (eg, 8*57:01P), each chain, MCAD)(eg, medium chain acyl dehydrogenase
0 CPT Changes: An Insider's View2012 deficiency!. K304E variant
0 CPT Assistant May 12:4, Jun 12:16. Aug 16:10, Nov 18:9 0
0
0
0
0
0 0 0 0 0 0 0
0 0
(When testing for the presence or absence of more than 0 0 0
0000000
0 0
0 0 0
0 0
0 0
0 0
2 alleles or allele groups at a locus, use 81380 for each 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
locus) 0 0 0 0 0 0 0
0
0 0 0 0
0
0 0 0
0 0 0
0 00 o o o o oa 0 0
0 0 0 0 00 0
0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
A= Revised code •=New code • .. =Contains new or revised text }E =Duplicate PlA test t+ =Category I PlA American Medical Association 629
81401 Pathology and Laboratory I Molecular Pathology CPT 2023
ACE (angiotensin converting enzyme) (eg, hereditary TORIA (torsin family I. member A [torsin A])(eg. early-
blood pressure regulation). insertion/deletion variant onset primary dystonia [DYT1 ]), 907 _909delGAG
(904_906delGAG) variant
AGTRI (angiotensin II receptor, type l)(eg, essential
~ CPT Changes: An Insider's View 2012, 2013. 2014. 2018, 2019
hypertension). 1166A>C variant
~ CPT Assistant May 12:4. Jul 13:12. Sep 13:4-5. 8, Jan 15:3,
BCKOHA (branched chain keto acid dehydrogenase El. Aug 16: 10, Nov 18:9. Jul 19:3
alpha polypeptide)(eg. maple syrup urine disease. type
81401 Molecular pathology procedure. Level 2 (eg, 2-10 SNPs. 1
lA). Y438N variant
methylated variant, or 1 somatic variant [typically using
CCR5 (chemokine C-C motif receptor 5)(eg. HIV nonsequencing target variant analysis]. or detection of a
resistance), 32-bp deletion mutation/794 825del32 dynamic mutation disorder/triplet repeat)
deletion
ABCCB (ATP-binding cassette, sub-family C[CFTR!MRP].
CLRNI (clarin I) (eg. Usher syndrome, type 3). N48K member 8) (eg, familial hyperinsulinism). common
variant variants (eg, c.3898-9G>A [c.3992-9G>A). F1388del)
F2 (coagulation factor 2) (eg. hereditary ABL I (ABL proto-oncogene I. non-receptor tyrosine
hypercoagulabilityL 1199G>A variant kinase)(eg, acquired imatinib resistance). T3151 variant
F5 (coagulation factor V) (eg. hereditary ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight
hypercoagulability), HR2 variant chain, MCAO)(eg, medium chain acyl dehydrogenase
deficiency), commons variants (eg, K304E, Y42H)
Fl (coagulation factor VII [serum prothrombin conversion
accelerator]) (eg, hereditary hypercoagulability), R3530 ADRB2 (adrenergic beta-2 receptor surface) (eg, drug
variant metabolism). common variants (eg, G16R. 027E)
Fl 3B (coagulation factor XIII, Bpolypeptide) (eg, APOB (apolipoprotein B)(eg, familial
hereditary hypercoagulability). V34L variant hypercholesterolemia type B). common variants (eg,
R35000, R3500W)
FGB (fibrinogen beta chain) (eg, hereditary ischemic heart
disease). -455G>A variant APOE (apolipoprotein E)(eg, hyperlipoproteinemia type
Ill. cardiovascular disease, Alzheimer disease). common
FGFRI (fibroblast growth factor receptor I) (eg, Pfeiffer
variants (eg, *2, *3, *4)
syndrome type 1. craniosynostosis). P252R variant
CBFB/MYH1 I (inv(16)) (eg, acute myeloid leukemia).
FGFR3 (fibroblast growth factor receptor 3) (eg, Muenke
qualitative. and quantitative. if performed
syndrome). P250R variant
CBS (cystathionine-beta-synthase) (eg, homocystinuria,
FKTN (fukutin)(eg, Fukuyama congenital muscular
cystathionine beta-synthase deficiency), common
dystrophy), retrotransposon insertion var!ant
variants (eg, 1278T. G307S)
GNE (glucosamine
CFH!ARMS2 (complement factor H/age-related
[UOP-N-acetyl]-2-epimerase/N-acetylmannosamine
maculopathy susceptibility 2)(eg, macular degeneration).
kinase)(eg, inclusion body myopathy 2 [IBM2]. Nonaka
common variants (eg, Y402H [CFH]. A69S [ARMS2])
myopathy), M712T variant
OEK/NUP214 (t(6;9))(eg, acute myeloid leukemia),
/VO (isovaleryl-CoA dehydrogenase)(eg, isovaleric
translocation analysis. qualitative. and quantitative, if
acidemia). A282V variant
performed
LCT (lactase-phlorizin hydrolase) (eg. lactose intolerance),
E2A/PBXI (t(1;19))(eg, acute lymphocytic leukemia).
13910 C>T variant
translocation analysis. qualitative. and quantitative. if
NEB (nebulin)(eg, nemaline myopathy 2). exon 55 performed
deletion variant
EML4/ALK (inv(2))(eg, non-small cell lung cancer).
PCDHl5 (protocadherin-related 15)(eg, Usher syndrome translocation or inversion analysis
type 1F). R245X variant
ETV6/RUNXI (t(12;21))(eg, acute lymphocytic leukemia).
SERPINEI (serpine peptidase inhibitor clade E. member I. translocation analysis. qualitative. and quantitative, if
plasminogen activator inhibitor -1. PAI- I) (eg. performed
thrombophilia). 4G variant
SHOC2 (soc-2 suppressor of clear homolog) (eg, Noonan-
like syndrome with loose anagen hair). S2G variant 0 0 0 0 0
0 0 0 0 0 0 0
SRY (sex determining region Y) (eg. 46,XX testicular 0
• 0
0
0
0
0
• 0
0
0
0
0
0
0
0 0
0
0 0 0 0 0 0 0 0 0 0 0
disorder of sex development. gonadal dysgenesis). gene 0
0 0 0 0 0 0 0 0 0 0 0 0
analysis 0
0
0
0
0
0 0 0 0 0 0 0 0 0
0 0 ° 0 0 0
0 00 0 0 0 0 00 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
630 *= Telemedicine ~ ==Audio-only +=Add-on code ,¥' ==FDA approval pending #==Resequenced code CY= Modifier 51 exempt 0 0 0 ==See pxix for details
CPT 2023 Pathology and Laboratory I Molecular Pathology 81401
EWSR1/ATF1 (t(12;22))(eg, clear cell sarcoma). LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson
transkication analysis, qualitative, and quantitative, if disease). common variants (eg, R1441G, G2019S, 12020T)
performed
MED12 (mediator complex subunit 12}(eg, FG syndrome
EWSR1/ERG (t(21;22}}(eg, Ewing sarcoma/peripheral type 1, Lujan syndrome). common variants (eg, R961W,
neuroectodermal tumor!. translocation analysis, N1007S)
qualitative. and quantitative, if performed
MEG3/DLK1 {maternally expressed 3 [non-protein
EWSR1/FL/1 (t(11;22}}(eg, Ewing sarcoma/peripheral codingVdelta-like 1homolog [Drosophila]} (eg,
neuroectodermal tumor). translocation analysis, intrauterine growth retardation). methylation analysis
qualitative, and quantitative, if performed
MLL!AFF1 (t{4; 11 }} (eg, acute lymphoblastic leukemia).
EWSR1/WT1 (t(11;22}}(eg, desmoplastic small round cell translocation analysis, qualitative. and quantitative, if
tumor), translocation analysis, qualitative, and performed
quantitative, if performed
MLL!MLLT3{t{9;11}}(eg, acute myeloid leukemial.
F11 (coagulation factor XI} (eg, coagulation disorder). translocation analysis, qualitative, and quantitative. if
common variants (eg, E117X (Type II), F283L (Type Ill), performed
IVS14del14, and IVS14+ 1G>A [Type I])
MT-ATP6 {mitochondrially encoded ATP synthase 6) (eg,
FGFR3 (fibroblast growth factor receptor 3) (eg, neuropathy with ataxia and retinitis pigmentosa [NARP].
achondroplasia, hypochondroplasial. common yariants Leigh syndrome). common variants (eg, m.8993T>G.
(eg, 1138G>A. 1138G>C. 1620C>A. 1620C>G) m.8993T>C)
FIP1L1/PDGFRA (del[4q12]}(eg, imatinib-sensitive chronic MT-ND4, MT-ND6 {mitochondrially encoded NADH
eosinophilic leukemia). qualitative, and quantitative, if dehydrogenase 4, mitochondrially encoded NADH
performed dehydrogenase 6) (eg, Leber hereditary optic neuropathy
[LHON]). common variants (eg. m.11778G>A. m.3460G>A.
FLG (filaggrin} (eg, ichthyosis vulgaris). common variants
m.14484T>C)
(eg, R501X, 2282del4, R2447X, S3247X, 3702delG)
MT-ND5 {mitochondrially encoded tRNA leucine 1
FOX01/PAX3(t(2;13)) (eg. alveolar rhabdomyosarcoma).
[UUA/G], mitochondrially encoded NADH dehydrogenase
translocation analysis, qualitative. and quantitative, if
5) (eg, mitochondrial encephalopathy with lactic acidosis
performed
and stroke-like episodes [MELAS]), common variants (eg,
FOX01/PAX7 (t(1;13}}(eg. alveolar rhabdomyosarcoma), m.3243A>G, m.3271T>C. m.3252A>G, m.13513G>A)
MT-RNR1 (mitochondrially encoded 12S RNA}(eg,
performed
nonsyndromic hearing loss). common variants (eg,
FUS!DDIT3 (t(12;16}}(eg, myxoid liposarcoma). m.1555A>G. m.1494C>T)
MT-TK (mitochondrially encoded tRNA lysine} (eg,
performed
myoclonic epilepsy with ragged-red fibers [MERRF]).
GALC (galactosylceramidase}(eg, Krabbe disease). common variants (eg. m.8344A>G. m.8356T>C)
common variants (eg, c.857G>A. 30-kb deletion)
MT-TL 1{mitochondrial/y encoded tRNA leucine 1
GALT (galactose-1-phosphate uridylyltransferase} (eg, [UUA!G]}(eg, diabetes and hearing loss). common
galactosemia). common variants (eg, 0188R, S135L, variants (eg, m.3243A>G, m.14709 T>C) MT-TL 1
K285N, T138M, L195P. Y209C, IVS2-2A>G. P171S. del5kb,
MT-TS1, MT-RNR1 (mitochondrially encoded tRNA serine
N314D, L218UN314D)
1[UCNJ, mitochondrially encoded 12S RNA} (eg,
HT 9 {imprinted maternally expressed transcript [non- nonsyndromic sensorineural deafness [including
protein coding]} (eg, Beckwith-Wiedemann syndrome). aminoglycoside-induced nonsyndromic deafness]),
methylation analysis common variants (eg. m.7445A>G. m.1555A>G)
IGH@/BCL2 {t{14;1B}}(eg. follicular lymphoma). MUTYH (mutY homolog [E. coli]} (eg, MYH-associated
translocation analysis; single breakpoint (eg, major polyposis). common variants (eg, Y165C, G382D)
breakpoint region [MBR] or minor cluster region [mer]).
NOD2 (nucleotide-binding oligomerization domain
qualitative or quantitative
containing 2) (eg. Crohn's disease. Blau syndrome I.
(When both MBR and mer breakpoints are performed, use common variants (eg, SNP 8, SNP 12, SNP 13)
81278)
0 0 0 0 0
KCN010T1 (KCN01 overlapping transcript 1[non-protein 0 0 0
0 • 0 0
0
0 0 0 0 0 0 0
coding]} (eg, Beckwith-Wiedemann syndrome). 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
methylation analysis 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
L/NC00518 (long intergenic non-protein coding RNA 518) 0 0 0 0 0 0 0 0 0
0 0 ° 0 0 0 0
(eg, melanoma). expression analysis 00 0 0 0 oo 0 0 0 00

0 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
A=Revisedcode •=New code ~ ~=Contains new or revised text H=Duplicate PLA test t~=Category I PLA American Medical Association 631
NPM1/ALK (t(2.5)) (eg, anaplastic large cell lymphoma). Uniparental disomy (UPD) (eg, Russell-Silver syndrome,
translocation analysis Prader-Willi/Angel man syndrome). short tandem repeat
(STR) analysis
PAXB/PPARG (t(2;3) (q13;p25)) (eg, follicular thyroid
carcinoma). translocation analysis
a 2021
CPT Changes: An Insider's View 2012, 2013. 2015, 2014, 2016,
PRAME (preferentially expressed antigen in melanoma) a CPTAssistant May 12:4, Jul 13:12. Sep 13:5, 9, Jan 15:3,
(eg, melanoma). expression analysis Aug 16:10, Nov 18:9, Aug 21:10
PRSS1 (protease, serine. 1[trypsin 1})(eg, hereditary 81403 Molecular pathology procedure, Level 4 (eg, analysis of
pancreatitis). common variants (eg, N291, A16V. R122H) single exon by DNA sequence analysis, analysis of> 1O
amplicons using multiplex PCR in 2 or more independent
PYGM (phosphorylase, glycogen. muscle) (eg, glycogen reactions, mutation scanning or duplication/deletion
storage disease type V, McArdle disease), common variants of 2-5 exons)
variants (eg, R50X, G205S)
ANG (angiogenin, ribonuclease. RNase A family, 5) (eg,
RUNX1/RUNX1T1 (t(8;21))(eg, acute myeloid leukemia) amyotrophic lateral sclerosis). full gene sequence
translocation analysis, qualitative. and quantitative. if
performed ARX (aristaless-related homeobox)(eg, X-linked
lissencephaly with ambiguous genitalia, X-linked mental
SS18/SSX1 (t(X;78))(eg, synovial sarcoma), translocation retardation), duplication/deletion analysis
analysis, qualitative, and quantitative, if performed
GEL (carboxyl ester lipase [bile salt-stimulated lipase])
SS18/SSX2 (t(X;18))(eg, synovial sarcoma). translocation (eg, maturity-onset diabetes of the young [MODY)),
analysis, qualitative, and quantitative, if performed targeted sequence analysis of exon 11 (eg, c.1785delC,
VWF (van Willebrand factor) (eg, von Willebrand disease c.1686delT)
type 2N), common variants (eg, T791 M, R816W, R854Q) CTNNB1 (catenin [cadherin-associated protein]. beta 1,
a CPT Changes: An Insider's View2012, 2013, 2014, 2016, 2017, BBkDaJ(eg, desmoid tumors), targeted sequence analysis
2018, 2019, 2021
(eg, exon 3)
a CPTAssistant May 12:4. Jul 13:12, Sep 13:5, Jan 15:3,
Aug 16:10, Nov 18:9. Jul 19:3 DAZ/SRY (deleted in azoospermia and sex determining
region Y)(eg, male infertility). common deletions (eg,
81402 Molecular pathology procedure, Level 3(eg,>10 SNPs.
AZFa, AZFb, AZFc. AZFd)
2-10 methylated variants, or 2-10 somatic variants
[typically using non-sequencing target variant analysis], DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha)
immunoglobulin and T-cell receptor gene rearrangements. (eg, acute myeloid leukemia). targeted sequence analysis
duplication/deletion variants of 1 exon, loss of (eg, exon 23)
heterozygosity [LOH]. uniparental disomy [UPDJ)
EPCAM (epithelial cell adhesion molecule)(eg, Lynch
Chromosome 1p-/19q- {eg, glial tumors). deletion syndrome). duplication/deletion analysis
analysis
FB (coagulation factor VIII) (eg, hemophilia A). inversion
Chromosome 18q- (eg. D18S55, D18S58. D18S61, analysis. intron 1 and intron 22A
D18S64, and D18S69) {eg, colon cancer). allelic
F12 (coagulation factor XII [Hageman factor])(eg,
imbalance assessment {ie. loss of heterozygosity)
angioedema. hereditary, type Ill; factor XII deficiency),
COL 1A 1/PDGFB (t(17;22)) {eg, dermatofibrosarcoma targeted sequence analysis of exon 9
protuberans). translocation analysis, multiple
FGFR3 (fibroblast growth factor receptor 3) (eg, isolated
breakpoints. qualitative, and quantitative, if performed
craniosynostosis), targeted sequence analysis (eg, exon 7)
CYP21A2 (cytochrome P450, family 21. subfamily A.
(For targeted sequence analysis of multiple FGFR3 exons.
polypeptide 2) (eg, congenital adrenal hyperplasia,
use 81404)
21-hydroxylase deficiency), common variants {eg, IVS2-
13G. P30L, 1172N. exon 6 mutation cluster [1235N, V236E. GJB1 (gap junction protein, beta 1)(eg, Charcot-Marie-
M238K], V281 L. L307FfsX6. Q318X. R356W, P453S. Tooth X-linked). full gene sequence
G11 OVfsX21, 30-kb deletion variant)
GNAO (guanine nucleotide-binding protein G[q] subunit
ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, alpha)(eg. uveal melanoma). common variants (eg, R183,
breast cancer) 0209)
MEFV (Mediterranean fever) (eg, familial Mediterranean
fever). common variants {eg, E148Q, P369S, F479L, 0 0 0 0 0
M6801. 1692del. M694V, M6941. K695R. V726A. A744S, 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
R761H) 0
0 0
0
0 0 0 0
0 0
0
0
0 0 0
0
0 0 0 0
TRD@ (T cell antigen receptor. delta) (eg, leukemia and 0 0
0 0 0
0
0 0
0 0 0
0
0
0 0 0 0 0 0 0 0 0 0
lymphoma). gene rearrangement analysis, evaluation to 0 0 0 0
00 0 00 0 0
detect abnormal clonal population 0
0 0 0 0
0
0 0 0
0
0
0 0 0 0 0 0 0 0 0
0 0
0
0
0
0
0
0
0
. 0
0
0
0
0
632 *= Telemedicine '4 =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code 61=Modifier51 exempt :>00=See p xix for details
,
Human erythrocyte antigen gene analyses (eg, SLC14A 1 RHO (Rh blood group, Dantigen) leg, hemolytic disease
[Kidd blood groupl BCAM [Lutheran blood group] ICAM4 of the fetus and newborn. Rh maternal/fetal
[Landsteiner-Wiener blood group] SLC4A 1[Diego blood compatibility). deletion analysis (eg, exons 4, 5, and 7,
group}, AOPI [Colton blood group}, ERMAP [Scianna pseudogene). performed on cell-free fetal DNA in
blood group}, RHCE [Rh blood group, CcEe antigens] KEL maternal blood
{Kell blood groupl DARC [Duffy blood group}, GYPA.
(For human erythrocyte gene analysis of RHO, use a
GYPB, GYPE [MNS blood group] ART4 [Dombrock blood
separate unit of 81403)
group])(eg, sickle-cell disease, thalassemia, hemolytic
transfusion reactions, hemolytic disease of the fetus or SH2D1A (SH2 domain containing IA) leg, X-linked
newborn). common variants lymphoproliferative syndrome). duplication/deletion
analysis
HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene
homolog)(eg, Costello syndrome), exon 2 sequence TWIST1 (twist homolog 1[Drosophila])(eg , Saethre-
Chotzen syndrome). duplication/deletion analysis
KCNC3 {potassium voltage-gated channel, Shaw-related
subfamily, member 3)(eg, spinocerebellar ataxia), UBA 1(ubiquitin-like modifier activating enzyme 1) leg,
targeted sequence analysis (eg, exon 2) spinal muscular atrophy, X-linked), targeted sequence
analysis leg, exon 15)
KCNJ2 (potassium inwardly-rectifying channel, subfamily
J, member 2)(eg, Andersen-Tawil syndrome), full gene VHL (von Hippel-Lindau tumor suppressor) leg, von
sequence Hippel-Lindau familial cancer syndrome), deletion/
duplication analysis
KCNJl 1(potassium inwardly-rectifying channel,
subfamily J, member 1l)(eg, familial hyperinsulinism). VWF (von Willebrand factor) leg, von Willebrand disease
full gene sequence types 2A, 28, 2M). targeted sequence analysis leg, exon
28)
Killer cell immunoglobulin-like receptor (KIR) gene family
(eg, hematopoietic stem cell transplantation), genotyping
Q CPTChanges: An Insider's View2012, 2013, 2015. 2014. 2016.
2017, 2018. 2019. 2021
of KIR family genes
Q CPT Assistant May 12:4, Jul 13:12, Sep 13:3, Jan 15:3,
Known familial variant not otherwise specified, for gene Aug 16:10, May 18:6, Nov 18:9, Jul 19:3. Aug 21 :10
listed in Tier 1 or Tier 2, or identified during a genomic 81404 Molecular pathology procedure. Level 5 leg, analysis of
sequencing procedure, ONA sequence analysis, each 2-5 exons by DNA sequence analysis, mutation scanning
variant exon or duplication/deletion variants of 6-10 exons. or
(For a known familial variant that is considered a characterization of a dynamic mutation disorder/triplet
common variant, use specific common variant Tier 1 or repeat by Southern blot analysis)
Tier 2 code) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain)
MC4R (melanocortin 4 receptor)(eg, obesity), full gene leg. short chain acyl-CoA dehydrogenase deficiency),
sequence targeted sequence analysis (eg, exons 5 and 6)
MICA (MHC class I polypeptide-related sequence A) (eg, AQP2 (aquaporin 2 [collecting duct]Jleg, nephrogenic
solid organ transplantation). common variants (eg, *001, diabetes insipidus), full gene sequence
*002) ARX (aristaless related homeobox)(eg, X-linked
MT-RNRI (mitochondrial/y encoded 12S RNA) (eg, lissencephaly with ambiguous genitalia, X-linked mental
nonsyndromic hearing loss), full gene sequence retardation). full gene sequence
MT-TSI (mitochondrially encoded tRNA serine 1) (eg, AVPR2 (arginine vasopressin receptor 2)1eg, nephrogenic
nonsyndromic hearing loss), full gene sequence diabetes insipidus). full gene sequence
NOP (Norrie disease [pseudoglioma]) (eg. Norrie disease), BBS10 (Bardet-Biedl syndrome 10)leg, Bardet-Biedl
duplication/deletion analysis syndrome). full gene sequence
NHLRCI (NHL repeat containing 1) (eg, progressive BTD (biotinidase) leg, biotinidase deficiency), full gene
myoclonus epilepsy). full gene sequence sequence
PHOX28 {paired-like homeobox 2b)(eg, congenital central C10orf2 (chromosome 10 open reading frame 2)1eg,
hypoventilation syndrome). duplication/deletion analysis mitochondrial ONA depletion syndrome), full gene
sequence
PLN {phosphola,mban) (eg, dilated cardiomyopathy,
hypertrophic cardiomyopathy). full gene sequence 0 0 0 0 0
0 0 0 0 0 0 0
RHO (Rh blood group, D antigen) (eg, hemolytic disease 0
0
0
0
0
0
0
0 0
0
0
• 0
0
0
0 0
0
0 0 0 0 0 0 0 0 0 0 0 0
of the fetus and newborn, Rh maternal/fetal
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
compatibility), deletion analysis (eg, exons 4. 5, and 7, 0 0
0
pseudogene)
0 0 0
0 0 ° 0 0 0 0 0 0 0 0 0 0 0
0 00
0 0 0 0
0 0 0 0
0 0 0 0 0
A= Revised code •=New code ..,. ~=Contains new or revised text *=Duplicate PlA test t+ =Category I PlA American Medical Association 633
81404 Pathology and Laboratory/ Molecular Pathology CPT 2023
CAV3 (caveolin 3)(eg, CAV3-related distal myopathy, GP1 BB (glycoprotein lb [platelet], beta polypeptide) (eg,
limb-girdle muscular dystrophy type 1C}, full gene Bernard-Soulier syndrome type 8). full gene sequence
sequence
(For common deletion variants of alpha globin 1 and
C040LG (C040 ligand) (eg, X-linked hyper lgM syndrome}, alpha globin 2 genes, use 81257)
full gene sequence
HNFTB (HNF1 homeobox B)(eg, maturity-onset diabetes
COKN2A (eye/in-dependent kinase inhibitor 2A)(eg, of the young [MODY]), duplication/deletion analysis
CDKN2A-related cutaneous malignant melanoma,
HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene
familial atypical mole-malignant melanoma syndrome}.
homolog)(eg, Costello syndrome}, full gene sequence
full gene sequence
HS03B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-
CLRN1(clarin1)(eg, Usher syndrome, type 3). full gene
and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid
sequence
dehydrogenase type II deficiency), full gene sequence
COX6B1 (cytochrome c oxidase subunit Vlb polypeptide 1)
HSOT TB2 (hydroxysteroid [TT-beta] dehydrogenase 2)(eg,
(eg, mitochondrial respiratory chain complex IV
mineralocorticoid excess syndrome). full gene sequence
deficiency}, full gene sequence
HSPBT (heat shock 27k0a pro.tein T)(eg, Charcot-Marie-
CPT2 (carnitine palf!litoyltransferase 2) (eg, carnitine
Tooth disease}, full gene sequence
palmitoyltransferase II deficiency}, full gene sequence
INS (insulin)(eg, diabetes mellitus), full gene sequence
CRX (cone-rod homeobox)(eg, cone-rod dystrophy 2.
Leber congenital amaurosis). full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily
J. member 1) (eg, Bartter syndrome), full gene sequence
CYP1B1 (cytochrome P450, family 1, subfamily B,
polypeptide T)(eg, primary congenital glaucoma}, full KCNJTO (potassium inwardly-rectifying channel,
gene sequence subfamily J, member TO)(eg, SeSAME syndrome, EAST
syndrome, sensorineural hearing loss). full gene
EGR2 (early growth response 2)(eg, Charcot-Marie-
sequence
Tooth), full gene sequence
LITAF (lipopolysaccharide-induced TNF factor) (eg,
EMO (emerin) (eg, Emery-Dreifuss muscular dystrophy).
Charcot-Marie-Tooth). full gene sequence
duplication/deletion analysis
MEFV (Mediterranean fever) (eg, familial Mediterranean
EPM2A (epilepsy, progressive myoclonus type 2A. Lafora
fever). full gene sequence
disease [laforin])(eg, progressive myoclonus epilepsy},
full gene sequence MEN1 (multiple endocrine neoplasia l)(eg, multiple
endocrine neoplasia type 1, Wermer syndrome),
FGF23 (fibroblast growth factor 23) (eg,
hypophosphatemic rickets}, full gene sequence
MMACHC (methylmalonic aciduria [cobalamin deficiency]
FGFR2 (fibroblast growth factor receptor 2) (eg,
cblC type, with homocystinuria) (eg, methylmalonic
craniosynostosis, Apert syndrome. Crouzon syndrome).
acidemia and homocystinuria), full gene sequence
targeted sequence analysis (eg, exons-8, 1O}
MPVT 7 (Mp VT 7 mitochondrial inner membrane protein)
FGFR3 (fibroblast growth factor receptor 3) (eg,
(eg, mitochondrial DNA depletion syndrome}, duplication/
achondroplasia. hypochondroplasia}, targeted sequence
deletion analysis
analysis (eg, exons 8, 11. 12, 13)
NOP (Norrie disease [pseudoglioma]) (eg, Norrie disease),
FHLT (four and a half LIM domains 7J(eg, Emery-Dreifuss
full gene sequence
muscular dystrophy}, full gene sequence
NOUFA T(NAOH dehydrogenase [ubiquinone] Talpha
FKRP (fukutin related protein) (eg, congenital muscular
subcomplex, T, 7.5k0a)(eg, Leigh syndrome.
dystrophy type 1C[MDCl C). limb-girdle muscular
mitochondrial complex I deficiency), full gene sequence
dystrophy [LGMD) type 21}, full gene sequence
NOUFAF2 (NAOH dehydrogenase [ubiquinone] 1alpha
FOXG1 (forkhead box GTJ(eg, Rett syndrome}. full gene
subcomplex, assembly factor 2) (eg, Leigh syndrome,
sequence
mitochondrial complex I deficiency). full gene sequence
FSHMOTA (facioscapulohumeral muscular dystrophy TAJ
(eg, facioscapulohumeral muscular dystrophy), evaluation
to detect abnormal (eg, deleted} alleles
0 0 0 0 0
FSHMO TA (facioscapulohumeral muscular dystrophy 1A) 0 0 0
0 0 0 0
0
0 0 0 0 0 0
(eg, facioscapulohumeral muscular dystrophy). 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
characterization of haplotype(s} (ie, chromosome 4A and
0 0 0 0 0 0 0 0 0 0 0 0
48 haplotypes) 0
0
0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
GH1 (growth hormone 1)(eg, growth hormone 0 00 0 0 0
0 00 0 0 0 0
0 0 0 0
deficiency), full gene sequence 0 0 0
0
0 0 0 0 0 0 0
0 0 0 • 0 0 0
0
634 *- Telemedicine '4 =Audio-only +=Add-on code .K =FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 00 =See pxix for details
CPT 2023 Pathology and Laboratory/ Molecular Pathology 81404
NDUFS4 (NADH dehydrogenase [ubiquinone] Fe-S protein SDHD (succinate dehydrogenase complex, subunit 0,
4, 1BkDa [NADH-coenzyme 0 reductase]) (eg, Leigh integral membrane protein){eg, hereditary
syndrome, mitochondrial complex I deficiency), full gene paraganglioma). full gene sequence
sequence
SGCG (sarcoglycan. gamma /35kDa dystrophin-associated
NIPA I (non-imprinted in Prader-Willi/Ange/man syndrome glycoprotein]) (eg, limb-girdle muscular dystrophy),
1)(eg, spastic paraplegia). full gene sequence duplication/deletion analysis
NLGN4X (neuroligin 4, X-linked) (eg, autism spectrum SH2DIA (SH2 domain containing 1A) (eg, X-linked
disorders), duplication/deletion analysis lymphoproliferative syndrome). full gene sequence
NPC2 (Niemann-Pick disease, type C2 [epididymal SLCl6A2 (solute carrier family 16, member 2 [thyroid
secretory protein E1])(eg, Niemann-Pick disease type C2). hormone transporter]){eg, specific thyroid hormone cell
tu 11 gene sequence transporter deficiency, Allan-Herndon-Dudley syndrome).
NROBI (nuclear receptor subfamily 0, group B. member 1)
(eg, congenital adrenal hypoplasia). full gene sequence SLC25A20 (solute carrier family 25 [carnitine/
acylcarnitine translocaseJ member 20)(eg, carnitine-
PDX1 (pancreatic and duodenal homeobox l)(eg.
acylcarnitine translocase deficiency), duplication/deletion
maturity-onset diabetes of the young [MODY]). full gene
analysis
sequence
SLC25A4 (solute carrier family 25 [mitochondrial carrier;
PHOX28 (paired-like homeobox 2b) (eg. congenital central
adenine nucleotide translocator], member 4) {eg,
hypoventilation syndrome). full gene sequence
progressive external ophthalmoplegia). full gene
PLP1 (proteolipid protein 1) (eg, Pelizaeus-Marzbacher sequence
disease. spastic paraplegia). duplication/deletion
SODI (superoxide dismutase I, soluble)(eg, amyotrophic
analysis
lateral sclerosis), full gene sequence
POBPI (polyglutamine binding protein 1)(eg, Renpenning
SPINKI (serine peptidase inhibitor, Kaza/ type 1){eg,
syndrome). duplication/deletion analysis
hereditary pancreatitis). full gene sequence
PRNP (prion protein) (eg, genetic prion disease). full gene
STKl I (serine/threonine kinase 11) {eg, Peutz-Jeghers
sequence
syndrome). duplication/deletion analysis
PROPI (PROP paired-like homeobox 1) (eg, combined
TACOI (translational activator of mitochondrial encoded
pituitary hormone deficiency), full gene sequence
cytochrome c oxidase I) (eg, mitochondrial respiratory
PRPH2 (peripherin 2 [retinal degeneration, slow])(eg, chain complex IV deficiency). full gene sequence
retinitis pigmentosa). full gene sequence
THAPI (THAP domain containing, apoptosis associated
PRSS1 {protease, serine. 1[trypsin 1]) (eg, hereditary protein l)(eg, torsion dystonia), full gene sequence
pancreatitis). full gene sequence
TOR1A (torsin family I, member A [torsin A]){eg, torsion
RAFI (v-raf-1 murine leukemia viral oncogene homolog I) dystonia), full gene sequence
(eg, LEOPARD syndrome). targeted sequence analysis (eg,
TTPA (tocopherol [alpha] transfer protein){eg, ataxia). full
exons 7. 12. 14, 17)
gene sequence
RET fret proto-oncogene)(eg, multiple endocrine
TTR (transthyretin) {eg, familial transthyretin
neoplasia, type 28 and familial medullary thyroid
amyloidosis). full gene sequence
carcinoma). common variants {eg, M918T.
2647 _2648delinsIT. A883F) TWIST1 (twist homolog I /Drosophila])(eg, Saethre-
Chotzen syndrome), full gene sequence
RHO (rhodopsin) {eg, retinitis pigmentosa). full gene
sequence TYR (tyrosinase [oculocutaneous albinism IA]){eg,
oculocutaneous albinism IA). full gene sequence
RPI (retinitis pigmentosa 1){eg, retinitis pigmentosa). full
gene sequence UGT1A I (UDP glucuronosyltransferase 1 family,
polypeptide A I) {eg, hereditary unconjugated
SCNIB (sodium channel. voltage-gated, type I, beta){eg,
hyperbilirubinemia [Crigler-Najjar syndrome]) full gene
Brugada syndrome). full gene sequence
sequence
SC02 (SCO cytochrome oxidase deficient homolog 2
[SC01L]) {eg, mitochondrial respiratory chain complex IV
deficiency). full gene sequence 0
0 0
0
0 0
0
0 0
0
0
0
0
0 0 0 0 0 0 0
0 0 0 0
SDHC (succinate dehydrogenase complex, subunit C. 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0 0
integral membrane protein, 15kDa)(eg, hereditary 0
0
0 0 0 0
0
0
0 0 0 0
0
0
0
0 0 0 0
paraganglioma-pheochromocytoma syndrome). 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0 0 0
duplication/deletion analysis 0
00
0
0 0
00
0
0 0 00
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0
A=Revised code •=New code ~ <Ill =Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 635
USH1G (Usher syndrome 16 [autosomal recessive])(eg, CHRNA4 (cholinergic receptor, nicotinic, alpha 4) (eg.
Usher syndrome. type 1). full gene sequence nocturnal frontal lobe epilepsy), full gene sequence
VHL (van Hippel-Lindau tumor suppressor) (eg, von CHRNB2 (cholinergic receptor, nicotinic, beta 2
Hippel-Lindau familial cancer syndrome), full gene [neuronal])(eg, nocturnal frontal lobe epilepsy), full gene
sequence sequence
VWF (van Willebrand factor) (eg, von Willebrand disease COX10 (COX10 homolog, cytochrome c oxidase assembly
type 1C). targeted sequence analysis (eg, exons 26, 27, protein) (eg. mitochondrial respiratory chain complex IV
37) deficiency). full gene sequence
ZEB2 (zinc finger E-box binding homeobox 2)(eg, Mowat- COX15 (COX15 homolog, cytochrome c oxidase assembly
Wilson syndrome). duplication/deletion analysis protein) (eg, mitochondrial respiratory chain complex IV
deficiency), full gene sequence
ZNF41 (zinc finger protein 41)(eg, X-linked mental
retardation 89). full gene sequence CPOX (coproporphyrinogen oxidase)(eg, hereditary
~ CPTChanges: An Insider's View2012, 2013, 2015. 2014. 2016. coproporphyria). full gene sequence
2018, 2020, 2019. 2021
- CTRC (chymotrypsin C) (eg, hereditary pancreatitis). full
~ CPTAssistantMay 12:4, Jul 13:12, Sep 13:6-7, 9, Jan 15:3.
Aug 16:10. May 18:6, Nov 18:9, Jul 19:3. Apr 20:9 gene sequence
81405 Molecular pathology procedure, Level 6 (eg. analysis of CYP1181 (cytochrome P450, family 11, subfamily B.
6-10 exons by DNA sequence analysis, mutation polypeptide 1)(eg. congenital adrenal hyperplasia). full
scanning or duplication/deletion variants of 11-25 exons. gene sequence
regionally targeted cytogenomic array analysis) CYP17A1 (cytochrome P450. family 17, subfamily A.
ABCD1 (ATP-binding cassette. sub-family D[ALO]. polypeptide 1) (eg, congenital adrenal hyperplasia). full
member f)(eg, adrenoleukodystrophy), full gene gene sequence
sequence CYP21A2 (cytochrome P450. family 21, subfamily A.
ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) polypeptide2) (eg, steroid 21-hydroxylase isoform,
(eg, short chain acyl-CoA dehydrogenase deficiency), full congenital adrenal hyperplasia). full gene sequence
gene sequence Cytogenomic constitutional targeted microarray analysis
ACTA2 (actin. alpha 2, smooth muscle, aorta) (eg, of chromosome 22q13 by interrogation of genomic
thoracic aortic aneurysms and aortic dissections). full regions for copy number and single nucleotide
gene sequence polymorphism (SNP) variants for chromosomal
abnormalities
ACTC1 (actin, alpha, cardiac muscle l)(eg, familial
hypertrophic cardiomyopathy). full gene sequence (When performing cytogenomic [genome-wide) analysis
for constitutional chromosomal abnormalities, see 81228,
ANKRD1 (ankyrin repeat domain 1) (eg, dilated 81229.81349)
cardiomyopathy). full gene sequence
APTX (aprataxin) (eg, ataxia with oculomotor apraxia 1). procedures separately when the specific analytes are
full gene sequence included as part of the microarray analysis of
ARSA (arylsulfatase A) (eg, arylsulfatase A deficiency). chromosome 22q13)
full gene sequence (Do not report 88271 when performing cytogenomic
BCKDHA (branched chain keto acid dehydrogenase E1. microarray analysis)
alpha polypeptide)(eg, maple syrup urine disease. type DBT (dihydrolipoamide branched chain transacylase E2)
1A). full gene sequence (eg. maple syrup urine disease, type 2), duplication/
BCS1L (BCS1-like [S. cerevisiae])(eg, Leigh syndrome. deletion analysis
mitochondrial complex Ill deficiency, GRACILE syndrome). DCX (doublecortin) (eg, X-linked lissencephaly), full gene
full gene sequence sequence
BMPR2 (bone morphogenetic protein receptor, type II DES (desmin)(eg, myofibrillar myopathy), full gene
[serine/threonine kinase]) (eg, heritable pulmonary sequence
arterial hypertension). duplication/deletion analysis
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg,
catecholaminergic polymorphic ventricular tachycardia). 0
0 0
0
0
0
0 0
0
0
0
0 0
full gene sequence 0 0 0 0 0 0
0
0 0
0
0
0
0 0
0
0
0 0
0
0
0
0 0
0
•
CASR (calcium-sensing receptor)(eg. hypocalcemia). full 0 0 0
0 0 0 0
0
0 0 0 0 0 0
gene sequence 0 0
0
0 0
0
0 0 0 0 0
0
0
0 0 0
00 0 00 0
CDKL5 (eye/in-dependent kinase-like 5)(eg, early infantile 0 0 0
0
0
0 0 0 0
0
0 9 0
epileptic encephalopathy), duplication/deletion analysis 0 0
0
0
0 9 0 0
0
0
0 0
0
0 0 0 0
0 0
636 *= Telemedicine ~ =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 00 = See pxix for details
••
DFNB59 {deafness, autosomal recessive 59) (eg, IDS (iduronate 2-sulfatase)(eg, mucopolysacchridosis,
autosomal recessive nonsyndromic hearing impairment), type II). full gene sequence
full gene sequence
IL2RG (interleukin 2 receptor, gamma)(eg, X-linked
DGUOK (deoxyguanosine kinase)(eg, hepatocerebral severe combined immunodeficiency), full gene sequence
mitochondrial DNA depletion syndrome), full gene
••
ISPD (isoprenoid synthase domain containing)(eg,
sequence
muscle-eye-brain disease, Walker-Warburg syndrome).
DHCR7 (7-dehydrocholesterol reductase)(eg, Smith- full gene sequence
Lemli-Opitz syndrome). full gene sequence
KRAS (Kirsten rat sarcoma viral oncogene homolog)(eg,
EIF282 (eukaryotic translation initiation factor 28, subunit Noonan syndrome), full gene sequence
•• 2 beta, 39k0a) (eg, leukoencephalopathy with vanishing

white matter), full gene sequence
EMO (emerin)(eg, Emery-Dreifuss muscular dystrophy),
full gene sequence
LAMP2 (lysosomal-associated membrane protein 2) (eg,
Danon disease). full gene sequence
LDLR (low density lipoprotein receptor) (eg, familial
hypercholesterolemia). duplication/deletion analysis
•
ENG (endoglin)(eg, hereditary hemorrhagic
MEN1 (multiple endocrine neoplasia l)(eg, multiple
telangiectasia, type 1), duplication/deletion analysis
endocrine neoplasia type 1, Wermer syndrome), full gene
EYA 1{eyes absent homolog 1[Drosophila}) (eg, branchio- sequence
oto-renal (BORJ spectrum disorders). duplication/deletion
MMM (methylmalonic aciduria fcobalamine deficiency}
analysis
=
type A) (eg, MMAA-related methylmalonic acidemia), full
FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann gene sequence
syndrome 2). full gene sequence
•
MMAB (methylmalonic aciduria fcobalamine deficiency}
FH {fumarate hydratase) (eg, fumarate hydratase type B)(eg, MMAA-related methylmalonic acidemia), full
deficiency, hereditary leiomyomatosis with renal cell gene sequence
•
cancer), full gene sequence
MP/ (mannose phosphate isomerase)(eg, congenital
FKTN (fukutin) (eg, limb-girdle muscular dystrophy disorder of glycosylation 1b), full gene sequence
(LGMD) type 2M or 2L), full gene sequence
MPV17 {MpV17 mitochondrial inner membrane protein)
FTSJ1 {FtsJ RNA methyltransferase homolog 1[E.coli}) (eg, mitochondrial DNA depletion syndrome). full gene
=
(eg, X-linked mental retardation 9). duplication/deletion sequence
analysis
MPZ (myelin protein zero)(eg, Charcot-Marie-Tooth). full
•
GABRG2 (gamma-aminobutyric acid [GABA} A receptor, gene sequence
gamma 2) (eg, generalized epilepsy with febrile seizures).
MTM1 {myotubularin 1)(eg, X-linked centronuclear
full gene sequence
myopathy), duplication/deletion analysis
GCH1 (GTP cyc/ohydrolase 1) (eg, autosomal dominant
MYL2 (myosin, light chain 2, regulatory. cardiac. slow)
dopa-responsive dystonia), full gene sequence
(eg, familial hypertrophic cardiomyopathy). full gene
=
•
GDAP1 {ganglioside-induced differentiation-associated
protein 1)(eg, Charcot-Marie-Tooth disease). full gene
sequence
GFAP (glial fibrillary acidic protein) (eg, Alexander
disease), full gene sequence
sequence
MYL3 {myosin, light chain 3, alkali, ventricular, skeletal,
slow) (eg, familial hypertrophic cardiomyopathy), full
gene sequence
MYOT {myotilin)(eg, limb-girdle muscular dystrophy). full
GHR {growth hormone receptor)(eg, Laron syndrome). full gene sequence
gene sequence
NDUFS7 {NADH dehydrogenase fubiquinone} Fe-S protein
GHRHR (growth hormone releasing hormone receptor) 7, 2DkDa [NADH-coenzyme Q reductase})(eg, Leigh
(eg, growth hormone deficiency). full gene sequence syndrome, mitochondrial complex I deficiency), full gene
sequence
GLA {galactosidase, alpha)(eg, Fabry disease). full gene
sequence
HNF1A (HNF1 homeobox A)(eg, maturity-onset diabetes
of the young [MODY]), full gene sequence
0 0 0 0 0
0 0 0 0 0 0
HNF18 {HNF1 homeobox B)(eg, maturity-onset diabetes 0 0 0
0 0 0 0
0 0
0 0 0 0 0 0 0 0
of the young [MODY]), full gene sequence 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
HTRA 1{HtrA serine peptidase 1) (eg, macular 0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ...
degeneration), full gene sequence
0 00 0 00 0 00
0 0 0 0 0 0 0 0 0 0
0 0
0 9 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
A.=Revised code • = New code .,. ..,. =Contains new or revised text *=Duplicate PlA test t'=Category IPLA American Medical Association 637
NDUFSB (NADH dehydrogenase [ubiquinone] Fe-S protein PSEN1 (presenilin l)(eg. Alzheimer disease). full gene
8. 23kDa [NADH-coenzyme 0 reductase])(eg. Leigh sequence
syndrome, mitochondrial complex I deficiency). full gene
RABlA (RABlA. member RAS oncogene family) (eg,
sequence
Charcot-Marie-Tooth disease). full gene sequence
NDUFV1 (NADH dehydrogenase [ubiquinone] f/avoprotein
RA/1 (retinoic acid induced l)(eg, Smith-Magenis
1, 51kDa)(eg, Leigh syndrome. mitochondrial complex I
syndrome). full gene sequence
REEPI (receptor accessory protein 1) (eg, spastic
NEFL (neurofilament, light polypeptide)(eg, Charcot-
paraplegia). full gene sequence
Marie-Tooth). full gene sequence
RET (ret proto-oncogene) (eg. multiple endocrine
NF2 (neurofibromin 2 [merlin]) (eg. neurofibromatosis,
neoplasia, type 2A and familial medullary thyroid
type 2). duplication/deletion analysis
carcinoma). targeted sequence analysis (eg. exons 10, 11,
NLGN3 (neuroligin 3) (eg, autism spectrum disorders). full 13-16)
gene sequence
RPSI 9 (ribosomal protein SI 9) (eg. Diamond-Blackfan .-
NLGN4X (neuroligin 4. X-linked)(eg, autism spectrum anemia). full gene sequence
disorders). full gene sequence
RRM28 (ribonucleotide reductase M2 B[TP53 inducible]) r
NPHP1 (nephronophthisis 1[juvenile]) (eg. Joubert (eg. mitochondrial DNA depletion). full gene sequence
syndrome). deletion analysis, and duplication analysis, if
SCO 1(SCO cytochrome oxidase deficient homolog 1) (eg, ,--
performed
mitochondrial respiratory chain complex IV deficiency).
NPHS2 (nephrosis 2, idiopathic, steroid-resistant full gene sequence
[podocin]) (eg, steroid-resistant nephrotic syndrome). full
SDHB (succinate dehydrogenase complex. subunit B. iron
gene sequence
sulfur)(eg. hereditary paraganglioma). full gene sequence
NSD1 (nuclear receptor binding SET domain protein 1)
SDHC (succinate dehydrogenase complex. subunit C.
(eg, Sotos syndrome). duplication/deletion analysis
integral membrane protein, 15kDa)(eg. hereditary
OTC (ornithine carbamoyltransferase) (eg. ornithine paraganglioma-pheochromocytoma syndrome). full gene -
transcarbamylase deficiency), full gene sequence sequence
PAFAH181 (platelet-activating factor acetylhydrolase 1b. SGCA (sarcoglycan, alpha [50kDa dystrophin-associated
regulatory subunit 1[45kDa])(eg, lissencephaly, Miller- glycoprotein])(eg, limb-girdle muscular dystrophy). full
Dieker syndrome). duplication/deletion analysis gene sequence
PARK2 (Parkinson protein 2, E3 ubiquitin protein ligase SGCB (sarcoglycan, beta [43kDa dystrophin-associated
[parkin])(eg, Parkinson disease). duplication/deletion
analysis
PCCA (propionyl CoA carboxylase, alpha polypeptide)(eg,
propionic acidemia. type 1). duplication/deletion analysis
glycoprotein])(eg, limb-girdle muscular dystrophy). full
gene sequence
SGCD (sarcoglycan, delta [35kDa dystrophin-associated
-
glycoprotein])(eg, limb-girdle muscular dystrophy). full
gene sequence
PCDH19 (protocadherin 19) (eg, epileptic
encephalopathy). full gene sequence SGCE (sarcoglycan, epsilon)(eg, myoclonic dystonia).
PDHA 1(pyruvate dehydrogenase [lipoamide] alpha 1) (eg,
lactic acidosis). duplication/deletion analysis SGCG (sarcoglycan, gamma [35kDa dystrophin-associated
glycoproteinj) (eg, limb-girdle muscular dystrophy). full
PDHB (pyruvate dehydrogenase [lipoamide] beta){eg,
gene sequence
lactic acidosis). full gene sequence
SHOC2 (soc-2 suppressor of clear homolog) (eg. Noonan-
PINK1 (PTEN induced putative kinase 1) (eg. Parkinson
like syndrome with loose anagen hair). full gene
disease). full gene sequence
sequence
PKLR (pyruvate kinase. liver and RBC)(eg, pyruvate
SHOX (short stature homeobox) (eg, Langer mesomelic
kinase deficiency). full gene sequence
dysplasia). full gene sequence
PLP1 (proteolipid protein 1) (eg, Pelizaeus-Merzbacher
SIL 1(SIL 1homolog, endoplasmic reticulum chaperone
disease, spastic paraplegia). full gene sequence
rs. cerevisiaej) {eg, ataxia). full gene sequence
POU1F1 (POU class 1homeobox 1) (eg, combined 0
0 0
pituitary hormone deficiency). full gene sequence 0 0
0
0
0 0
0
0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
PRX (periaxin)(eg, Charcot-Marie-Tooth disease). full 0
gene sequence
0
0
0
0
0 0 0
0
0
0 0 0 0 0 0
0
° 0
0 0 0 0 0 0 0 0 0 • 0
0 0 0 0 0
POBPI (polyglutamine binding protein 1) (eg, Renpenning 00
0 0 0 0 00 0 0 0 0
0 0 0 0 0
syndrome). full gene sequence 0 0 0
0 0 0 0 0 0
0
0 0 0 0
0
0 0 0
0
0
0 0
638 *= Telemedicine '4 =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code ~=Modifier 51 exempt O OO=See pxix for details
SLC2A 1(solute carrier family 2 [facilitated glucose TNN/3 (troponin I, type 3 [cardiac]J(eg, familial
transporter}, member 1) (eg, glucose transporter type 1 hypertrophic cardiomyopathy), full gene sequence
[GLUT 1] deficiency syndrome), full gene sequence
TPM1 (tropomyosin 1[alpha])(eg, familial hypertrophic
SLC16A2 (solute carrier family 16, member 2 [thyroid cardiomyopathy), full gene sequence
hormone transporter])(eg, specific thyroid hormone cell
TSCJ (tuberous sclerosis 1) (eg. tuberous sclerosis),
transporter deficiency, Allan-Herndon-Dudley syndrome).
full gene sequence
TYMP (thymidine phosphorylase) (eg, mitochondrial DNA
SLC22A5 (solute carrier family 22 [organic cation/
depletion syndrome). full gene sequence
carnitine transporterl member 5)(eg, systemic primary
carnitine deficiency), full gene sequence VWF (van Willebrand factor) (eg, von Willebrand disease
type 2N), targeted sequence analysis (eg, exons 18-20,
SLC25A20 (solute carrier family 25 [carnitine/
23-25)
acylcarnitine translocasel member 20)(eg, carnitine-
acylcarnitine translotase deficiency), full gene sequence WTJ (Wilms tumor J)(eg, Denys-Orash syndrome.
familial Wilms tumor). full gene sequence
SMAD4 (SMAD family member 4) (eg, hemorrhagic
telangiectasia syndrome, juvenile polyposis), duplication/ ZEB2 (zinc finger E-box binding homeobox 2)(eg, Mowat-
deletion analysis Wilson syndrome), full gene sequence
SPAST (spastin) (eg, spastic paraplegia), duplication/
a CPT Changes: An Insider's View 2012. 2013, 2014. 2015, 2016,
2018. 2019, 2021. 2022
deletion analysis
a CPTAssistant May 12:4, Jul 13:12, Sep 13:8. 10, Jan 15:3,
SPGl (spastic paraplegia 7 [pure and complicated Aug 16:10. May 18:6, Sep 18:15. Nov 18:9. Jul 19:3
autosomal recessive]) (eg, spastic paraplegia). 81406 Molecular pathology procedure, Level 7 (eg, analysis of
duplication/deletion analysis 11-25 exons by DNA sequence analysis, mutation
SPRED1 (sprouty-related. EVH1 domain containing 1)(eg, scanning or duplication/deletion variants of 26-50 exons)
Legius syndrome), full gene sequence ACADVL (acyl-CoA dehydrogenase, very long chain)(eg,
STAT3 (signal transducer and activator of transcription 3 very long chain acyl-coenzyme A dehydrogenase
[acute-phase response factor])(eg. autosomal dominant deficiency), full gen~ sequence
hyper-lgE syndrome), targeted sequence analysis (eg, ACTN4 (actinin, alpha 4)(eg, focal segmental
exons 12, 13, 14, 16, 17. 20. 21) glomerulosclerosis). full gene sequence
STK11 (serine/threonine kinase 11) (eg. Peutz-Jeghers AFG3l2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae])
syndrome), full gene sequence (eg, spinocerebellar ataxia), full gene sequence
SURF1 (surfeit 1) (eg, mitochondrial respiratory chain AIRE (autoimmune regulator)(eg, autoimmune
complex IV deficiency), full gene sequence polyendocrinopathy syndrome type 1), full gene sequence
TARDBP (TAR DNA binding protein) (eg, amyotrophic ALDHlA1(aldehyde dehydrogenase 7 family, member A1)
lateral sclerosis). full gene sequence (eg, pyridoxine-dependent epilepsy), full gene sequence
TBX5 (T-box 5)(eg, Holt-Oram syndrome), full gene AN05 (anoctamin 5)(eg. limb-girdle muscular dystrophy),
sequence full gene sequence
TCF4 (transcription factor 4) (eg, Pitt-Hopkins syndrome). ANOSJ (anosmin-J)(eg, Kallmann syndrome 1), full gene
duplication/deletion analysis sequence
TGFBR1 (transforming growth factor, beta receptor 1) (eg, APP (amyloid beta [A4] precursor protein) (eg, Alzheimer
Marfan syndrome). full gene sequence disease). full gene sequence
TGFBR2 (transforming growth factor, beta receptor 2) (eg. ASST (argininosuccinate synthase 1) (eg. citrullinemia
Marfan syndrome), full gene sequence type I), full gene sequence
THRB (thyroid hormone receptor, beta)(eg. thyroid ATL 1(atlastin GTPase 1) (eg, spastic paraplegia), full
hormone resistance, thyroid hormone beta receptor gene sequence
deficiency), full gene sequence or targeted sequence
analysis of >5 exons
TK2 (thymidine kinase 2, mitochondrial) (eg,
mitochondrial DNA depletion syndrome), full gene 0 0 0 0 0
0 0 0
sequence 0
0
0
0
0
0 0
0
0
0
0
0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
TNNC1 (troponin Ctype 1[slow])(eg, hypertrophic 0
0
0 0
0 0
0
0
0 0 0 0
0 0
cardiomyopathy or dilated cardiomyopathy). full gene 0 0 0
0
0 0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 0 0
sequence 0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0
0 0
0 ' 0
0
0 0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
A=Revised code •=New code ~ <1111 =Contains new or revised text H=Ouplicate PlA test t+=Category I PLA American Medical Association 639
ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 DBT (dihydrolipoamide branched chain transacylase EL)
polypeptide)(eg, familial hemiplegic migraine). full gene (eg, maple syrup urine disease, type 2). full gene
sequence sequence
ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, DLAT (dihydrolipoamide S-acetyltransferase) (eg,
Wilson disease). full gene sequence pyruvate dehydrogenase E2 deficiency), full gene
sequence
BBST (Bardet-Biedl syndrome T)(eg, Bardet-Biedl
syndrome), full gene sequence DLD (dihydrolipoamide dehydrogenase)(eg. maple syrup
urine disease. type Ill). full gene sequence
BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl
syndrome). full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular
dysplasia/cardiomyopathy 11 ). full gene sequence
BCKDHB (branched-chain keto acid dehydrogenase El,
beta polypeptide)(eg. maple syrup urine disease, type DSG2 (desmoglein 2) (eg, arrhythmogenic right
1B). full gene sequence ventricular dysplasic;i/cardiomyopathy 1O). full gene
sequence
BEST1 (bestrophin l)(eg, vitelliform macular dystrophy),
full gene sequence DSP (desmoplakin) (eg, arrhythmogenic right ventricular
dysplasia/cardiomyopathy 8). full gene sequence
BMPR2 (bone morphogenetic protein receptor. type II
[serine/threonine kinase])(eg, heritable pulmonary EFHCI (EF-hand domain IC-terminal] containing I) (eg.
arterial hypertension). full gene sequence juvenile myoclonic epilepsy), full gene sequence
BRAF (B-Raf proto-oncogene. serine/threonine kinase) EIF2B3 (eukaryotic translation initiation factor 2B, subunit
(eg, Noonan syndrome). full gene sequence 3 gamma, 58kDa) (eg, leukoencephalopathy with
vanishing white matter). full gene sequence
BSCL2 (Berardinelli-Seip congenital lipodystrophy 2
[seipin})(eg, Berardinelli-Seip congenital lipodystrophy). EIF2B4 (eukaryotic translation initiation factor 2B, subunit
full gene sequence 4 delta, 67kDa)(eg, leukoencephalopathy with vanishing
white matter). full gene sequence
BTK (Bruton agammaglobulinemia tyrosine kinase)(eg.
X-linked agammaglobulinemia). full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit
5 epsilon, 82kDa)(eg, childhood ataxia with central
CACNB2 (calcium channel. voltage-dependent, beta 2
nervous system hypomyelination/vanishing white
subunit) (eg, Brugada syndrome). full gene sequence
matter). full gene sequence
CAPN3 (ca/pain J)(eg, limb-girdle muscular dystrophy
ENG (endoglin)(eg, hereditary hemorrhagic
[LGMD] type 2A. calpainopathy). full gene sequence
telangiectasia, type 1). full gene sequence
CBS (cystathionine-beta-synthase) (eg, homocystinuria.
EYA I (eyes absent homolog I [Drosophila]) (eg, branchio-
cystathionine beta-synthase deficiency). full gene
oto-renal [BOA] spectrum disorders). full gene sequence
sequence
FB (coagulation factor Vlll)(eg, hemophilia A).
CDHT (cadherin I. type I, E-cadherin [epithelial]) (eg.
hereditary diffuse gastric cancer). full gene sequence
FAH (fumarylacetoacetate hydrolase
CDKL5 (eye/in-dependent kinase-like 5)(eg. early infantile
[fumarylacetoacetase])(eg, tyrosinemia. type 1). full gene
epileptic encephalopathy), full gene sequence
sequence
CLCNI (chloride channel 1, skeletal muscle)(eg,
FASTKD2 (FAST kinase domains 2) (eg, mitochondrial
myotonia cE>ngenita). full gene sequence
respiratory chain complex IV deficiency). full gene
CLCNKB (chloride channel, voltage-sensitive Kb) (eg, sequence
Bartter syndrome 3 and 4b), full gene sequence
F/G4 (FIG4 homolog, SACT lipid phosphatase domain
CNTNAP2 (contactin-associated protein-like 2) (eg, containing [S. cerevisiae]) (eg, Charcot-Marie-Tooth
Pitt-Hopkins-like syndrome 1). full gene sequence disease). full gene sequence
COL6A2 (collagen, type VI, alpha 2) (eg, collagen type FTSJI (FtsJ RNA methyltransferase homolog 1[E.coli])
VI-related disorders). duplication/deletion analysis (eg. X-linked mental retardation 9). full gene sequence
CPTIA (carnitine palmitoyltransferase IA [liver])(eg, FUS (fused in sarcoma)(eg, amyotrophic lateral
carnitine palmitoyltransferase 1A [CPT1A] deficiency), full sclerosis). full gene sequence
gene sequence 0 • 0
0 0 0 0 0
CRBT (crumbs homolog I [Drosophila])(eg , Leber
0 0 0
0
0
0 " 0
0
0
0
0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
congenital amaurosis). full gene sequence 0 0
0 0 0
CREBBP (GREB binding protein) (eg. Rubinstein-Taybi 0

0
0
0
0
0
0
0
0
0
0 0
0
0
0
0 0
• 0
0
0
0
0
0
0
syndrome). duplication/deletion analysis 0 0 0 0 0 0 0 00 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0
0 0
0
640 *= Telemedicine ,. =Audio-only +=Add-on code ,..-=FDA approval pending #=Resequenced code t9 =Modifier 51 exempt o= =-See Pxix for details
GAA (glucosidase, alpha; acid)(eg, glycogen storage KCN01 (potassium voltage-gated channel, KOT-like
disease type II [Pompe disease]). full gene sequence subfamily, member 1)(eg, short QT syndrome. long QT
syndrome). full gene sequence
GALC (galactosylceramidase) (eg, Krabbe disease). full
gene sequence KCN02 (potassium voltage-gated channel, KOT-like
subfamily, member 2)(eg, epileptic encephalopathy). full
GALT (galactose-1-phosphate uridy/yltransferase) (eg.
gene sequence
galactosemia), full gene sequence
LDB3 (LIM domain binding 3)(eg, familial dilated
GARS (glycyl-tRNA synthetase)(eg, Charcot-Marie-Tooth
cardiomyopathy, myofibrillar myopathy). full gene
disease), full gene sequence
sequence
GCDH (glutaryl-CoA dehydrogenase)(eg, glutaricacidemia
LDLR (low density lipoprotein receptor)(eg, familial
type 1). full gene sequence
hypercholesterolemia). full gene sequence
GCK (glucokinase [hexokinase 4)) (eg, maturity-onset
LEPR (leptin receptor) (eg, obesity with hypogonadism).
diabetes of the young [MODY]), full gene sequence
full gene sequence
GLUD1 (glutamate dehydrogenase 1)(eg, familial
LHCGR (luteinizing hormone/choriogonadotropin receptor)
hyperinsulinism). full gene sequence
(eg. precocious male puberty). full gene sequence
GNE (glucosamine
LMNA (Jamin NC) (eg, Emery-Dreifuss muscular
[UDP-N-acetyl]-2-epimerase/N-acetylmannosamine
dystrophy [EDMD1, 2 and 3] limb-girdle muscular
kinase)(eg, inclusion body myopathy 2 [IBM2], Nonaka
dystrophy [LGMD] type 1B, dilated cardiomyopathy
myopathy), full gene sequence
[CMD1AJ, familial partial lipodystrophy [FPLD2]). full gene
GRN (granulin) (eg, frontotemporal dementia), full gene sequence
sequence
LRP5 (low density /ipoprotein receptor-related protein 5)
HADHA (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA (eg, osteopetrosis), full gene sequence
thiolase/enoyl-CoA hydratase [trifunctional protein] alpha
MAP2K7 (mitogen-activated protein kinase 1)(eg,
subunit)(eg, long chain acyl-coenzyme A dehydrogenase
cardiofaciocutaneous syndrome). full gene sequence
MAP2K2 (mitogen-activated protein kinase 2) (eg,
HADHB (hydroxyacy/-CoA dehydrogenase/3-ketoacyl-CoA
cardiofaciocutaneous syndrome). full gene sequence
thiolase/enoyl-CoA hydratase [trifunctional protein], beta
subunit) (eg, trifunctional protein deficiency), full gene MAPT (microtubu/e-associated protein tau) (eg.
sequence frontotemporal dementia), full gene sequence
HEXA (hexosaminidase A, alpha polypeptide) (eg, Tay- MCCC1 (methylcrotonoyl-CoA carboxylase 1[alpha/) (eg.
Sachs disease), full gene sequence 3-methylcrotonyl-CoA carboxylase deficiency). full gene
sequence
HLCS (HLCS holocarboxylase synthetase)(eg,
holocarboxylase synthetase deficiency), full gene MCCC2 (methylcrotonoyl-CoA carboxylase 2 [beta]) (eg,
sequence 3-methylcrotonyl carboxylase deficiency), full gene
sequence
HMBS (hydroxymethylbilane synthase) (eg, acute
intermittent porp yria), full gene sequence MFN2 (mitofusin 2) (eg. Charcot-Marie-Tooth disease),
full gene sequence
HNF4A (hepatocyte nuclear factor 4, alpha) (eg, maturity-
onset diabetes of the young [MODY]}, full gene sequence MTM1(myotubularin1)(eg. X-linked centronuclear
/DUA (iduronidase, alpha-L-) (eg, mucopolysaccharidosis
type I), full gene sequence MUT (methylmalonyl CoA mutase) (eg, methylmalonic
acidemia), full gene sequence
INF2 (inverted formin, FH2 and WH2 domain containing)
(eg. focal segmental glomerulosclerosis). full gene MUTYH (mutY homolog ff. coli])(eg, MYH-associated
sequence polyposis). full gene sequence
/VD (isovaleryl-CoA dehydrogenase)(eg, isovaleric NDUFS1 (NADH dehydrogenase [ubiquinone] Fe-S protein
acidemia), full gene sequence 1, 75kDa [NADH-coenzyme 0 reductase])(eg, Leigh
syndrome. mitochondrial complex I deficiency). full gene
JAG1ljagged1)(eg, Alagille syndrome). duplication/
sequence
deletion analysis
0 0 0 0
0 0 0
JUP (junction p/akoglobin) (eg, arrhythmogenic right 0
0
0
0
0
0 0
0
0
0
0
0
0
0 0 0 0
ventricular dysplasia/cardiomyopathy 11 ). full gene 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0 0
sequence 0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0 0
0 0 0 0 0 0 0 0 0 0 0 0
KCNH2 (potassium voltage-gated channel, subfamily H 0 0 0 0
00 0 00 0 00
[eag-related]. member 2)(eg, short QT syndrome, long QT 0
0 0 0
0
0
0 0 0 0
0
0
0 0 0 0 0 0 0 0 0
syndrome), full gene sequence 0
0
0
0 0 0
0
0
0 0 0
0 0 0
A=Revised code • = New code ll> "'=Contains new or revised text H=Duplicate PLA test ti=Category IPLA American Medical Association 641
NF2 (neurofibromin 2 [merlinf)(eg, neurofibromatosis, POLG (polymerase [DNA directed], gamma) (eg, Alpers-
type 2). full gene sequence Huttenlocher syndrome. autosomal dominant progressive
external ophthalmoplegia), full gene sequence
NOTCH3 (notch 3) (eg, cerebral autosomal dominant
arteriopathy with subcortical infarcts and POMGNTT (protein 0-linked mannose beta1,2-N
leukoencephalopathy [CADASIL]), targeted sequence acetylglucosaminyltransferase) (eg, muscle-eye-brain
analysis (eg, exons 1-23) disease. Walker-Warburg syndrome). full gene sequence
NPCT (Niemann-Pick disease. type CT)(eg, Niemann-Pick POMTT (protein-0-mannosyltransferase T) (eg. limb-
disease), full gene sequence girdle muscular dystrophy [LGMD] type 2K. Walker-
Warburg syndrome), full gene sequence
NPHPT (nephronophthisis T[juvenilef)(eg, Joubert
syndrome), full gene sequence POMT2 (protein-0-mannosyltransferase 2) (eg, limb-
girdle muscular dystrophy [LGMDJ type 2N. Walker-
NSDT (nuclear receptor binding SET domain protein T)
Warburg syndrome), full gene sequence
(eg. Sotos syndrome), full gene sequence
PPOX (protoporphyrinogen oxidase)(eg, variegate
OPA T(optic atrophy T) (eg, optic atrophy), duplication/
porphyria), full gene sequence
deletion analysis
PRKAG2 (protein kinase, AMP-activated, gamma 2 non-
OPTN (optineurin)(eg, amyotrophic lateral sclerosis), full
catalytic subunit) (eg, familial hypertrophic
gene sequence
cardiomyopathy with Wolff-Parkinson-White syndrome.
PAFAHTBT {platelet-activating factor acetylhydrolase Tb, lethal congenital glycogen storage disease of heart), full
regulatory subunit 1[45kDaf)(eg. lissencephaly, Miller- gene sequence
Dieker syndrome), full gene sequence
PRKCG {protein kinase C, gamma)(eg. spinocerebellar
PAH (phenylalanine hydroxylase)(eg, phenylketonuria). ataxia), full gene sequence
full gene sequence
PSEN2 (presenilin 2 [Alzheimer disease 4/) (eg, Alzheimer
PARK2 (Parkinson protein 2, E3 ubiquitin protein ligase disease), full gene sequence
[parkinf)(eg. Parkinson disease), full gene sequence
PTPN1 T(protein tyrosine phosphatase, non-receptor type
PAX2 {paired box 2) (eg, renal coloboma syndrome), full TT) (eg, Noonan syndrome, LEOPARD syndrome), full gene
gene sequence sequence
PC {pyruvate carboxylase)(eg, pyruvate carboxylase PYGM {phosphorylase, glycogen, muscle)(eg, glycogen
deficiency), full gene sequence storage disease type V, McArdle disease). full gene
sequence
PCCA (propionyl CoA carboxylase, alpha polypeptide)(eg,
propionic acidemia, type 1). full gene sequence RAFT (v-raf-T murine leukemia viral oncogene homolog 1)
(eg, LEOPARD syndrome). full gene sequence
PCCB (propionyl CoA carboxylase, beta polypeptide) (eg,
propionic acidemia), full gene sequence RET (ret proto-oncogene) (eg, Hirschsprung disease), full
gene sequence
PCDH15 {protocadherin-related T5)(eg, Usher syndrome
type 1F). duplication/deletion analysis RPE65 (retinal pigment epithelium-specific protein 65kDa)
(eg. retinitis pigmentosa. Leber congenital amaurosis).
PCSK9 (proprotein convertase subtilisin/kexin type 9) (eg,
full gene sequence
familial hypercholesterolemia), full gene sequence
RYRT (ryanodine receptor 1, skeletal)(eg, malignant
PDHA T(pyruvate dehydrogenase [lipoamidef alpha T) (eg,
hyperthermia), targeted sequence analysis of exons with
lactic acidosis). full gene sequence
functionally-confirmed mutations
PDHX (pyruvate dehydrogenase complex, component X)
SCN4A (sodium channel, voltage-gated, type IV, alpha
(eg, lactic acidosis). full gene sequence
subunit) (eg, hyperkalemic periodic paralysis). full gene
PHEX (phosphate-regulating endopeptidase homolog, sequence
X-linked)(eg, hypophosphatemic rickets). full gene
SCNNTA (sodium channel, nonvoltage-gated Talpha) (eg,
sequence
pseudohypoaldosteronism). full gene sequence
PKD2 (polycystic kidney disease 2 [autosomal dominant])
(eg, polycystic kidney disease), full gene sequence
PKP2 (plakophilin 2) (eg, arrhythmogenic right ventricular
0 0 0 0 0
dysplasia/cardiomyopathy 9). full gene sequence
PNKD (paroxysmal nonkinesigenic dyskinesia) (eg, 0
. 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0 0 0 0 0 0 0 0
paroxysmal nonkinesigenic dyskinesia). full gene 0

0
0
0
0 0
0 0 0 0 0 0 0 0 0 0
0 0
sequence 0 0 0
0 0 ° 0 0 0 0
0 0 ° 0 0
0 00 0 00 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0
642 *=Telemedicine iC=Audio-only +=Add-on code ,-'=FDAapprovalpending #=Resequenced code ~=Modifier51 exempt O O O =Seepxixfordetails
CPT 2023 Pathology and Laboratory I Molecular Pathology 8140&--411407
SCNN1 B (sodium channel, nonvoltage-gated 1, beta) (eg, TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis).
Liddle syndrome, pseudohypoaldosteronism). full gene duplication/deletion analysis
sequence
UBE3A (ubiquitin protein ligase E3A)(eg, Angelman
SCNN1G (sodium channel, nonvoltage-gated 1, gamma) syndrome). full gene sequence
(eg. Liddle syndrome, pseudohypoaldosteronism), full
UMOO (uromodulin)(eg, glomerulocystic kidney disease
gene sequence
with hyperuricemia and isosthenuria}, full gene sequence
SOHA (succinate dehydrogenase complex, subunit A.
VWF (von Willebrand factor) Ivon Willebrand disease
f/avoprotein [Fp])(eg, Leigh syndrome. mitochondrial
type 2A). extended targeted sequence analysis (eg, exons
complex II deficiency), full gene sequence
11-16, 24-26. 51, 52)
SETX (senataxin)(eg, ataxia). full gene sequence
WAS (Wiskott-Aldrich syndrome {eczema-
SGCE (sarcoglycan. epsilon)(eg. myoclonic dystonia). full thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full
gene sequence gene sequence
SH3TC2 (SH3 domain and tetratricopeptide repeats 2)
0 Cf'T Changes: An Insider's View2012 . 2013. 2014. 2016, 2017.
2018. 2020
(eg. Charcot-Marie-Tooth diseasel. full gene sequence
Q CPTAssistantMay 12:4. Jul 13:12. Sep 13:5-6, 8, 11. Jan 15:3.
SLC9A6 (solute carrier family 9 {sodium/hydrogen Aug 16:10. Apr 17:10, May 18:6, Nov 18:9, Feb 20:10. Mar 20:13
exchangerl member 6) (eg, Christianson syndrome}, full 81407 Molecular pathology procedure. Level 8 (eg, analysis of
gene sequence 26-50 exons by DNA sequence analysis. mutation
SLC26A4 (solute carrier family 26, member 4)(eg, scanning or duplication/deletion variants of >50 exons.
Pendred syndrome). full gene sequence sequence analysis of multiple genes on one platform)
SLC37A4 (solute carrier family 37 {glucose-6-phosphate ABCCB (ATP-binding cassette. sub-family C[CFTR/MRPl
transporterl member 4) (eg. glycogen storage disease member 8) (eg, familial hyperinsulinism). full gene
type lb). full gene sequence sequence
SMA04 (SMAO family member 4) (eg, hemorrhagic AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-
telangiectasia syndrome, juvenile polyposis), full gene glucanotransferase) (eg. glycogen storage disease type
sequence Ill). full gene sequence
SOS1 (son of sevenless homolog 1)(eg, Noonan AH/1 fAbelson helper integration site 1) (eg, Joubert
syndrome. gingival fibromatosis), full gene sequence syndrome). full gene sequence
SPAST (spastin) (eg, spastic paraplegia). full gene APOB (apo/ipoprotein BJ(eg. familial
sequence hypercholesterolemia type Bl full gene sequence
SPG7 (spastic paraplegia 7 {pure and complicated ASPM (asp {abnormal spindle] homolog, microcephaly
autosomal recessive])(eg, spastic paraplegia), full gene associated {Orosophila])(eg, primary microcephaly), full
sequence gene sequence
STXBP1 (syntaxin-binding protein 1)(eg, epileptic CH07 (chromodomain helicase ONA binding protein 7)
encephalopathy), full gene sequence (eg, CHARGE syndrome). full gene sequence
TAZ (tafazzin) (eg. methylglutaconic aciduria type 2. Barth COL4A4 (collagen, type IV, alpha 4)(eg, Alport syndrome).
syndrome). full gene sequence full gene sequence
TCF4 (transcription factor 4)(eg, Pitt-Hopkins syndrome). COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome).
full gene sequence duplication/deletion analysis
TH (tyrosine hydroxylase)(eg, Segawa syndrome). full COL6A 1(collagen, type VI, alpha 1) (eg, collagen type
gene sequence VI-related disorders). full gene sequence
TMEM43 (transmembrane protein 43)(eg, COL6A2 (collagen. type VI. alpha 2) (eg, collagen type
arrhythmogenic right ventricular cardiomyopathy). full VI-related disorc!<>r•!. f11ll g<:?ne sequence
gene sequence COL6A3 (collagen. type VI. alpha 3)(eg, collagen type
TNNT2 (troponin T. type 2 {cardiac]) (eg, familial VI-related disorders). full gene sequence
hypertrophic cardiomyopathy). full gene sequence
TRPC6 (transient receptor potential cation channel, 0 0 0 0 0
subfamily C. member 6) (eg, focal segmental 0
0
0
0
0 0
0
0
0
0
0 0
0
0
glomerulosclerosis). full gene sequence 0 0

0
0
0 0
0
0 0
0 "0 0
0
0
,,
0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0
TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis}, full 0 0 0
0
0 0 0
0
0
gene sequence
0 0 0
0 0
0 0 0 0
• 0 0
0 0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 • 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
A =Revised code •=New code • •=Contains new or revised text *=Duplicate PlA test ti =Category I PLA American Medical Association 643
CREBBP (GREB binding protein)(eg, Rubinstein-Taybi TMEMBl (transmembrane protein Bl)(eg, Joubert
syndrome!. full gene sequence syndrome). full gene sequence
FB (coagulation factor Vlll)(eg , hemophilia A). full gene TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis I. full
sequence gene sequence
JAG1ljagged1)1eg, Alagille syndrome), full gene USH1C (Usher syndrome 1C [autosomal recessive,
sequence severe]) leg, Usher syndrome, type 1). full gene sequence
KDM5C (lysine [Kl-specific demethylase 5C) (eg, X-linked VPS138 (vacuolar protein sorting 13 homolog B[yeast])
mental retardation). full gene sequence (eg, Cohen syndrome), duplication/deletion analysis
KIM0796 (KIM0196)(eg, spastic paraplegia). full gene WDRB2 (WO repeat domain 62)(eg, primary autosomal
sequence recessive microcephaly). full gene sequence
L1CAM (L 1 cell adhesion molecule) leg, MASA syndrome,
0 CPT Changes: An Insider's View2012, 2013, 2014, 2019. 2020
X-linked hydrocephaly), full gene sequence O CPT AssistantMay 12:4, Jul 13:12, Sep 13:14. Jan 15:3.
Aug 16:10. May 18:6. Nov 18:9, Jul 19:3
LAMB2 (laminin, beta 2 [laminin SJ) (eg, Pierson
81408 Molecular pathology procedure, Level 9 (eg, analysis of
syndrome), full gene sequence
>50 exons in a single gene by DNA sequence analysis)
MYBPC3 (myosin binding protein C, cardiac) (eg, familial
ABCA4 (ATP-binding cassette, sub-family A [ABC1J,
hypertrophic cardiomyopathy), full gene sequence
member 4) (eg, Stargardt disease. age-related macular
MYHB (myosin, heavy chain 6, cardiac muscle, alpha) (eg, degeneration). full gene sequence
familial dilated cardiomyopathy), full gene sequence
ATM (ataxia telangiectasia mutated) leg, ataxia
MYHl (myosin, heavy chain 7, cardiac muscle, beta) (eg, telangiectasia). full gene sequence
familial hypertrophic cardiomyopathy, Liang distal
CDH23 (cadherin-related 23)(eg, Usher syndrome, type
1). full gene sequence
MYOlA (myosin VI/A) leg, Usher syndrome, type 1). full
CEP290 (centrosomal protein 290k0a) (eg, Joubert
gene sequence
syndrome), full gene sequence
NOTCH1 (notch 1)(eg, aortic valve disease), full gene
COL1A 1(collagen, type I. alpha 1) leg. osteogenesis
sequence
imperfecta, type I), full gene sequence
NPHS1 (nephrosis 1, congenital, Finnish type [nephrin])
COL 1A2 (collagen, type I, alpha 2)(eg. osteogenesis
leg, congenital Finnish nephrosis), full gene sequence
imperfecta, type I). full gene sequence
OPA 1(optic atrophy 1) leg, optic atrophy), full gene
COL4A1 (collagen, type IV, alpha 1)(eg, brain small·
sequence
vessel disease with hemorrhage), full gene sequence
PCDH15 (protocadherin-related 15Jleg, Usher syndrome,
CDL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen])
type 1). full gene sequence
(eg, Alport syndrome). full gene sequence
PKD1 (polycystic kidney disease 1[autosomal dominant])
COL4A5 (collagen, type IV, alpha 5Jleg, Alport syndrome).
(eg, polycystic kidney disease). full gene sequence
full gene sequence
PLCE1 (phospholipase C, epsilon 1)(eg, nephrotic
DMD (dystrophin)(eg, Duchenne/Becker muscular
syndrome type 3). full gene sequence
dystrophy), full gene sequence
SCN1A (sodium channel, voltage-gated, type 1, alpha
DYSF (dysferlin, limb girdle muscular dystrophy 28
subunit)(eg, generalized epilepsy with febrile seizures),
[autosomal recessive])(eg. limb-girdle muscular
full gene sequence
dystrophy), full gene sequence
SCN5A (sodium channel, voltage-gated, type V, alpha
FBN1 (fibril/in 1) leg. Marfan syndrome). full gene
subunit)(eg, familial dilated cardiomyopathy), full gene
sequence
sequence
ITPR1(inositol1,4,5-trisphosphate receptor, type 1)(eg.
SLC12A 1(solute carrier family 12 [sodium/potassium/
spinocerebellar ataxia). full gene sequence
chloride transporters], member 1Jleg, Bartter syndrome),
full gene sequence LAMA2 (laminin. alpha 2) (eg, congenital muscular
dystrophy). full gene sequence
SLC12A3 (solute carrier family 12 [sodium/chloride
0
transporters], member 3Jleg, Gitelman syndrome). full 0
0
0 0 0 0
0
0
0 0 0 0 0 0
0 0
gene sequence 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0
0 0 0 0
SPG11 (spastic paraplegia 11 [autosomal recessive])(eg, 0
0
0 0 0
0
0
0
0 0 0
0
spastic paraplegia), full gene sequence 0 0

0
0 0
0 0 • 0 0 0
0
0 0
0 0
0
0
00 0 00 0
SPTBN2 (spectrin, beta, non-erythrocytic 2) leg, 0
0 0 0
0
0
0 0 0 0
0
0 0 0 0 0 0 0 0 0
spinocerebellar ataxia). full gene sequence 0 0
0
0 0 0
0
0 0
0 0 0 0 0
644 *= Telemedicine i4 =Audio-only +=Add-on code ft"= FDA approval pending #=Resequenced code ~=Modifier 51 exempt =~=See Pxix for details
CPT 2023 Pathology and Laboratory I GSPs and Other Molecular Multianalyte Assays 81408-81479
LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson developmental delay. The exome and genome procedures
disease), full gene sequence are designed to evaluate the genetic material in totality or
MYH11 (myosin, heavy chain 11, smooth muscle) (eg, near totality. Although commonly used to identify
thoracic aortic aneurysms and aortic dissections), full sequence (base) changes, they can also be used to identify
gene sequence copy number, structural changes, and abnormal zygosity
patterns which may be performed in combination or may
NEB (nebulin)(eg, nemaline myopathy 2), full gene require separately performed methods and analyses.
sequence
Another unique feature of GSPs is the ability to
NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1). full "re-query" or re-evaluate the sequence data (eg, complex
gene sequence phenotype such as developmental delay is reassessed when
PKHD 1(po/ycystic kidney and hepatic disease 1) (eg,
new genetic knowledge is attained, or for a separate
autosomal recessive polycystic kidney disease), full gene unrelated clinical indication). The analyses listed below
sequence represent groups of genes that are often performed by
GSPs; however, the analyses may also be performed by
RYR1 (ryanodine receptor 1, skeletal)(eg, malignant other molecular techniques (eg, polymerase chain
hyperthermia), full gene sequence reaction [PCR] methods and microarrays). These codes
RYR2 (ryanodine receptor 2 [cardiac]) (eg, should be used when the components of the descriptor(s)
catecholaminergic polymorphic ventricular tachycardia, are fulfilled regardless of the technique used to provide
arrhythmogenic right ventricular dysplasia). full gene the analysis, unless specifically noted in the code
sequence or targeted sequence analysis of> 50 exons descriptor. When a GSP assay includes gene(s) that is
listed in more than one code descriptor, the code for the
USH2A (Usher syndrome 2A [autosomal recessive, mild])
(eg, Usher syndrome, type 2), full gene sequence
most specific test for the primary disorder sought should
be reported, rather than reporting multiple codes for the
VPS138 (vacuolar protein sorting 13·homolog 8 [yeast]) same gene(s). When all of the components of the
(eg, Cohen syndrome), full gene sequence descriptor are not performed, use individual Tier I codes,
VWF (van Willebrand factor) (eg, von Willebrand disease Tier 2 codes, or 81479 (Unlisted molecular pathology
types 1 and 3), full gene sequence procedure).
@ CPT Changes: An Insider's View2012, 2013. 2014 Testing for somatic alterations in neoplasms may be
@ CPT AssistantMay 12:4. Jul 13:12, Sep 13:4-5. 14. Jan 15:3, reported differently based on whether combined methods
Aug 16:10, May 18:6. Nov 18:9
and analyses are used for both DNA and RNA analytes,
# 81479 Unlisted molecular pathology procedure or if separate methods and analyses are used for each
@ CPT Changes: An Insider's View 2013 analyte (DNA analysis only, RNA analysis only). For
@ CPTAssistantJul 13:12, Sep 13:4, 8. Jan 15:3, Apr 16:4. targeted genomic sequence DNA analysis or DNA and
Aug 16:10. Sep 16:10. Apr 17:10, Jun 18:8. Sep 18:15, Nov 18:9. RNA analysis using a single combined method, report
Dec 18:10. May 19:5, Jun 19:11. Oct 20:8. Dec 20:14. Feb 21:14 81445, 81450, or 81455. For targeted genomic sequence
RNA analysis when performed using a separate method,
report 81449, 81451, 81456. For targeted genomic
Genomic Sequencing sequence DNA analysis and RNA analysis performed
Procedures and Other separately rather than via a combined method, report
81445, 81450, or 81455 for the DNA analysis and report
Molecular Multianalyte 81449, 81451, or 81456 for the RNA analysis.<1111
Assays Low-pass sequencing: a method of genome sequencing

intended for cytogenomic analysis of chromosomal
.,..Genomic sequencing procedures (GSPs) and other abnormalities, such as that performed for trait mapping
molecular multianalyte assays GSPs are DNA or RNA or copy number variation, typically performed to an
sequence analysis methods that simultaneously assay average depth of sequencing ranging from 0.1 to 5X.
multiple genes or genetic regions relevant to a clinical The assays in this section represent discrete genetic values,
situation. They may target specific combinations of genes properties, or characteristics in which the measurement or
or genetic material, or assay the exome or genome. The analysis of each analyte is potentially of independent
technology typically used for genomic sequencing is medical significance or useful in medical management. In
referred to as next generation sequencing (NGS) or contrast to multianalyte assays with algorithmic analyses
massively parallel sequencing (MPS) although other 0 0
0 0
technologies may be employed. GSPs are performed on • 0 "0 0
0 0 0 0
0 0
0 0 0 0
nucleic acids from germline or neoplastic samples. 0
0 0 0 0 0
0
0 0
0
0
0 0 0
0 0
Examples of applications include aneuploidy analysis of 0
0
0 0 0 0 0 0
0
0
0 0 0
0
0
0
0 0
cell-free circulating fetal DNA, gene panels for somatic 0 0 0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
alterations in neoplasms, and sequence analysis of the 0

00
0 0 0 0
0 0 0 0 00
exome or genome to determine the cause of 0

0 0
0 0
0 0 0 0 0 0
0 0 0 0 0
.& =Revised code e =New code .,.. ..,. =Contains new or revised text H =Duplicate PLA test t+ =Category I PLA American Medical Association 645
81410-81422 Pathology and Laboratory I GSPs and Other Molecular Multianalyte Assays CPT 2023
(MAAAs), the assays in this section do not represent # 81419 Epilepsy genomic sequence analysis panel, must include
algorithmically combined results to obtain a risk score or analyses for ALDH7A1, CACNA1A, CDKL5, CHD2,
other value, which in itself represents a new and distinct GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG.
medical property that is of independent medical PRRT2, SCN1A, SCN18, SCN2A, SCNBA, SLC2A1,
significance relative to the individual, component test SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2,
results. and ZEB2
(For cytogenomic [genome-wide] analysis for
constitutional chromosomal abnormalities, see 81228, 81415 Exome (eg, unexplained constitutional or heritable
81229,81405,81406) disorder or syndrome); sequence analysis
81410 Aortic dysfunction or dilation (eg, Marfan syndrome, 0 CPT Assistant Jan 15:3
Loeys Dietz syndrome, Ehler Danlos syndrome type IV,
arterial tortuosity syndrome); genomic sequence analysis + 81416 sequence analysis. each comparator exome (eg,
panel, must include sequencing of at least 9 genes. parents. siblings) (List separately in addition to code
including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, for primary procedure)
ACTA2, SLC2A 10, SMAD3, and MYLK 0 CPT Changes: An Insider's View 2015
0 CPT Changes: An Insider's View 2015 0 CPT Assistant Jan 15:3
0 CPT Assistant Jan 15:3 (Use 81416 in conjunction with 81415)
81411 duplication/deletion analysis panel, must include 81417 re-evaluation of previously obtained exome sequence
analyses for TGFBR1, TGFBR2, MYH11, and COL3A 1 (eg, updated knowledge or unrelated condition/
0 CPT Changes: An Insider's View 2015 syndrome)
0 CPT Assistant Jan 15:3 0 CPT Changes: An Insider's View 2015
81412 Ashkenazi Jewish associated disorders (eg, Bloom 0 CPT Assistant Jan 15:3
syndrome, Canavan disease, cystic fibrosis, familial (Do not report 81417 for incidental findings)
dysautonomia, Fanconi anemia group C, Gaucher disease.
Tay-Sachs disease), genomic sequence analysis panel, (Do not report 81349 when analysis for chromosomal
must include sequencing of at least 9 genes, including abnormalities is performed by sequence analysis
ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, included in 81415, 81416)
MCOLN1, and SMPD1 (For cytogenomic [genome-wide] copy number
0 CPT Changes: An Insider's View2016 assessment. see 81228, 81229)
0 CPT Assistant Apr 16:4, Nov 18:9
81413 Cardiac ion channelopathies (eg, Brugada syndrome. long
QT syndrome, short QT syndrome, catecholaminergic 81419 Code is out of numerical sequence. See 81413-81416
polymorphic ventricular tachycardia); genomic sequence 81420 Fetal chromosomal aneuploidy (eg, trisomy 21,
analysis panel, must include sequencing of at least 10 monosomy X) genomic sequence analysis panel,
genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, circulating cell-free fetal DNA in maternal blood, must
KCNH2, KCNJ2, KCN01, RYR2, and SCN5A include analysis of chromosomes 13, 18, and 21
0 CPT Assistant Apr 17:3 0 CPT Assistant Jan 15:3, Dec 15:17, Apr 18:11
81414 duplication/deletion gene analysis panel. must (Do not report 81228, 81229, 88271 when performing
include analysis of at least 2 genes. including KCNH2 genomic sequencing procedures or other molecular
and KCNQ1 multianalyte assays for copy number analysis)
abnormalities is performed by sequence analysis
(For genomic sequencing panel testing for included in 81425, 81426)
cardiomyopathies. use 81439)
81422 Fetal chromosomal microdeletion(s) genomic sequence
(Do not report 81413, 81414 in conjunction with 81439 analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome).
when performed on the same date of service) circulating cell-free fetal DNA in maternal blood
#e 81418 Drug metabolism (eg, pharmacogenomics) genomic 0 CPT Changes: An Insider's View 2017
sequence analysis panel, must include testing of at least 0 CPT Assistant Apr 17:3
6 genes, including CYP2C19, CYP2D6, and CYP2D6
0 0 0 0
duplication/deletion analysis 0
0
0
0
0 0
0
0
0
0
0 0
0
0 0
0 0
0
0
0
0 0
0
0
0 0
0
0
0
0 0
0
0
0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0
0 0 0 0 0
Q 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0
646 *= Telemedicine '4 =Audio-only +=Add-on code ,V =FDA approval pending #=Resequenced code ~=Modifier 51 exempt ~00 =See p xix for details
CPT 2023 Pathology and Laboratory I GSPs and Other Molecular Multianalyte Assays 81443-81436
(Do not report 81228. 81229, 88271 when performing 81430 Hearing loss {eg, nonsyndromic hearing loss. Usher
genomic sequencing procedures or other molecular syndrome. Pendred syndrome); genomic sequence
multianalyte assays for copy number analysis) analysis panel, must include sequencing of at least 60
genes. including COH23, CLRN1. GJB2. GPR98, MTRNR1.
MYOlA, MY015A. PCOH15. OTOF. SLC26A4. TMC1,
TMPRSS3. USH1C, USH1G. USH2A. and WFS1
included in 81425, 81426)
Q CPT Changes: An Insider's View 2015
# 81443 Genetic testing for severe inherited conditions (eg, cystic Q CPT Assistant Jan 15:3
fibrosis. Ashkenazi Jewish-associated disorders [eg,
81431 duplication/deletion analysis panel, must include
Bloom syndrome. Canavan disease. Far.coni anemia type
C, mucolipidosis type VI, Gaucher disease. Tay-Sachs copy number analyses for STRCand OFNB1 deletions
disease]. beta hemoglobinopathies. phenylketonuria. in GJ82 and GJ86 genes
galactosemia). genomic sequence analysis panel. must Q CPT Changes: An Insider's View 2015
include sequencing of at least 15 genes (eg. ACADM. Q CPT Assistant Jan 15:3
ARSA. ASPA. ATP7B. BCKDHA. BCKOHB, BLM. CFTH. 81432 Hereditary breast cancer-related disorders leg, hereditary
OHCRl. FANCC. G6PC. GM. GALT, GBA. GBE1. HBB. breast cancer, hereditary ovarian cancer, hereditary
HEXA. IKBKAP. MCOLN1, PAH) endometrial cancer); genomic sequence analysis panel,
Q CPT Changes: An Insider's View 2019 must include sequencing of at least 10 genes, always
Q CPT Assistant Nov 18:9, Jul 19:3 including BRCA 1, BRCA2, CDH1. MLH1. MSH2. MSH6.
(If spinal muscular atrophy testing is performed PALB2. PTEN, STK11. and TP53
separately, use 81329) Q CPT Changes: An Insider's View 2016, 201 B
Q CPT Assistant Apr 16:4, May 19:5, Feb 21:14
(If testing is performed only for Ashkenazi Jewish-
associated disorders. use 81412) 81433 duplication/deletion analysis panel, must include
analyses for BRCA 1, BRCA2. MLH1. MSH2, and
(If FMR1 [expanded allele] testing is performed STK11
separately, use 81243) Q CPT Changes: An Insider's View2016
(If hemoglobin A testing is performed separately, use Q CPT Assistant Apr 16:4
81257) 81434 Hereditary retinal disorders leg, retinitis pigmentosa.
(Do not report 81443 in conjunction with 81412) Leber congenital amaurosis. cone-rod dystrophy),
genomic sequence analysis panel, must include
81425 Genome (eg, unexplained constitutional or heritable sequencing of at least 15 genes. including ABCA4.
disorder or syndrome); sequence analysis CNGA 1, CRB1, EYS, PDE6A. POE68, PRPF31, PRPH2,
Q CPT Changes: An Insider's View 2015 ROH12, RHO. RP1. RP2. RPE65. RPGR. and USH2A
Q CPT Assistant Jan 15:3 Q CPT Changes: An Insider's View 2016
+ 81426 sequence analysis. each comparator genome leg, Q CPT Assistant Apr 16:4
parents. siblings) (List separately in addition to code 81435 Hereditary colon cancer disorders {eg, Lynch syndrome,
for primary procedure) PTEN hamartoma syndrome. Cowden syndrome. familial
Q CPT Changes: An Insider's View 2015 adenomatosis polyposis); genomic sequence analysis
Q CPT Assistant Jan 15:3 panel. must include sequencing of at least 10 genes.
(Use 81426 in conjunction with 81425) including APC. BMPR1A. CDH1, MLH1. MSH2, MSH6.
MUTYH, PTEN. SMAD4. and STK11
81427 re-evaluation of previously obtained genome Q CPT Changes: An Insider's View2015, 2016
sequence leg, updated knowledge or unrelated Q CPTAssistantJan 15:3, Apr 16:4, Feb 21 :14
condition/syndrome)
Q CPT Changes: An Insider's View 2015 81436 duplication/deletion analysis panel, must include
Q CPT Assistant Jan 15:3 analysis of at least 5 genes, including MLH1. MSH2,
EPCAM. SMA04. and STK11
{Oo not report 81427 for incidental findings) Q CPT Changes: An Insider's View 2015, 2016
{Do not report 81349 when analysis for chromosomal Q CPT Assistant Jan 15:3. Apr 16:4
included in 81425, 81426)
(For copy number assessment by cytogenomic [genome-
wide] analysis for constitutional chromosomal 0 0 0 0 0
abnormalities. see 81228. 81229) 0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
D 0 0 0
0 D 0 D 0 D 0 0 0 0
(For cytogenomic [genome-wide) analysis for 0 0 0 0 0 0 0 0
0 0 0 D 0
constitutional chromosomal abnormalities interrogation 0 0
0 0 0
0
D 0
D D 0
0
0
0 0 0 D 0 0 0 0 0 0 0 0 0
of genomic regions for copy number and loss-of- 0 0 D 0
DO 0 00 0 00
heterozygosity variants. low-pass sequencing analysis, 0
0 0 0 0
D
0 D 0 0
0
0 0
use 81349) 0
0 0
0
D
0 D
D
0 0
0
0
0 0
0
0 0
0 0 0 0 0 0
0 0
A= Revised code e =New code II> .... =Contains new or revised text H =Duplicate PLA test ti= Category I PLA American Medical Association 647
81437-81456 Pathology and Laboratory I GSPs and Other Molecular Multianalyte Assays CPT 2023
81437 Hereditary neuroendocrine tumor disorders (eg, medullary least 12 genes. including BRAF, CBL, HRAS, KRAS,
thyroid carcinoma, parathyroid carcinoma, malignant MAP2KT, MAP2K2, NRAS, PTPNT T. RAFT, RITT, SHOC2,
pheochromocytoma or paraganglioma); genomic and SOST
sequence analysis panel, must include sequencing of at 0 CPT Changes: An Insider's View2016
least 6 genes. including MAX SDHB, SDHC, SDHD, 0 CPT Assistant Apr 16:4
TMEMT27, and VHL
0 CPT Assistant Apr 16:4 ... 81445 Targeted genomic sequence analysis panel, solid organ
neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A. EGFR,
81438 duplication/deletion analysis panel, must include
ERB82, KIT. KRAS. MET. NRAS. PDGFRA. PDGFRB, PGR,
analyses for SDHB, SDHC, SDHD, and VHL
PIK3CA. PTEN, RET), interrogation for sequence variants
and copy number variants or rearrangements, if
performed; DNA analysis or combined DNA and RNA
# 81448 Hereditary peripheral neuropathies (eg, Charcot-Marie- analysis
Tooth, spastic paraplegia). genomic sequence analysis 0 CPT Changes: An Insider's View 2015. 2016. 2023
panel, must include sequencing of at least 5 peripheral 0 CPTAssistantJan15:3. Apr 16:4
neuropathy-related genes (eg, BSCL2, GJBT, MFN2, MPZ.
REEPT, SPAST. SPGT T. SPTLCT)
0 CPT Changes: An Insider's View 2018 • 81449 RNA analysis
0 CPT Assistant May 18:6 0 CPT Changes: An Insider's View 2023
81439 Hereditary cardiomyopathy (eg, hypertrophic (For copy number assessment by microarray, use 81406)
cardiomyopathy, dilated cardiomyopathy, arrhythmogenic
.& 81450 Targeted genomic sequence analysis panel,
right ventricular cardiomyopathy), genomic sequence
hematolymphoid neoplasm or disorder, 5-50 genes (eg,
analysis panel, must include sequencing of at least 5
BRAF, CEBPA. DNMT3A. EZH2, FLT3, IDHT, IDH2, JAK2,
cardiomyopathy-related genes (eg, DSG2, MYBPC3,
KIT. KRAS, MLL, NOTCH1, NPMT, NRASJ, interrogation
MYHl, PKP2, TTN)
for sequence variants, and copy number variants or
rearrangements, or isoform expression or mRNA
0 CPTAssistantApr17:3, Sep 18:15, Dec 20:14
expression levels, if performed; DNA analysis or
(Do not report 81439 in conjunction with 81413, 81414 combined DNA and RNA analysis
when performed on the same date of service) 0 CPT Changes.· An Insider's View 2015. 2016. 2023
(For genomic sequencing panel testing for cardiac ion

0 CPT Assistant Jan 15:3. Apr 16:4. Feb 21 :14
channelopathies, see 81413, 81414) • 81451 RNA analysis

#e 81441 Inherited bone mac.row failure syndromes (IBMFS) (eg,
Fanconi anemia, dyskeratosis congenita, Diamond- (For copy number assessment by microarray, use 81406)
Blackfan anemia, Shwachman-Diamond syndrome,
.& 81455 Targeted genomic sequence analysis panel, solid organ
GATA2 deficiency syndrome, congenital amegakaryocytic
or hematolymphoid neoplasm or disorder. 51 or greater
thrombocytopenia) sequence analysis panel, must include
genes (eg, ALI( BRAF, CDKN2A. CEBPA. DNMT3A. EGFR,
sequencing of at least 30 genes, including BRCA2, BR/PT.
ERB82, EZH2. FLT3, IDHT, IDH2, JAK2, KIT. KRAS, MET.
DKCT, FANCA. FANCB, FANCC, FANCD2, FANCE. FANCF,
MLL, NOTCHT, NPMT, NRAS. PDGFRA. PDGFRB, PGR,
FANCG, FANCI, FANCL, GATAT, GATA2, MPL, NHP2,
PIK3CA. PTEN, REn. interrogation for sequence variants
NOPTO, PALB2, RAD5TC, RPL11, RPL35A. RPL5, RPSTD.
and copy number variants or rearrangements, or isoform
RPST9, RPS24, RPS26, RPSl, SBDS, TERT. and TINF2
expression or mRNA expression levels, if performed;
DNA analysis or combined DNA and RNA analysis
81440 Nuclear encoded mitochondrial genes (eg, neurologic or 0 CPT Changes: An Insider's View 2015, 2016, 2023
myopathic phenotypes), genomic sequence panel, must 0 CPT Assistant Jan 15:3. Apr 16:4. Feb 21 :14
include analysis of at least 100 genes, including BCSTL,
CTOorf2, COQ2, COXTO, DGUOK, MPVTl, OPAT, PDSS2, • 81456 RNA analysis
POLG, POLG2, RRM28, SCOT. SC02, SLC25A4, SUCLA2, 0 CPT Changes: An Insider's View 2023
SUCLGT, TAl. TK2, and TYMP (For copy number assessment by microarray, use 81406)
0 CPT Assistant Jan 15:3
81441 Code is out of numerical sequence. See 81437-81442 0 0 0 0

0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0
81442 Noonan spectrum disorders (eg, Noonan syndrome. 0 0
0 0 0 0 0 0 0
0 0 0 0 • 0 0 0 0 0
cardio-facio-cutaneous syndrome, Costello syndrome, 0
0 0 0 0 0 0
0 0 0 0 0 0
LEOPARD syndrome, Noonan-like syndrome), genomic 0 0 0
0 0
sequence analysis panel, must include sequencing of at

0 0
0 0 ° 0 0 0 0 0 0 0
0 0
00 0 00
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0
648 *= Telemedicine ~=Audio-only +=Add-on code ..K =FDA approval pending #=Resequenced code (S.)= Modifier 51 exempt 0 0 0 =See p xix for details
CPT 2023 Pathology and Laboratory I Multianalyte Assays with Algorithmic Analyses 81460-81471
..,.(For targeted genomic sequence DNA analysis and procedure(s) that are inputs co the MAAAs may be
RNA analysis performed separately rather than via a provided on the associated laboratory report; however,
combined method. report 81445. 81450, 81455 for the these assays are not separately reported using additional
DNA analysis and report 81449. 81451, 81456 for the codes.
RNA analysis)•
The format for the code descriptors of MAAAs usually
"'(For targeted genomic sequence RNA analysis using a include (in order):
separate method. see 81449, 81451, 81456)•
• Disease type (eg, oncology, autoimmune, tissue
81460 Whole mitochondrial genome (eg, Leigh syndrome. rejection),
mitochondrial encephalomyopathy. lactic acidosis, and
stroke-like episodes [MELAS]. myoclonic epilepsy with • Material(s) analyzed (eg, DNA, RNA, protein,
ragged-red fibers [MERFF). neuropathy, ataxia. and antibody) ,
retinitis pigmentosa [NARP). Leber hereditary optic • Number of markers (eg, number of genes, number of
neuropathy [LHON)). genomic sequence. must include proteins),
sequence analysis of entire mitochondrial genome with
heteroplasmy detection • Methodology(ies) (eg, microarray, real-time [RTJ-PCR,
0 CPT Changes: An Insider's View 2015 in situ hybridization [ISHJ, enzyme linked
immunosorbenc assays [ELISA]),
Whole mitochondrial genome large deletion analysis • Number of functional domains (if indicated),
81465
panel (eg, Kearns-Sayre syndrome. chronic progressive • Specimen type (eg, blood, fresh tissue, formalin-fixed
external ophthalmoplegia). including heteroplasmy paraffin-embedded),
detection. if performed
• Algorithm result type (eg, prognostic, diagnostic},
0 CPT Assistant Jan 15:3 • Report (eg, probability index, risk score)
81470 X-linked intellectual disability (XLID) (eg. syndromic and In contrast to GSPs and other molecular multianalyte
non-syndromic XLID); genomic sequence analysis panel. assays, the assays in this section represent algorithmically
must include sequencing of at least 60 genes. including combined results of analyses of multiple analytes co
ARX, ATRX, COKLS, FG01, FMR1, HUWE1, IL1RAPL, obtain a risk score or oc.her value which in itself represents
KOMSC, L1CAM, MECP2, ME012, M/01, OCRL, a new and distinct medical property chat is of
RPS6KA3, and SLC16A2 independent medical significance relative co the
0 CPT Changes: An Insider's View 2015 individual component test results in clinical context in
0 CPT Assistant Jan 15:3 which the assay is performed.
81471 duplication/deletion gene analysis, must include MAAAs, including those chat do not have a Category I
analysis of at least 60 genes. including ARX. ATRX. code, may be found in Appendix 0. MAAAs that do not
COKLS, FG01, FMR1. HUWE1, IL1RAPL, KOMSC, have a Category I code are identified in Appendix 0 by a
L1CAM, MECP2, ME012, M/01, OCRL. RPS6KA3, and four-digit number followed by the leccer "M." The
SLC16A2 Category I MAAA codes that are included in this
0 CPT Changes: An Insider's View 2015 subsection are also included in Appendix 0. All MAAA
0 CPT Assistant Jan 15:3 codes are listed in Appendix 0 along with the procedure's
81479 Code is out of numerical sequence. See 81407-81411 proprietary name. In order to report a MAAA code, the
analysis performed must fulfill the code descriptor and, if
proprietary, must be the test represented by the
Multianalyte Assays with proprietary name listed in Appendix 0.
When a specific MAAA procedure is not listed below or
Algorithmic Analyses in Appendix 0 , the procedure must be reported using the
Multianalyte Assays with Algorithmic Analyses (MAAAs) Category I MAAA unlisted code (81599).
are procedures that utilize multiple results derived from These codes encompass all analytical services required (eg,
panels of analyses of various types, including molecular cell lysis, nucleic acid stabilization, extraction, digestion,
pathology assays, fluorescent in situ hybridization assays, amplification, hybridization, and detection) in addition
and non-nucleic acid based assays (eg, proteins,
polypeptides, lipids, carbohydrates). Algorithmic analysis
using the results of these assays as well as other patient 0 0 0 0 0
0 0 0 0 0 0
information (if used) is then performed and typically 0 0 0
0
0 0 0
0 0
0 0 0 0 0
reported as a numeric score(s) or as a probability. MAAAs 0 0
0
0
0 0 0
0 0 0 0 0
0
0 0
are typically unique to a single clinical laboratory or 0
0
0
0 0 0
0
'I
0
0
0 0
0 0 0
0
0 0
manufacturer. The results of individual component 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 00 0 0 0 0 00 0 0 0 0 00
0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
.6. =Revised code e =New code ..,. •=Contains new or revised text *=Duplicate PlA test ti= Category I PLA American Medical Association 649
81490-81596 Pathology and Laboratory/ Multianalyte Assays with Algorithmic Analyses CPT 2023
to the algorithmic analysis itsel£ Procedures that are 81510 Fetal congenital abnormalities, biochemical assays of
required prior to cell lysis (eg, microdissection, codes three analytes (AFP. uE3, hCG [any form]), utilizing
88380 and 88381) should be reported separately. maternal serum, algorithm reported as a risk score
81490 Autoimmune (rheumatoid arthritis). analysis of 12

a CPT Changes: An Insider's V1ew2013
biomarkers using immunoassays, utilizing serum, (Do not report 81510 in conjunction with 82105, 82677,
prognostic algorithm reported as a disease activity score 84702)
a CPT Changes: An Insider's View 2016 81511 Fetal congenital abnormalities, biochemical assays of four
(Do not report 81490 in conjunction with 86140) analytes (AFP. uE3, hCG [any form]. DIA) utilizing maternal
serum, algorithm reported as a risk score (may includP.
# 81595 Cardiology (heart transplant). mRNA. gene expression additional results from previous biochemical testing)
profiling by real-time quantitative PCR of 20 genes (11
content and 9 housekeeping), utilizing subtraction of
a CPT Changes: An Insider's View 2013
peripheral blood, algorithm reported as a rejection risk score (Do not report 81511 in conjunction with 82105, 82677,
a CPT Changes: An Insider's View 2016 84702, 86336)
81493 Coronary artery disease, mRNA. gene expression 81512 Fetal congenital abnormalities, biochemical assays of
profiling by real-time RT-PCR of 23 genes. utilizing whole five analytes (AFP. uE3, total hCG, hyperglycosylated hCG,
peripheral blood, algorithm reported as a risk score DIA) utilizing maternal serum. algorithm reported as a
a CPT Changes: An Insider's View 2016 risk score
a CPT Changes: An Insider's View2013
(Do not report 81512 in conjunction with 82105, 82677,
81503 Code is out of numerical sequence. See 81536-81541 84702, 86336)
81504 Code is out of numerical sequence. See 81542-81554 81513 Infectious disease, bacterial vaginosis, quantitative real-
81506 Endocrinology (type 2 diabetes), biochemical assays of time amplification of RNA markers for Atopobium
seven analytes (glucose, HbA1c, insulin, hs-CRP. vaginae, Gardnerella vaginalis, and Lactobacillus species,
adiponectin, ferritin, interleukin 2-receptor alpha), utilizing vaginal-fluid specimens, algorithm reported as a
utilizing serum or plasma, algorithm reporting a risk score positive or negative result for bacterial vaginosis
a CPT Changes: An Insider's View 2013 a CPT Changes: An Insider's View2021
(Do not report 81506 in conjunction with constituent
a CPTAssistant Mar 21 :8
components [ie, 82728, 82947, 83036, 83525, 86141], 81514 Infectious disease, bacterial vaginosis and vaginitis,
84999 [for adopectin], and 83520 [for interleukin quantitative real-time amplification of DNA markers for
2-receptor alpha]) Gardnerella vaginalis, Atopobium vaginae, Megasphaera
type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-
81507 Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence 2), and Lactobacillus species (L. crispatus and L. jensenii).
analysis of selected regions using maternal plasma, utilizing vaginal-fluid specimens, algorithm reported as a
algorithm reported as a risk score for each trisomy positive or negative for high likelihood of bacterial
a CPT Changes: An Insider's View2014 vaginosis, includes separate detection of Trichomonas
a CPTAssistant Apr 18:11 vaginalis and/or Candida species (C. albicans. C.
(Do not report 81228, 81229, 88271 when performing tropicalis, C. parapsilosis, C. dubliniensis), Candida
genomic sequencing procedures or other molecular glabrata, Candida krusei, when reported
multianalyte assays for copy number analysis) a CPT Changes: An Insider's View2021
(For cytogenomic [genome-wide] analysis for
a CPTAssistant Mar 21:8
constitutional chromosomal abnormalities interrogation (Do not report 81514 in conjunction with 87480, 87481,
of genomic regions for copy number and loss-of- 87482,87510,87511,87512,87660,87661)
heterozygosity variants, low-pass sequencing analysis, # 81596 Infectious disease, chronic hepatitis Cvirus (HCV)
use 81349) infection, six biochemical assays (ALT. A2-macroglobulin,
81508 Fetal congenital abnormalities, biochemical assays of apolipoprotein A-1, total bilirubin, GGT, and haptoglobin)
two proteins (PAPP-A, hCG [any form]), utilizing maternal utilizing serum, prognostic algorithm reported as scores
serum, algorithm reported as a risk score for fibrosis and necroinflammatory activity in liver
a CPT Changes: An Insider's View2013 a CPT Changes: An Insider's View 2019
(Do not report 81508 in conjunction with 84163, 84702)
a CPT Assistant Jul 19:3
0
81509 Fetal congenital abnormalities, biochemical assays of 0
0
0 0
0
0
0
0
0 0
0
0
0
0 0 0 0 0 0
three proteins (PAPP-A, hCG [any form]. DIA), utilizing 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0 0
maternal serum, algorithm reported as a risk score 0 0 0
a CPT Changes: An Insider's View 2013 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(Do not report 81509 in conjunction with 84163, 84702, 0

00
0
0 0
00
0
0 0
0 0 0 0 0 0
86336) 0
0 0
0 0
0 0
0
0 0
0 0
0
0
0
0 0
0 0 0 0
0 0
650 *= Telemedicine i4 =Audio-only +=Add-on code .#= FDA approval pending #=Resequenced code IS>= Modifier 51 exempt 0 0 0 =Seep xix for details
CPT 2023 Pathology and Laboratory I Multianalyte Assays with Algorithmic Analyses 81518-81541
81518 Oncology (breast), mRNA, gene expression profiling by 81529 Oncology (cutaneous melanoma), mRNA, gene expression
real-time RT-PCR of 11 genes (7 content and 4 profiling by real-time RT-PCR of 31 genes (28 content and
housekeeping), utilizing formalin-fixed paraffin- 3 housekeeping), utilizing formalin-fixed paraffin-
embedded tissue, algorithms reported as percentage risk embedded tissue, algorithm reported as recurrence risk,
for metastatic recurrence and likelihood of benefit from including likelihood of sentinel lymph node metastasis
extended endocrine therapy 0 CPT Changes: An Insider's View2021
81535 Oncology"(gynecologic). live tumor cell culture and
0 CPT Assistant Jul 19:3
chemotherapeutic response by DAPI stain and
# 81522 Oncology (breast). mRNA, gene expression profiling by morphology, predictive algorithm reported as a drug
RT-PCR of 12 genes (8 content and 4 housekeeping). response score; first single drug or drug combination
utilizing formalin-fixed paraffin-embedded tissue, 0 CPT Changes: An Insider's View 2016
algorithm reported as recurrence risk score
+ 81536 each additional single drug or drug combination (List
81519 Oncology (breast). mRNA, gene expression profiling by 0 CPT Changes: An Insider's View2016
real-time RT-PCR of 21 genes. utilizing formalin-fixed
(Use 81536 in conjunction with 81535)
paraffin-embedded tissue. algorithm reported as
recurrence score 81538 Oncology (lung). mass spectrometric 8-protein signature.
0 CPT Changes: An Insider's View2015 including amyloid A utilizing serum, prognostic and
0 CPT Assistant Jan 15:3 predictive algorithm reported as good versus poor overall
survival
81520 Oncology (breast). mRNA gene expression profiling by
hybrid capture of 58 genes (50 content and 8
housekeeping). utilizing formalin-fixed paraffin- # 81500 Oncology (ovarian). biochemical assays of two proteins
embedded tissue. algorithm reported as a recurrence risk (CA-125 and HE4). utilizing serum, with menopausal
score status. algorithm reported as a risk score
0 CPT Assistant Jun 18:8 0 CPT Assistant Jun 19: 11
81521 Oncology (breast). mRNA, microarray gene expression (Do not report 81500 in conjunction with 86304, 86305)
profiling of 70 content genes and 465 housekeeping
# 81503 Oncology (ovarian), biochemical assays of five proteins
genes, utilizing fresh frozen or formalin-fixed paraffin-
(CA-125, apolipoprotein A1, beta-2 microglobulin.
embedded tissue, algorithm reported as index related to
transferrin, and pre-albumin). utilizing serum, algorithm
risk of distant metastasis
reported as a risk score
0 CPT Assistant Jun 18:8
(Do not report 81521 in conjunction with 81523 for the
84134,84466,86304)
same specimen)
81539 Oncology (high-grade prostate cancer). biochemical assay
of four proteins (Total PSA. Free PSA. Intact PSA. and
81523 Oncology (breast). mRNA. next-generation sequencing human kallikrein-2 [hK2]), utilizing plasma or serum,
gene expression profiling of 70 content genes and 31 prognostic algorithm reported as a probability score
housekeeping genes. utilizing formalin-fixed paraffin- 0 CPT Changes: An Insider's View 2017
embedded tissue, algorithm reported as index related to 0 CPT Assistant Apr 17:4
risk to distant metastasis
81541 Oncology (prostate). mRNA gene expression profiling by
(Do not report 81523 in conjunction with 81521 for the
real-time RT-PCR of 46 genes (31 content and 15
same specimen)
housekeeping), utilizing formalin-fixed paraffin-
81525 Oncology (colon). mRNA, gene expression profiling by embedded tissue, algorithm reported as a disease-
real-time RT-PCR of 12 genes (7 content and 5 specific mortality risk score
housekeeping). utilizing formalin-fixed paraffin- 0 CPT Changes: An Insider's View 2018
embedded tissue. algorithm reported as a recurrence 0 CPT ~ssistant Aug 18:8
score
81528 Oncology (colorectal) screening, quantitative real-time 0 0 0 0 0
0
target and signal amplification of 10 DNA markers (KRAS 0
0
0
0
0
0 0
0
0
0
0
0
0
0
0 0 0 0 0 0
mutations. promoter methylation of NDRG4 and BMPJ'{ 0 0 0 0 0 D 0
• 0
0 0 0 0 0
and fecal hemoglobin. utilizing stool, algorithm reported 0 0 0 0 0 0 0 0
0
0 0 0
0 0 0
0
0 0
as a positive or negative result 0 0 0 0 0 0 0 0 0
0 0 ° 0 0 0 0
0 0
0 0 0 0 00
0 0
0 0 0 0 00
0 0
D 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(Do not report 81528 in conjunction with 81275, 82274) 0 0 D 0 0 0
A= Revised code •=New code IJI> • = Contains new or revised text *=Duplicate PlA test ti =Category I PlA American Medical Association 651
81542--82010 Pathology and Laboratory/ Chemistry CPT 2023
81542 Oncology (prostate). mRNA, microarray gene expression 81596 Code is out of numerical sequence. See 81513-~1520
profiling of 22 content genes, utilizing formalin-fixed
81599 Unlisted multianalyte assay with algorithmic analysis
paraffin-embedded tissue, algorithm reported as
metastasis risk score

0 CPT Assistant Apr 18:11. Jun 18:8, Jun 19:11
0 CPT Assistant Oct 20:8 (Do not use 81599 for multianalyte assays with
algorithmic analyses listed in Appendix 0)
(81545 has been deleted)
81551 Oncology (prostate). promoter methylation profiling by Chemistry
real-time PCR of 3 genes (GSTP1. APC, RASSFI). utilizing
formalin-fixed paraffin-embedded tissue, algorithm
The material for examination may be from any source
reported as a likelihood 'at prostate cancer detection on unless otherwise specified in the code descriptor. When
repeat biopsy an analyte is measured in multiple specimens from
0 CPT Changes: An Insider's View2016 different sources, or in specimens that are obtained at
different times, the analyte is reported separately for each
source and for each specimen. The examination is
# 81546 Oncology (thyroid). mRNA. gene expression analysis of quantitative unless specified. To report an organ or
10, 196 genes, utilizing fine needle aspirate. algorithm disease oriented panel, see codes 80048-80076.
reported as a categorical result (eg, benign or suspicious)
0 CPT Changes: An Insider's View 2021 Clinical information or mathematically calculated values,
which are not specifically requested by the ordering
# 81504 Oncology (tissue of origin). microarray gene expression physician and are derived from the results of other
profiling of> 2000 genes, utilizing formal!n-fixed ordered or performed laboratory tests, are considered part
paraffin-embedded tissue, algorithm reported as tissue of the ordered test procedure(s) and therefore are not
similarity scores
separately reportable service(s).
When the requested analyte result is derived using a
# 81540 Oncology (tumor of unknown origin). mRNA. gene
calculation that requires values from nonrequested
expression profiling by real-time RT-PCR of 92 genes (87
laboratory analyses, only the requested analyte code
content and 5 housekeeping) to classify tumor into main
should be reported.
cancer type and subtype, utilizing formalin-fixed paraffin-
embedded tissue, algorithm reported as a probability of a When the calculated analyte determination requires
predicted main cancer type and subtype values derived from other requested and nonrequested
0 CPT Changes: An Insider's View 2016 laboratory analyses, the requested analyte codes
(including those calculated) should be reported.
81552 Oncology (uveal melanoma). mRNA, gene expression
profiling by real-time RT-PCR of 15 genes (12 content and An exception to the above is when an analyte (eg, urinary
3 housekeeping), utilizing fine needle aspirate or creatinine) is performed to compensate for variations in
formalin-fixed paraffin-embedded tissue. algorithm urine concentration (eg, microalbumin, thromboxane
reported as risk of metastasis metabolites) in random urine samples; the appropriate
0 CPT Changes: An Insider's View 2020 CPT code is reported for both the ordered analyte and
0 CPT Assistant Jan 20:10 the additional required analyte. When the calculated
81554 Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), result(s) represent an algorithmically derived numeric
mRNA. gene expression analysis of 190 genes. utilizing score or probability, see the appropriate multianalyte
transbronchial biopsies. diagnostic algorithm reported as assay with algorithmic analyses (MAAA) code or the
categorical result (eg. positive or negative for high MAAA unlisted code (81599).
probability of usual interstitial pneumonia [UIP]) 82009 Ketone body(s) (eg. acetone, acetoacetic acid, beta-
0 CPT Changes: An Insider's View 2021 hydroxybutyrate); qualitative
0 CPT Assistant Mar 21 :6 0 CPT Changes: An Insider's View 2013
81560 Transplantation medicine (allograft rejection. pediatric 0 CPT Assistant Oct 11: 11. Jun 15: 10
liver and small bowel), measurement of donor and third- 82010 quantitative
party-induced CD154+T-cytotoxic memory cells, utilizing 0 CPT Changes: An Insider's View2013
whole peripheral blood, algorithm reported as a rejection 0 CPT Assistant Oct 11: 11
risk score
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0 0
(Do not report 81560 in conjunction with 85032, 86353, 0

0 0
0 0
0 0 0
• 0
0 0 0 0 0
0
0
0
86821,88184,88185,88187,88230,88240,88241, 0
0
0
0 0
0 0 0 0
0
0 0
0 0
0 0
0018M) 0 0 0
0 0 ° 0 0 0 0
0 0 ° 0 0
0 00 0 0 0
0 00 0 0 0 0 0
0
0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 ~ 0 0
0 0
0
0 0 0
.. 0
652 *=Telemedicine '4=Audio--0nly +=Add--0ncode .#'=FDAapproval pending #=Resequenced code 6>=Modifier51 exempt O O O =Seepxixfordetails
CPT 2023 Pathology and Laboratory I Chemistry 82013-82180
82013 Acetylcholinesterase 82107 AFP-L3 fraction isoform and total AFP (including ratio)
(For gastric acid analysis. use 82930)
82108 Aluminum
(Acid phosphatase. see 84060-84066)
82120 Amines. vaginal fluid, qualitative
82016 Acylcarnitines; qualitative, each specimen
82017 quantitative. each specimen
(For combined pH and amines test for vaginitis, use
82120 and 83986)
82127 Amino acids; single, qualitative. each specimen
(For carnitine. use 82379)
82024 Adrenocorticotropic hormone (ACTH)
82128 multiple. qualitative. each specimen
82030 Adenosine. 5-monophosphate, cyclic (cyclic AMP) @ CPT Assistant Nov 98:24
82040 Albumin; serum. plasma or whole blood 82131 single, quantitative, each specimen
@ CPT Changes: An Insider's View 2009 @ CPT Assistant May 98:11, Nov 98:24
@ CPT Assistant Dec 99:2
82135 Aminolevulinic acid, delta (ALA)
82136 Amino acids, 2 to 5 amino acids. quantitative, each
82043 urine (eg, microalbumin). quantitative specimen
@ CPT Changes: An Insider's View2018 @ CPT Assistant Nov 98:24
@ CPT Assistant Summer 94:2
82139 Amino acids, 6 or more amino acids, quantitative, each
82044 urine (eg, microalbumin). semiquantitative (eg. specimen
reagent strip assay) @ CPT Assistant Nov 98:24
82140 Ammonia
@ CPT Assistant Summer 94:2, Mar 98:3, Sep 02:10
82143 Amniotic fluid scan (spectrophotometric)
(For prealbumin, use 84134)
(For L/S ratio, use 83661)
82045 ischemia modified
@ CPT Changes: An Insider's View 2005 (Amobarbital, use 80345)
# 82042 other source, quantitative, each specimen 82150 Amylase
@ CPT Changes: An Insider's View 2001, 2018 82154 Androstanediol glucuronide
(For total protein, see 84155, 84156, 84157, 84160) @ CPT Assistant Summer 94:5
82075 Alcohol (ethanol); breath 82157 Androstenedione

@ CPT Changes: An Insider's View 2015, 2021 82160 Androsterone
82077 any specimen except urine and breath, immunoassay 82163 Angiotensin II
(eg, IA, EIA. ELISA. RIA. EMIT, FPIA) and enzymatic
methods (eg, alcohol dehydrogenase) 82164 Angiotensin I - converting enzyme (ACE)
@ CPT Changes: An Insider's View 2021 (Antidiuretic hormone (ADH), use 84588)
(For definitive drug testing for alcohol [ethanol). use (Antimony, use 83015)
80320)
(Antitrypsin. alpha-1-, see 82103, 82104)
82085 Aldolase
82172 Apolipoprotein, each
82088 Aldosterone
@ CPT AssistantOct 10:7 82175 Arsenic
(Alkaline phosphatase. see 84075, 84080) (For heavy metal screening, use 83015)
(Alphaketoglutarate, see 82009, 82010) 82180 Ascorbic acid (Vitamin C), blood
(Alpha tocopherol [Vitamin El. use 84446) (Aspirin, see acetylsalicylic acid, 80329, 80330, 80331)
82103 Alpha-1-antitrypsin; total 0 0 0 0 0

0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0
82104 phenotype 0 0
0
0 0
0
0 0
0
0 0
0
0
0 0 0 0 0 0 0 0
82105 Alpha-fetoprotein (AFP); serum 0

0
0
0
0 0 0
0
0
0
0
0 0 0
0
• 0
0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
82106 amniotic fluid
0
0
00
0
0
0
0
0
0
0
0
0
0
0
00
0
0
0
0
0
0
0
0
0
0 • 0
00
0
II .,
0 0 0 0
0 0
0 0 0 0 0
A= Revised code e =New code II> -'4 =Contains new or revised text *=Duplicate PLA test ti= Category I PLA American Medical Association 653
82190-82435 Pathology and Laboratory I Chemistry CPT 2023
(For salicylate by immunoassay or enzymatic methods, 82330 ionized

use 80179) 0 CPT Assistant Apr 13:10
(Atherogenic index, blood. ultracentrifugation. 82331 after calcium infusion test

quantitative, use 83701)
82340 urine quantitative. timed specimen
82190 Atomic absorption spectroscopy, each analyte
82355 Calculus; qualitative analysis
0 CPT Assistant Oct 10:7
82232 Beta-2 microglobulin
82360 quantitative analysis, chemical
(Bicarbonate, use 82374)
82365 infrared spectroscopy
82239 Bile acids; total
82370 X-ray diffraction
82240 cholylglycine 0 CPT Changes: An Insider's View 2001
(For bile pigments, urine. see 81000-81005) (Carbamates, see individual listings)
82247 Bilirubin; total 82373 Carbohydrate deficient transferrin
0 CPT Assistant Nov 98:24, Apr 99:6, Dec 99:1, Jan 00:7, Dec 08:5, 0 CPT Changes: An Insider's View2001
Apr 10:11
82374 Carbon dioxide (bicarbonate)
82248 direct 0 CPT Assistant Dec 99:2. Apr 13:10
0 CPT Assistant Nov 98:24, Apr 99:6, Dec 99:1. Apr 10:11
(See also 82803)
82252 feces, qualitative
82375 Carboxyhemoglobin; quantitative
82261 Biotinidase, each specimen 0 CPT Changes: An Insider's View2009
82376 qualitative
82270 Blood. occult. by peroxidase activity (eg, guaiac), 0 CPT Changes: An Insider's View 2009
qualitative; feces, consecutive collected specimens with
single determination. for colorectal neoplasm screening (For transcutaneous measurement of carboxyhemoglobin.
(ie, patient was provided 3 cards or single triple card for use 88740)
consecutive collection) 82378 Carcinoembryonic antigen (CEA)
0 CPT Changes: An Insider's View 2002, 2006 0 CPT Assistant Fall 93:25, Aug 96:11
0 CPT Assistant Sep 03:15, Feb 06:7. Apr 08:5
82379 Carnitine (total and free). quantitative. each specimen
82271 other sources 0 CPT Assistant Nov 98:24
0 CPT Assistant Feb 06:7 (For acylcarnitine. see 82016, 82017)
82272 Blood, occult. by peroxidase activity (eg, guaiac). 82380 Carotene

qualitative, feces, 1-3 simultaneous determinations, 82382 Catecholamines; total urine
performed for other than colorectal neoplasm screening
82383 blood
0 CPT Assistant Feb 06:7, Apr 08:5, Jun 09:10 82384 fractionated
(Blood urea nitrogen [BUN). see 84520, 84525) (For urine metabolites. see 83835, 84585)
82274 Blood, occult. by fecal hemoglobin determination by 82387 Cathepsin-D
immunoassay, qualitative, feces. 1-3 simultaneous
determinations 82390 Ceruloplasmin
0 CPT Changes: An Insider's View 2002 82397 Chemiluminescent assay
82286 Bradykinin
0 CPT Assistant Fall 93:25. Oct 10:7
0 CPTAssistantOct10:7 82415 Chloramphenicol

82300 Cadmium 0 CPT Assistant Aug 05:9. Oct 10:7
0 CPT Assistant Aug 05:9. Oct 10:7 82435 Chloride; blood

82306 Vitamin D; 25 hydroxy, includes fraction(s}. if performed
0 CPTAssistantDec 99:2. Apr 13:10

0 0 0 0 0
0 0 0 0 0 0 0
#82652 1, 25 dihydroxy, includes fraction(s). if performed 0 0 0
0 0 0 0
0 0
0
0 0
0 0
0 0 0
0
0 0
0 0
0 0 0
0 0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
82308 Calcitonin 0
0 0
0
0 0 0
0 0 ° 0 0 0 0 0 0 0 0 0 0
82310 Calcium; total 0 00

0 0 0 0 0
0 00
0 0
0 0 0 0 00
0 CPT Assistant Dec 99:2 0 0 0

0
0
0
0 0 0 0 0 0
0
0 0 0 0 0 0
0 0 0 0
0
654 *
= Telemedicine '4 =Audio-only +=Add-on code j( =FDA approval pending #=Resequenced code 19 =Modifier 51 exempt 0 0 0 =See pxix for details
82436 urine 82550 Creatine kinase (CK). (CPK); total

@ CPT Assistant Feb 98:1. Dec 99:2
82438 other source
0 CPT Assistant Jul 03:7 82552 isoenzymes
@ CPT Assistant Feb 98:1
(For sweat collection by iontophoresis. use 89230)
82553 MB fraction only
82441 Chlorinated hydrocarbons. screen
@ CPT Assistant Feb 98:1. Oct 21 :14
(Cholecalciferol [Vitamin DJ. use 82306)
82554 isoforms
82465 Cholesterol, serum or whole blood, total @ CPT Assistant Feb 98:1
82565 Creatinine; blood
0 CPT Assistant Dec 99:2, Mar 00:11 , Feb 05:9
0 CPT Assistant Dec 99:2, Apr 13:10
(For high density lipoprotein [HDL]. use 83718)
82570 other source
82480 Cholinesterase; serum
82575 clearance
82482 RBC
82585 Cryofibrinogen
82485 Chondroitin 8 sulfate. quantitative
82595 Cryoglobulin. qualitative or semi-quantitative (eg,
(Chorionic gonadotropin, see gonadotropin, 84702. cryocrit)
82495 Chromium @ CPT AssistantOct 10:7
@ CPT Assistant Oct 10:7 (For quantitative. cryoglobulin. see 82784. 82785)
82507 Citrate (Crystals. pyrophosphate vs urate. use 89060)
@ CPT Assistant Aug 05:9, Oct 10:7
82600 Cyanide
(Cocaine. qualitative analysis. use 80353) @ CPT Assistant Aug 05:9. Oct 10:7
(Codeine. qualitative analysis. use 80361) 82607 Cyanocobalamin (Vitamin 8-12);
(Complement, see 86160-86162) 0 CPT Assistant Oct 21 :14
82523 Collagen cross links. any method 82608 unsaturated binding capacity
82525 Copper (Cyclic AMP. use 82030)
(Coproporphyrin. see 84119. 84120) (Cyclosporine. use 80158)
(Corticosteroids, use 83491) 82610 Cystatin C

82528 Corticosterone 0 CPT Assistant Apr 08:5. Aug 08:13
82530 Cortisol; free 82615 Cystine and homocystine, urine. qualitative
@ CPT Assistant Summer 94:3
82626 Dehydroepiandrosterone (DHEA)
82533 total 0 CPT Assistant Summer 94:4
(Do not report 82626 in conjunction with 80327, 80328 to
(C-peptide. use 84681) identify anabolic steroid testing for testosterone)
82540 Creatine 82627 Dehydroepiandrosterone-sulfate (DHEA-S)
82542 Column chromatography, includes mass spectrometry. if 0 CPT Assistant Summer 94:4
performed (eg, HPLC. LC, LC/MS. LC/MS-MS, GC, GC/ (Delta-aminolevulinic acid (ALA). use 82135)
MS-MS. GC/MS. HPLC/MS). non-drug analyte(s) not
elsewhere specified. qualitative or quantitative. each 82633 Desoxycorticosterone. 11 -
specimen 82634 Deoxycortisol, 11-
@ CPTChanges: An Insider's View2015, 2016
0 CPT Assistant Nov 98:24-25, Apr 15:3 (Dexamethasone suppression test. use 80420)
(Do not report more than one unit of 82542 for each (Diastase, urine. use 82150)
specimen) 0 0 0
0 0 0 0 0 0
0 0 0 0 0
0
0
(For column chromatography/mass spectrometry of drugs 0 0
0
0 0 0 0
0
0 0
0 0 0 0 0 0 0 0
or substances, see 80305, 80306, 80307. 80320-80377. or 0 0 0 0
0 0 0 0 0
specific analyte code(s] in the Chemistry section) 0 0 0 0 0
0
0 0 0 0 0
0
0
0 0
0 0 ° 0 0 0 0
0 0 ° 0 0 0 0
0 00 0 0 0 0 00 0 0 0 0 00
0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
.A= Revised code e = New code .,. ..,. =Contains new or revised text *=Duplicate PlA test ti= Category I PLA American Medical Association 655
82638 Dibucaine number 82705 Fat or lipids. feces; qualitative

~ CPT Assistant Aug 05:9, Oct 10:7
(Dichloroethane. use 82441 l
82710 quantitative
(Dichloromethane, use 82441)
82715 Fat differential, feces, quantitative
(Diethylether. use 84600)
82725 Fatty acids, nonesterified
82642 Dihydrotestosterone (DHT)
@ CPT Changes: An Insider's View 2019 82726 Very long chain fatty acids
(For dihydrotestosterone analysis for anabolic drug
testing, see 80327, 80328) 82728 Ferritin
(Dipropylacetic acid, use 80164) (Fetal hemoglobin. see hemoglobin 83030, 83033, and
85460)
(Dopamine, see 82382-82384)
(Fetoprotein. alpha-1. see 82105, 82106)
(Duodenal contents. see individual enzymes; for
intubation and collection. see 43756, 43757) 82731 Fetal fibronectin. cervicovaginal secretions. semi-
quantitative
82735 Fluoride
82656 Elastase, pancreatic (EL-1 ). fecal; qualitative or semi-
(Foam stability test. use 83662)
quantitative
@ CPT Changes: An Insider's View 2005, 2022 82746 Folic acid; serum
@ CPT Assistant Sep 05:9
82747 RBC
# 82653 quantitative
(Follicle stimulating hormone [FSH]. use 83001 l
82757 Fructose. semen
82657 Enzyme activity in blood cells. cultured cells. or tissue.
not elsewhere specified; nonradioactive substrate. each (Fructosamine. use 82985)
specimen
(Fructose. TLC screen. use 84375)
82759 Galactokinase. RBC
82658 radioactive substrate, each specimen
@ CPT Assistant Nov 98:25 82760 Ga lactose
82664 Electrophoretic technique, not elsewhere specified 82775 Galactose-1-phosphate uridyl transferase; quantitative
(Endocrine receptqr assays, see 84233-84235) 82776 screen
82668 Erythropoietin 82777 Galectin-3

82670 Estradiol; total
@ CPT Changes: An Insider's View 2021 82784 Gammaglobulin (immunoglobulin); lgA, lgD, lgG, lgM,
each
# 82681 free. direct measurement (eg, equilibrium dialysis)
@ CPf Changes: An Insider's View 2010
@ CPT Changes: An Insider's View 2021 @ CPT Assistant Spring 94:31. Aug 00:11
82671 Estrogens; fractionated
82785 lgE
82672 total @ CPTChanges: An Insider's View2010
@ CPT AssistantSpring 94:31
(Estrogen receptor assay, use 84233)
(For allergen specific lgE, see 86003, 86005)
82677 Estriol
82787 immunoglobulin subclasses (eg, lgGl. 2. 3, or 4). each
82679 Estrone
@ CPT Changes: An Insider's View2001. 2010
(For definitive drug testing for alcohol [ethanol]. use @ CPT AssistantOct 10:7
80320)
(Gamma-glutamyltransferase [GGT]. use 82977)
(For alcohol [ethanol) by immunoassay or enzymatic
methods. use 82077) 0 0 0 0 0
0 0 0 0
0 0 0 0
'o
0 0 0 0
0
0
0
0
0
0
0
0 0 0 0 0 0 0
0 0 0 0 0 0
82693 Ethylene glycol 0
0
0 0 0 0
0
0
0 0 0 0
0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
82696 Etiocholanolone 0 0 0 0
00 0 00 0
@ CPT Assistant Oct 10:7 0
0 0 0 0
0
0 0 0 0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
(For fractionation of ketosteroids, use 83593) 0
0
0 0 0
· 656 *=Telemedicine ~=Audio-only +=Add-on code ,N' =FDA approval pending #=Resequenced code 6l=Modifier 51 exempt OOO=See pxix for details
CPT2023 Pathology and Laboratory I Chemistry 82800-83013
82800 Gases, blood, pH only (For semiquantitative urine glucose, see 81000. 81002,
0 CPT Assistant Aug 05:9, Oct 10:7 81005, 81099)
82803 Gases, blood. any combination of pH, pC0 2, p02, C0 2, 82955 Glucose-6-phosphate dehydrogenase (G6PD); quantitative
HC03 (including calculated 02 saturation!;
82960 screen
(Use 82803 for 2 or more of the above listed analytes)
(For glucose tolerance test with medication, use 96374 in
82805 with 02 saturation. by direct measurement, except addition)
pulse oximetry
82962 Glucose. blood by glucose monitoring device(sl cleared by
82810 Gases, blood, 02 saturation only, by direct measurement. the FDA specifically for home use
except pulse oximetry 0 CPT Assistant Summer 94:4, Jan 99:10. Nov 10:10. Oct 11 :8
(For pulse oximetry, use 94760) 82963 Glucosidase, beta

82820 Hemoglobin-oxygen affinity (p0 2 for 50% hemoglobin 82965 Glutamate dehydrogenase
saturation with oxygen!
82977 Glutamyltransferase, gamma (GGT)
0 CPT Assistant Dec 99:1
(For gastric acid analysis, use 82930)
82978 Glutathione
82930 Gastric acid analysis, includes pH if performed, each
82979 Glutathione reductase, ABC
specimen
0 CPT Changes: An Insider's View2011 (Glycohemoglobin, use 83036)
0 CPTAssistantOct10:7, Dec 10:7. Sep 11:3
82985 Glycated protein
82938 Gastrin after secretin stimulation 0 CPT Assistant Summer 94:2
82941 Gastrin (Gonadotropin, chorionic, see 84702, 84703)

83001 Gonadotropin; follicle stimulating hormone (FSH)
(Gentamicin, use 80170) 0 CPT Assistant Aug 05:9, Oct 10:7
(GGT, use 829771 83002 luteinizing hormone (LH)

(For a qualitative column chromatography procedure [eg, (For luteinizing releasing factor [LAH]. use 83727)
gas liquid chromatography], use the appropriate specific
83003 Growth hormone, human (HGH) (somatotropin)
analyte code, if available, or 82542)
0 CPTAssistant0ct21:14
82943 Glucagon
(For antibody to human growth hormone, use 86277)
82945 Glucose. body fluid, other than blood
83006 Growth stimulation expressed gene 2 (ST2, Interleukin 1
receptor like-1)
82946 Glucagon tolerance test 0 CPT Changes: An Insider's View2015
82947 Glucose; quantitative, blood (except reagent strip) 83009 Helicobacter pylori, blood test analysis for urease
0 CPT Changes: An Insider's View 2001 activity, non-radioactive isotope (eg, C-13)
0 CPT Assistant Summer 93:14, Summer 94:5. Sep 99:10, Dec 99:2. 0 CPT Changes: An Insider's View 2005
Jun 02:3, Feb05:9, Apr 13:10, May21:8. Oct21:14
(For H. pylori. breath test analysis for urease activity, see
82948 blood, reagent strip 83013, 83014)
0 CPTAssistantSummer94:5, Jan 99:10, Nov 10:10, Oct 11:8
83010 Haptoglobin; quantitative
82950 post glucose dose (includes glucose!
83012 phenotypes
0 CPT Assistant Sep 99:10, Jun 02:3. Feb 05:9
83013 Helicobacter pylori; breath test analysis for urease
82951 tolerance test (GTI). 3 specimens (includes glucose)
activity, non-radioactive isotope (eg, C-131
0 CPT Assistant Feb 01:10, Feb 05:9. Oct 10:7
0 CPT Changes: An Insider's View2001. 2002. 2005
+ 82952 tolerance test, each additional beyond 3 specimens ~ CPT Assistant Nov 98:25, Feb 99:8. Nov 99:45
(List separately in addition to code for primary
procedure)
0 CPT Assistant Feb 01:10, Oct 10:7. Dec 10:7 0
0
0 0
0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0 0
0 0 0 0 0 0
(Use 82952 in conjunction with 82951) 0
0 0
0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
(For insulin tolerance test, see 80434, 80435) 0 0 0
0
0 0 0 0 0
0
0 0 • 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(For leucine tolerance test, use 80428) 0 00 0 0 0 0 00

0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0 0 0
0 0
A=Revised code •=New code .. ~=Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 657
83014--83519 Pathology and Laboratory I Chemistry CPT 2023
83014 drug administration 83069 urine

83070 Hemosiderin, qualitative
0 CPT Assistant Nov 98:25, Feb 99:8, Nov 99:45
(HIM. use 83497)
(For H. pylori. stool, use 87338. For H. pylori, liquid
scintillation counter, see 78267, 78268. For H. pylori, (For a qualitative column chromatography procedure [eg,
immunoassay, use 87339) high performance liquid chromatography]. use the
appropriate specific analyte code. if available, or 82542)
(For H. pylori. blood test analysis for urease activity, use
83009) 83080 b-Hexosaminidase, each assay
83015 Heavy metal (eg. arsenic. barium. beryllium. bismuth,
antimony. mercury); qualitative. any number of analytes 83088 Histamine

(Hollander test. see 43754, 43755)
83090 Homocysteine
83018 quantitative, each, not elsewhere specified
0 CPT Assistant Jan 01 :13. Oct 10:7
0 CPT Assistant Apr 22: 14
83150 Homovanillic acid (HVA)
(Use an analyte-specific heavy metal quantitative code,
0 CPT Assistant Aug 05:9, Oct 10:7
instead of 83018. when available)
(Hormones, see individual alphabetic listings in
83020 Hemoglobin fractionation and quantitation; Chemistry section)
electrophoresis (eg, A2, S. C, and/or Fl
0 CPT Assistant Nov 98:25 (For hydrogen/methane breath test, use 91065)
83021 chromatography (eg, A2, S, C, and/or F) 83491 Hydroxycorticosteroids, 17- (17-0HCS)

0 CPT Assistant Nov 98:25. Dec 99:7 0 CPT Assistant Aug 05:9, Oct 10:7
(For glycosylated [A1c] hemoglobin analysis, by (For cortisol. see 82530, 82533. For deoxycortisol, use
electrophoresis or chromatography, in the absence of an 82634)
identified hemoglobin variant. use 83036) 83497 Hydroxyindolacetic acid, 5-(HIM)
83026 Hemoglobin; by copper sulfate method, non-automated (For urine qualitative test. use 81005)
83030 F(fetal). chemical (5-Hydroxytryptamine. use 84260)
83033 F(fetal). qualitative 83498 Hydroxyprogesterone. 17-d
83500 Hydroxyproline; free
83036 glycosylated (A 1C) 0 CPT Assistant Aug 05:9. Oct 10:7
0 CPT Changes.· An Insider's View 2006
0 CPT Assistant Summer 94:2. Feb 06:7. Oct 06:15 83505 total
(For glycosylated [A 1CJ hemoglobin analysis. by 83516 Immunoassay for analyte other than infectious agent
electrophoresis or chromatography, in the setting of an antibody or infectious agent antigen; qualitative or
identified hemoglobin variant. see 83020, 83021) semiquantitative, multiple step method
(For fecal hemoglobin detection by immunoassay, use 0 CPT Assistant Nov 98:25. Mar 22:11
82274)
83518 qualitative or semiquantitative, single step method
83037 glycosylated (A 1C) by device cleared by FDA for home (eg, reagent strip)
use
0 CPT Assistant Fall 93:26
0 CPT Assistant Feb 06:7, Oct 06:15
83519 quantitative. by radioimmunoassay (eg, RIA)
83045 methemoglobin, qualitative
83050 methemoglobin, quantitative 0 CPT Assistant Fall 93:26. Summer 94:2
(For transcutaneous quantitative methemoglobin

determination, use 88741)
0 0 0 0 0
83051 plasma 0 0 0 0
0 0 0 0
0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
83060 sulfhemoglobin. quantitative 0 0 0 0 0 0 0 0 • o o 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
83065 thermolabile 0
0
0 0
0
0 0
0 0 0 0 0 0 0 0 0 0 0
83068 unstable, screen 0 00

0 0
0 0 0 00
0 0
0 0 0 0 00
0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0
658 *= Telemedicine '4 =Audio-only +=Add-on code ~=FDA approval pending #=Resequenced code &=Modifier 51 exempt 0 0 0 =See p xixfor details
83520 quantitative, not otherwise specified 83633 Lactose, urine, qualitative

(For tolerance, see 82951, 82952)
(For breath hydrogen/methane test for lactase deficiency,
(For immunoassays for antibodies to infectious agent use 91065)
antigens, see analyte and method specific codes in the
Immunology section) 83655 Lead
(For immunoassay of tumor antigen not elsewhere 83661 Fetal lung maturity assessment; lecithin sphingomyelin
specified, use 86316) (L/S) ratio
(lmmunoglobulins, see 82784, 82785)
83662 foam stability test

83521 lmmunoglobulin light chains (ie, kappa, lambda), free,
each 83663 fluorescence polarization
83525 Insulin; total 83664 lamellar body density

(For proinsulin, use 84206)
(For phosphatidylglycerol, use 84081)

83527 free
0 CPT Assistant Summer 94:5 83670 Leucine aminopeptidase (LAP)
lnterleukin-6 (IL-6) 83690 Lipase
83695 Lipoprotein (a)
83528 Intrinsic factor 0 CPT Changes: An Insider's View 2006
(For intrinsic factor antibodies, use 86340)

0 CPT Assistant Feb 06:7
83698 Lipoprotein-associated phospholipase A2 (Lp-PLAil

0 CPT Changes: An Insider's View200J.
83540 Iron 0 CPT Assistant Oct 10:7
83700 Lipoprotein, blood; electrophoretic separation and
83550 Iron binding capacity quantitation
83570 lsocitric dehydrogenase (IOH) 0 CPT Changes: An Insider's View 2006
0 CPT Assistant Feb 06:7. Oct 10:7
(lsonicotinic acid hydrazide, INH, see code for specific
method) 83701 high resolution fractionation and quantitation of
lipoproteins including lipoprotein subclasses when
(lsopropyl alcohol, use 80320) performed (eg, electrophoresis, ultracentrifugation)
83582 Ketogenic steroids, fractionation 0 CPT Changes: An Insider's View2006
(Ketone bodies, for serum, see 82009, 8201 O; for urine,
see 81000-81003) 83704 quantitation of lipoprotein particle number(s) (eg, by
nuclear magnetic resonance spectroscopy), includes
83586 Ketosteroids, 17-(17-KS); total lipoprotein particle subclass(es), when performed
83593 fractionation 0 CPT Changes: An Insider's View2006, 2017
0 CPT Assistant Oct 10:7 0 CPT Assistant Feb 06:7
83605 Lactate (lactic acid) 83718 Lipoprotein, direct measurement; high density cholesterol
0 CPT Assistant Aug 05:9. Oct 10:7 (HOL cholesterol)
0 CPT Assistant Oct 99:11 , Mar 00:11 , Feb05:9
83615 Lactate dehydrogenase (LO), (LOH);
0 CPT Assistant Fall 93:25, Feb 98:1, Dec 99:2 83719 VLOL cholesterol
0 CPT Assistant Oct 99: 11
83625 isoenzymes, separation and quantitation
0 CPT AssistantFall 93:25, Feb 98:1 83721 LOL cholesterol
0 CPT Assistant Nov 98:25, Oct 99:11
83630 Lactoferrin, fecal; qualitative
0 CPT Assistant Feb 06:7 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
83631 quantitative 0 0
0 0
0 0
0 0
0
0 0 0 0
0 0
0 0
0
0
0 0
0 0
0
0
I> 0
0
0 CPT Assistant Feb 06:7, Jan 07:29
0
0
0 0
0 0
0
0
0
0
0
0
0 0
0 0
0
0
0
0
0
0
0 0
0 0 0 0
83632 Lactogen, human placental (HPL) human chorionic 0
00
0 0 0
0
II
0
00
0 0 0
0 0
00
0
somatomammotropin 0
0 0
0 0
0 0
0
0 0
0 0
0 0
0
0 0
0 0
0 0 0 0
•=Revised code •=New code • •=Contains new or revised text ){=Duplicate PLA test tJ.=Category I PLA American Medical Association 659
83722 small dense LDL cholesterol (For oligoclonal bands. use 83916)
83874 Myoglobin
(For fractionation by high resolution electrophoresis or @ CPT Assistant Feb 98:1
ultracentrifugation. use 83701)
83876 Myeloperoxidase (MPO)
(For lipoprotein particle numbers and subclasses analysis 0 CPT Changes: An Insider's View2009
by nuclear magnetic resonance spectroscopy. use 83704)
83880 Natriuretic peptide
83727 Luteinizing releasing factor (LAH) 0 CPT Changes: An Insider's View2003
(Luteinizing hormone [LH). use 83002) 0 CPT Assistant Jul 03:7
(Macroglobulins. alpha-2, use 86329) 83883 Nephelometry, each analyte not elsewhere specified
83735 Magnesium 83885 Nickel
83775 Malate dehydrogenase 83915 Nucleotidase 5'-
(Maltose tolerance, see 82951, 82952) 83916 0ligoclonal immune (oligoclonal bands)
(Mammotropin. use 84146)
83918 Organic acids; total. quantitative. each specimen
83785 Manganese 0 CPT Changes: An Insider's View 2001
83789 Mass spectrometry and tandem mass spectrometry (eg. 0 CPT AssistantMar96:11. Nov 98:26
MS. MS/MS. MALO!, MS-TOF. GTOF). non-drug analyte(s) 83919 qualitative. each specimen
not elsewhere specified, qualitative or quantitative. each 0 CPT Assistant Nov 98:26
specimen
0 CPT Changes: An Insider's View 2016 83921 Organic acid. single, quantitative
@ CPT Assistant Nov 98:26, Oct 10:7 0 CPT Changes: An Insider's View2001
(Do not report more than one unit of 83789 for each 83930 Osmolality; blood
specimen) 83935 urine
(For column chromatography/mass spectrometry of drugs (For tear osmolarity using microfluidic analysis, use
or substances. see 80305. 80306, 80307, 80320-80377. or 83861) .
specific analyte code[s] in the Chemistry section)
83937 Osteocalcin (bone g1a protein)
83825 Mercury, quantitative 0 CPT Assistant Summer 94:5
(Mercury screen. use 83015) 83945 Oxalate
83835 Metanephrines 83950 Oncoprotein; HER-2/neu
(For catecholamines. see 82382-82384) 0 CPT Changes: An Insider's View2002, 2009
(Methamphetamine, see 80324. 80325, 80326) (For tissue. see 88342. 88365)
(Methane breath test. use 91065) 83951 des-gamma-carboxy-prothrombin (DCP)

83857 Methemalbumin
83970 Parathormone (parathyroid hormone)
(Methemoglobin. see hemoglobin 83045. 83050)
(Pesticide, quantitative. see code for specific method. For
(Methyl alcohol. use 80320) screen for chlorinated hydrocarbons. use 82441)
(Microalbumin, see 82043 for quantitative. see 82044 for 83986 pH; body fluid, not otherwise specified
semiquantitative)
83861 Microfluidic analysis utilizing an integrated collection 0 CPT Assistant Sep 13:13, May 16:14
and analysis device. tear osmolarity
83987 exhaled breath condensate
@ CPT AssistantOec 10:7
(For blood pH. see 82800. 82803)
(Microglobulin, beta-2. use 82232)
(Phenobarbital. use 80345)
(For microfluidic tear osmolarity of both eyes. report 0
0 0
83861 twice) 0
0
0
0
0
0
0
0 0
0 0
83864 · Mucopolysaccharides. acid. quantitative 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
83872 Mucin. synovial fluid (Ropes test) 0 0
0 0 0 0 0 0 0 0 0 0
0 0 ° 0 0
83873 Myelin basic protein. cerebrospinal fluid 0 00

0 0
0 0 0 0 00
0 0
0 0 0 •
0 0
@ CPT Changes: An Insider's View2002 0 0 0
0 0
0 0 0
0
0 0 0
0 0
0 0 0
0
•
660 *=Telemedicine '4 =Audio-only +=Add-on code .K = FDA approval pending #=Resequenced code \S>=Modifier 51 exempt OOO=See pxix for details
CPT 2023 Pathology and Laboratory/ Chemistry 83993-84181
83992 Code is out of numerical sequence. See Definitive Drug 84135 Pregnanediol
Testing subsection
84138 Pregnanetriol
83993 Calprotectin, fecal
84140 Pregnenolone
0 CPT Assistant Apr 08:5, Oct 10:7
84143 17-hydroxypregnenolone
84030 Phenylalanine (PKU), blood
(Phenylalanine-tyrosine ratio, see 84030, 84510)
84144 Progesterone
84035 Phenylketones, qualitative
(Progesterone receptor assay, use 84234)
84060 Phosphatase, acid; total
(For proinsulin, use 84206)
84066 pro static
84145 Procalcitonin (PCT)
84075 Phosphatase, alkaline; 0 CPT Changes: An Insider's View 2010
84146 Prolactin
84078 heat stable (total not included)
84150 Prostaglandin, each
84080 isoenzymes
84152 Prostate specific antigen (PSA); complexed (direct
84081 Phosphatidylglycerol measurement)
(Phosphates inorganic, use 84100) 0 CPT Changes: An Insider's View 2001
(Phosphates, organic, see code for specific method. For 84153 total
cholinesterase, see 82480, 82482) 0 CPT AssistantFall 93:26, May 96:10, Aug 96:10, Jan 97:10,
Nov 98:26, Aug 99:5, Dec 99: 10
84085 Phosphogluconate, 6-, dehydrogenase, RBC
84154 free
84087 Phosphohexose isomerase 0 CPTAssistantNov98:26, Aug 99:5, Dec 99:10
84155 Protein, total, except by refractometry; serum, plasma or
84100 Phosphorus inorganic (phosphate); whole blood
0 CPT Assistant Dec 99:2, Aug 05:9, Oct 10:7 0 CPT Changes: An Insider's View 2004, 2009
84105 urine 0 CPT Assistant Dec 99:2, Jan 00:7
(Pituitary gonadotropins, see 83001-83002) 84156 urine

(PKU, see 84030, 84035)
84157 other source (eg, synovial fluid, cerebrospinal fluid)
84106 Porphobilinogen, urine; qualitative 0 CPT Changes: An Insider's View 2004
84110 quantitative 84160 Protein, total, by refractometry, any source
84112 Evaluation of cervicovaginal fluid for specific amniotic 0 CPT Changes: An Insider's View2004
fluid protein(s) (eg, placental alpha microglobulin-1 (For urine total protein by dipstick method, use 81000-
[PAMG-1]. placental protein 12 [PP12]. alpha-fetoprotein). 81003)
qualitative, each specimen
0 CPT Changes: An Insider's View 2011, 2014 84163 Pregnancy-associated plasma protein-A (PAPP-A)
0 CPT Assistant Oct 10:8, Dec 10:8 0 CPT Changes: An Insider's View 2005
84119 Porphyrins, urine; qualitative 84165 Protein; electrophoretic fractionation and quantitation,
serum
84120 quantitation and fractionation 0 CPT Changes: An Insider's View 2004, 2005
84126 Porphyrins, feces, quantitative 84166 electrophoretic fractionation and quantitation, other
(Porphyrin precursors, see 82135, 84106, 84110) fluids with concentration (eg, urine, CSF)
(For protoporphyrin, RBC, see 84202, 84203)
84181 Western Blot, with interpretation and report, blood or
84132 Potassium; serum, plasma or whole blood other body fluid
O cPT Assistant Dec 99:2, Jun 02:3, Apr 13:10 0
0
0 0
0
0
0
0 0
0
0
0
0 0 0 0 0
0 0 0 0
84133 urine 0
0
0
0
0 0 0
0
0 0 0
0 0 0
0
0
0 0 0 0 0
0 0
84134 Prealbumin 0 0
0 0
0
0
0 0
0
0
0 0
0 0
0
0
0
(For microalbumin, see 82043, 82044)

0 0 0
0 0 ° 0 0 0 0 0 0 0 0 0 Q 0
0 00 0 0 0 0 00
0 0 0 0 0 0 00
0 0
0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
A=Revised code • = New code Iii>- <1111 = Contains new or revised text *=Duplicate PLA test ti =Category I PLA American Medical Association 661
84182 Western Blot. with interpretation and report. blood or (Somatomammotropin. use 83632)
other body fluid, immunological probe for band
(Somatotropin, use 83003)
identification, each
0 CPT Assistant Oct 10:7 84305 Somatomedin
(For Western Blot tissue analysis, use 88371)
84307 Somatostatin
84202 Protoporphyrin, RBC; quantitative
84311 Spectrophotometry, analyte not elsewhere specified

84203 screen
84315 Specific gravity (except urine)
84206 Proinsulin
(For specific gravity, urine, see 81000-81003)
(Pseudocholinesterase. use 82480)
(Stone analysis, see 82355-82370)
84207 Pyridoxal phosphate (Vitamin B-6)
(For suppression of growth stimulation expressed gene 2
84210 Pyruvate
[ST2) testing, use 83006)
84220 Pyruvate kinase
84375 Sugars. chromatographic, TLC or paper chromatography
84228 Quinine
84376 Sugars (mono-, di-. and oligosaccharides); single
qualitative. each specimen
84233 Receptor assay; estrogen 0 CPT Assistant Nov 98:26-27, Dec 99:7
84234 progesterone 84377 multiple qualitative. each specimen

84235 endocrine. other than estrogen or progesterone
0 CPT Assistant Nov 98:26-27, Jul 03:7
(specify hormone) 84378 single quantitative. each specimen

84238 non-endocrine (specify receptor)
0 CPT Assistant Nov 98:26-27
0 CPT Changes: An Insider's View 2006 84379 multiple quantitative. each specimen
0 CPT Assistant Nov 05:14 0 CPT Assistant Nov 98:26-27, Dec 99:7, Jul 03:7
84244 Renin 84392 Sulfate. urine

84252 Riboflavin (Vitamin B-2) 0 CPT Assistant Oct 10:7
(Sulfhemoglobin. use hemoglobin, 83060)

(Salicylates. see 80329, 80330, 80331)
{T-3, see 84479-84481)
(For salicylate by immunoassay or enzymatic methods.
use 80179) (T-4. see 84436-84439)
(Secretin test. see 99070, 43756, 43757 and appropriate 84402 Testosterone; free
analyses) 0 CPT Assistant Aug 05:9. Oct 10:7
84255 Selenium 84403 total
84260 Serotonin 84410 bioavailable. direct measurement (eg. differential
(For urine metabolites (HIAA). use 83497) precipitation)
84270 Sex hormone binding globulin (SHBG)
(Do not report 84402. 84403 in conjunction with 80327,
80328 to identify anabolic steroid testing for
84275 Sialic acid testosterone)
(Sickle hemoglobin. use 85660) 84425 Thiamine (Vitamin B-1)
84285 Silica 84430 Thiocyanate
84295 Sodium; serum, plasma or whole blood #9 84433 Thiopurine S-methyltransferase (TPMT)
0 CPT AssistantOec 99:2, Oct 10:7. Apr 13:10
84300 urine
0 CPT Assistant Aug 05:9, Oct 10:7 0
0
0 0
0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0 0
0 0 0 0
84302 other source 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0

0
0
0
0 0 0
0
0
0
0
0 0 0
0
0 CPT Assistant Jul 03:7 0 0 0

0 0
0 0
0
0 0 0
0 0
0 0
0
0
00 0 00 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
662 *= Telemedicine ~ =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 0 00 =See p xix for details
84431 Thromboxane metabolite(s). including thromboxane if 84490 feces. quantitative, 24-hour collection
performed, urine 0 CPT Assistant Oct 10:7
84510 Tyrosine
(For concurrent urine creatinine determination, use 84431 0 CPT Assistant Oct 10:7
in conjunction with 82570)
(Urate crystal identification, use 89060)
84432 Thyroglobulin
84512 Troponin. qualitative
0 CPT Assistant Nov 97:29, Jan 98:6, Feb 98:1
(Thyroglobulin, antibody, use 86800)
(For troponin, quantitative assay, use 84484)
(Thyrotropin releasing hormone [TRH] test. see 80438,
80439)
84520 Urea nitrogen; quantitative
0 CPT Assistant Dec 99:2, Apr 13:10
84525 semiquantitative (eg, reagent strip test)
84436 Thyroxine; total 0 CPT Assistant Mar 98:3
0 CPT Assistant Fall 93:25, Summer 94:3
84540 Urea nitrogen, urine
84437 requiring elution (eg, neonatal)
84545 Urea nitrogen, clearance
84439 free
84550 Uric acid; blood
84442 Thyroxine binding globulin (TBG) 0 CPT Assistant Dec 99:2
84443 Thyroid stimulating hormone (TSH) 84560 other source
84577 Urobilinogen, feces, quantitative
84445 Thyroid stimulating immune globulins (TSI)
84578 Urobilinogen, urine; qualitative
0 CPT Assistant Summer 94:3 84580 quantitative, timed specimen
(Tobramycin, use 80200) 84583 semiquantitative
84446 Tocopherol alpha (Vitamin El (Uroporphyrins, use 84120)
84449 Transcortin (cortisol binding globulin) (Valproic acid [dipropylacetic acid]. use 80164)
84585 Vanillylmandelic acid (VMA). urine
84450 Transferase; aspartate amino (AST) (SGOT)
84586 Vasoactive intestinal oeptide (VIP)
84460 alanine amino (ALT) (SGPT)
84588 Vasopressin (antidiuretic hormone, ADH)
84466 Transferrin
84590 Vitamin A
Oron binding capacity, use 83550)
(Vitamin 8-1, use 84425)
84478 Triglycerides
0 CPT Assistant Dec 99:2. Mar 00:11. Feb 05:9
84479 Thyroid hormone (T3 or T4) uptake or thyroid hormone
binding ratio (TH8R) (Vitamin 8-12. use 82607)
0 CPT Assistant Fall 93:25. Sumnier 94:3 (Vitamin C, use 82180)
84480 Triiodothyronine T3; total (TI-3) (Vitamin D, see 82306, 82652)
84481 free (Vitamin E, use 84446)
84482 reverse
84484 Troponin, quantitative

0 CPT Assistant Nov 97:29, Jan 98:6, Feb 98:1
0
0
0 0
0
0
0
0 0
0
0
0
0 0 0
0 0 0 0 0 0
(For troponin. qualitative assay, use 84512) 0 0
0
0 0 0
0
0 0 0
0 0 0
0
0
0 0 0 0 0 0
84485 Trypsin; duodenal fluid 0

0
0
0
0 0
0
0
0 0 0 0 0 0
0
0
0 0
0
0 0 0 0
84488 feces, qualitative
0 0 0
0 0 ° 0 0 0 0 0 0 0
00 0 00 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
A= Revised code e = New code .., <Ill =Contains new or revised text * = Duplicate PlA test ti= Category I PlA American Medical Association 663
84591-85044 Pathology and Laboratory I Hematology and Coagulation CPT 2023
84591 Vitamin. not otherwise specified 85007 blood smear. microscopic examination with manual
0 CPT Changes: An Insider's View 2001 differential WBC count
0 CPT Assistant Oct 21:14 0 CPT Changes: An Insider's View 2003
84597 Vitamin K
0 CPT Assistant Jul 03:7. Jan 04:26
0 CPT Assistant Oct 10:7 85008 blood smear. microscopic examination without
manual differential WBC count
(VMA. use 84585)
84600 Volatiles (eg, acetic anhydride. diethylether) 0 CPT Assistant Jul 03:8. Jan 04:26
0 CPT Changes: An Insider's View 2015 .
(For other fluids [eg. CSF). see 89050. 89051)
85009 manual differential WBC count, buffy coat
(For carbon tetrachloride. dichloroethane.
dichloromethane. use 82441)
0 CPT Assistant Jul 03:7, Jan 04:26
(For isopropyl alcohol and methanol, use 80320)
(Eosinophils. nasal smear. use 89190)
(Volume. blood, RISA or Cr-51. see 78110, 78111)
85013 spun microhematocrit
84620 Xylose absorption test. blood and/or urine
85014 hematocrit (Hct)
(For administration. use 99070) 0 CPT Changes: An Insider's View 2003
84630 Zinc 0 CPT Assistant Jul 03:7
84681 C-peptide 85018 hemoglobin (Hgb)

84702 Gonadotropin, chorionic (hCG); quantitative
(For other hemoglobin determination. see 83020-83069)
84703 qualitative (For immunoassay, hemoglobin, fecal, use 82274)
(For urine pregnancy test by visual color comparison. use (For transcutaneous hemoglobin measurement, use
81025) 88738)
84704 free beta chain 85025 complete (CBC). automated (Hgb, Hct. RBC, WBC and
platelet count) and automated differential WBC count
0 CPT Assistant Apr 08:5. Aug 08:13. Oct 10:7
0 CPT Assistant Jul 00:11 . Jul 03:7. Jan 04:26. Jul 11:16
84830 Ovulation tests, by visual color comparison methods for
human luteinizing hormone 85027 complete (CBC). automated (Hgb. Hct, RBC. WBC and
platelet count)
0 CPT Assistant Oct 10:7. Jun 15:10
84999 Unlisted chemistry procedure 0 CPT Assistant Jul 03:8. Jan 04:26. May 21 :9
0 CPT Assistant Oct 00:24. Aug 05:9. Oct 10:7, Dec 10:7, Apr 15:3,
Oct21:14 85032 manual cell count (erythrocyte, leukocyte. or platelet)
each
(For definitive testing of a drug, not otherwise specified. 0 CPT Changes: An Insider's View 2003
see 80299, 80375, 80376. 80377) 0 CPT Assistant Jul 03:8, Nov03:15
85041 red blood cell (RBC). automated

Hematology and Coagulation 0 CPT Changes: An Insider's View2003
0 CPT ~ssistant Jul 03:8
(For blood banking procedures, see Transfusion (Do not report code 85041 in conjunction with 85025 or
Medicine) 85027)
(Agglutinins. see Immunology) 85044 reticulocyte. manual
(Antiplasmin, use 85410) 0 CPT Changes: An Insider's View2003
(Antithrombin Ill, see 85300, 85301)

85002 Bleeding time

0 CPT Assistant Aug 05:9 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0 0 0 0
0 0 0
85004 Blood count; automated differential WBC count 0 0
0
0
0 0 0 0
0
0
0 0

0
0
0
0 0 0
0
0
0
0
0
0 0 0
0
0
0 CPT Assistant Jan 04:26 0 0 0 0 0

0 0 0 0 0
0 0
0 0
•
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0
0
664 *= Telemedicine ,. =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code 19= Modifier 51 exempt 0 0 0 =Seep xix for details
CPT 2023 Pathology and Laboratory I Hematology and Coagulation 85045-85379
85045 reticulocyte. automated 85291 factor XIII (fibrin stabilizing). screen solubility
85292 prekallikrein assay (Fletcher factor assay)
85293 high molecular weight kininogen assay (Fitzgerald
85046 reticulocytes, automated, including 1 or more cellular factor assay)
parameters (eg, reticulocyte hemoglobin content
[CHr]. immature reticulocyte fraction [IRF]. 85300 Clotting inhibitors or anticoagulants; antithrombin Ill,
reticulocyte volume [MRV], RNA content). direct activity
measurement 0 CPT Assistant Aug 05:9
85301 antithrombin Ill. antigen assay
85302 protein C, antigen
85048 leukocyte (WBC). automated
0 CPT Changes: An Insider's View 2003 85303 protein C. activity
0 CPT Assistant Jul 03:8 85305 protein S, total
85049 platelet. automated 85306 protein S. free
85307 Activated Protein C(APC) resistance assay
85055 Reticulated platelet assay 0 CPT Changes: An Insider's View 2001
85335 Factor inhibitor test
85060 Blood smear. peripheral. interpretation by physician with
written report 85337 Thrombomodulin
85097 Bone marrow. smear interpretation (For mixing studies for inhibitors. use 85732)
0 CPT Changes: An Insider's View 2002 85345 Coagulation time; Lee and White
0 CPT Assistant Winter 92:17, Jul 98:4. Mar 03:22
85347 activated
(For special stains. see 88312, 88313) 0 CPT Assistant Apr 19:11
(For bone biopsy, see 20220, 20225, 20240, 20245, 85348 other methods
20250, 20251)
(Differential count. see 85007 et seq)
85130 Chromogenic substrate assay
(Duke bleeding time. use 85002)
(Circulating c:::iti-coagulant screen [mixing studies]. see (Eosinophils. nasal smear. use 89190)
85611, 85732) 85360 Euglobulin lysis
85170 Clot retraction {Fetal hemoglobin, see 83030, 83033, 85460)
85175 Clot lysis time, whole blood dilution 85362 Fibrin(ogen) degradation (split) products (FOP) (FSP);
(Clotting factor I [fibrinogen]. see 85384, 85385) agglutination slide, semiquantitative
85210 Clotting; factor II. prothrombin. specific (lmmunoelectrophoresis, use 86320)

0 CPT Assistant Aug 05:9 85366 paracoagulation
{See also 85610-85613) 85370 quantitative
85220 factor V {AcG or proaccelerin). labile factor 85378 Fibrin degradation products, D-dimer; qualitative or
semiquantitative
85230 factor VII (proconvertin. stable factor)
85240 factor VIII {AHG). 1-stage 0 CPT Assistant Jul 03:8
85244 factor VIII related antigen 85379 quantitative
85245 factor VIII. VW factor. ristocetin cofactor (For ultrasensitive and standard sensitivity quantitative
85246 factor VIII. VW factor antigen D-dimer. use 85379)
85247 factor VIII. von Willebrand factor, multimetric analysis

85250 factor IX (PTC or Christmas)
0 0 0 0 0
0 0 0 0 0 0 0
85260 factor X {Stuart-Prower) 0 0 0
0 0 0 0
0
0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
85270 factor XI {PTA) 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0
85280 factor XII (Hageman) 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0
0
00 0 0 • o 0 0
00
85290 factor XIII {fibrin stabilizing) 0 0 0
0 0
0
0 0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
.&=Revised code •=New code .,. ~=Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 665
85380-85675 Pathology and Laboratory I Hematology and Coagulation CPT 2023
85380 ultrasensitive (eg, for evaluation for venous 85540 Leukocyte alkaline phosphatase with count
thromboembolism). qualitative or semiquantitative
85547 Mechanical fragility. ABC
0 CPT Assistant Jul 03:8 85549 Muramidase
85384 Fibrinogen; activity (Nitroblue tetrazolium dye test. use 86384)
85555 Osmotic fragility. ABC; unincubated
85385 antigen 85557 incubated
85390 Fibrinolysins or coagulopathy screen. interpretation and (Packed cell volume, use 85013)
report
0 CPT Assistant Apr 19: 11 (Partial thromboplastin time. see 85730, 85732)
85396 Coagulation/fibrinolysis assay, whole blood (eg, (Parasites, blood [eg, malaria smears]. use 87207)
viscoelastic clot assessment). including use of any (Plasmin. use 85400)
pharmacologic additive(s). as indicated, including
interpretation and written report, per day (Plasminogen. use 85420)
0 CPT Changes: An Insider's View 2004 (Plasminogen activator. use 85415)
0 CPT Assistant Apr 19: 11
85576 Platelet. aggregation (in vitro), each agent
85397 Coagulation and fibrinolysis, functional activity, not 0 CPT Changes: An Insider's View2003
otherwise specified (eg, ADAMTS-13), each analyte 0 CPT Assistant Jul 96:10. Apr 19:11
(For thromboxane metabolite[s). including thromboxane. if
85400 Fibrinolytic factors and inhibitors; plasmin performed, measurement[s] in urine. use 84431)
85597 Phospholipid neutralization; platelet
85410 alpha-2 antiplasmin 0 CPT Changes: An Insider's View 2011
85415 plasminogen activator 0 CPT Assistant Oct 10:8. Dec 10:8, Apr 11 :9
85420 plasminogen. except antigenic assay 85598 hexagonal phospholipid

85421 plasminogen. antigenic assay 0 CPT Assistant Oct 10:8. Dec 10:8, Apr 11:9
(Fragility, red blood cell, see 85547, 85555-85557) 85610 Prothrombin time;
85441 Heinz bodies; direct 0 CPT Assistant Aug 05:9
85445 induced. acetyl phenylhydrazine 85611 substitution. plasma fractions. each

(Hematocrit [PCVJ, see 85014. 85025, 85027) 85612 Russell viper venom time (includes venom); undiluted
(Hemoglobin, see 83020-83068, 85018. 85025. 85027) 85613 diluted
85460 Hemoglobin or RBCs. fetal, for fetomaternal hemorrhage; (Red blood cell count. see 85025. 85027. 85041)
differential lysis (Kleihauer-Betke)
85635 Reptilase test
0 CPT AssistantFall 93:25
(Reticulocyte count, see 85044, 85045)
(See also 83030. 83033)
85651 Sedimentation rate. erythrocyte; non-automated
(Hemolysins, see 86940. 86941)
85652 automated
85461 rosette
85660 Sickling of ABC, reduction
85475 Hemolysin. acid
(Hemoglobin electrophoresis, use 83020)
(See also 86940, 86941)
(Smears [eg, for parasites, malaria]. use 87207)
85520 Heparin assay
0 CPT Assistant Aug 05:9 85670 Thrombin time; plasma
85525 Heparin neutralization 85675 titer

85530 Heparin-protamine tolerance test 0 0 0 0 0
85536 Iron stain, peripheral blo;id

0
0
0
0
0
0
., 0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0 0 0 0
0 0
0 0
0 0
0
0
0 0
0 0
0
0
0 0 0 0 0 0
0 0 0 0
(For iron stains on bone marrow or other tissues with 0 0 0
0 0
0 0 0 0 0
0 0
0 0
physician evaluation. use 88313) 0

00
0
0
0
00
0
0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
0 0 0
0
666 *= Telemedicine '4 =Audio-only +=Add-on code ,¥ = FOA approval pending #=Resequenced code 6l =Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory I Immunology 85705-86078
85705 Thromboplastin inhibition, tissue (Anti-DNA use 86225)

(Anti-deoxyribonuclease titer. use 86215)
(For individual clotting factors, see 85245-85247)
85730 Thromboplastin time, partial (PTT); plasma or whole
86021 Antibody identification; leukocyte antibodies
blood
86022 platelet antibodies
85732 substitution, plasma fractions, each
0 CPT Assistant Apr 11 :9 86023 platelet associated immunoglobulin assay
85810 Viscosity 86036 Antineutrophil cytoplasmic antibody (ANCA); screen,
each antibody
(von Willebrand factor assay, see 85245-85247)
(WBC count, see 85025, 85027, 85048, 89050)
86037 titer, each antibody
85999 Unlisted hematology and coagulation procedure 0 CPT Changes: An Insider's View 2022
0 CPT Assistant Aug 05:9. Oct 09:12, Aug 17:10 86038 Antinuclear antibodies (ANA);
' 0 CPT Assistant Feb 22:15
Immunology 86039 titer

(Acetylcholine receptor antibody, see 83519, 86255,
(Antistreptococcal antibody, ie, anti-DNAse, use 86215)
86256)
(Antistreptokinase titer, use 86590)
# 86015 Actin (smooth muscle) antibody (ASMA), each
(Actinomyces. antibodies to, use 86602) 86052 Code is out of numerical sequence. See 86060-86078
(Adrenal cortex antibodies. see 86255, 86256) 86053 Code is out of numerical sequence. See 86060-86078
86000 Agglutinins, febrile (eg, Brucella, Francisella, Murine 86060 Antistreptolysin O; titer
typhus. Qfever, Rocky Mountain spotted fever, scrub (For antibodies to infectious agents, see 86602-86804)
typhus), each antigen
0 CPT Assistant Aug 05:9 86063 screen
(For antibodies to infectious agents, see 86602-86804) (For antibodies to infectious agents. see 86602-86804)
86001 Allergen specific lgG quantitative or semiquantitative, (Blastomyces, antibodies to, use 86612)
each allergen # 86051 Aquaporin-4 (neuromyelitis optica [NMO]) antibody;
0 CPT Changes: An Insider's View 2001 enzyme-linked immunosorbent immunoassay (ELISA)
(Agglutinins and autohemolysins, see 86940, 86941) 0 CPT Changes: An Insider's View 2022
86003 Allergen specific lgE; quantitative or semiquantitative,
crude allergen extract. each # 86052 cell-based immunofluorescence assay (CBA), each
0 CPT Assistant Spring 94:31 0 CPT Assistant Apr 22:3
(For total quantitative lgE, use 82785) # 86053 flow cytometry (ie, fluorescence-activated cell sorting
[FACS]), each
86005 qualitative. multiallergen screen (eg, disk, sponge,
card)

0 CPT Assistant Spring 94:31 860TI Blood bank physician services; difficult cross match and/
or evaluation of irregular antibody(s), interpretation and
86008 quantitative or semiquantitative. recombinant or written report
purified component, each
0 CPT Changes: An Insider's View 2018 86078 investigation of transfusion reaction including
suspicion of transmissible disease. interpretation and
(For total qualitative lgE, use 83518) written report
(Alpha-1 antitrypsin, see 82103, 82104) 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0
(Alpha-1 feta-protein, see 82105, 82106) 0 0
0
0 0
0
0
0
0 0
0
0
0 0 0 0 0 0 0 0
(Anti-AChR [acetylcholine receptor] antibody titer, see 0

0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0 0
86255, 86256) 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0 d 0
00 0 00 0 00
0 0 0 0 0
(Anticardiolipin antibody, use 86147) 0
0
0 0 0
0
0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0
A= Revised code •=New code ..,. '4 =Contains new or revised text *=Duplicate PLA test ti= Category IPLA American Medical Association 667
- I
86079-86294 Pathology and Laboratory I Immunology CPT 2023
86079 authorization for deviation from standard blood (Coombs test. see 86880-86886)
banking procedures (eg, use of outdated blood,
transfusion of Rh incompatible units). with written
86200 Cyclic citrullinated peptide (CCP), antibody
report
0 CPT Assistant Mar 06:6
(Brucella, antibodies to, use 866221
86215 Deoxyribonuclease. antibody
(Candida, antibodies to, use 86628. For skin testing, use 0 CPT Assistant Aug 05:9
86485)
86225 Deoxyribonucleic acid (DNA) antibody; native or double
86140 C-reactive protein; stranded
(Echinococcus. antibodies to, see code for specific
method)
(Candidiasis, use 86628)
(For HIV antibody tests. see 86701-86703)
86141 high sensitivity (hsCRPI
86226 single stranded
O CPT Changes: An Insider's View2002
86146 Beta 2 Glycoprotein I antibody, each
(Anti D.S., DNA, IFA. eg, using C.Lucilae, see 86255 and
86256)
86147 Cardiolipin (phospholipid) antibody, each lg class
86231 Endomysial antibody (EMA), each immunoglobulin (lg)
class
# 86152 Cell enumeration using immunologic selection and 0 CPT Changes: An Insider's View 2022
identification in fluid specimen (eg, circulating tumor 0 CPT Assistant Mar 22:11
cells in blood);
86235 Extractable nuclear antigen, antibody to, any method (eg,
nRNP. SS-A, SS-8. Sm, RNP. Sc170, J01 ). each antibody
(For physician interpretation and report. use 86153. For
86255 Fluorescent noninfectious agent antibody; screen. each
cell enumeration with interpretation and report, use
antibody
86152 and 861531
0 CPT Assistant Nov 98:27. Feb 22:15, Mar 22:11
# 86153 physician interpretation and report. when required
86256 titer. each antibody
(For cell enumeration, use 86152. For cell enumeration
(Fluorescent technique for antigen identification in tissue.
with interpretation and report. use 86152 and 86153)
use 88346; for indirect fluorescence. see 88346, 88350)
(For flow cytometric immunophenotyping, see 88184-
(FTA, use 86780)
88189)
(Gel [agar) diffusion tests, use 86331)
(For flow cytometric quantitation, see 86355, 86356.
86357,86359,86360,86361,86367) 86258 Gliadin (deamidated) (DGP) antibody, each
immunoglobulin (lg) class
86148 Anti-phosphatidylserine (phospholipid) antibody
0 CPT Assistant Nov 97:30, Jul 03:8, Nov 03:5
(To report antiprothrombin [phospholipid cofactor)
antibody, use 86849) 86277 Growth hormone. human (HGH), antibody
86152 Code is out of numerical sequence. See 86146-86155 86280 Hemagglutination inhibition test (HAI)
86153 Code is out of numerical sequence. See 86146-86155 (For rubella, use 86762)
86155 Chemotaxis assay, specify method (For antibodies to infectious agents. see 86602-86804)
(Clostridium difficile toxin, use 87230) 86294 Immunoassay for tumor antigen, qualitative or
semiquantitative (eg, bladder tumor antigen)
(Coccidioides. antibodies to, see 86635. For skin testing, 0 CPT Changes: An Insider's View 2001
use 86490)
(For qualitative NMP22 protein, use 86386)
86156 Cold agglutinin; screen
86157 titer
0
0
0 0
- 0
0
0
0
0 0
0
0
0
0
86160 Complement; antigen, each component 0 0

0
0
0
0 0
0
0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
86161 functional activity, each component 0
0
0 0 0 0
0
0
0 0 0 0
0
0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
86162 total hemolytic (CH50) 0 0 0 0
00 0 00
0 0 0 0 1 0 0
0 0 0 0 0 0
86171 Complement fixation tests, each antigen 0 0
0 0 0 0 0
0 0 0 0
0
..
0 0 0 0
0 0
0 0 0 0
0
668 *=Telemedicine '4 =Audio-only +=Add-on code ,#'=FDA approval pending #=Resequenced code 6l=Modifier 51 exempt 0 0 0 -See Pxix for details
CPT 2023 Pathology and Laboratory I Immunology 86300--86356
86300 Immunoassay for tumor antigen, quantitative; CA 15-3 86325 other fluids (eg, urine, cerebrospinal fluid) with
(27.29) concentration
86327 crossed (2-dimensional assay)
86301 CA 19-9
86329 lmmunodiffusion; not elsewhere specified
86304 CA 125
86331 gel diffusion. qualitative (Ouchterlony), each antigen
(For measurement of serum HER-2/neu oncoprotein, see
or antibody
83950)
86332 Immune complex assay
(For hepatitis delta agent, antibody, use 86692)
86334 lmmunofixation electrophoresis; serum
86305 Human epididymis protein 4 (HE4)
86335 other fluids with concentration (eg, urine, CSF)
86308 Heterophile antibodies; screening
(For antibodies to infectious agents, see 86602-86804)
86336 lnhibin A
86309 titer 0 CPT Changes: An Insider's View2002
(For antibodies to infectious agents, see 86602-86804) 86337 Insulin antibodies

86310 titers after absorption with beef cells and guinea pig 86340 Intrinsic factor antibodies
kidney
(Leptospira. antibodies to, use 86720)
(Histoplasma, antibodies to. use 86698. For skin testing,
(Leukoagglutinins. use 86021)
use 86510)
86341 Islet cell antibody
(Human growth hormone antibody, use 86277)
86343 Leukocyte histamine release test (LHR)
86316 Immunoassay for tumor antigen, other antigen,
86344 Leukocyte phagocytosis
quantitative (eg, CA 50, 72-4. 549). each
0 CPT Changes: An Insider's View 2001 86352 Cellular function assay involving stimulation (eg, mitogen
0 CPT Assistant May 96:11. Aug 96:11. Apr 98:15. Aug 99:5. or antigen) and detection of biomarker (eg, ATP)
Dec 99:10 0 CPT Changes: An Insider's View 2010
86317 Immunoassay for infectious agent antibody, quantitative. 86353 Lymphocyte transformation. mitogen (phytomitogen) or
not otherwise specified antigen induced blastogenesis
(Malaria antibodies. use 86750)
(For immunoassay techniques for non-infectious agent
(For cellular function assay involving stimulation and
antigens, see 83516, 83518, 83519, 83520)
detection of biomarker, use 86352)
(For particle agglutination procedures, use 86403)
86355 B cells. total count
(For infectious agent antigen detection by immunoassay 0 CPT Changes: An Insider's View 2006
technique. see 87301-87451 . For infectious agent antigen 0 CPT Assistant Mar 06:6. Apr 08:5
detection by immunoassay technique with direct optical
[ie, visual] observation, see 87802-87899) 86356 Mononuclear cell antigen, quantitative (eg, flow
cytometry), not otherwise specified, each antigen
86318 Immunoassay for infectious agent antibody(ies). 0 CPT Changes: An Insider's View2008
qualitative or semiquantitative. single-step method (eg, 0 CPT Assistant Apr 08:5
reagent strip);
0 CPT Changes: An Insider's View 2021 (Do not report 88187-88189 for interpretation of 86355,
86356,86357, 86359, 86360, 86361,86367)
severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) (coronavirus disease [COVID-19]) 0 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
~ 0 0 0 0 0 0 0 0
(For severe acute respiratory syndrome coronavirus 2 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
[S.ARS-CoV-2] [coronavirus disease {COVID-19}] antibody 0 0 0 0
0
0 0 0 0
0
0
testing using multiple-step method. use 86769) 0 0 0 0

0 0 0 0 0 0 0
0 0 0 ,.o 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
86320 lmmunoelectrophoresis; serum 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0
0 0
"'-=Revised code • = New code Ill> ~ = Contains new or revised text H =Duplicate PLA test t~ =Category I PLA American Medical Association 669
86362~92 Pathology and Laboratory/ Immunology CPT 2023
# 86362 Myelin oligodendrocyte glycoprotein (MOG-lgG1) 86403 Particle agglutination; screen. each antibody
antibody; cell-based immunofluorescence assay (CBA), 0 CPT Assistant Aug 05:9
each
86406 titer. each antibody
0 CPT Assistant Apr 22:3 (Pregnancy test. see 84702, 84703)
# 86363 flow cytometry (ie. fluorescence-activated cell sorting (Rapid plasma reagin test (RPR). see 86592. 86593)
[FAGS]), each
0 CPT Assistant Apr 22:3 86409 Code is out of numerical sequence. See 86376-86386
86357 Natural killer (NK) cells, total count 86413 Code is out of numerical sequence. See 86376-86386
0 CPT Changes: An Insider's View 2006 86430 Rheumatoid factor; qualitative
0 CPT Assistant Mar 06:6, Apr 08:5
86431 quantitative
# 86364 Tissue transglutaminase, each immunoglobulin (lg) class
0 CPT Changes: An Insider's View 2022 (Serologic test for syphilis, see 86592, 86593)
0 CPT Assistant Mar 22:11 86480 Tuberculosis test, cell mediated immunity antigen
86359 T cells; total count response measurement; gamma interferon
0 CPT Assistant Nov 97:30, Apr 08:5 0 CPT Changes: An Insider's View 2006. 2011
0 CPT Assistant Mar 06:6. Oct 10:7. Dec 10:8, Dec 19:13
86360 absolute CD4 and CDS count, including ratio
0 CPT Assistant Nov 97:30, Jan 07:29. Apr 08:5 86481 enumeration of gamma interferon-producing T-cells in
cell suspension
86361 absolute CD4 count 0 CPT Changes: An Insider's View 2011
0 CPT Assistant Nov 97:30, Apr 08:5 0 CPT Assistant Oct 10:8, Dec 10:8, Dec 19:13
86362 Code is out of numerical sequence. See 86355-86364 86485 Skin test; candida
86363 Code is out of numerical sequence. See 86355-86364 (For antibody, candida. use 86628)
86364 Code is out of numerical sequence. See 86356-86360 86486 unlisted antigen, each
86367 Stem cells lie. CD34), total count 0 CPT Changes: An Insider's View2008
0 CPT Changes: An Insider's View 2006 86490 coccidioidomycosis
0 CPT Assistant Mar 06:6. Apr 08:5, Oct 13:3
86510 histoplasmosis
(For flow cytometric immunophenotyping for the 0 CPT Assistant Aug 05:9
assessment of potential hematolymphoid neoplasia. see
88184-88189) (For histoplasma, antibody, use 86698)
86376 Microsomal antibodies (eg, thyroid or liver-kidney). each 86580 tuberculosis, intradermal
86381 Mitochondrial antibody (eg, M2). each (For tuberculosis test, cell mediated immunity
0 CPT Changes: An Insider's View2022 measurement of gamma interferon antigen response. use
86480)
86382 Neutralization test, viral
(For skin tests for allergy, see 95012-95199)
# 86408 Neutralizing antibody, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID- (Smooth muscle antibody, use 86015)
19]); screen (Sporothrix, antibodies to, see code for specific method)
86590 Streptokinase. antibody
# 86409 titer
(Streptolysin 0 antibody, see antistreptolysin 0, 86060.
# 86413 Severe acute respiratory syndrome coronavirus 2 (SARS-
86063)
CoV-2) (coronavirus disease [COVID-19]) antibody,
quantitative 86592 Syphilis test. non-treponemal antibody; qualitative (eg,
0 CPT Changes: An Insider's View 2022 VDRL. RPR. ART)
86384 Nitroblue tetrazolium dye test (NTD)
0 0
86386 Nuclear Matrix Protein 22 (NMP22). qualitative 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0 0
0
0
0 0
0
0
0
0 0
0
0
0 0
0 0 0 0 0
(Ouchterlony diffusion. use 86331) 0 0
0 0 0
0
0 0
0
• 0
0
0
(Platelet antibodies, see 86022, 86023)

0 0 0
0 0
0 0 0 0 0
0 0
0 0 0
•
00 0 00 0
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
670 *= Telemedicine ~ =Audio-only +=Add-on code .#'=FDA approval pending #=Resequenced code 6l =Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory I Immunology 86593-86666
(For antibodies to infectious agents, see 86602-86804) 86615 Bordetella
86593 quantitative 86617 Borrelia burgdorferi (Lyme disease) confirmatory test

0 CPT Changes: An Insider's Vie11. l010 (eg, Western Blot or immunoblot)
(For antibodies to infectious agents, see 86602-86804) 86618 Borrelia burgdorferi (Lyme disease)
(Tetanus antibody, use 86774) 86619 Borrelia (relapsing fever)
(Thyroglobulin antibody, use 86800) 86622 Bruce Ila
(Thyroglobulin. use 84432) 86625 Campylobacter
(Thyroid microsomal antibody, use 86376) 86628 Candida
(For toxoplasma antibody, see 86777-86778) (For skin test, candida, use 86485)
86596 Voltage-gated calcium channel antibody, each 86631 Chlamydia
0 CPT Changes: An Insider's View 2022 86632 Chlamydia. lgM
The following codes (86602-86804) are qualitative or 0 CPT Assistant Nov 97:31
semiquantitative immunoassays performed by multiple- (For chlamydia antigen, see 87270, 87320. For fluorescent
step methods for the detection of antibodies to infectious antibody technique. see 86255, 86256)
agents. For immunoassays by single-step method (eg,
reagent strips), see codes 86318, 86328. Procedures for 86635 Coccidioides
the identification of antibodies sliould be coded as (For severe acute respiratory syndrome coronavirus 2
precisely as possible. For example, an antibody to a virus [SARS-CoV-2] [coronavirus disease {COVI0-19}] antibody
could be coded with increasing specificity for virus, tPsting, see 86328, 86769)
family, genus, species, or type. In some cases, further
86638 Coxiella burnetii (Q fever)
precision may be added to codes by specifying the class of
immunoglobulin being detected. When multiple tests are 86641 Cryptococcus
done to detect antibodies to organisms classified more
86644 cytomegalovirus (CMV)
precisely than the specificity allowed by available codes, it
is appropriate to code each as a separate service. For 86645 cytomegalovirus (CMV). lgM
example, a test for antibody to an enterovirus is coded as 0 CPT Assistant Jul 03:7
86658. Coxsackie viruses are enteroviruses, but there are 86648 Diphtheria
no codes for the individual species of enterovirus. If assays
are performed for antibodies to coxsackie A and B species, 86651 encephalitis, California (La Crosse)
each assay should be separately coded. Similarly, if 86652 encephalitis, Eastern equine
multiple assays are performed for antibodies of different
immunoglobulin classes, each assay should be coded 86653 encephalitis, St. Louis
separately. When a coding option exists for reporting IgM 86654 encephalitis, Western equine
specific antibodies (eg, 86632), the corresponding
86658 enterovirus (eg, coxsackie, echo, polio)
nonspecific code (eg, 8663 I) may be reported for
performance of either an antibody analysis not specific (Trichinella, antibodies to, use 86784)
for a particular immunoglobulin class or for an IgG (Trypanosoma, antibodies to, see code for specific
analysis. method)
(For the detection of antibodies other than those to (Tuberculosis. use 86580 for skin testing)
infectious agents, see specific antibody [eg, 86015,
86021-86023, 86376, 86800, 86850-86870] or specific (Viral antibodies. see code for specific method)
method [eg, 83516, 86255, 86256]) 86663 Epstein-Barr (EB) virus, early antigen (EA)
(For infectious agent/antigen detection, see 87260- 86664 Epstein-Barr (EB) virus, nuclear antigen (ESNA)
87899)
86665 Epstein-Barr (EB) virus, viral capsid (VCA)
86602 Antibody; actinomyces ·
0 CPT Assistant Aug 05:9 86666 Ehrlichia
86603
adenovirus
0 0
86606 Aspergillus 0
0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
0 0 0 0
0 0 0 0 0
86609 bacterium, not elsewhere specified 0 0 0
0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0
86611 Bartone Ila 0 0 0 0 0
0
0 0 0 0 0
0
0 Q. 0
0 0 0
0
00
0
0
0 0
00
0
0 0
00
0 0 0 0 0 0
0 0
86612 Blastomyces 0
0 0
0
0
0 0
0
0 0
0
0
0 0
0
0 0
0 0 0 0
0 0
•=Revised code •=New code Ill> ~ =Contains new or revised text H =Duplicate PlA test U =Category I PlA American Medical Association 671
86668-86778 Pathology and Laboratory I Immunology CPT 2023
86668 Francisella tularensis 86708 Hepatitis A antibody (HAAb)

86671 fungus. not elsewhere specified
0 CPTChanges: An Insider's View2001, 2016
0 CPT Assistant Nov 97:31 -32. Jun 00:11
86674 Giardia lamblia
86709 Hepatitis A antibody (HAAb). lgM antibody
86677 Helicobacter pylori 0 CPT Changes: An Insider's View2016
0 CPT Assistant Jan 98:6 0 CPT Assistant Nov 97:31-32. Jun 00:11
86682 helminth, not elsewhere specified 86710 Antibody; influenza virus
86684 Haemophilus influenza 86711 JC (John Cunningham) virus
86687 HTLV-1 0 CPT Changes: An Insider's View 2013
86688 HTLV-11 86713 Legionella
86689 HTLV or HIV antibody, confirmatory test (eg. Western 86717 Leishmania
Blot) 86720 Leptospira
86723 Listeria monocytogenes
86692 hepatitis. delta agent
86727 lymphocytic choriomeningitis
86732 mucormycosis
(For hepatitis delta agent. antigen, use 87380)
86694 herpes simplex. non-specific type test 86735 mumps
86695 herpes simplex. type 1 86738 mycoplasma
86696 herpes simplex. type 2 86741 Neisseria meningitidis

0 CPT Changes: An Insider's View 2001 86744 Nocardia
86698 histoplasma 86747 parvovirus
86701 HIV-1 36750 Plasmodium (malaria)
0 CPT Assistant Aug 05:9, Mar 08:3, Apr 08:5
86753 protozoa, not elsewhere specified
86702 HIV-2
86756 respiratory syncytial virus
0 CPT Assistant Mar 08:3, Apr 08:5
86757 Rickettsia
86703 HIV-1 and HIV-2, single result
0 CPT Assistant Nov 97:31. Mar 08:3. Apr 08:5 86759 rotavirus
(For HIV-1 antigen(s) with HIV-1 and HIV-2 antibodies. 86762 rubella
single result, use 87389)
86765 rubeola
(When HIV immunoassay [HIV testing 86701-86703 or
86788 Salmonella
87389) is performed using a kit or transportable
instrument that wholly or in part consists of a single use. 86769 severe acute respiratory syndrome coronavirus 2
disposable analytical chamber. the service may be (SARS-CoV-2) (coronavirus disease [COVID-19])
identified by adding modifier 92 to the usual code) 0 CPT Changes: An Insider's View 2021
(For HIV-1 antigen. use 87390) (For severe acute respiratory syndrome coronavirus 2
[SARS-CoV-2) [coronavirus disease {COVID-19}) antibody
(For HIV-2 antigen. use 87391)
testing using single-step method, use 86328)
(For confirmatory test for HIV antibody (eg, Western Blot).
86771 Shigella
use 86689)
86774 tetanus
86704 Hepatitis B core antibody (HBcAb); total
0 CPT Changes: An Insider's View 2001 86777 Toxoplasma
86778 Toxoplasma. lgM
86705 lgM antibody
0 CPT Assistant Nov 97:31-32 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0
86706 Hepatitis B surface antihody (HBsAb) 0 0 0 0 0 0 0 0
0 CPT Assistant Nov 97:31 -32 0

0 0 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0
86707 Hepatitis Be antibody (HBeAb) 0 0 0 0 0 0 0 0 0 0
0 0 ° 0 0
0 CPT Assistant Nov 97:31 -32 0 00

0 0
0 0
0
0 00
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
672 *= Telemedicine ,. =Audio-only +=Add-on code .N' = FDA approval pending #=Resequenced code IS)= Modifier 51 exempt 0 0 0 =See pxix for details
CPT 2023 Pathology and Laboratory I Immunology 86780--86849
86780 Treponema pallidum (Use 86826 in conjunction with 86825)

(Do not report 86825, 86826 in conjunction with 86355,
(For syphilis testing by non-treponemal antibody analysis, 86359, 88184-88189 for antibody surface markers
see 86592-86593) integral to crossmatch testing)
86784 Trichinella (For autologous HLA crossmatch, see 86825, 86826)
86787 varicella-zoster (For lymphocytotoxicity visual crossmatch, see 86805,

86806)
86788 West Nile virus. lgM
0 CPT Changes: An Insider's View 2007 86828 Antibody to human leukocyte antigens (HLA), solid phase
assays (eg, microspheres or beads, ELISA, flow
86789 West Nile virus
cytometry); qualitative assessment of the presence or
absence of antibody(ies) to HLA Class I and Class II HLA
86790 virus, not elsewhere specified antigens
Yersinia
86793
86829 qualitative assessment of the presence or absence of
86794 Zika virus. lgM
antibody(ies) to HLA Class I or Class II HLA antigens
86800 Thyroglobulin antibody
(If solid phase testing is performed to assess presence or
absence of antibody to both HLA classes, use 86828)
(For thyroglobulin, use 84432)
86830 antibody identification by qualitative panel using
86803 Hepatitis Cantibody; complete HLA phenotypes, HLA Class I
0 CPT Assistant Nov 97:31-32 0 CPT Changes: An Insider's View2013
86804 confirmatory test (eg. immunoblot) 86831 antibody identification by qualitative panel using
0 CPT Assistant Nov 97:31 -32 complete HLA phenotypes, HLA Class II
Tissue Typing 86832 high definition qualitative panel for identification of
86805 Lymphocytotoxicity assay, visual crossmatch; with antibody specificities (eg, individual antigen per bead
titration methodology), HLA Class I
86806 without titration
86833 high definition qualitative panel for identification of
86807 Serum screening for cytotoxic percent reactive antibody antibody specificities (eg, individual antigen per bead
(PAA); standard method methodology), HLA Class II
0 CPT Assistant Jun 01 :11 0 CPT Changes: An Insider's View 2013
86808 quick method (If solid phase testing is performed to test for HLA Class I
0 CPT Assistant Jun 01 :11 or II antibody after treatment [eg, to remove lgM
86812 HLA typing; A, 8, or C(eg, A10, 87, 827), single antigen antibodies or other interfering substances]. report 86828-
86833 once for each panel with the untreated serum and
0 CPT Assistant Mar 03:23. Jun 06: 17
once for each panel with the treated serum)
86813 A 8. or C, multiple antigens
86834 semi-quantitative panel (eg, titer), HLA Class I
0 CPT Assistant Mar 03:23, Jun 06: 17
86816 DR/DO. single antigen
86835 semi-quantitative panel (eg, titer). HLA Class II
86817 DR/00, multiple antigens
86849 Unlisted immunology procedure
0 CPT Assistant Mar 98:10, Dec 19:13
86821 lymphocyte culture. mixed (MLC)
86825 Human leukocyte antigen (HLA) crossmatch, non-

cytotoxic (eg. using flow cytometry); first serum sample
or dilution 0
0
0 0
0
0
0
0 0
0
0
0
0 0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0 0
0
0
0
0 0 0 0 0 0 0 0
+ 86826 each additional serum sample or sample dilution (List 0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0 0
separately in addition to primary procedure) 0 0
0 0
0 0 0 0 0
0
0 0 0
• 0
0
00
0 0 0
0
0
0
00
0 0 0
0 0
00
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 D 0 0 0 0
.&=Revised code •=New code ..,. '4 = Contains new or revised text M=Duplicate PlA test t~ =Category I PlA American Medical Association 673
86850-86965 Pathology and Laboratory I Transfusion Medicine CPT 2023
Transfusion Medicine 86910 Blood typing, for paternity testing, per individual; ABO,
Rh and MN
(For apheresis, use 36511, 365121 86911 each additional antigen system
(For therapeutic phlebotomy, use 99195) 86920 Compatibility test each unit; immediate spin technique
86850 Antibody screen, ABC, each serum technique 0 CPT Assistant Mar 06:6
0 CPT Assistant Fall 93:25. Aug 05:9. Apr 08:5 86921 incubation technique
86860 Antibody elution (ABC). each elution 0 CPT Assistant Mar 06:6
86870 Antibody identification. ABC antibodies, each panel for 86922 antiglobulin technique
each serum technique 0 CPT Assistant Mar 06:6
0 CPT Assistant Fall 93:25, Mar 01 :10 86923 electronic
86880 Antihuman globulin test (Coombs test); direct, each 0 CPT Changes: An Insider's View 2006
antiserum 0 CPT Assistant Mar 06:6
86885 indirect, qualitative, each reagent red cell (Do not use 86923 in conjunction with 86920-86922 for
same unit crossmatch)
0 CPT Assistant Apr 08:5 86927 Fresh frozen plasma, thawing, each unit
86886 indirect, each antibody titer 86930 Frozen blood, each unit; freezing (includes preparation)
0 CPT Assistant Apr 08:5 0 CPT Assistant Apr 96:2, Jul 03:8
(For indirect antihuman globulin [Coombs] test for ABC 86931 thawing
antibody screening, use 86850) 0 CPT Changes: An Insider's View 2003
(For indirect antihuman globulin [Coombs] test for ABC 0 CPT Assistant Jul 03:8
antibody identification using reagent red cell panels. use 86932 freezing (includes preparation) and thawing
86890 Autologous blood or component, collection processing 0 CPT Assistant Jul 03:8
and storage; predeposited 86940 Hemolysins and agglutinins; auto. screen, each
86941 incubated
86891 intra- or postoperative salvage
86945 Irradiation of blood product, each unit
86900 Blood typing, serologic; ABO 0 CPT Assistant Dec 07:14
0 CPT Assistant Aug 05:9 86950 Leukocyte transfusion
86901 Rh (D)
0 CPT Changes: An Insider's View2015 (For allogeneic lymphocyte infusion, use 38242)
0 CPT Assistant Fall 93:25 (For leukapheresis, use 36511)
86902 antigen testing of donor blood using reagent serum, 8696ll Volume reduction of blood or blood product (eg. red blood
each antigen test cells or platelets). each unit
0 CPT Assistant Oct 10:8. Dec 10:8 0 CPT Assistant Mar 06:6
(If multiple blood units are tested for the same antigen. 86965 Pooling of platelets or other blood products
86902 should be reported once for each antigen for each 0 CPT Assistant Oct 10:8, Dec 10:8
unit tested)
(For harvesting, preparation. and injection[s] of platelet
86904 antigen screening for compatible unit using patient rich plasma, use 0232T)
serum, per unit screened
0 CPT Changes: An Insider's View 2015 (For harvesting, preparation, and injection[s) of
autologous white blood cell/autologous protein solution,
86905 ABC antigens, other than ABO or Rh (DI. each use 0481T)
0 0 0 0 0
86906 Rh phenotyping, complete 0 0 0 0
0 0 0 0
0
0 0 0 0 0
0 0
0
0
0
0
0 0
0
0
0 0
0
0
0
0
0 0
0
0
0
0 0 0
(For human erythrocyte antigen typing by molecular 0
0
0
0 0 0 0
0
0
0 0 0
0 0
pathology techniques, use 81403) 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0
0 0 0 0 0 0 0 00 0 0 0 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0
674 *=Telemedicine ~=Audio-only +=Add-oncode ..K=FDAapprovalpending #=Resequenced code ~=Modifier51 exempt OO~=Seepxixfordetails
CPT 2023 Pathology and Laboratory I Microbiology 86970--87088
86970 Pretreatment of ABCs for use in ABC antibody detection, 87046 stool. aerobic, additional pathogens, isolation and
identification, and/or compatibility testing; incubation presumptive identification of isolates, each plate
with chemical agents or drugs, each 0 CPT Changes: An Insider's View2001. 2002. 2004. 2005
86971 incubation with enzymes, each 87070 any other source except urine, blood or stool, aerobic,
with isolation and presumptive identification of
86972 by density gradient separation
isolates
86975 Pretreatment of serum for use in ABC antibody 0 CPT Changes: An Insider's View 2001, 2004
identification; incubation with drugs, each 0 CPT Assistant Aug 97:18, Nov01:10, Oct 03:10, Nov 11:11
86976 by dilution (For urine, use 87088)

86977 incubation with inhibitors, each 87071 quantitative, aerobic with isolation and presumptive
by differential red cell absorption using patient ABCs identification of isolates, any source except urine,
86978
or ABCs of known phenotype, each absorption blood or stool
86985 Splitting of blood or blood products, each unit 0 CPT Assistant Jun 02:3, Sep 03:3
0 CPT Assistant Apr 96:2. May 12:11
(For urine, use 87088)
86999 Unlisted transfusion medicine procedure
0 CPT Assistant Aug 05:9. Nov 05:14. Mar 09:10, Apr 09:9.
87073 quantitative, anaerobic with isolation and
May12:11 presumptive identification of isolates, any source
except urine. blood or stool
Microbiology 0 CPT Assistant Jun 02:3
(For definitive identification of isolates, use 87076 or

Includes bacteriology, mycology, parasitology, and virology. 87077. For typing of isolates see 87140-87158)
Presumptive identification of microorganisms is defined 87075 any source, except blood, anaerobic with isolation
as identification by colony morphology, growth on and presumptive identification of isolates
selective media, Gram stains, or up to three tests (eg, 0 CPT Changes: An Insider's View 2001, 2004
catalase, oxidase, indole, urease). Definitive identification
of microorganisms is defined as an identification to the 87076 anaerobic isolate, additional methods required for
genus or species level that requires additional tests (eg, definitive identification, each isolate
biochemical panels, slide cultures). If additional studies 0 CPT Changes: An Insider's View 2001
involve molecular probes, nucleic acid sequencing, 87077 aerobic isolate, additional methods required for
chromatography, or immunologic techniques, these definitive identification, each isolate
should be separately coded using 87140-87158, in 0 CPT Changes: An Insider's View2001
addition to definitive identification codes. The molecular 0 CPTAssistantNov01:10, Nov 11:10
diagnostic codes (eg, 81161, 81200-81408) are not to be
87081 Culture, presumptive, pathogenic organisms, screening
used in combination with or instead of the procedures
only; r
represented by 87140-87158. For multiple specimens/
0
CPT Changes: An Insider's View2001
sites use modifier 59. For repeat laboratory tests
: ) CPT Assistant Nov 01:10
performed on the same day, use modifier 91.
87084 with colony estimation from density chart
87003 Animal inoculation, small animal, with observation and
dissection 87086 Culture, bacterial; quantitative colony count, urine
87015 Concentration (any type), for infectious agents

0 CPT Assistant Nov 11 :10
87088 with isolation and presumptive identification of each

(Do not report 87015 in conjunction with 87177)
isolate, urine
87040 Culture, bacterial; blood, aerobic, with isolation and 0 CPT Changes: An Insider's View2001, 2007
presumptive identification of isolates (includes anaerobic 0 CPT Assistant Nov 11 :10
culture, if appropriate)
0 CPT Assistant Aug 97:18, Jun 02:2, Oct 10:17. Dec 10:17
87045 stool, aerobic, with isolation and preliminary 0 0 0

. 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
examination leg, KIA, LIA). Salmonella and Shigella 0
0
0
0 0
0
0
0 0 0 0 0 0 0 0
..•
0
species 0 0 0 0 0 0 0 0
0 0 0 0 0
0 CPT Changes: An Insider's View 2001. 2002. 2004 0 0
0 0 0
0
0 0
0 0 0
0
0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0
A=Revised code • = New code .. ~=Contains new or revised text *=Duplicate PLA test t!=Category I PLA American Medical Association 675
87101-87181 Pathology and Laboratory / Microbiology CPT 2023
87101 Culture, fungi (mold or yeast) isolation. with presumptive # 87154 identification of blood pathogen and resistance
identification of isolates; skin, hair, or nail typing, when performed. by nucleic acid (ONA or
0 CPT Changes: An Insider's View2001 RNA) probe. multiplexed amplified probe technique
0 CPT Assistant Sep 99:10, Aug 05:9 including multiplex reverse transcription. when
performed, per culture or isolate. 6 or more targets
87102 other source (except blood)
87103 blood
87152 identification by pulse field gel typing
87106 Culture, fungi, definitive identification, each organism; 0 CPT Changes: An Insider's View 2001
yeast 0 CPT Assistant May 12:5, Sep 13:3
0 CPT Changes: An Insider's View2001 (Do not report 87152 in conjunction with 81161, 81200-
87107 mold 81408)
0 CPT Changes: An Insider's View2001 87153 identification by nucleic acid sequencing method.
87109 Culture, mycoplasma, any source each isolate (eg, sequencing of the 16S rRNA gene)
87110 Culture, chlamydia, any source
0 CPT Changes: An Insider's View 2001 0 CPT Assistant May 12:5, Sep 13:3

(For immunofluorescence staining of shell vials. use
87140) 87158 other methods
0 CPT Assistant Nov 01:10, Sep 03:3
87116 Culture, tubercle or other acid-fast bacilli (eg, TB, AFB,
mycobacteria) any source, with isolation and presumptive 87164 Dark field examination. any source (eg, penile, vaginal,
identification of isolates oral, skin); includes specimen collection
87166 without collection
(For concentration, use 87015)
87168 Macroscopic examination; arthropod
87118 Culture, mycobacterial. definitive identification. each 0 CPT Changes: An Insider's View2001
isolate
87169 parasite
87140 Culture, typing; immunofluorescent method, each
87172 Pinworm exam (eg, cellophane tape prep)
antiserum
0 CPT Assistant Nov 01 :10. Sep 03:3 87176 Homogenization, tissue, for culture
87143 gas liquid chromatography (GLC) or high pressure
liquid chromatography (HPLC) method 87177 Ova and parasites, direct smears. concentration and
0 CPT Changes: An Insider's View 2001 identification
87147 immunologic method, other than immunofluorescence
0 CPT Assistant Jul 03:8, Nov 03: 15, Mar 06:6
(eg, agglutination grouping), per antiserum (Do not report 87177 in conjunction with 87015)
0 CPT Changes: An Insider's View 2001 (For direct smears from a primary source, use 872071
0 CPT Assistant Apr 02:18, Oct 03:10
(For coccidia or microsporidia exam. use 87207)
87149 identification by nucleic acid (ONA or RNA) probe,
direct probe technique, per culture or isolate, each (For complex special stain (trichrome, iron hematoxylin},
organism probed use 872091
(For nucleic acid probes in cytologic material, use 88365)
0 CPT Assistant Nov 01:10. May 12:5. Sep 13:3
87181 Susceptibility studies, antimicrobial agent; agar dilution
(Do not report 87149 in conjunction with 81161. 81200- method, per agent (eg, antibiotic gradient strip)
81408)
87150 identification by nucleic acid (ONA or RNA) probe. 0 CPT Assistant Nov 01 :10
amplified probe technique, per culture or isolate,
each organism probed
O cPT Assistant May 12:5. Sep 13:3 0 0 0 0
0 0 0 0 0 0
0 0 0 0
0 0 0 0
(Do not report 87150 in conjunction with 81161, 81200- 0
0
0
0
0 0 0
0
0 0 0
0 0 0
0 ..
0 0 0
81408) 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
0 00 0 00 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0
0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
D 0
676 *=Telemedicine ~=Audio-only +=Add-on code .K=FDAapprovalpending #=Resequenced code 6)=Modifier51 exempt O O O =Seepxixfordetails
CPT2023 Pathology and Laboratory I Microbiology 87184-87255
87184 disk method, per plate (12 or fewer agents) 87220 Tissue examination by KOH slide of samples from skin,
0 CPT Changes: An Insider's View 2001 hair, or nails for fungi or ectoparasite ova or mites (eg,
0 CPT Assistant Nov 01 :10 scabies)
enzyme detection (eg, beta lactamase), per enzyme
87185
0 CPT Changes: An Insider's View 2001 87230 Toxin or antitoxin assay, tissue culture (eg, Clostridium
0 CPT Assistant Nov 01 :10 difficile toxin)
87186 microdilution or agar dilution (minimum inhibitory 87250 Virus isolation; inoculation of embryonated eggs, or small
concentration [MIC] or bre:ikpoint), each multi- animal. includes observation and dissection
antimicrobial, per plate 0 CPT Changes: An Insider's View 2001
87252 tissue culture inoculation, observation, and
0 CPT Assistant Nov 01 :10 presumptive identification by cytopathic effect
+ 87187 microdilution or agar dilution, minimum lethal 0 CPT Changes: An Insider's View2001
concentration (MLC), each plate (List separately in 87253 tissue culture, additional studies or definitive
addition to code for primary procedure) identification (eg, hemabsorption, neutralization,
0 CPT Changes: An Insider's View 2001 immunofluorescence stain), each isolate
0 CPT Assistant Nov 01 :10 0 CPT Changes: An Insider's View 2001
(Use 87187 in conjunction with 87186 or 87188) (Electron microscopy, use 883481
87188 macrobroth dilution method, each agent (Inclusion bodies in tissue sections, see 88304-88309; in
0 CPT Changes: An Insider's View 2001 smears. see 87207-87210; in fluids, use 88106)
87254 centrifuge enhanced (shell vial) technique. includes
87190 mycobacteria, proportion method. each agent identification with immunofluorescence stain, each
0 CPT Changes: An Insider's View 2001 virus
(For other mycobacterial susceptibility studies, see 0 CPT Changes: An Insider's View2001, 2003
87181,87184,87186,or87188) 0 CPT Assistant Jul 03:8
87197 Serum bactericidal titer (Schlichter test) (Report 87254 in addition to 87252 as appropriate)
87205 Smear, primary source with interpretation; Gram or 87255 including identification by non-immunologic method.
Giemsa stain for bacteria, fungi, or cell types other than by cytopathic effect (eg, virus specific
0 CPT Changes: An Insider's View2001 enzymatic activity)
0 CPT Assistant Aug 05:9, Oct 09:12 0 CPT Changes: An Insider's View 2003
87206 fluorescent and/or acid fast stain for bacteria, fungi,
parasites, viruses or cell types These codes are intended for primary source only. For
0 CPT Changes: An Insider's View 2001 similar studies on culture material, refer to codes 87140-
87158. Infectious agents by antigen detection,
87207 special stain for inclusion bodies or parasites (eg, immunofluorescence microscopy, or nucleic acid probe
malaria, coccidia, microsporidia. trypanosomes, techniques should be reported as precisely as possible.
herpes viruses)
The molecular pathology procedures codes {81161,
81200-81408) are not to be used in combination with or
0 CPT Assistant Jul 03:8, Mar 06:6
instead of the procedures represented by 87471-87801.
(For direct smears with concentration and identification. The most specific code possible should be reported. If
use 87177) there is no specific agent code, the general methodology
(For thick smear preparation, use 87015)
code(eg,87299,87449,87797,87798,87799,87899)
should be used. For identification of antibodies to many
(For fat, meat. fibers. nasal eosinophils, and starch, see of the listed infectious agents, see 86602-86804. When
miscellaneous section) separate results are reported for different species or strain
87209 complex special stain (eg, trichrome, iron of organisms, each result should be coded separately. Use
hemotoxylin) for ova and parasites modifier 59 when separate results are reported for
0 CPT Changes: An Insider's View 2006 different species or strains that are described by the same
0 CPT Assistant Mar 06:6 code.
87210 wet mount for iilfectious agents (eg, saline, India ink, 0
0 0
0
0
0
0 0
0
0
0
0 0
KOH preps) 0 0
0
0
0
0 0
0
0
0
0
0 0 0 0
0
0 0 0
0 0
0
0 0
0
0 0 0
0
0 0

0
0
0
0
0
0
0 0
0
0
0
0
0
0
0 0
0
0 0
0
0
0
0
0
0
0
0
0
0 0 0 0
(For KOH examination of skin, hair or na;ls, see 87220) 0
00
0
0 0
00
0
0 0
00
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
A=Revised code • = New code Ill- ..,. =Contains new or revised text H=Duplicate PLA test ti=Category IPLA American Medical Association 677
87260-87337 Pathology and Laboratory/ Microbiology CPT2023
When identifying infectious agents on primary-source 87299 not otherwise specified, each organism
specimens (eg, tissue, smear) microscopically by direct/ 0 CPT Changes: An Insider's View 2001
indirect immunofluorescent assay [IFA] techniques, see 0 CPT Assistant Nov 97:32, Nov 01 :10
87260-87300. When identifying infectious agents on 87300 Infectious agent antigen detection by immunofluorescent
primary-source specimens or derivatives via non- technique, polyvalent for multiple organisms, each
microscopic immunochemical techniques with polyvalent antiserum
fluorescence detection (ie, fluorescence immunoassay 0 CPT Changes: An Insider's View 2001
[FIA]), see 87301-87451, 87802-87899. When 0 CPT Assistant Aug 05:9
identifying infectious agents on primary-source specimens
using antigen detection by immunoassay with direct (For physician evaluation of infectious disease agents by
optical (ie, visual) observation, see 87802-87899. immunofluorescence, use 88346)
87260 Infectious agent antigen detection by immunofluorescent 87301 Infectious agent antigen detection by immunoassay
technique; adenovirus technique (eg, enzyme immunoassay [EIA), enzyme-linked
immunosorbent assay [ELISA), fluorescence immunoassay
[FIA). immunochemiluminometric assay [IMCA)).
qualitative or semiquantitative; adenovirus enteric types
87265 Bordetella pertussis/parapertussis 40/41
0 CPT Assistant Nov 97:32 0 CPT Changes: An Insider's View2016. 2022
87267 Enterovirus, direct fluorescent antibody (DFA) 0 CPT Assistant Nov 97:32. Nov 99:46
0 CPT Assistant Jul 03:8 87305 Aspergillus

87269 giardia 0 CPT Changes: An Insider's View2007, 2016, 2022
0 CPT Changes: An Insider's View 2004 87320 Chlamydia trachomatis

87270 Chlamydia trachomatis 0 CPT Changes. An Insider's View 2016, 2022

87271 Cytomegalovirus, direct fluorescent antibody (DFA) 87324 Clostridium difficile toxin(s)
0 CPT Changes: An Insider's View2001 , 2016, 2022
87272 cryptosporidium
87327 Cryptococcus neoformans
0 CPT Changes: An Insider's View2001, 2016. 2022
87273 Herpes simplex virus type 2 (For Cryptococcus latex agglutination. use 86403)
0 CPT Changes: An Insider~ View2001 87328 cryptosporidium
87274 Herpes simplex virus type 1 0 CPT Changes: An Insider's View2004. 2016. 2022

0 CPT Assistant Nov 97:32 87329 giardia

87275 influenza Bvirus 0 CPT Changes: An Insider's View 2004, 2016, 2022
0 CPT Changes: An Insider's View 2001 87332 cytomegalovirus

87276 influenza A virus 0 CPT Changes: An Insider's View 2016, 2022
0 CPT Assistant Nov 97:32, May 09:6

87278 Legionella pneumophila 87335 Escherichia coli 0157

87279 Parainfluenza virus, each type
(For giardia antigen, use 87329)
87280 respiratory syncytial virus 87336 Entamoeba histolytica dispar group

0 CPTChanges: An Insider's View2001. 2016. 2022
87281 Pneumocystis carinii 87337 Entamoeba histolytica group

0 CPT Changes: An Insider's View 200~ . 2016, 2022
87283 Rubeo la
0
0 0
0
0
0
0 0
0
0 •
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0 0
0
0
0
•
87285 Treponema pallidum 0 0 0 0 0 0 0
0 0 0 0
0
0
0 0
0
0 0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0 0 0 0
87290 Varicella zoster virus 0
00
0
0 0
00
0
0 0
0
0
.. 0 CPT Assistant Nov 97:32
0
0 0
0
0 0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0
0 0
0 0
0 0 0
678 *=Telemedicine ~=Audio-only +=Add-on code .K= FDAapprovalpending #=Resequeocedcode <S>=Modifier51 exempt O O O =Seepxixfordetails
CPT 2023 Pathology and Laboratory/ Microbiology 87338-87482
87338 Helicobacter pylori, stool 87428 Code is out of numerical sequence. See 87425-87430
0 CPT Changes: An Insider's View 2000, 2016, 2022
87430 Streptococcus, group A
87339 Helicobacter pylori 0 CPT Assistant Nov 97:32
0 CPT Changes: An Insider's View2001, 2016, 2022
87449 not otherwise specified, each organism
(For H. pylori, stool, use 87338. For H. pylori, breath and 0 CPTChanges: An Insider's View2001, 2016, 2022
blood by mass spectrometry, see 83013, 83014. For H. 0 CPT Assistant Nov 97:32. Jan 00:11, Nov 01:10
pylori, liquid scintillation counter. see 78267, 78268)
(87 450 has 6een deleted. For infectious agent antigen
87340 hepatitis B surface antigen (HBsAg) detection by immunoassay technique, see 87301-87451.
0 CPT Changes: An Insider's View 2016, 2022 For infectious agent antigen detection by immunoassay
0 CPT Assistant Nov 97:32. Jan 00:11 technique with direct optical [ie, visual) observation, see
87802-87899)
..,.(For quantitative hepatitis B surface antigen [HBsAg),
use 87467)• 87451 polyvalent for multiple organisms, each polyvalent
antiserum
87341 hepatitis B surface antigen (HBsAg) neutralization
0 CPT Changes: An Insider's View 2001, 2016, 2022
0 CPT Changes: An Insider's View 2001, 2016. 2022
• 87467 Hepatitis B surface antigen (HBsAg), quantitative

87350 hepatitis Be antigen (HBeAg)
0 CPT Assistant Nov 97:32 ..,.(For qualitative hepatitis B surface antigen [HBsAg),
use 87340)•
87380 hepatitis, delta agent
0 CPT Changes: An Insider's View2016, 2022 • 87468 Infectious agent detection by nucleic acid (DNA or RNA);
0 CPT Assistant Nov 97:32 Anaplasma phagocytophilum, amplified probe technique
87385 Histoplasma capsulatum
0 CPT Changes: An Insider's View 2016, 2022 • 87469 Babesia microti, amplified probe technique
0 CPT Assistant Nov 97:32 0 CPT Changes: An Insider's View 2023
87389 HIV-1 antigen(s). with HIV-1 and HIV-2 antibodies, 87471 Bartonella henselae and Bartonella quintana,
single result amplified probe technique
0 CPT Changes: An Insider's View 2012, 2016, 2022 0 CPT Assistant May 12:5. Sep 13:3. Oct 20:11
87390 HIV-1 87472 Bartonella henselae and Bartonella quintana,

0 CPT Changes: An Insider's View 2016, 2022 quantification
0 CPT Assistant Nov 97:32 0 CPT Assistant Sep 13:3
87391 HIV-2 87475 Borrelia burgdorferi, direct probe technique

0 CPT Changes: An Insider's View2016, 2022 0 CPT Assistant May 12:5, Sep 13:3
il7476 Borrelia burgdorferi. amplified probe technique
87400 Influenza. A or B, each 0 CPT Assistant Sep 13:3
0 CPT Changes: An Insider's View 2001, 2016. 2022
• 87478 Borrelia miyamotoi, amplified probe technique
0 CPT Assistant Jun 01 :11, Dec 01 :6, Aug 05:9, May 09:6
87420 respiratory syncytial virus
87480 Candida species. direct probe technique
0 CPT Assistant May 12:5, Sep 13:3, Mar21:8
87425 87481 Candida species. amplified probe technique

rotavirus
0 CPT Assistant Sep 13:3, Mar 21 :8
0 CPT Assistant Nov 97:32 87482 Candida species. quantification

87426 severe acute respiratory syndrome coronavirus (eg.
0 CPT Assistant Sep 13:3, Mar 21 :8
SARS-CoV, SARS-CoV-2 [CDVID-19))

# 87428 severe acute respiratory syndrome coronavirus (eg,

0 0 0 0 0
SARS-CoV, SARS-CoV-2 [COVID-19)) and influenza 0 0 0 0
0 0 0 0
0
virus types A and B 0
0
0
0
0
0
0
0
0
0
0
0
0 • 0
0
0
0
0 0
0 0
0 0
0
0
0 0
0 0
0
0
0 0
0
0 0 0 0 0 0
0 'lo 0
0
87427 Shiga-like toxin 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0 0 0
0 CPT Changes: An Insider's View 2001, 2016. 2022 0

00
0 0 0
0
0
0
00
0 0 0
0
0
0
00
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
A = Revised code • = New code ... •=Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 679
87483-87520 Pathology and Laboratory/ Microbiology CPT 2023
87483 central nervous system pathogen (eg, Neisseria 87502 influenza virus, for multiple types or sub-types,
meningitidis, Streptococcus pneumoniae. Listeria. includes multiplex reverse transcription, when
Haemophilus influenzae. E. coli, Streptococcus performed, and multiplex amplified probe technique,
agalactiae, enterovirus, human parechovirus. herpes first 2 types or sub-types
simplex virus type 1 and 2. human herpesvirus 6, 0 CPT Changes: An Insider's View 2011, 2012, 2015, 2016
cytomegalovirus. varicella zoster virus, Cryptococcus), 0 CPT Assistant Oct 10:8, Dec 10:8, Sep 13:3
includes multiplex reverse transcription. when
performed, and multiplex amplified probe technique, + 87503 influenza virus. for multiple types or sub-types,
multiple types or subtypes, 12-25 targets includes multiplex reverse transcription, when
performed, and multiplex amplified probe technique,
each additional influenza virus type or sub-type
87484 Code is out of numerical sequence. See 87496-87500 beyond 2 (List separately in addition to code for
primary procedure)
87485 Chlamydia pneumoniae, direct probe technique
0 CPT Assistant May 12:5, Sep 13:3
0 CPTChanges.· An Insider's View2011, 2015, 2016
0 CPT Assistant Oct 10:8, Dec 10:8, Sep 13:3
87486 Chlamydia pneumoniae, amplified probe technique
0 CPT Assistant Sep 13:3
87505 gastrointestinal pathogen (eg, Clostridium difficile, E.
87487 Chlamydia pneumoniae, quantification
coli. Salmonella. Shigella, norovirus, Giardia),
0 CPT AssistantSep 13:3
includes multiplex reverse transcription, when
87490 Chlamydia trachomatis, direct probe technique performed. and multiplex amplified probe technique,
0 CPT Assistant Se~ 13:3 multiple types or subtypes, 3-5 targets
87491 Chlamydia trachomatis, amplified probe technique
0 CPT Assistant Jun 13:14, Sep 13:3 87506 gastrointestinal pathogen (eg, Clostridium difficile, E.
coli, Salmonella. Shigella, norovirus, Giardia),
87492 Chlamydia trachomatis, quantification
includes multiplex reverse transcription. when
performed. and multiplex amplified probe technique,
87493 Clostridium difficile, toxin gene(s). amplified probe multiple types or subtypes, 6-11 targets
technique 0 CPT Changes: An Insider's View 2015
87507 gastrointestinal pathogen (eg, Clostridium difficile. E.
0 CPT Assistant Sep 10:8, May 12:5, Sep 13:3
coli, Salmonella, Shigella. norovirus, Giardia),
87495 cytomegalovirus, direct probe technique includes multiplex reverse transcription. when
0 CPT Assistant May 12:5, Sep 13:3 performed. and multiplex amplified probe technique.
multiple types or subtypes, 12-25 targets
87496 cytomegalovirus, amplified probe technique 0 CPT Changes: An Insider's View 2015, 2018
87510 Gardnerella vaginalis. direct probe technique
87497 cytomegalovirus. quantification 0 CPT Assistant Aug 05:9, May 12:5, Sep 13:3, Mar 21 :8
87511 Gardnerella vaginalis. amplified probe technique
#• 87484 Ehrlichia chaffeensis, amplified probe technique 0 CPT Assistant May 12:5, Sep 13:3, Mar 21 :8
87512 Gardnerella vaginalis, quantification
87498 enterovirus, amplified probe technique, includes 0 CPT Assistant Sep 13:3, Mar 21 :8
reverse transcription when performed
0 CPT Changes: An Insider's View2007 , 2013, 2014 87516 hepatitis Bvirus, amplified probe technique
0 CPT Assistant May 12:5, Sep 13:3 0 CPT Assistant Sep 13:3
87500 vancomycin resistance (eg, enterococcus species van 87517 hepatitis Bvirus. quantification
A. van B), amplified probe technique 0 CPT Assistant Sep 13:3
0 CPT Changes: An Insider's View2006 87520 hepatitis C, direct probe technique
0 CPT Assistant Apr 08:5, May 12:5, Sep 13:3 0 CPT Assistant Sep 13:3
87501 influenza virus, includes reverse transcription, when
performed, and amplified probe technique, each type
or subtype
0 CPT Changes: An Insider's View 2011 , 2015
0 0 0 0 0
0 CPT Assistant Oct 10:8, Dec 10:8, May 12:5, Sep 13:3 0
0
0
0
0
0
0
0
0 0
0
0
0 0 0 0
0
0 0 0
0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 ° 0 •
0 00 0 0 0 0 00 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0
680 *= Telemedicine '4 =Audio-only +=Add-on code .#=FDA approval pending #=Resequenced code 19= Modifier 51 exempt 000 =See pxix for details
CPT 2023 Pathology and Laboratory I Microbiology 87521-87580
87521 hepatitis C, amplified probe technique, includes # 87624 Human Papillomavirus (HPV). high-risk types (eg. 16.
reverse transcription when performed 18,31,33.35,39,45,51,52,56,58,59,68)
0 CPT Changes: An Insider's View2013 , 2014 0 CPT Changes: An Insider's View2015
'0 CPT Assistant Sep 13:3 0 CPT Assistant Oct 15:10
87522 hepatitis C, quantification, includes reverse (When both low-risk and high-risk HPV types are
transcription when performed performed in a single assay, use only 87624)
# 87625 Human Papillomavirus (HPV). types 16 and 18 only,
~ CPT Assistant Sep 13:3
includes type 45, if performed
87525 hepatitis G. direct probe technique 0 CPT Changes: An Insider's View 2015
0 CPT Assistant Sep 13:3 0 CPT Assistant Jun 15:10, Oct 15:10
87526 hepatitis G, amplified probe technique (For Human Papillomavirus [HPV] detection of five or
0 CPT Assistant Sep 13:3 greater separately reported high-risk HPV types [ie.
genotyping]. use 0500T)
87527 hepatitis G, quantification
0 CPT Assistant Sep 13:3 87540 Legionella pneumophila. direct probe technique
Herpes simplex virus, direct probe technique
0 CPT Assistant May 12:5. Sep 13:3
87528
0 CPT Assistant May 12:5. Sep 13:3 87541 Legionella pneumophila, amplified probe technique
Herpes simplex virus, amplified probe technique
87529
0 CPT Assistant Sep 13:3 87542 Legionella pneumophila. quantification
87530 Herpes simplex virus, quantification

0 CPT Assistant Sep 13:3 87550 Mycobacteria species, direct probe technique
87531 Herpes virus-6. direct probe technique

0 CPT Assistant May 12:5, Sep 13:3
0 CPT Assistant Sep 13:3 87551 Mycobacteria species. amplified probe technique
87532 Herpes virus-6, amplified probe technique

0 CPT Assistant Sep 13:3 87552 Mycobacteria species. quantification

87533 Herpes virus-6, quantification
0 CPT Assistant Sep 13:3 87555 Mycobacteria tuberculosis. direct probe technique
87534 HIV-1, direct probe technique
0 CPT Assistant May 12:5. Sep 13:3 87556 Mycobacteria tuberculosis, amplified probe technique
87535 HIV-1, amplified probe technique. includes reverse
transcription when performed 87557 Mycobacteria tuberculosis, quantification

0 CPT Changes: An Insider's View2013. 2014 0 CPT Assistant Sep 13:3
0 CPT Assistant Mar 08:3, Sep 13:3
87560 Mycobacteria avium-intracellulare. direct probe
87536 HIV-1. quantification. includes reverse transcription technique
when performed 0 CPT Assistant Sep 13:3
87561 Mycobacteria avium-intracellulare. amplified probe
technique
87537 HIV-2. direct probe technique 0 CPT Assistant Sep 13:3
0 CPT Assistant Sep 13:3 87562 Mycobacteria avium-intracellulare, quantification
87538 HIV-2, amplified probe technique, includes reverse 0 CPT Assistant Sep 13:3
transcription when performed 87563 Mycoplasma genitalium, amplified probe technique
87539 HIV-2, quantification, includes reverse transcription 87580 Mycoplasma pneumoniae, direct probe technique
when performed
0 0 0 0 0
0 0
#87623 Human Papillomavirus (HPV). low-risk types (eg. 6, 11, 0
0
0
0
0
0 0
0
0
0
0
0 0
0 0 0 0 0 0
42, 43, 44) 0
0 0 0 0 0
0
0 0 0 0 0
0
0 0
0
0 0
0
0
0 0
0
0
0 0
0
0
0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 00 00 0 0 0 0 00
0 0 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
A= Revised code •=New code .,. ~=Contains new or revised text *=Duplicate PlA test U=Category I PlA American Medical Association 681
87581-87652 Pathology and Laboratory I Microbiology CPT 2023
87581 Mycoplasma pneumoniae, amplified probe technique 87635 severe acute respiratory syndrome coronavirus 2
0 CPT Assistant Sep 13:3 (SARS-CoV-2) (coronavirus disease [COVID-19]).
amplified probe technique
87582 Mycoplasma pneumoniae. quantification
0 CPT Changes: An Insider's View 2021 '
87590 Neisseria gonorrhoeae, direct probe technique
87636 severe acute respiratory syndrome coronavirus 2
0 CPT Assistant May 12:5. Sep 13:3
(SARS-CoV-2) (coronavirus disease [COVJ0-19]) and
87591 Neisseria gonorrhoeae, amplified probe technique influenza virus types A and B. multiplex amplified
0 CPT Assistant Jun 13:14, Sep 13:3 probe technique
87592 Neisseria gonorrhoeae, quantification
0 CPT Assistant Sep 13:3 87637 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (coronavirus disease [COVID-19]),
influenza virus types A and B, and respiratory
87624 Code is out of numerical sequence. See 87538-87541 syncytial virus, multiplex amplified probe technique
(For nucleic acid detection of multiple respiratory

87631 respiratory virus (eg, adenovirus. influenza virus,
infectious agents, not including severe acute respiratory
coronavirus, metapneumovirus, parainfluenza virus.
syndrome coronavirus 2 [SARS-CoV-2] [coronavirus
respiratory syncytial virus, rhinovirus). includes
disease {COVI0-19}]. see 87631 , 87632, 87633)
multiplex reverse transcription, when performed, and
multiplex amplified probe technique, multiple types or (For nucleic acid detection of multiple respiratory
subtypes, 3-5 targets infectious agents, including severe acute respiratory
0 CPT Changes: An Insider's View 2013, 2015 syndrome coronavirus 2 [SARS-CoV-2] [coronavirus
0 CPT Assistant Sep 13:3. Apr 20:3 disease {COVI0-19}] in conjunction with additional
target[s] beyond influenza virus types A and B and
87632 respiratory virus (eg. adenovirus. influenza virus, respiratory syncytial virus, see 87631. 87632. 87633)
coronavirus, metapneumovirus, parainfluenza virus,
respiratory syncytial virus, rhinovirus). includes .,.it=or infectious agent genotype analysis by nucleic acid
multiplex reverse transcription, when performed, and [DNA or RNA] for severe acute respiratory syndrome
multiplex amplified probe technique, multiple types or coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVI0-
subtypes, 6-11 targets 19}]. mutation identification in targeted region[s]. use
0 CPT Changes: An Insider's View 2013, 2015 87913)<1111
0 CPT Assistant Sep 1H . Apr 20:3 .,.(For SARS-CoV-2 variant analysis, use 87913)<1111
87633 respiratory virus (eg. adenovirus. influenza virus. 87640 Staphylococcus aureus, amplified probe technique
coronavirus. metapneumovirus. parainfluenza virus. 0 CPT Changes: An Insider's View 2007
respiratory syncytial virus. rhinovirus). includes
multiplex reverse transcription, when performed, and
0 CPT Assistant Aug 07:7. May 12:5, Sep 13:3
multiplex amplified probe technique, multiple types or 87641 Staphylococcus aureus. methicillin resistant.
subtypes. 12-25 targets amplified probe technique
0 CPT Changes: An Insider's View2013. 2015 0 CPT Changes: An Insider's View2007
0 CPT Assistant Sep 13:3. Apr 20:3 0 CPT Assistant Aug 07:7, Sep 13:3
(Use 87631-87633 for nucleic acid assays which detect (For assays that detect methicillin resistance and identify
multiple respiratory viruses in a multiplex reaction [ie. Staphylococcus aureus using a single nucleic acid
single procedure with multiple results]) sequence, use 87641)
(For assays that are used to type or subtype influenza 87650 Streptococcus. group A, direct probe technique
viruses only, see 87501-87503) 0 CPT Assistant Sep 13:4
(For assays that include influenza viruses with additional 87651 Streptococcus. group A, amplified probe technique
respiratory viruses. see 87631-87633) 0 CPT Assistant Sep 13:4
(For detection of multiple infectious agents not otherwise 87652 Streptococcus. group A, quantification
specified which report a single result, see 87800, 87801) 0 CPT Assistant Sep 13:4
87634 respiratory syncytial virus. amplified probe technique

0 CPT Changes. An Insider's View 2018 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0 0 0 0
0 0
!For assays that include respiratory syncytial virus with 0 0
0
0
0 0 0
0 0
0
0 0 0
additional respiratory viruses, see 87631. 87632. 87633) 0

0
0
0 0 0
0
0
0
0
0 0 0
0
0
0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0
0
00
0 0 0
0
0
0 0 o.
0 0 0
0
0
0 •
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0
682 *= Telemedicine ~=Audio-only +=Add-on code #=FDA approval pending #=Resequenced code IS>= Modifier 51 exempt 0 0 0 =See p xix for details
CPT 2023 Pathology and Laboratory I Microbiology 87653-87906
87653 Streptococcus, group B. amplified probe technique 87806 Code is out of numerical sequence. See 87802-87903
O CPT Changes: An Insider's View 2007 87807 respiratory syncytial virus
O CPT Assistant Aug 07:7. Sep 13:3 0 CPT Changes: An Insider's View 2005. 2022
87660 Trichomonas vaginalis, direct probe tec~;·,ique
# 87811 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (coronavirus disease [COVID-19])
@ CPTAssistantMay 12:5. Sep 13:3, Mar21 :8
87661 Trichomonas vaginalis, amplified probe technique 87808 Trichomonas vaginalis
0 CPT Changes: An Insider's View2D07. 2022
0 CPT Assistant Mar 21 :8
87809 adenovirus
87662 Zika virus, amplified probe technique 0 CPT Changes: An Insider's View 2008, 2022
87797 Infectious agent detection by nucleic acid (DNA or RNA). 87810 Chlamydia trachomatis
not otherwise specified; direct probe technique. each
organism

0 CPT Assistant Nov 97:34, Jan 98:6
@ CPT Assistant Nov 97:34, Nov 01:10, Aug 05:9. May 12:5, 87811 Code is out of numerical sequence. See 87804-87809
Sep 13:3, Aug 16:10
87850 Neisseria gonorrhoeae
87798 amplified probe technique, each organism 0 CPT Changes: An Insider's View 2022
0 CPT Changes: An Insider's View 2001 0 CPT Assistant Nov 97:34, Jan 98:6
0 CPT Assistant Nov 97:34. Nov 01:10, Aug 07:7. Sep 13:3.
87880 Streptococcus, group A
Oct 20:11
87799 quantification. each organism 0 CPT Assistant Nov 97:34, Jan 98:6, Dec 98:8
O CPT Changes: An Insider's View 2001
0 CPT Assistant Nov 97:34. Sep 13:3 87899 not otherwise specified
87800 Infectious agent detection by nucleic acid {ONA or RNA). 0 CPT Assistant Jan 98:6, Jun 01 :11
multiple organisms; direct probe(s) technique
0 CPT Changes: An Insider's View 2001 87900 Infectious agent drug susceptibility phenotype prediction
0 CPT Assistant Aug 05:9. May 12:5, Sep 13:3, Aug 16: 10 using regularly updated genotypic bioinformatics
87801 amplified probe{s) technique 0 CPT AssistantMar06:6, May 12:5, Sep 13:3, Dec 15:17
0 CPT Assistant May 12:5, Jun 13:14, Sep 13:3, Mar21 :8 # 87910 Infectious agent genotype analysis by nucleic acid (DNA
or RNA); cytomegalovirus
{For each specific organism nucleic acid detection from a 0 CPT Changes: An Insider's View 2013
primary source. see 87 471-87660. For detection of 0 CPT Assistant Sep 13:3
specific infectious agents not otherwise specified, see
87797, 87798, or 87799 1 time for each agent) {For infectious agent drug susceptibility phenotype
prediction for HIV-1, use 87900)
{For detection of multiple infectious agents not otherwise
specified which report a single result, see 87800, 87801) (For Human Papillomavirus [HPV] for high-risk types [ie,
genotyping], of five or greater separately reported HPV
(Do not use 87801 for nucleic acid assays that detect types. use 0500T)
multiple respiratory viruses in a multiplex reaction [ie,
single procedure with multiple results]. see 87631-87633) 87901 HIV-1, reverse transcriptase and protease regions
0 CPT Changes: An Insider's View 2001 . 2002, 2011, 2013
87802 Infectious agent antigen detection by immunoassay with 0 CPT Assistant Aug 05:9. Mar 06:6, Oct 10:9, Dec 10:9,
direct optical (ie. visual) observation; Streptococcus. May 12:5. Sep 13:3
group B
0 CPT Changes: An Insider's View 2002. 2022 # 87906 HIV-1, other region {eg, integrase. fusion)
0 CPT Assistant Jun 03: 12 0 CPT Changes: An Insider's View2011
0 CPT Assistant Oct 10:8. Dec 10:8, Sep 13:3
87803 Clostridium difficile toxin A
0 0 0 0 0
0 0 0 0 0 0 0
0 0
# 87806 HIV-1 antigen{s). with HIV-1 and HIV-2 antibodies 0 0
0
0
0
0 0
0
0
0
0
0 0
0 CPT Changes: An Insider's View 2015. 2022 0 0
0
0
0 0 0
0 0
0
0
0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
87804 Influenza 0 0 0 0 0
0
0 0 0 0 0
0
0 0 0
0 0 0 0
0
00
0
0 0
00
0
0 0
00
0 CPTAssistantJun 03:11-12. May09:6 0
0
0
0
0 0
0
0
0
0
0
0 0
0
0
0
0 0
0
0
0
0 • 0
0
0
0
0
0 0
0
A=Revised code •=New code II> ~=Contains new or revised text H=Duplicate PlA test ti=Category I PlA American Medical Association 683
87912-88120 Pathology and Laboratory/ Cytopathology CPT 2023
(For infectious agent drug susceptibility phenotype 88012 infant with brain
prediction for HIV-1, use 87900)
88014 stillborn or newborn with brain
# 87912 Hepatitis B virus
88016 macerated stillborn
0 CPT Assistant Sep 13:3 88020 Necropsy (autopsy), gross and microscopic; without CNS
87902 Hepatitis Cvirus 88025 with brain
88027 with brain and spinal cord
0 CPTAssistantMay12:5. Sep 13:3. Nov 15:11. Dec 15:17
88028 infant with brain
# • 87913 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (coronavirus disease [COVI0-19)). 88029 stillborn or newborn with brain
mutation identification in targeted region(s) 88036 Necropsy (autopsy), limited. gross and/or microscopic;
0 CPT Changes: An Insider's View 2023 regional
""(For infectious agent detection by nucleic acid [DNA or 88037 single organ
RNA) for severe acute respiratory syndrome coronavirus 2
[SARS-CoV-2) [coronavirus disease {COVID-19}). see 88040 Necropsy (autopsy); forensic examination
87635,87636.87637)<111 88045 coroner's call
""(For SARS-CoV-2 variant analysis, use 87913)<111 88099 Unlisted necropsy (autopsy) procedure
87903 Infectious agent phenotype analysis by nucleic acid (DNA
or RNA) with drug resistance tissue culture analysis. HIV
1; first through 10 drugs tested Cytopathology
0 CPT Assistant Apr 04: 15, Mar 06:6. May 12:3. Sep 13:3 88104 Cytopathology, fluids, washings or brushings, except
cervical or vaginal; smears with interpretation
+ 87904 each additional drug tested (List separately in 0 CPT Assistant Spring 91 :6, Fall 94:3, Aug 05:9
addition to code for primary procedure)
0 CPT Changes: An Insider's View 2001. 2002. 2006 88106 simple filter method with interpretation
0 CPT Assistant Apr 04:15. Mar06:6. May 12:3, Sep 13:3 0 CPT Changes: An Insider's View 2007
0 CPT Assistantfall 94:3
(Do not report 88106 in conjunction with 88104)
87905 Infectious agent enzymatic activity other than virus (eg,
sialidase activity in vaginal fluid) (For nongynecological selective cellular enhancement
0 CPT Changes: An Insider's View2009 including filter transfer techniques, use 88112)
(For virus isolation including identification by non- 88108 Cytopathology, concentration technique, smears and
immunologic method, other than by cytopathic effect, use interpretation (eg, Saccomanno technique)
87255) 0 CPT Assistant Fall 94:3, Nov 97:34. Jan 98:6
87906 Code is out of numerical sequence. See 87802-87903 (For cervical or vaginal smears, see 88150-88155)
87910 Code is out of numerical sequence. See 87802-87903 (For gastric intubation with lavage, see 43754, 43755)
87912 Code is out of numerical sequence. See 87802-87903 (For x-ray localization, use 74340)
87913 Code is out of numerical sequence. See 87899-87904 88112 Cytopathology, selective cellular enhancement technique
with interpretation (eg. li_quid based slide preparation
87999 Unlisted microbiology procedure method). except cervical or vaginal
0 CPT Assistant Aug 05:9 0 CPT Changes: An Insider's View 2004
(Do not report 88112 with 88108)

Anatomic Pathology 88120 Cytopathology, in situ hybridization (eg, FISH). urinary
tract specimen with morphometric analysis, 3-5
molecular probes. each specimen; manual
Postmortem Examination 0 CPT Changes: An Insider's View 2011
Procedures 88000 through 88099 represent physician 0 CPT Assistant Oct 10:9, Dec 10:9
services only. Use modifier 90 for outside laboratory 0 0 0
.. 0 0 .. 0
services. 0 0 0
0
0 0 0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
88000 Necropsy (autopsy), gross examination only; without CNS
0 0 0 0
0 CPT Assistant Aug 05:9 0
0
0
0
0 0 0
0
0
0
0
0
0
0
0 0 0
0
0
0
0 0 0 0 0 0
88005 with brain 0 00 0 0 0
0 00
~ 0 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
88007 with brain and spinal cord
. 0 0
0 0 0 0
.. 0
0
684 *= Telemedicine '4 =Audio-only +=Add-on code ,Y =FDA approval pending #=Resequenced code (Y=Modifier 51 exempt O O O =See pxix for details
CPT 2023 Pathology and Laboratory / Cytopathology 88121-88166
88121 usjng computer-assisted technology 88147 Cytopathology smears. cervical or vaginal; screening by
0 CPT Changes: An Insider's View 2011 automated system under physician supervision
0 CPT AssistantDct 10:9, Dec 10:9 0 CPT Assistant Nov 97:35, Nov 98:28. Jan 99:11. May 99:6.
Nov 99:46, Mar 04:6
(For morphometric in situ hybridization on cytologic
specimens other than urinary tract. see 88367, 88368) 88148 screening by automated system with manual
rescreening under physician supervision
(For more tl'an 5 probes. use 88399)
88125 Cytopathology, forensic (eg, sperm) 0 CPT Assistant Jan 99: 1. May 99:6. Nov 99:46. Mar 04:6
88130 Sex chromatin identification; Barr bodies 88150 Cytopathology. slides. cervical or vaginal; manual
screening under physician supervision
88140 peripheral blood smear. polymorphonuclear
drumsticks
0 CPT Assistant Winter 91 :19. Nov 97:34-35, Nov 98:28. May 99:6.
Mar04:5 -
0 CPT Assistant Nov 98:27-28, Mar 06:6
88152 with manual screening and computer-assisted
(For Guard stain, use 88313) rescreening under physician supervision
Codes 88141-88155, 88164-88167, 88174-88175 are 0 CPT Assistant Nov 97:35. Jan 98:6, May 99:6, Mar 04:5
used to report cervical or vaginal screening by various 88153 with manual screening and rescreening under
methods and to report physician interpretation services. physician supervision
Use codes 88150, 88152, 88153 to report conventional 0 CPT Assistant Nov 97:34-35, Nov 98:28. May 99:6, Mar 04:5,
Pap smears that are examined using non-Bethesda Mar05:16
reporting. Use codes 88164-88167 to report conventional
Pap smears that are examined using the Bethesda System of
+ 88155 Cytopathology, slides, cervical or vaginal. definitive
hormonal evaluation (eg, maturation index, karyopyknotic
reporting. Use codes 88142-88143 to report liquid-based
index. estrogenic index) (list separately in addition to
specimens processed as thin-layer preparations that are
code[s] for other technical and interpretation services)
examined using any system of reporting (Bethesda or non-
0 CPT Assistant Nov 97:35, Nov 98:28. May 99:6. Nov 99:46,
Bethesda)_ Use codes 88174-88175 to report automated Mar04:5, May 11:10
screening ofliquid-based specimens that are examined
using any system of reporting (Bethesda or non-Bethesda). (Use 88155 in conjunction with 88142, 88143, 88147,
Within each of these three code families choose the one 88148,88150,88152.88153,88164-88167,88174-88175)
code that describes the screening method(s) used. Codes 88160 Cytopathology, smears, any other source; screening and
88141and88155 should be reported in addition to the interpretation
screening code chosen when the additional services are 0 CPT Assistant Jan 98:6
provided. Manual rescreening requires a complete visual
88161 preparation. screening and interpretation
reassessment of the entire slide initially screened by either
0 CPT Assistant Aug 97:18. Jan 98:6
an automated or manual process. Manual review represents
an assessment of selected cells or regions of a slide 88162 extended study involving over 5 slides and/or multiple
identified by initial automated review. stains
88141 Cytopathology, cervical or vaginal (any reporting system). (For aerosol collection of sputum. use 89220)
requiring interpretation by physician (For special stains, see 88312-88314)
0 CPT Assistant Nov 97:35, Jan 98:6. Jan 99: 11. May 99:6.
Nov 99:46. Mar 04:6, Mar 05:16, May 11 :10. Dec 11 :17 88164 Cytopathology, slides, cervical or vaginal {the Bethesda
System); manual screening under physician supervision
(Use 88141 in conjunction with 88142, 88143, 88147,
88148.88150,88152,88153,88164-88167,88174-88175)
0 CPT Assistant Nov 98:28. May 99:6, Mar 04:5
88165 with manual screening and rescreening under

88142 Cytopathology, cervical or vaginal (any reporting system),
physician supervision
collected in preservative fluid, automated thin layer
preparation; manual screening under physician
0 CPT Assistant Nov 98:28. May 99:6, Mar 04:5, Mar 05:16
supervision 88166 with manual screening and computer-assisted

0 CPT Assistant Nov 97:34-35. Jan 98:6, Nov 98:28. May 99:6, rescreening under physician supervision
Jul 03:7. Mar 04:4 0 CPT Assistant Nov 98:28, May 99:6, Mar 04:5
88143 with manual screening and rescreening under
0 CPT Assistant Nov 97:34-35. Nov 98:28. May 99:6, Jul 03:7. 0 0 0 0 0
Mar04:4,Mar05:16 o 0 0 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 • 0
0
0
0
0
(For automated screening of automated thin layer 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0
preparation, see 88174, 88175) 0 0
0 0 0
0
0 0
0 0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0 0
_.=Revised code •=New code ..,. ..,. =Contains new or revised text *=Duplicate PLA test t.l.=Category I PLA American Medical Association 685
88167---88199 Pathology and Laboratory I Cytogenetic Studies CPT 2023
88167 with manual screening and computer-assisted 88182 Flow cytometry, cell cycle or DNA analysis
rescreening using cell selection and review under 0 CPT Aosistant Oct 13:3
(For DNA ploidy analysis by morphometric technique, use
0 CPT Assistant Nov 98:28. May 99:6. Jul 03:7, Mar 04:5
88358)
(For collection of specimen via fine needle aspiration
88184 Flow cytometry, cell surface, cytoplasmic. or nuclear
biopsy, see 10004, 10005, 10006, 10007, 10008, 10009,
marker, technical component only; first marker
10010, 10011, 10012, 10021)
88172 Cytopathology, evaluation of fine needle aspirate; 0 CPT Assistant Dec 07:14. Oct 13:3
immediate cytohistologic study to determine adequacy
for diagnosis, first evaluation episode, each site
+ 88185 each additional marker (List separately in addition to
code for first marker)
O cPTChanges: An Insider's View2001, 2011
O cPT AssistantFall 93:26. Fall 94:2. Dec 98:8, Aug 07:15.
0 CPT Assistant Dec 07:14, Oct 13:3
Oct 10:9, Dec 10:9. Jan 16:12, Apr 19:4
(The evaluation episode represents a complete set of (Report 88185 in conjunction with 88184)
cytologic material submitted for evaluation and is 88187 Flow cytometry, interpretation; 2 to 8 markers
independent of the number of needle passes or slides 0 CPT Changes: An Insider's View 2005
prepared. A separate evaluation episode occurs if the 0 CPT Assistant Apr 05:14. Oct 13:3
proceduralist provider obtains additional material from
the same site. based on the prior immediate adequacy 88188 9 to 15 markers
assessment. or a separate lesion is aspirated) 0 CPT Changes: An Insider's View 2005
0 CPT Assistant Apr 05:14. Oct 13:3
88173 interpretation and report
0 CPT Assistant Fall 93:26. Fall 94:2. Dec 98:8, Oct 10:9. 88189 16 or more markers
Dec 10:9, Apr 19:4 0 CPT Changes: An Insider's View2005
0 CPT AssistantApr05:14. Oct 13:3
(Report one unit of 88173 for the interpretation and
report from each anatomic site, regardless of the number (Do not report 88187-88189 for interpretation of 86355,
of passes or evaluation episodes performed during the 86356,86357,86359, 86360,86361,86367)
aspiration procedure)
(For assessment of circulating antibodies by flow
(For fine needle aspirate biopsy, see 10004, 10005, 10006, cytometric techniques, see analyte and method-specific
10007, 10008, 10009, 10010, 10011 , 10012, 10021) codes in the Chemistry section [83516-83520) or
Immunology section [86000-86849))
(Do not report 88172, 88173 in conjunction with 88333
and 88334 for the same specimen) (For cell enumeration using immunologic selection and
identification in fluid specimen [eg, circulating tumor
#+ 881n immediate cytohistologic study to determine
cells in blood). see 86152, 86153)
adequacy for diagnosis. each separate additional
evaluation episode, same site (List separately in 88199 Unlisted cytopathology procedure
(For electron microscopy, use 88348)
0 CPT Assistant Oct 10:9, Dec 10:9, Jan 16:12. Apr 19:4
(When repeat immediate evaluation episode(s) is
required on subsequent cytologic material from the same
Cytogenetic Studies
site, eg, following determination the prior sampling that Molecular pathology procedures should be reported using
was not adequate for diagnosis, use 1 unit of 88177 for the appropriate code from Tier 1 (81161 , 81200-81383),
each additional evaluation episode) Tier 2 {81400-81408), Genomic Sequencing Procedures
(Use 88177 in conjunction with 88172) and Other Molecular Multianalyce Assays (81410-81471),
or Multianalyce Assays with Algorithmic Analyses (81500-
88174 Cytopathology, cervical or vaginal (any reporting system), 81512) sections. If no specific code exists, one of the
collected in preservative fluid, automated thin layer unlisted codes {81479 or 81599) should be used.
preparation; screening by automated system. under
physician supervision (For acetylcholinesterase, use 82013)
0 CPT Changes: An Insider's View 2003 (For alpha-fetoprotein, serum or amniotic fluid, see
0 CPT Assistant Jul 03:9. Mar 04:4 82105, 82106)
88175 with screening by automated system and manual 0
0
0 0 0 0
0
0
0
0 0
rescreening or review, under physician supervision 0
0
0
0
0
0 0
0 0
0
0
0 0
0 0
0 CPT Changes: An Insider's View 2003. 2006 0
0 0 0 0 0 0 • 0 0 0
0 0
0 CPT Assistant Jul 03:9, Mar 04:4. Mar 06:6. May 11 :10 0 0 0 0 0 0
0
0 0 0 0 0 0
0
0 0 0 0 0 0 0 0 0 0
0 0 ° 0 0
(For manual screening, see 88142, 88143) 0 0 0 0 0 0 0

0 0 0 0
881n Code is out of numerical sequence. See 88172-88175 0 0 0

0
0
0 0
0
0
0 0 0
0
0 •
686 *= Telemedicine '4 =Audio-only +=Add-on code ,., =FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 00~= See pxix for details
CPT 2023 Pathology and Laboratory I Surgical Pathology 8823~299
(For laser microdissection of cells from tissue sample. (For cytogenomic [genome-wide] analysis for
see 88380) constitutional chromosomal abnormalities, see 81228,
81229.81349,81405, 81406.81479)
Tissue culture for non-neoplastic disorders; lymphocyte
O CPT Assistant Nov 98:29, Oct 99:2. Aug 05:9. May 08:5 (For genomic sequencing procedures or other molecular
multianalyte assays for copy number analysis using
88233 skin or other solid tissue biopsy circulating cell-free fetal DNA in maternal blood, see
0 CPT Assistant Nov 98:29. Oct 99:2. May 08:5
81420.81422.81479)
88235 amniotic fluid or chorionic villus cells 88272 chromosomal in situ hybridization. analyze 3-5 cells
0 CPT Assistant Nov 98:29, Oct 99:2. May 08:5 (eg. for derivatives and markers)
88237 Tissue culture for neoplastic disorders; bone marrow. 0 CPT AssistantNov96:29, Mar 99:10. Oct 99:3. Jun 02:11.
blood cells Jul 05:1. May 08:5. May 12:5. Sep 13:3
O CPT Assistant Nov 98:29. Oct 99:2. May 08:5 88273 chromosomal in situ hybridization, analyze 10-30 cells
solid tumor (zg, for microdeletions)
88239
0 CPT Assistant Nov 98:29. Oct 99:2. May 08:5 0 CPT AssistantNov96:29. Mar 99:10. Oct 99:3, Jun 02:11.
Jul 05:1 . May 08:5, May 12:5. Sep 13:3
88240 Cryopreservation. freezing and storage of cells, each cell
line
88274 interphase in situ hybridization. analyze 25-99 cells
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 03:9. May 08:5. Oct 13:3
0 CPT Assistant Nov 98:29, Mar 99:10, Oct 99:3, Jun 02:11 .
Jul 05: 1. May 08:5. May 12:5. Sep 13:3
(For therapeutic cryopreservation and storage, use 38207)
88275 interphase in situ hybridization, analyze 100-300 cells
88241 Thawing and expansion of frozen cells. each aliquot 0 CPT Assistant Nov 98:29. Mar 99:10. Oct 99:3, Jun 02:11.
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 03:9. May 08:5. Oct 13:3 Jul 05:1, May08:5. May 12:5. Sep 13:3
(For therapeutic thawing of previous harvest, use 38208) 88280 Chromosome analysis; additional karyotypes. each study
0 CPT Assistant Jul 05:1. May 08:5
88245 Chromosome analysis for breakage syndromes; baseline
Sister Chromatid Exchange (SCE), 20-25 cells 88283 additional specialized banding technique (eg, NOR,
0 CPT Assistant Nov 98:29, Oct 99:2, Jul 05:1, May 08:5 C-banding)
0 CPT Assistant Jul 05:1. May 08:5
88248 baseline breakage, score 50-100 cells. count 20 cells,
2 karyotypes (eg, for ataxia telangiectasia. Fanconi 88285 additional cells counted, each study
anemia, fragile X) 0 CPT Assistant Jul 05:1. Dec07:14. May08:5. May 11 :10
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 05: 1, May 08:5 88289 additional high resolution study
88249 score 100 cells. clastogen stress (eg, diepoxybutane. 0 CPT Assistant Oct 99:3, Jul 05:1
mitomycin C, ionizing radiation. UV radiation) 88291 Cytogenetics and molecular cytogenetics, interpretation
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 05: 1. May 08:5 and report
88261 Chromosome analysis; count 5 cells, 1 karyotype. with 0 CPT Assistant Nov 98:29. Oct 99:3. Jul 05:1, May 08:5
banding Unlisted cytogenetic study
88299
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 05:1. May 08:5
88262 count 15-20 cells, 2 karyotypes. with banding
0 CPT Assistant Nov 98:29. Oct 99:2. May 08:5. May 11: 10.
Aug 19:11 Surgical Pathology
88263 count 45 cells for mosaicism, 2 karyotypes. with Services 88300 through 88309 include accession,
banding examination, and reporting. They do not include the
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 05:1. May 08:5
services designated in codes 88311 through 88365 and
88264 analyze 20-25 cells 88399, which are coded in addition when provided.
0 CPT Assistant Nov 98:29, Oct 99:2. Jul 05:1. May 08:5. The unit of service for codes 88300 through 88309 is the
Aug 19:11
specimen.
88267 Chromosome analysis, amniotic fluid or chorionic villus. A specimen is defined as tissue or tissues that is (are)
count 15 cells. 1 karyotype, with banding
submitted for individual and separate attention, requiring
individual examination and pathologic diagnosis. Two or
88269 Chromosome analysis. in situ for amniotic fluid cells, 0 0
count cells from 6-12 colonies. 1 karyotype, with banding 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 CPT Assistant Jul 05:1 0 0
0
0
0
0 O'
0
0
0 0
0
0
0
0 0
0
0
0 0
0 0 0 0 0 0
0 0
88271 Molecular cytogenetics; ONA probe, each (eg, FISH) 0 0 0 0
0
0 0 0 0
0
0
0
0 CPT Assistant Nov 98:29. Mar 99:10. Oct99:3, Jun 02:11.
0
00
0 0
0 0
0 0 0 0 0
0 0
0 0 0 0
0 00 0 00
Jul 05:1. May08:5. May12:5. Sep 13:3. Feb20:10 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
.A=Revised code • = New code .. <Ill =Contains new or revised text *=Duplicate PLA test ti =Category I PLA American Medical Association 687
88300-88304 Pathology and Laboratory I Surgical Pathology CPT 2023
more such specimens from the same patient (eg, separately Artery, atheromatous plaque
identified endoscopic biopsies, skin le5ions) are each Bartholir's gland cyst
appropriately assigned an individual code reflective of its
proper level of service. Bone fragment(s). other than pathologic fracture
Service code 88300 is used for any specimen that in the Bursa/synovial cyst
opinion of the examining pathologist can be accurately Carpal tunnel tissue
diagnosed without microscopic examination. Service code
Cartilage, shavings
88302 is used when gross and microscopic examination is
performed on a specimen to confirm identification and Cholesteatoma
the absence of disease. Service codes 88304 through Colon, colostomy stoma
88309 describe all other specimens requiring gross and
microscopic examination, and represent additional Conjunctiva - biopsy/pterygium
ascending levels of physician work. Levels 88302 through Cornea
88309 are specifically defined by the assigned specimens.
Diverticulum - esophagus/small intestine
Any unlisted specimen should be assigned to the code
Oupuytren's contracture tissue
which most closely reflects the physician work involved
when compared to other specimens assigned to that code. Femoral head, other than fracture
(Do not report 88302-88309 on the same specimen as Fissure/fistula
part of Mohs surgery) Foreskin. other than newborn
88300 Level I - Surgical pathology, gross examination only Gallbladder
~ CPT Assistant Winter 91:18. Sep 00:10. Aug 05:9. Jun 21 :6,
Aug 21 :3. 6-7 Ganglion cyst
88302 Level II - Surgical pathology, gross and microscopic Hematoma

examination Hemorrhoids
Appendix, incidental Hydatid of Morgagni
Fallopian tube. sterilization lntervertebral disc
Fingers/toes. amputation. traumatic Joint. loose body
Foreskin, newborn Meniscus
Hernia sac. any location Mucocele, salivary
Hydrocele sac Neuroma - Morton's/traumatic
Nerve Pilonidal cyst/sinus
Skin. plastic repair Polyps, inflammatory - nasal/sinusoidal
Sympathetic ganglion Skin - cyst/tag/debridement
Testis, castration Soft tissue. debridement
Vaginal mucosa. incidental Soft tissue. lipoma
Vas deferens. sterilization Spermatocele
~ CPT Assistant Winter 91 :18. Sep 00:10. Nov 06:1 , Jan 07:29.
Dec 11 :1 7. Feb 14:10, Jun 21:6. Aug 21:3, 6-7 Tendon/tendon sheath
•(Use 0751T in conjunction with 88302 when the Testicular appendage

digitization of glass microscope slides is performed)<llll Thrombus or embolus
Tonsil and/or adenoids
88304 Level Ill - Surgical pathology, gross and microscopic Varicocele
examination
Vas deferens. other than sterilization
Abortion, induced
0 0 0 0
Abscess 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
0 0 0 0 0 0 0 0 0
Aneurysm - arterial/ventricular 0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
Anus. tag 0 0 0 0 0
0
0 0 0 0 0
0
0 0
0 0 0 0
00 0 00 0 0
Appendix. other than incidental 0
0 0 0
0
0
0 0 0
0
0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
688 *= Telemedicine '4 =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 0 0 =Seep xix for details
CPT 2023 Pathology and Laboratory I Surgical Pathology 88305
Vein, varicosity Omentum, biopsy

Ovary with or without tube, non-neoplastic
0 CPT Assistant Winter 91 :18. Spring 91 :2, Aug 97:18, Sep 00:10,
Jan 07:29, Dec 11:17. Jun 21 :6, Aug 21 :3, 6-7 Ovary, biopsy/wedge resection
..,.(Use 0752T in conjunction with 88304 when the Parathyroid gland
digitization of glass microscope slides is performed)'4
Peritoneum, biopsy
88305 Level IV - Suri;iccil,pathology, gross and microscopic
Pituitary tumor
examination
Placenta, other than third trimester
Abortion - spontaneous/missed
Pleura/pericardium - biopsy/tissue
Artery, biopsy
Polyp, cervical/endometrial
Bone marrow, biopsy
Polyp, colorectal
Bone exostosis
Polyp, stomach/small intestine
Brain/meninges, other than for tumor resection
Prostate, needle biopsy
Breast. biopsy, not requiring microscopic evaluation of
surgical margins Prostate. TUR
Breast. reduction mammoplasty Salivary gland, biopsy
Bronchus, biopsy Sinus, paranasal biopsy
Cell block, any source Skin. other than cyst/tag/debridement/plastic repair
Cervix, biopsy Small intestine, biopsy
Colon, biopsy Soft tissue, other than tumor/mass/lipoma/debridement
Duodenum, biopsy Spleen
Endocervix, curettings/biopsy Stomach, biopsy
Endometrium, curettings/biopsy Synovium
Esophagus, biopsy Testis. other than tumor/biopsy/castration
Extremity, amputation, traumatic Thyroglossal duct/brachia I cleft cyst
Fallopian tube, biopsy Tongue, biopsy
Fallopian tube, ectopic pregnancy Tonsil, biopsy
Femoral head, fracture Trachea, biopsy
Fingers/toes, amputation, non-traumatic Ureter. biopsy
Gingiva/oral mucosa, biopsy Urethra, biopsy
Heart valve Urinary bladder. biopsy
Joint. resection Uterus. with or without tubes and ovaries, for prolapse
Kidney. biopsy Vagina, biopsy
Larynx, biopsy Vulva/labia. biopsy
Leiomyoma(s), uterine myomectomy - without uterus 0 CPT Changes: An Insider's View 2002
0 CPT Assistant Winter 90:2. Winter 91 :18, Spring 91 :6,
Lip, biopsy/wedge resection Winter 92:17, Aug 97:18, Jul 98:4. Nov 98:29-30, Jul 00:4.
Sep 00:10, Dec 00:15, Jul 05:13, Nov 06:1. Jan 07:29. Dec 11 :17,
Lung, transbronchial biopsy Jun 21 :6, Aug 21 :3. 6-7
Lymph node, biopsy ..,.(Use 0753T in conjunction with 88305 when the
Muscle, biopsy digitization of glass microscope slides is performed)'4
Nasal mucosa, biopsy 0

0
0
0
0
.. 0
0
0 0 0
0
0
0
0 0 0 0
0 0 0 0 0 0 0 0
0
0 0 0 0
Nasopharynx/oropharynx, biopsy 0 0 0 0
0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0
0 0 0
Nerve, biopsy 0 0 0
0 0
0- 0 0 0 0
0 0
0 0 0 0 0
0 00 0 0 0 0 00
Odontogenic/dental cyst 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0
0
•=Revised code • = New code • .. =Contains new or revised text *=Duplicate PLA test U =Category I PLA American Medical Association 689
88307-88311 Pathology and Laboratory I Surgical Pathology CPT2023
88307 Level V - Surgical pathology, gross and microscopic ll>(Use 0754T in conjunction with 88307 when the
examination digitization of glass microscope slides is performed)"4
Adrenal. resection 88309 Level VI - Surgical pathology, gross and microscopic
examination
Bone - biopsy/curettings
Bone resection
Bone fragmentjs). pathologic fracture
Breast, mastectomy - with regional lymph nodes
Brain. biopsy
Colon, segmental resection for tumor
Brain/meninges, tumor resection
Colon. total resection
Breast. excision of lesion, requiring microscopic
evaluation of surgical margins Esophagus, partial/total resection
Breast, mastectomy - partial/simple Extremity, disarticulation
Cervix, conization Fetus. with dissection
Colon, segmental resection, other than for tumor Larynx. partial/total resection - with regional lymph
nodes
Extremity. amputation. non-traumatic
Lung - total/lobe/segment resection
Eye, enucleation
Pancreas, total/subtotal resection
Kidney, partial/total nephrectomy
Prostate, radical resection
Larynx, partial/total resection
Small intestine. resection for tumor
Liver, biopsy - needle/wedge
Soft tissue tumor, extensive resection
Liver, partial resection
Stomach - subtotal/total resection for tumor
Lung, wedge biopsy
Testis, tumor
Lymph nodes, regional resection
Tongue/tonsil -resection for tumor
Mediastinum, mass
Urinary bladder, partial/total resection
Myocardium. biopsy
Uterus, with or without tubes and ovaries. neoplastic
Odontogenic tumor
Vulva. total/subtotal resection
Ovary with or without tube. neoplastic
0 CPT Assistant Winter 91 :18. Spring 91 :2. Fall 93:2, 26, Jul 00:4.
Pancreas, biopsy Sep 00:10. Dec 03:11. Nov 06:1. Jan 07:29. Dec 11:18. Feb 14:10.
Jun 21 :6, Aug 21 :3. 6
Placenta, third trimester
ll>(Use 0755T in conjunction with 88309 when the
Prostate. except radical resection digitization of glass microscope slides is performed)"4
Salivary gland (For fine needle aspiration biopsy, see 10004, 10005.
Sentinel lymph node 10006, 10007. 10008, 10009, 10010, 10011. 10012, 10021)
Small intestine, resection, other than for tumor (For evaluation of fine needle aspirate. see 88172-88173)
Soft tissue mass (except lipoma)- biopsy/simple excision (Oo not report 88302-88309 on the same specimen as
part of Mohs surgery)
Stomach - subtotal/total resection, other than for tumor
+ 88311 Decalcification procedure (List separately in addition to
Testis, biopsy code for surgical pathology examination)
Thymus. tumor 0 CPT Assistant Winter 92: 18. Jul 98:4, Jun 02: 11. Nov 02:7.
Nov 06:1, Dec 11:18. Jun 21 :6. Aug 21 :3. 6
Thyroid, total/lobe
Ureter, resection
Urinary bladder, TUR
Uterus, with or without tubes and ovaries, other than 0 0 0 0 0
0 0 0 0 0
neoplastic/prolapse 0 0
0
0
0 0 0
0
0
0
0 0 0 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0 CPT Assistant Winter 91 :18, Winter 92:18, Jul 98:4, Nov 98:29- 0
0
0
0 0 0
0
0
0
0
0
0 0 0
0
0
0
30. Jul 99:10. Jul 00:4. Sep 00:10. Dec 00:15. Dec 03:11. 0 0
0
0 0 0 0 0
0
0 0 0
0 0
Nov 06:1. Jan 07:29. Dec 11 :17, Jun 21 :6, Aug 21 :3. 6 00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0 0
690 *= Telemedicine '4 =Audio-only +=Add-on code .#=FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 0 0 =See p xix for details
CPT 2023 Pathology and Laboratory I Surgical Pathology 88312~
88312 Special stain including interpretation and report; Group I 88321 Consultation and report on referred slides prepared
for microorganisms (eg, acid fast, methenamine silver) elsewhere
O CPT Changes: An Insider's View2004, 2010, 2012 0 CPT Assistant Winter 91 :19, Apr 97:9, Oct 00:7. Dec 02:10,
O CPT Assistant Winter 91 :19. Jun 02:11. Nov 02:7. Nov 06:1 . Jan 10:11 . Dec 11:18, Jun 13:15, Feb 22:6
Dec 11 :18
88323 Consultation and report on referred material requiring
.,.(Use 0756T in conjunction with 88312 when the preparation of slides
digitization of glass microscope slides is performed)<lll 0 CPT AssistantWinter91 :19, Apr 97:9, Oct 00:7. Dec 02:10.
Dec 11:18. Jun 13:15, Feb 22:6
(Report one unit of 88312 for each special stain, on each
surgical pathology block, cytologic specimen, or 88325 Consultation, comprehensive, with review of records and
hematologic smear) specimens, with report on referred material
0 CPT Assistant Winter 91 :19, Apr 97:9, Dec 02:10. Dec 11 :18.
88313 Group II, all other (eg, iron, trichrome), except stain Jun 13:15, Feb 22:6
for microorganisms, stains for enzyme constituents,
or immunocytochemistry and immunohistochemistry 88329 Pathology consultation during surgery;
0 CPT Changes: An Insider's View2010, 2012 0 CPT Assistant Winter 91 :19. Apr 97:12, Aug 97:18, Jan 07:29,
Dec 11:18
0 CPT Assistant Jun 02: 11. Nov 02:7. Mar 03:22, Nov 03:15,
Jun 06:17, Nov 06:1, Dec 11 :18 88331 first tissue block, with frozen section(s), single
.,.(Use 0757T in conjunction with 88313 when the sped men
digitization of glass microscope slides is performed)<lll 0 CPT Changes: An Insider's View2001
0 CPT Assistant Winter 91 :19, Spring 91 :2. Apr 97:12.
(Report one unit of 88313 for each special stain. on each Aug 97:18. Jul 00:4. Nov 02:7, Mar 06:6. Nov 06:1,
surgical pathology block. cytologic specimen. or Jan 07:29. Oct 10:9, Dec 10:9, Dec 11: 18
hematologic smearl
+ 88332 each additional tissue block with frozen section(s)
(For immunocytochemistry and immunohistochemistry, (List separately in addition to code for primary
use 883421 procedure)
+ 88314 histochemical stain on frozen tissue block (List 0 CPT Changes: An Insider's View 2011
separately in addition to code for primary procedure) 0 CPT Assistant Winter 91 :19, Apr 97:12. Aug 97:18. Jul 00:4,
Mar 06:6. Jan 07:29, Oct 10:9. Dec 10:9. Dec 11 :18
0 CPT AssistantNov02:7. Nov06:1 , Dec 11:18 (Use 88332 in conjunction with 88331)
(Use 88314 in conjunction with 17311-17315, 88302- 88333 cytologic examination (eg, touch prep, squash prep),
88309. 88331, 88332) initial site
.,.(Use 0758T in conjunction with 8831 4 when the
digitization of glass microscope slides is performed)<lll

0 CPT Assistant Mar 06:6, Jan 07:29, Jun 08:15, Dec 10:9,
Dec 11:18
(Do not report 88314 with 17311-17315 for routine frozen
+ 88334 cytologic examination (eg, touch prep, squash prep).
section stain [eg, hematoxylin and eosin, toluidine blue). each additional site (List separately in addition to
performed during Mohs surgery. When a nonroutine code for primary procedure)
histochemical stain on frozen tissue during Mohs surgery
is utilized, report 88314 with modifier 59)
0 CPT Changes: An Insider's View 2006. 2011
0 CPT Assistant Mar 06:6, Jan 07:29, Oct 10:9. Dec 11: 18
(Report one unit of 88314 for each special stain on each
(Use 88334 in conjunction with 88331, 88333)
frozen surgical pathology block)
(For intraoperative consultation on a specimen requiring
(For a special stain performed on frozen tissue section
both frozen section and cytologic evaluation, use 88331
material to identify enzyme constituents, use 88319)
and 88334)
(For determinative histochemistry to identify chemical
(For percutaneous needle biopsy requiring intraprocedural
components, use 883131
cytologic examination, use 88333)
88319 Group Ill, for enzyme constituents
(Do not report 82333 <:::-:d C3334 for non-intraoperative
cytologic examination, see 88160-88162)
(Do not report 88333 and 88334 for intraprocedural
.,.(Use 0759T in conjunction with 88319 when the cytologic evaluation of fine needle aspirate, see 88172)
digitization of glass microscope slides is performed)<lll
0 0 0 0 0
(For each stain on each surgical pathology block, 0 0 0 0
0 0 0 0
0
0 0 0 0 0 0 0
cytologic specimen, or hematologic smear, use one unit 0 0
0
0 0
0
0 0
0
0 0
0
0
0 0 0 0 0 0 0 0
of 88319) 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0
0
(For detection of enzyme constituents by 0 0
0 0
0 0 0 0 0
0 0
0 0 0 0 0
immunohistochemical or immunocytochemical technique. 00

0 0
0 0
00
0 0
0 0
00
0 0 0 0
use 88342) 0 0 0 0
0 0
0
0 0
0 0 0 0
0
0 0
0 0
0 0 0 0
0
A=Revised code •=New code .,.. <Ill =Contains new or revised text H=Ouplicate Pl.A test U=Category I PLA American Medical Association 691
88342--88363 Pathology and Laboratory I Surgical Pathology CPT 2023
88342 lmmunohistochemistry or immunocytochemistry, per 88355 Morphometric analysis; skeletal muscle
specimen; initial single antibody stain procedure 0 CPT Assistant Dec 11 :18
0 CPTChanges: An Insider's View2004. 2015, 2014
0 CPT AssistantWinter91:17, Jul 00:10, Nov02:6-7. Nov 06:1.
88356 nerve l
Dec 11:18.Jun 14:15.Jun 15:11 0 CPTAssistantDec11:18, Jun 14:15
""(Use 0760T in conjunction with 88342 when the 88358 tumor (eg. DNA ploidy)
digitization of glass microscope slides is performed)<llll 0 CPT Changes: An Insider's View 2004
(For quantitative or semiquantitative

0 CPT Assistant Jul 98:4. Jul 99:11. Jun 02:11, Jun 06:17,
Dec 11:18
immunohistochemistry, see 88360, 88361)
(Do not report 88358 with 88313 unless each procedure
#+ 88341 each additional single antibody stain procedure (List is for a different special stain)
0 CPT Changes: An Insider's View 2015 88360 Morphometric analysis, tumor immunohistochemistry (eg,
0 CPT Assistant Jun 15:11 Her-2/neu, estrogen receptor/progesterone receptor).
quantitative or semiquantitative, per specimen. each
(Use 88341 in conjunction with 88342) single antibody stain procedure; manual
""(Use 0761T in conjunction with 88341 when the 0 CPT Changes: An Insider's View 2005, 2015
digitization of glass microscope slides is performed)<llll 0 CPTAssistantDec11:18, Jun 14:15
(For multiplex antibody stain procedure. use 88344) ""(Use 0763T in conjunction with 88360 when the
digitization of glass microscope slides is performed)<llll
88344 each multiplex antibody stain procedure
88361 using computer-assisted technology
0 CPT Assistant Jun 15: 11 0 CPT Changes: An Insider's View 2004, 2005. 2015
0 CPTAssistantDec11:18, Jun 14:15
""(Use 0762T in conjunction with 88344 when the
digitization of glass microscope slides is performed)..,.. (Do not report 88360, 88361 in conjunction with 88341.
88342. or 88344 unless each procedure is for a different
(Do not use more than one unit of 88341. 88342. or 88344 antibody)
for the same separately identifiable antibody per
specimen) (Morphometric analysis of a multiplex antibody stain
should be reported with one unit of 88360 or 88361, per
(Do not report 88341, 88342, 88344 in conjunction with specimen)
88360, 88361 unless each procedure is for a different
antibody) (For morphometric analysis using in situ hybridization
techniques, see 88367, 88368)
(When multiple separately identifiable antibodies are
applied to the same specimen [ie, multiplex antibody (When semi-thin plastic-embedded sections are
stain procedure]. use one unit of 88344) performed in conjunction with morphometric analysis,
only the morphometric analysis should be reported; if
(When multiple antibodies are applied to the same slide performed as an independent procedure, see codes
that are not separately identifiable, [eg, antibody 88300-88309 for surgical pathology.)
cocktails]. use 88342, unless an additional separately
identifiable antibody is also used. then use 88344) 88362 Nerve teasing preparations
0 CPT Assistant Dec 11 :18
88346 lmmunofluorescence, per specimen; initial single
antibody stain procedure 88363 Examination and selection of retrieved archival (ie,
0 CPT Changes: An Insider's View 2016 previously diagnosed) tissue(s) for molecular analysis (eg,
0 CPTAssistantDec11:18 KRAS mutational analysis)
#+ 88350 each additional single antibody stain procedure (List 0 CPT Assistant Oct 10:10. Dec 10:10, Dec 11:18
0 CPT Changes: An Insider's View2016 88364 Code is out of numerical sequence. See 88334-88372
(Report 88350 in conjunction with 88346)

(Do not report 88346 and 88350 for fluorescent in situ
hybridization studies. see 88364, 88365, 88366. 88367.
88368, 88369, 88373. 88374. and 88377) 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0
(Do not report 88346 and 88350 for multiplex 0 0
0
0 0
0
0 0
0
0
0
0
0 0 0 0 0 0 0 0
immunofluorescence analysis. use 88399) 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0
0 0
88348 Electron microscopy, diagnostic 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0
0 CPT Assistant Dec 11 :18 0

00
0 0 0
0
0
0
00
0 0 0
0
0
0
0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0
0 0 0 0
0 0 0 0
692 *= Telemedicine '4 =Audio-only +=Add-on code ,..-=FDA approval pending #=Resequenced code (9= Modifier 51 exempt 000 =Seep xix for details
CPT 2023 Pathology and Laboratory I In Vivo (eg, Transcutaneous) Laboratory Procedures 88365-88399
88365 In situ hybridization (eg, FISH). per specimen; initial 88375 Optical endomicroscopic image(s). interpretation and
single probe stain procedure report, real-time or referred, each endoscopic session
0 CPT Assistant Jun 02:11, Mar 05:16, Dec 11 :18, May 12:3, 0 CPT Assistant Aug 13:5
Sep 13:3. Nov 18:11. Jun 21 :6. Aug 21 :3. 6
(Do not report 88375 in conjunction with 43206, 43252.
#+ 88364 each additional single probe stain procedure (List 0397T)

88380 Microdissection (ie. sample preparation of
microscopically identified target); laser capture
88366 each multiplex probe stain procedure 0 CPT Changes: An Insider's View 2002, 2008
0 CPT Changes: An Insider's View2015 0 CPT AssistantApr02:17. Apr 08:5, Dec 11 :18, May 12:8, 10,
Sep 13:3
(Do not report 88365, 88366 in conjunction with 88367,
88368, 88374. 88377 for the same probe) 88381 manual
88367 Morphometric analysis, in situ hybridization (quantitative
or semi-quantitative). using computer-assisted 0 CPTAssistantApr08:5, Dec 11:18. May 12:8. 10, Sep 13:3
technology, per specimen; initial single probe stain (Do not report 88380 in conjunction with 88381)
procedure
88387 Macroscopic examination, dissection. and preparation of
tissue for non-microscopic analytical studies (eg. nucleic
0 CPTAssistantMar05:16, Oct 10:9. Dec 11:18. May 12:5.
acid-based molecular studies); each tissue preparation
Sep 13:3
(eg, a single lymph node)
#+ 88373 each additional single probe stain procedure (List : ) CPT Changes: An Insider's View 2010
separately in addition to code for primary procedure) 0 CPT Ass1stant'Jec 11 :18
(Do not report 88387 for tissue preparation for
(Use 88373 in conjunction with 88367) microbiologic cultures or flow cytometric studies)
# 88374 each multiplex probe stain procedure (Do not report 88387 in conjunction with 88388, 88329-
0 CPT Changes: An Insider's View 2015 88334)
(Do not report 88367, 88374 in conjunction with 88365, + 88388 in conjunction with a touch imprint. intraoperative
88366, 88368, 88377 for the same probe) consultation, or frozen section, each tissue
88368 Morphometric analysis, in situ hybridization (quantitative preparation (eg, a single lymph node) (List separately
or semi-quantitative). manual, per specimen; initial single in addition to code for primary procedure)
probe stain procedure :) CPT Changes: An Insider's View 2010
0 CPT Changes: An Insider's View 2005. 2015 0CPTAssistantDec11:18
0 CPT Assistant Mar 05:16. Oct 10:9. Dec 11 :18, May 12:5, (Use 88388 in conjunction with 88329-88334)
Sep 13:3
(Do not report 88387 or 88388 for tissue preparation for
+ 88369 each additional single probe stain procedure (List microbiologic cultures or flow cytometric studies)
0 CPT Changes: An Insider's View 2015 88399 Unlisted surgical pathology procedure
0 CPT Assistant Jun 14:15. Jun 21 :6, Aug 21 :3. 6
# 88377 each multiplex probe stain procedure
0 CPT Changes: An Insider's View2015 In Vivo (eg, Transcutaneous)
(Do not report 88368 or 88377 in conjunction with
88365, 88366, 88367, 88374 for the same probe)
Laboratory Procedures
(For morphometric in situ hybridization evaluation of (For all in vivo measurements not specifically listed, use
88749)
urinary tract cytologic specimens. see 88120. 88121)
88371 Protein analysis of tissue by Western Blot. with (For wavelength fluorescent spectroscopy of advanced
interpretation and report; glycation end products [skin]. use 88749)
0 CPT Assistant Dec 11 :18, Dec 15:17 0 0 0 0 0
88372 immunological probe for band identification. each

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
•
0 CPT Assistant Dec 11 :8 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0 0
0 0 0 0 0 0
0
0 0
0
0
0 0
0
0
0
0
0
0
0 0
• 0
0 0
0
0
0
0
0
0
0 0
0 0
00
0 0 0
0
0
0 00
0 0 0
0
0
00
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
&=Revised code • = New code ~ <1111 =Contains new orrevised text H=Duplicate PLA test ti=Category I PLA American Medical Association 693
88720--89259 Pathology and Laboratory I Reproductive Medicine Procedures CPT 2023
88720 Bilirubin, total, transcutaneous (Paternity tests, use 86910)

0 CPT Assistant Dec 10:10, May 20:14 89220 Sputum, obtaining specimen, aerosol induced technique
(separate procedure)
(For transdermal oxygen saturation, see 94760-94762) 0 CPT Changes: An Insider's View 2004
88738 Hemoglobin (Hgb), quantitative, transcutaneous 0 CPT Assistant Aug 05:9. Sep 11 :4
0 CPT Changes: An Insider's View 201 O 89230 Sweat collection by iontophoresis
(For in vitro hemoglobin measurement. use 85018) 0 CPT Changes: An Insider's View 2004
0 CPT Assistant Sep 11 :4
88740 Hemoglobin, quantitative, transcutaneous, per day;
carboxyhemoglobin 89240 Unlisted miscellaneous pathology test
0 CPT Assistant Nov 05:14. Jan 07:30. Sep 11 :4
(For in vitro carboxyhemoglobin measurement, use 82375)
I
88741 methemoglobin
0 CPT Changes: An Insider's View 2009 Reproductive Medicine
(For in vitro quantitative methemoglobin determination,
use 83050)
Procedures
88749 Unlisted in vivo (eg, transcutaneous) laboratory service
89250 Culture of oocyte(s)/embryo(s). less than 4 days;
0 CPT Assistant Oct 10:10. Dec 10:10 0 CPT Assistant Nov 97:35-36. Jan 98:6. Oct 98:1. Apr 04:2.
May 04:16. Jun 04:9, Sep 11 :4
89251 with co-culture of oocyte(s)/embryos
Other Procedures 0 CPT Changes: An Insider's View 2004
0 CPT Assistant Nov 97:35-36. Jan 98:6, Oct 98:1. Apr 04:2
89049 Caffeine halothane contracture test (CHCT) for malignant
(For extended culture of oocyte[s]/embryo[s). see 89272)
hyperthermia susceptibility, including interpretation and
report 89253 Assisted embryo hatching, microtechniques (any method)
0 CPT Changes: An Insider's View 2006 0 CPT Assistant Nov 97:35-36, Jan 98:6. Oct 98:1. Apr 04:2,
0 CPT Assistant Mar 06:6. May06:19. Sep 11:4 May 04:16. Jun 04:9
89050 Cell count, miscellaneous body fluids (eg, cerebrospinal 89254 Oocyte identification from follicular fluid
fluid, joint fluid). except blood; 0 CPT Assistant Nov 97:35-36, Jan 98:6, Oct 98:1. Apr 04:2.
0 CPT Changes: An Insider's View 2002 May 04:16, Jun 04:9
0 CPT Assistant Aug 05:9. Sep 11 :4 89255 Preparation of embryo for transfer (any method)
89051 with differential count 0 CPT Assistant Nov 97:35-36, Jan 98:6. Oct 98:1, Apr 04:2.
May 04:16, Jun 04:9
89257 Sperm identification from aspiration (other than seminal
89055 Leukocyte assessment, fecal, qualitative or
fluid)
semiquantitative
0 CPT Assistant Nov 97:35-36, Jan 98:6. Oct 98:1, Nov 98:30,
Apr04:2
0 CPT Assistant Jul 03:9. Sep 11 :4
(For semen analysis, see 89300-89320)
89060 Crystal identification by light microscopy with or without
polarizing lens analysis, tissue or any body fluid (except (For sperm identification from testis tissue, use 89264)
urine) 89258 Cryopreservation; embryo(s)
0 CPT Assistant Nov 97:36, Jan 98:6, Oct 98:1, Apr 04:2. 4
(Do not report 89060 for crystal identification on paraffin- 89259 sperm
embedded tissue)
0 CPT Assistant Nov 97:36, Jan 98:6, Oct 98:1, Apr 04:2. 4
89125 Fat stain, feces, urine, or respiratory secretions
(For cryopreservation of reproductive tissue, testicular,
0 CPT Changes: An Insider's View 2001 use 89335)
0 0 0 0 0
89160 Meat fibers. feces 0
0
0
0
0
0
0 0 0 0 0
0 0 0
0 CPT Assistant Sep 11 :4 0
0 0
0
0
0
0 0
0
0
0 0
0
0
0
0
0 0
0
0
89190 Nasal smear for eosinophils

0
0
0
0
0 0 0
0
0
0
0 0
0 "
0 0 0
0 0
0 0 0
0 0
0 0 0 0 0
0 0
0 0 0
0 00 0 00
0 0 0 0
0 0 0
(Occult blood, feces, use 82270) 0 0
0 0 0
0
0
0
0
0
0
0
0 0 0 0 0 0
0 0 0 0
0 0 0 0
0 0 0
694 *= Telemedicine ~=Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code (S) =Modifier 51 exempt 0 0 0 =See p xix for details
CPT 2023 Pathology and Laboratory I Reproductive Medicine Procedures 892~53
89260 Sperm isolation; simple prep (eg, sperm wash and swim- 89322 volume, count. motility, and differential using strict
up) for insemination or diagnosis with semen analysis morphologic criteria (eg, Kruger)
0 CPT Assistant Nov 97:36, Jan 98:6, Oct 98:1. Apr 04:3-4 0 CPT Changes: An Insider's View2008
89261 complex prep (eg, Per.::oll gradient, albumin gradient)

for insemination or diagnosis with semen analysis 89325 Sperm antibodies

0 CPT Assistant Nov 97:36, Jan 98:6, Oct 98:1 . Apr 04:3-4
(For medicolegal identification of sperm, use 88125)
(For semen analysis without sperm wash or swim-up, use
89329 Sperm evaluation; hamster penetration test
89320)
89330 cervical mucus penetration test. with or without
89264 Sperm identification from testis tissue, fresh or
spinnbarkeit test
cryopreserved
0 CPT Assistant Nov 98:30, Apr 04:3-4
0 CPT Assistant Nov 05: 14
89331 Sperm evaluation. for retrograde ejaculation, urine

(For biopsy of testis, see 54500, 54505)
(sperm concentration. motility. and morphology, as
(For sperm identification from aspiration, use 89257) indicated)
(For semen analysis, see 89300-89320)
89268 Insemination of oocytes
(For semen analysis on concurrent semen specimen. see
89300-89322 in conjunction with 89331)
0 CPT Assistant Apr 04:3-4
(For detection of sperm in urine. use 81015)
89272 Extended culture of oocyte(sl/embryo(s), 4-7 days
0 CPT Changes: An Insider's View 2004 89335 Cryopreservation. reproductive tissue. testicular
0 CPT Assistant Apr 04:3-4 0 CPT Changes: An Insider's View2004
89280 Assisted oocyte fertilization, microtechnique; less than or

equal to 10 oocytes (For cryopreservation of embryo[s]. use 89258. For

0 CPT Changes: An Insider's View2004 cryopreservation of sperm. use 89259; for mnture
0 CPT Assistant Apr 04:3-4 oocytes, use 89337)
89281 greater than 10 oocytes 89337 Cryopreservation. mature oocyte(s)
0 CPT Assistant Apr 04:3-4
89342 Storage (per year); embryo(s)
89290 Biopsy, oocyte polar body or embryo blastomere, 0 CPT Changes: An Insider's View 2004
microtechnique (for pre-implantation genetic diagnosis); 0 CPT Assistant Apr 04:5
less than or equal to 5 embryos
89343 sperm/semen
89291 greater than 5 embryos
89344 reproductive tissue, testicular/ovarian
0 CPT Assistant Apr 04:3, 5
89300 Semen analysis; presence and/or motility of sperm
89346 oocyte(sl
including Huhner test (post coital)
0 CPT Assistant Nov 97:36. Jul 98:10, Oct 98:4, Apr 04:3, Aug 05:9
89310 motility and count (not including Huhner test)
89352 Thawing of cryopreserved; embryo(sl
0 CPT Assistant Jul 03:9, Apr 04:3
89320 volume, count, motility, and differential
89353 sperm/semen, each aliquot
0 CPT Assistant Apr 04:3. Apr 08:5
(Skin tests, see 86485-86580 and 95012-95199)
89321 sperm presence and motility of sperm, if performed 0 0 0 0 0
0 CPT Changes: An Insider's View 2001. 2008 0
0 "' 0
0
0
0
0
0
0
0
0
0
0 0
0
(To report Hyaluronan binding assay [HBA). use 89398)

0
0 0
0
0
0
0 !>
0
• 0 0
0
0
0
0 0
0
0
0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
.A= Revised code •=New code .... •=Contains new or revised text *=Duplicate PLA test t~ =Category I PLA American Medical Association 695
89354--0002U Pathology and Laboratory I Proprietary Laboratory Analyses CPT 2023
89354 reproductive tissue. testicular/ovarian Codes in this subsection are released on a quarterly basis
0 CPT Changes: An Insider's View 2004 to expedite dissemination for reporting. PI.A codes will
0 CPT Assistant Apr 04:5 be published electronically on the AMA CPT website
89356 oocytes. each aliquot (ama-assn.org/cpt-pla-codes), distributed via CPT data
files on a quarterly basis, and, at a minimum, made
0 CPT Assistant Apr 04:5. Aug 05:9
available in print annually in the CPT codebook. See the
Introduction section of the CPT code set for a complete
89398 Unlisted reproductive medicine laboratory procedure list of the dates of release and implementation.
0 CPT Changes: An Insider's View 201 O
All codes that are included in this section are also
included in Appendix 0, with the procedure's proprietary
name. In order to report a PI.A code, the analysis
performed must fulfill the code descriptor and must be
Proprietary Laboratory the test represented by the proprietary name listed in
Analyses Appendix 0. In some instances, the descriptor language
of PI.A codes may be identical and the code may only be
Proprietary laboratory analyses (Pl.A) codes describe differentiated by the listed proprietary name in Appendix
proprietary clinical laboratory analyses and can be either 0. When more than one PI.A has an identical descriptor,
provided by a single ("sole-source") laboratory or licensed the codes will be denoted by the symbol "*·"
or marketed to multiple providing laboratories (eg, All PI.A tests will have assigned codes in the PI.A section
cleared or approved by the Food and Drug of the code set. Any PI.A coded test(s) that satisfies
Administration [FDA]). Category I criteria and has been accepted by the CPT
This subsection includes advanced diagnostic laboratory Editorial Panel will be designated by the addition of the
tests (ADLTs) and clinical diagnostic laboratory tests symbol "t+" to the existing PI.A code and will remain in
(CDLTs), as defined under the Protecting Access to the PI.A section of the code set.
Medicare Act (PAMA) of2014. These analyses may If a proprietary test has already been accepted for a
include a range of medical laboratory tests including, but Category I code and a code has not been published,
not limited to, multianalyte assays with algorithmic subsequent application for a PI.A code will take precedence.
analyses (MAAA) and genomic sequencing procedures The code will only be placed in the PI.A section.
(GSP). The descriptor nomenclature follows, where
possible, existing code conventions (eg, MAAA, GSP). The accuracy of a PI.A code is to be maintained by the
original applicant, or the current owner of the test kit or
Unless specifically noted, even though the Proprietary laboratory performing the proprietary test.
Laboratory Analyses section of the code set is located at the
end of the Pathology and Laboratory section of the code A new PI.A code is required when:
set, a PI.A code does not fulfill Category I code criteria. l. Additional nucleic acid (DNA or RNA) and/or
PI.A codes are not required to fulfill the Category I protein analysis(es) are added to the current PI.A test,
criteria. The standards for inclusion in the PI.A section are: or
• The test must be commercially available in the United 2. The name of the PI.A test has changed in association
States for use on human specimens and with changes in test performance or test
• The clinical laboratory or manufacturer that offers the characteristics.The addition or modification of the
test must request the code. therapeutic applications of the test require submission
of a code change application, but it may not require a
For similar laboratory analyses that fulfill Category I new code number.
criteria, see codes listed in the numeric 80000 series.
0001U Red blood cell antigen typing, ONA, human erythrocyte
When a PI.A code is available to report a given
antigen gene analysis of 35 antigens from 11 blood
proprietary laboratory service, that PI.A code takes groups. utilizing whole blood, common ABC alleles
precedence. The service should not be reported with any reported
other CPT code(s) and other CPT code(s) should not be 0 CPT Changes: An Insider's View 2018
used to report services that may be reported with that
specific PI.A code. These codes encompass all analytical 0002U Oncology lcolorectal}, quantitative assessment of three
services required for the analysis (eg, cell lysis, nucleic urine metabolites !ascorbic acid, succinic acid and
acid stabilization, extraction, digestion, amplification, carnitine) by liquid chromatography with tandem mass
hybridization and detection). For molecular analyses, 0
0 0 0 0 0 0 0
additional procedures that are required prior to cell lysis 0 0 0
0 0 0 0
0
0 0 0 0 0
0 0 0
(eg, microdissection [codes 88380 and 88381]) may be 0 0 0 0 0 0 0
0
0 0 0
0
reported separately. 0
0
0
0
0 0
0 0 0 0
0 0
0 0
0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 00 00 0
0 0 0 0 0 0 0
0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0
696 *= Telemedicine ~=Audio-only +=Add-on code ,¥'= FDA approval pending #=Resequenced code ~=Modifier 51 exempt 0 0 0 =Seep xix for details
CPT 2023 Pathology and Laboratory I Proprietary Laboratory Analyses 0003U--0027U
spectrometry (LC-MS/MS) using multiple reaction 0017U Oncology (hematolymphoid neoplasia). JAK2mutation,
monitoring acquisition, algorithm reported as likelihood DNA. PCR amplification of exons 12-14 and sequence
of adenomatous polyps analysis, blood or bone marrow, report of JAK2mutation
0 CPT Changes: An Insider's View 2018 not detected or detected
0 CPT Assistant Aug 18:4 0 CPT Changes: An Insider's View 2018
0003U Oncology (ovarian) biochemical assays of five proteins 0018U Oncology (thyroid), microRNA profiling by RT-PCR of 10
(apolipoprotein A-1. CA 125 II, follicle stimulating microRNA sequences. utilizing fine needle aspirate.
hormone, human epididymis protein 4, transferrin). algorithm reported as a positive or negative result for
utilizing serum, algorithm reported as a likelihood score moderate to high risk of malignancy
0005U Oncology (prostate) gene expression profile by real-time 0019U Oncology, RNA. gene expression by whole transcriptome
RT-PCR of 3 genes (ERG. PCA3, and SPDEF). urine. sequencing. formalin-fixed paraffin-embedded tissue or
algorithm reported as risk score fresh frozen tissue, predictive algorithm reported as
0 CPT Changes: An Insider's View 2018 potential targets for therapeutic agents
(0006U has been deleted)
. 0021 U Oncology (prostate). detection of 8 autoantibodies (ARF 6.

0007U Drug test(s). presumptive, with definitive confirmation of
NKX3-1, 5'-UTR-BM11, CEP 164, 3'-UTR-Ropporin.
positive results. any number of drug classes, urine.
Desmocollin, AURKAIP-1. CSNK2A2). multiplexed
includes specimen verification including DNA
immunoassay and flow cytometry serum, algorithm
authentication in comparison to buccal DNA, per date of
reported as risk score
service
0008U Helicobacter pylori detection and antibiotic resistance,

A 0022U Targeted genomic sequence analysis panel.
cholangiocarcinoma and non-small cell lung neoplasia.
ONA. 16S and 23S rRNA. gyrA. pbp1. rdxA and rpoB. next
DNA and RNA analysis, 1-23 genes, interrogation for
generation sequencing, formalin-fixed paraffin-embedded
sequence variants and rearrangements, reported as
or fresh tissue or fecal sample. predictive, reported as
presence/absence of variants and associated therapy(iesl
positive or negative for resistance to clarithromycin.
to consider
fluoroquinolones. metronidazole, amoxicillin, tetracycline.
and rifabutin
0 CPT Changes: An Insider's View 2018, 2020 0023U Oncology (acute myelogenous leukemia). DNA,
genotyping of internal tandem duplication, p.D835. p.
0009U Oncology (breast cancer). ERBB2(HER2) copy number by
1836. using mononuclear cells. reported as detection or
FISH. tumor cells from formalin-fixed paraffin-embedded
non-detection of FLT3 mutation and indication for or
tissue isolated using image-based dielectrophoresis
against the use of midostaurin
(DEP) sorting, reported as ERBB2 gene amplified or non-
amplified
0 CPT Changes: An Insider's View 2018 0024U Glycosylated acute phase proteins (GlycA). nuclear
magnetic resonance spectroscopy, quantitative
0010U Infectious disease (bacterial), strain typing by whole
genome sequencing, phylogenetic-based report of strain
relatedness. per submitted isolate 0025U Tenofovir. by liquid chromatography with tandem mass
0 CPT Changes: An Insider's View 2018 spectrometry (LC-MS/MS). urine. quantitative
0011U Prescription drug monitoring, evaluation of drugs present
by LC-MS/MS. using oral fluid. reported as a comparison 0026U Oncology (thyroid). DNA and mRNA of 112 genes, next-
to an estimated steady-state range, per date of service generation sequencing, fine needle aspirate of thyroid
including all drug compounds and metabolites nodule, algorithmic analysis reported as a categorical
0 CPT Changes: An Insider's View 2018 result ('Positive, high probability of malignancy" or
' Negative, low probability of malignancy")
ll>(0012U has been deleted)~
ll>(OD13U has been deleted)~
0027U JAK2 (Janus kinase 2) (eg, myeloproliferative disorder)
ll>(0014U has been deleted)~ gene analysis. targeted sequence analysis exons 12-15
0016U Oncology (hematolymphoid neoplasia). RNA. BCR/ABL 1
major and minor breakpoint fusion transcripts, 0 0 0 0

0 0
quantitative PCR amplification, blood or bone marrow, 0
0
0
0
0
0 0
0
0
0
0
0
0 0
0 0
report of fusion not detected or detected with 0
0 0 • 0
0
q 0 0
0 0
0
0
0 0 0 0
0 0
quantitation 0
0
0 0 0 0
0
0
0 0 0 0
0
0
0
0 0
0 0
0 0
0
0 0 0
0 0
0 0
0
0 0 0
00 0 00 0 00
0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
&=Revised code •=New code Ill> ~=Contains new or revised text H=Duplicate PIA test tJ.=Category I PIA American Medical Association 697
0029U--0051U Pathology and Laboratory I Proprietary Laboratory Analyses CPT 2023
0029U Drug metabolism (adverse drug reactions and drug 0042U Borrelia burgdorferi, antibody detection of 12
response). targeted sequence analysis (ie, CYP1A2, recombinant protein groups. by immunoblot. lgG
CYP2C1~ CYP2C~ CYP2D~ CYP3A4. CYP3A~ CYP4F2. 0 CPT Changes: An Insider's View2019
SLC0181, VKORC1 and rs12777823)
0043U Tick-borne relapsing fever Borrelia group. antibody
detection to 4 recombinant protein groups, by
0030U Drug metabolism (warfarin drug response). targeted immunoblot, lgM
sequence analysis (ie. CYP2C9. CYP4F2. VKORC1, 0 CPT Changes: An Insider's View 2019
rs12777823)
0044U Tick-borne relapsing fever Borrelia group. antibody
detection to 4 recombinant protein groups. by
0031U CYP1A2 (cytochrome P450 family 1, subfamily A. member immunoblot, lgG
2J(eg, drug metabolism) gene analysis. common variants 0 CPT Changes: An Insider's View 2019
(ie. *1 F. *1 K. *6, *7)
0045U Oncology (breast ductal carcinoma in situ). mRNA. gene
expression profiling by real-time RT-PCR of 12 genes (7
0032U COMT (catecho/-0-methyltransferase) (eg, drug content and 5 housekeeping). utilizing formalin-fixed
metabolism) gene analysis, c.472G>A (rs4680) variant paraffin-embedded tissue. algorithm reported as
0 CPT Changes: An Insider's View 2019 recurrence score
0033U HTR2A (5-hydroxytryptamine receptor 2A}, HTR2C
(5-hydroxytryptamine receptor 2C)(eg, citalopram 0046U FLT3 (fms-related tyrosine kinase 3)(eg, acute myeloid
metabolism) gene analysis. common variants (ie. HTR2A leukemia) internal tandem duplication (ITD) variants,
rs7997012 [c.614-2211T>C]. HTR2Crs3813929 quantitative
[c.-759C>n and rs1414334 [c.551-3008C>G]) 0 CPT Changes: An Insider's View 2019
0047U Oncology (prostate). mRNA, gene expression profiling by
0034U TPMT (thiopurine S-methyltransferase}, NUDT15 (nudix real-time RT-PCR of 17 genes (12 content and 5
hydroxylase 15)(eg, thiopurine metabolism) gene housekeeping), utilizing formalin-fixed paraffin-
analysis, common variants (ie, TPMT*2. *3A. *38, *3C. embedded tissue, algorithm reported as a risk score
*4, *5, *6. *8, *12; NUDT15*3, *4, *5) 0 CPT Changes: An Insider's View 2019
0048U Oncology (solid organ neoplasia). DNA. targeted
0035U Neurology (prion disease). cerebrospinal fluid. detection sequencing of protein-coding exons of 468 cancer-
of prion protein by quaking-induced conformational associated genes, including interrogation for somatic
conversion, qualitative mutations and microsatellite instability. matched with
0 CPT Changes: An Insider's View 2019 normal specimens, utilizing formalin-fixed paraffin-
embedded tumor tissue, report of clinically significant
0036U Exome (ie. somatic mutations). paired formalin-fixed
mutation(s)
paraffin-embedded tumor tissue and normal specimen.
sequence analyses
0 CPTChanges: An Insiders View2019
0 CPT Changes: An Insider's View 2019 0049U NPM1 (nucleophosmin)(eg, acute myeloid leukemia)
gene analysis. quantitative
0037U Targeted genomic sequence analysis, solid organ
neoplasm. DNA analysis of 324 genes, interrogation for
sequence variants, gene copy number amplifications, OOSOU Targeted genomic sequence analysis panel, acute
gene rearrangements. microsatellite instability and tumor myelogenous leukemia, DNA analysis. 194 genes.
mutational burden interrogation for sequence variants. copy number variants
0 CPT Changes: An Insider's View 2019 or rearrangements
0038U Vitamin D. 25 hydroxy D2 and D3. by LC-MS/MS. serum
microsample. quantitative 0051U Prescription drug monitoring, evaluation of drugs present

0 CPT Changes: An Insider's View2019 by liquid chromatography tandem mass spectrometry (LC-
MS/MS). urine or blood, 31 drug panel. reported as
0039U Deoxyribonucleic acid (DNA) antibody, double stranded,
quantitative results. detected or not detected. per date of
high avidity
service
0 CPT Changes: An Insider:~ View 2019. 2022
0040U BCR!ABL1 (t(9;22))(eg, chronic myelogenous leukemia)
translocation analysis. major breakpoint. quantitative
0
0 0
0
0
0
0 0
0
0
0
..
0 0
0 0 0 0 0 0
0 0 0 0
0
0041U Borrelia burgdorferi. antibody detection of 5 recombinant 0
0 0
0
0
0 0 0
0 0
0
0
0 0
protein groups, by immunoblot. lgM 0

0
0
0
0 0 0
0
0
0
0
0 0 0
0
0 0
0 0
0 0 0 0 0
0 0
0 0 0
00 0 00 0 0
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0
698 *= Telernedicine '4 =Audio-only +=Add-on code )f =FDA approval pending #=Resequenced code \9 =Modifier 51 exempt O O O =See pxix for details
CPT 2023 Pathology and Laboratory I Proprietary Laboratory Analyses 0052U-0073U
0052U Lipoprotein, blood, high resolution fractionation and 0066U Placental alpha-micro globulin-1 (PAMG-1 ). immunoassay
quantitation of lipoproteins. including all five major with direct optical observation. cervico-vaginal fluid.
lipoprotein classes and subclasses of HDL, LDL. and VLDL each specimen
by vertical auto profile ultracentrifugation 0 CPT Changes: An Insider's View2020
0067U Oncology (breast). immunohistochemistry, protein
0053U Oncology (prostate cancer), FISH analysis of 4 genes expression profiling of 4 biomarkers (matrix
(ASAP1, HOAC9, CH01 and PTEN), needle biopsy metalloproteinase-1 [MMP-1]. carcinoembryonic antigen-
specimen, algorithm reported as probability of higher related cell adhesion molecule 6 [CEACAM6].
tumor grade hyaluronoglucosaminidase [HYAL 1). highly expressed in
0 CPT Changes: An Insider's View 2019 cancer protein [HEC1 }), formalin-fixed paraffin-embedded
precancerous breast tissue. algorithm reported as
0054U Prescription drug monitoring, 14 or more classes of drugs
carcinoma risk score
and substances, definitive tandem mass spectrometry
with chromatography, capillary blood, quantitative report
with therapeutic and toxic ranges. including steady-state 0068U Can(lida species panel (C. albicans, C. glabrata, C.
range for the prescribed dose when detected. per date of parapsilosis, C. kruseii, C. tropicalis, and C. auris).
service amplified probe technique with qualitative report of the
0 CPT Changes: An Insider's View 2019 presence or absence of each species
OOSSU Cardiology (heart transplant), cell-free DNA, PCR assay of
.0 CPT Changes: An Insider's View 2020
96 DNA target sequences (94 single nucleotide 0069U Oncology (colorectal). microRNA, RT-PCR expression
polymorphism targets and two control targets). plasma profiling of miR-31-3p, formalin-fixed paraffin-embedded
0 CPT Changes: An Insider's View 2019 tissue, algorithm reported as an expression score
""(0056U has been deleted)'4
0070U CYP406 (cytochrome P450, family 2, subfamily 0,

0058U Oncology (Merkel cell carcinoma). detection of antibodies
polypeptide 6)(eg. drug metabolism) gene analysis.
to the Merkel cell polyoma virus oncoprotein (small T
common and select rare variants (ie, *2, *3, *4, *4N, *5,
antigen), serum, quantitative
*6, *7, *8, *9, *10, *11, *12. *13. *14A, *148, *15, *17,
*29, *35, *36, *41, *57, *61. *63. *68, *83, *xN)
0059U Oncology (Merkel cell carcinoma), detection of antibodies 0 CPT Changes: An Insider's View 2020
to the Merkel cell polyoma virus capsid protein (VP1 ),
serum, reported as positive or negative
+ 0071U CYP206 (cytochrome P450, family 2, subfamily 0,
polypeptide 6)(eg. drug metabolism) gene analysis. full
0 CPT Changes: An.Insider's View2019
gene sequence (List separately in addition to code for
0060U Twin zygosity, genomic-targeted sequence analysis of primary procedure)
chromosome 2, using circulating cell-free fetal DNA in 0 CPT Changes: An Insider's View 2020
maternal blood
(Use 0071 U in conjunction with 0070U)
+ 0072U CYP206 (cytochrome P450, family 2, subfamily 0.
0061U Transcutaneous measurement of five biomarkers (tissue
polypeptide 6)(eg. drug metabolism) gene analysis.
oxygenation [St0 2]. oxyhemoglobin [ctHb0 2],
targeted sequence analysis (ie. CYP206-2Dlhybrid gene)
deoxyhemoglobin [ctHbR]. papillary and reticular dermal
(List separately in addition to code for primary procedure)
hemoglobin concentrations [ctHb1 and ctHb2]), using
spatial frequency domain imaging (SFDI) and multi-
spectral analysis (Use 0072U in conjunction with 0070U)

+ 0073U CYP206 (cytochrome P450, family 2, subfamily 0,
0062U Autoimmune (systemic lupus erythematosus), lgG and polypeptide 6)(eg, drug metabolism) gene analysis,
lgM analysis of 80 biomarkers, utilizing serum, algorithm targeted sequence analysis (ie. CYP207-206 hybrid gene)
reported with a risk score (List separately in addition to code for primary procedure)
0063U Neurology (autism), 32 amines by LC-MS/MS, using (Use 0073U in conjunction with 0070U)
plasma, algorithm reported as metabolic signature
associated with autism spectrum disorder
0064U Antibody, Treponema pallidum, total and rapid plasma 0

0
0 0
0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0
reagin (APR). immunoassay, qualitative 0 0 0 0 0 0 0
0
0 0
9
0
0 0 0 0
0 0
0 0 0 0 0
0 0
0 0
0
0 0 0 0 0 0 0 0 0 0 0
0 0
0065U Syphilis test. non-treponemal antibody, immunoassay, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
qualitative (RPR) 0 0 0 0 0 0 0 00 0 0 0 0 00
0 0 0 0
0
0 0
0
0
0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0
A=Revised code •=New code ll> '4 =Contains new or revised text tE=Duplicate PlA test ti =Category IPlA American Medical Association 699
0074U-0094U Pathology and Laboratory I Proprietary Laboratory Analyses CPT 2023
+ 0074U CYP206 (cytochrome P450, family 2, subfamily D, 0084U Red blood cell antigen typing, DNA, genotyping of 1O
polypeptide 6)(eg, drug metabolism) gene analysis, blood groups with phenotype prediction of 37 red blood
targeted sequence analysis (ie, non-duplicated gene cell antigens
when duplication/multiplication is trans) {List separately 0 CPT Changes: An Insider's View £ll20
in addition to code for primary procedure)
0086U Infectious disease (bacterial and fungal). organism
{Use 0074U in conjunction with 0070U)
identification, blood culture. using rRNA FISH, 6 or more
+ 0075U CYP206 (cytochrome P450, family 2, subfamily D, organism targets, reported as positive nr negative with
polypeptide 6)(eg, drug metabolism) gene analysis. phenotypic minimum inhibitory concentration (MIC)-
targeted sequence analysis {ie, 5' gene duplication/ based antimicrobial susceptibility
multiplication) (List separately in addition to code for 0 CPT Changes: An Insider's View 2020
primary procedure)
0087U Cardiology (heart transplant), mRNA gene expression
profiling by microarray of 1283 genes, transplant biopsy
(Use 0075U in conjunction with 0070U) tissue. allograft rejection and injury algorithm reported as
a probability score
+ 0076U CYP206 (cytochrome P450, family 2, subfamily D,
polypeptide 6)(eg, drug metabolism) gene analysis,
targeted sequence analysis {ie. 3' gene duplication/ 0088U Transplantation medicine (kidney allograft rejection),
multiplication) (List separately in addition to code for microarray gene expression profiling of 1494 genes.
primary procedure) utilizing transplant biopsy tissue. algorithm reported as a
0 CPT Changes: An Insider's View 2020 probability score for rejection
(Use 0076U in conjunction with 0070U)
0089U Oncology (melanoma), gene expression profiling by

0077U lmmunoglobulin paraprotein {M-protein). qualitative,
RTqPCR, PRAME and LINC00518, superficial collection
immunoprecipitation and mass spectrometry, blood or
using adhesive patch(es)
urine. including isotype
0078U Pain management {opioid-use disorder) genotyping panel,

.A. 0090U Oncology (cutaneous melanoma). mRNA gene expression
profiling by RT-PCR of 23 genes (14 content and 9
16 common variants (ie, ABCBT, COMT, DATT, DBH. DOR,
housekeeping), utilizing formalin-fixed paraffin-
DRDT, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR,
embedded (FFPE) tissue. algorithm reported as a
MTHFR, MUOR, OPRKT, OPRMT ), buccal swab or other
categorical result (ie, benign, intermediate, malignant)
germline tissue sample, algorithm reported as positive or
negative risk of opioid-use disorder
0 CPT Changes: An Insider's View2020 0091U Oncology (colorectal) screening, cell enumeration of
circulating tumor cells. utilizing whole blood, algorithm,
0079U Comparative DNA analysis using multiple selected
for the presence of adenoma or cancer. reported as a
single-nucleotide polymorphisms {SNPs), urine and
positive or negative result
buccal DNA. for specimen identity verification
0092U Oncology (lung), three protein biomarkers. immunoassay

ooaou Oncology (lung), mass spectrometric analysis of galectin-
using magnetic nanosensor technology, plasma,
3-binding protein and scavenger receptor cysteine-rich
algorithm reported as risk score for likelihood of
type 1 protein M130, with five clinical risk factors (age,
malignancy
smoking status, nodule diameter, nodule-spiculation
status and nodule location), utilizing plasma. algorithm
reported as a categorical probability of malignancy 0093U Prescription drug monitoring, evaluation of 65 common
0 CPT Changes: An Insider's View 2020 drugs by LC-MS/MS, urine, each drug reported detected
or not detected
0082U Drug test(s), definitive. 90 or more drugs or substances.
definitive chromatography with mass spectrometry, and
presumptive, any number of drug classes. by instrument 0094U Genome (eg, unexplained constitutional or heritable
chemistry analyzer {utilizing immunoassay), urine, report disorder or syndrome), rapid sequence analysis
of presence or absence of each drug, drug metabolite or 0 CPT Changes: An Insider's View 2020
substance with description and severity of significant
interactions per date of service 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0 0
0 0 0 0 0 0 0
0083U Oncology, response to chemotherapy drugs using motility 0 0 0 0
contrast tomography, fresh or frozen tissue, reported as 0 0 0 0 0 00 0 0 0 0 0 0 0
00 0 0 0 0 0 00
likelihood of sensitivity or resistance to drugs or drug
0 0 0
combinations 0 0
0 0 0 0 00
0 0

0
0
0
0 0 0
0
0 0 0
0
0
0
0
700 *= Telemedicine '4 =Audio--0nly +=Add-on code ,K =FDA approval pending #=Resequenced code (S) =Modifier 51 exempt 0 0 0 =See pxix for details
0095U Inflammation (eosinophilic esophagitis). ELISA analysis of 0107U Clostridium difficile toxin(s) antigen detection by
eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and immunoassay technique. stool. qualitative, multiple-step
major basic protein (PRG2 [proteog/ycan 2, pro eosinophil method
major basic protein]), specimen obtained by swallowed 0 CPT Changes: An Insider's View 2020
nylon string, algorithm reported as predictive probability
0108U Gastroenterology (Barrett's esophagus). whole slide-
index for active eosinophilic esophagitis
digital imaging, including morphometric analysis,
computer-assisted quantitative immunolabeling of 9
0096U Human papillomavirus (HPV), high-risk types (ie, 16, 18, protein biomarkers (p16. AMACR, p53, CD68, COX-2,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine CD45RO, HIF1a, HER-2, K20) and morphology, formalin-
0 CPT Changes: An Insider's View 2020 fixed paraffin-embedded tissue, algorithm reported as
risk of progression to high-grade dysplasia or cancer
.,..(0097U has been deleted)..,.
(0098U has been ,deleted)
0109U lnfectiou~ disease (Asperr,illus species), real-time PCR for
(0099U has been deleted) detection of DNA from 4 species (A. fumigatus, A.
terreus, A. niger, and A. f/avus), blood, lavage fluid, or
(01 DOU has been deleted)
tissue. qualitative reporting of presence or absence of
0101U Hereditary colon cancer disorders (eg, Lynch syndrome, each species
PTEN hamartoma syndrome, Cowden syndrome, familial 0 CPT Changes: An Insider's View 2020
adenomatosis polyposis). genomic sequence analysis
0110U Prescription drug monitoring, one or more oral oncology
panel utilizing a combination of NGS, Sanger, MLPA, and
drug(s) and substances, definitive tandem mass
array CGH, with mRNA analytics to resolve variants of
spectrometry with chromatography, serum or plasma
unknown significance when indicated (15 genes
from capillary blood or venous blood, quantitative report
[sequencing and deletion/duplication). EPCAM and
with steady-state range for the prescribed drug(s) when
GREM1 (deletion/duplication only])
detected
0102U Hereditary breast cancer-related disorders (eg, hereditary
0111U Oncology (colon cancer). targeted KRAS(codons 12, 13,
br!Jast cancer, hereditary ovarian cancer, hereditary
and 61) and NRAS(codons 12, 13, and 61) gene analysis,
endometrial cancer), genomic sequence analysis panel
utilizing formalin-fixed paraffin-embedded tissue
utilizing a combination of NGS, Sanger, MLPA, and array
CGH, with mRNA analytics to resolve variants of 0 CPT Changes: An Insider's View2020
unknown significance when indicated (17 genes 0112U lnfectio•Js agent detection and identification. targeted
[sequencing and deletion/duplication]) seqllence analysis (16S and 18S rRNA genes) with dr1.1g-
0 CPT Changes: An Insider's View 2020 resistance gene
0103U Hereditary ovarian cancer (eg, hereditary ovarian cancer, 0 CPT Changes: An Insider's View 2020
hereditary endometrial cancer), genomic sequence 0113U Oncology (prostate). measurement of PCA3 and
analysis panel utilizing a combination of NGS, Sanger, TMPRSS2-ERG in urine and PSA in serum following
MLPA, and array CGH, with mRNA analytics to resolve prostatic massage, by RNA amplification and
variants of unknown significance when indicated (24 fluorescence-based detection, algorithm reported as risk
genes [sequencing and deletion/duplication]. EPCAM score
[deletion/duplication only]) 0 CPT Changes: An Insider's View 2020
0114U Gastroenterology (Barrett's esophagus), VIM and CCNA 1
0105U Nephrology (chronic kidney disease), multiplex methylation analysis, esophageal cells, algorithm
electrochemiluminescent immunoassay (ECLIA) of tumor reported as likelihood for Barrett's esophagus
necrosis factor receptor 1A, receptor superfamily 2 0 CPT Changes: An Insider's View 2020
(TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1)
combined with longitudinal clinical data, including APOL 1 0115U Respiratory infectious agent detection by nucleic acid
genotype if available, and plasma (isolated fresh or (DNA and RNA). 18 viral types and subtypes and 2
frozen), algorithm reported as probability score for rapid bacterial targets, amplified probe technique, including
kidney function decline (RKFD) multiplex reverse transcription for RNA targets, each
analyte reported as detected or not detected
0106U Gastric emptying, serial collection of 7 timed breath
specimens. non-radioisotope carbon-13 (13C) spirulina
0 0 0 0 0
substrate. analysis of each specimen by gas isotope ratio 0
0
0
0
0
0 • 0
0
0
c
0
0
0
0
mass spectrometry, reported as rate of 13C0 2 excretion 0 0
0
0
0 0 0
0
• 0 0
0 • 0
0 0
0
0
0 0
0
0 0 0 0
0
0
0 0 0 0
0
0
0
0 0 0 0
0 0 0
0 0
0 0 0 0 0
0 0
0 0 0
°" 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0
A= Revised code •=New code ""' ..,. =Contains new orrevised text *=Duplicate PLA test ti= Category IPLA American Medical Association 701
0116U--013&U Pathology and Laboratory I Proprietary Laboratory Analyses CPT 2023
0116U Prescription drug monitoring, enzyme immunoassay of 35 + 0130U Hereditary colon cancer disorders (eg, Lynch syndrome.
or more drugs confirmed with LC-MS/MS, oral fluid, PTEN hamartoma syndrome, Cowden syndrome, familial
algorithm results reported as a patient-compliance adenomatosis polyposis), targeted mRNA sequence
measurement with risk of drug to drug interactions for analysis panel (APC, CDH1, CHEK2, M!_H7, MSH2, MSH6,
prescribed medications MUTYH, PMS2, PTEN, and TP53}(List separately in
0 CPT Changes: An Insider's View 2020 addition to code for primary procedure)
0117U Pain management. analysis of 11 endogenous analytes
(methylmalonic acid, xanthurenic acid, homocysteine, (Use 0130U in conjunction with 81435, 0101U)
pyroglutamic acid. vanilmandelate, 5-hydroxyindoleacetic
acid. hydroxymethylglutarate. ethylmalonate,
+ 0131U Hereditary breast cancer-related disorders (eg,
hereditary breast cancer, hereditary ovarian cancer,
3-hydroxypropyl mercapturic acid (3-HPMA). quinolinic
hereditary endometrial cancer). targeted mRNA sequence
acid. kynurenic acid). LC-MS/MS, urine, algorithm
analysis panel (13 genes) (List separately in addition to
reported as a pain-index score with likelfhood of atypical
code for primary procedure)
biochemical function associated with pain
(Use 0131 U in conjunction with 81162. 81432. 0102U)

0118U Transplantation medicine. quantification of donor-derived
cell-free DNA using whole genome next-generation + 0132U Hereditary ovarian cancer-related disorders (eg,
sequencing, plasma. reported as percentage of donor- hereditary breast cancer, hereditary ovarian cancer.
derived cell-free DNA in the total cell-free DNA hereditary endometrial cancer), targeted mRNA sequence
0 CPT Changes: An Insider's View 2020 analysis panel (17 genes) (List separately in addition to
code for primary procedure)
0119U Cardiology, ceramides by liquid chromatography-tandem
mass spectrometry, plasma, quantitative report with risk
score for major cardiovascular events (Use 0132U in conjunction with 81162, 81432. 0103U)
+ 0133U Hereditary prostate cancer-related disorders, targeted
0120U Oncology (B-cell lymphoma classification). mRNA, gene mRNA sequence analysis panel (11 genes) (List
expression profiling by fluorescent probe hybridization of separately in addition to code for primary procedure)
58 genes (45 content and 13 housekeeping genes), 0 CPT Changes: An Insider's View 2020
formalin-fixed paraffin-embedded tissue, algorithm
(Use 0133U in conjunction with 81162)
reported as likelihood for primary mediastinal B-cell
lymphoma (PMBCL) and diffuse large B-cell lymphoma + 0134U Hereditary pan cancer (eg, hereditary breast and ovarian
(DLBCL) with cell of origin subtyping,in the latter cancer, hereditary endometrial cancer, hereditary
0 CPT Changes.-An Insider's View 2020 colorectal cancer). targeted mRNA sequence analysis
panel (18 genes) (list separately in addition to code for
(Do not report 0120U in conjunction with 0017M)
primary procedure)
0121U Sickle cell disease. microfluidic flow adhesion (VCAM-1 ). 0 CPT Changes: An Insider's View 2020
whole blood
(Use 0134U in conjunction with 81162, 81432, 81435)
+ 0135U Hereditary gynecological cancer (eg. hereditary breast
0122U Sickle cell disease. microfluidic flow adhesion
and ovarian cancer. hereditary endometrial cancer,
(P-Selectin). whole blood
hereditary colorectal cancer), targeted mRNA sequence
analysis panel (12 genes) (List separately in addition to
0123U Mechanical fragility, RBC. shear stress and spectral code for primary procedure)
analysis profiling 0 CPT Changes: An Insider's View 2020
+ 0136U ATM (ataxia telangiectasia mutated}(eg, ataxia
(0125U has been deleted) telangiectasia) mRNA sequence analysis (List separately
in addition to code for primary procedure)
0129U Hereditary breast cancer-related disorders (eg, 0 0 0 0 0
hereditary breast cancer, hereditary ovarian cancer. 0
!'
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
hereditary endometrial cancer). genomic sequence 0
0 0
0
0
0 0 0
0 0
0
0
0 0 0
0
analysis and deletion/duplication analysis panel (ATM. 0
0 0 0 0
0
0
0 0 0 0
0
0
0
0 0 0 0
BRCA 1, BRCA2, CDH1. CHEK2, PAL82, PTEN, and TP53} 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0
00
0 0 0
0 0
00
0 0 0
0 0
00
0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0
0 0 0 0
0
702 *=Telemedicine '4=Audio-only +=Add-oocode .K=FDAapprovalpending #=Resequenced code ~=Modifier51 exempt O O O =Seepxixfordetails
CPT 2023 Pathology and Laboratory/ Proprietary Laboratory Analyses 0137U-0153U
PALB2 (partner and localizer of BRCA2) (eg, breast and 0146U Drug assay, definitive, 80 or more drugs or metabolites.
pancreatic cancer) mRNA sequence analysis (List urine, by quantitative liquid chromatography with tandem
separately in addition to code for primary procedure) mass spectrometry (LC-MS/MS) using multiple reaction
0 CPT Changes: An Insider's View2020 monitoring (MRM). with drug or metabolite description,
comments including sample validation, per date of
service
BRCA 7(BRCA 1. DNA repair associated), BRCA2 (BRCA2. 0 CPT Changes: An Insider's View2021
DNA repair associated) (eg, hereditary breast and ovarian
0147U Drug assay, definitive. 85 or more drugs or metabolites.
cancer) mRNA sequence analysis (List separately in
urine, quantitative liquid chromatography with tandem
mass spectrometry (LC-MS/MS) using multiple reaction
monitoring (MRM). with drug or metabolite description.
(Use 0138U in conjunction with 81162) comments including sample validation, per date of
service
0 CPT Changes: An Insider:~ View2021
0140U Infectious disease (fungi), fungal pathogen identification.
0148U Drug assay, definitive, 100 or more drugs or metabolites.
DNA (15 fungal targets). blood culture, amplified probe
technique. each target reported as detected or not
detected
monitoring (MRM). with drug or metabolite description,
comments including sample validation. per date of
0141U Infectious disease (bacteria and fungi). gram-positive service
organism identification and drug resistance element 0 CPT Changes: An Insider's View 2021
detection, DNA (20 gram-positive bacterial targets. 4
0149U Drug assay, definitive, 60 or more drugs or metabolites.
resistance genes. 1 pan gram-negative bacterial target. 1
pan Candida target). blood culture. amplified probe
technique. each target reported as detected or not
detected
service
0142U Infectious disease (bacteria and fungi). gram-negative 0 CPT Changes: An Insider's View2021
bacterial identification and drug resistance element
detection, DNA (21 gram-negative bacterial targets, 6
* 0150U Drug assay, definitive, 120 or more drugs or metabolites.
urine, quantita~ive liquid chromatography with tandem
resistance genes. 1 pan gram-positive bacterial target. 1
pan Candida target), amplified probe technique. each
target reported as detected or not detected
service
Drug assay, definitive. 120 or more drugs or metabolites, 0 CPT Changes: An Insider's View 2021
(For additional PLA code with identical clinical descriptor.
see 0143U. See Appendix 0 to determine appropriate
monitoring (MRM). with drug or metabolite description,
code assignment)
service ..,.(0151 U has been deleted)"ill
0152U Infectious disease (bacteria, fungi, parasites, and DNA
(For additional PLA code with identical clinical descriptor, viruses). microbial cell-free DNA, plasma, untargeted
see 0150U. See Appendix 0 to determine appropriate next-generation sequencing, report for significant
code assignment) positive pathogens
0144U Drug assay, definitive, 160 or more drugs or metabolites,
urine, quantitative liquid chromatography with tandem 0153U Oncology (breast). mRNA, gene expression profiling by
mass spectrometry (LC-MS/MS) using multiple reaction next-generation sequencing of 101 genes. utilizing
monitoring (MRM). with drug or metabolite description, formalin-fixed paraffin-embedded tissue. algorithm
comments including sample validation, per date of reported as a triple negative breast cancer clinical
service subtype(s) with information on immune cell involvement
0145U Drug assay, definitive, 65 or more drugs or metabolites, 0

0
0
0
0
0
0 0
0
0
0
0
0 0 0
urine, quantitative liquid chromatography with tandem 0 0
0
0
0
0 0
0
0
0
0
0 0 0 0 0 0 0 0
0
mass spectrometry (LC-MS/MS) using multiple reaction 0 0 0 0 0 0 0 0
0 0 0 0 0
monitoring (MRM). with drug or metabolite description, 0 0
0 0 0
0
0 0
0 0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 0
comments including sample validation, per date of 0 0 0 0 0
00 0 00 0 00
service 0
0 0 0
0
0
0 0 0
0
0

0 0
0
0
0
0
0 0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
0 0 0
A= Revised code e = New code .,. "ill =Contains new or revised text *=Duplicate PLA test ti= Category IPLA American Medical Association 703
0154U---0169U Pathology and Laboratory I Proprietary Laboratory Analyses CPT 2023
0154U Oncology (urothelial cancer), RNA, analysis by real-time + 0162U Hereditary colon cancer (Lynch syndrome). targeted
RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) mRNA sequence analysis panel (MLH1, MSH2, MSH6,
gene analysis (ie, p.R248C [c.742C>n. p.S249C PMS2) (List separately in addition to code for primary
[c.746C>Gl. p.G37DC [c.1108G>Tl. p.Y373C [c.1118A>G]. procedure)
FGFR3-TACC3v1. and FGFR3-TACC3v3). utilizing formalin- 0 CPT Changes: An Insider's View 2021
fixed paraffin-embedded urothelial cancer tumor tissue,
(Use 0162U in conjunction with 81292, 81295, 81298.
reported as FGFR gene alteration status
81317. 81435)
0 CPT Assistant Jun 20: 11 0163U Oncology (colorectal) screening, biochemical enzyme-
linked immunosorbent assay (ELISA) of 3 plasma or
0155U Oncology (breast cancer). DNA. PIK3CA
serum proteins (teratocarcinoma derived growth factor-1
(phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
[TDGF-1. Cripto-1]. carcinoembryonic antigen [CEA).
subunit alpha) (eg. breast cancer) gene analysis (ie,
extracellular matrix protein [ECM)), with demographic
p.C42DR. p.E542K. p.E545A. p.E545D [g.1635G>T only),
data (age, gender, CRC-screening compliance) using a
p.E545G, p.E545K. p.0546E. p.0546R, p.H1047L. p.
proprietary algorithm and reported as likelihood of CRC or
H1047R. p.H1047Y). utilizing formalin-fixed paraffin-
advanced adenomas
embedded breast tumor tissue, reported as PIK3CA gene
mutation status

0 CPT Assistant Jun 20:11 0164U Gastroenterology (irritable bowel syndrome [IBS)),
immunoassay for anti-CdtB and anti-vinculin antibodies,
0156U Copy number (eg, intellectual disability, dysmorphology),
utilizing plasma, algorithm for elevated or not elevated
sequence analysis
qualitative results
+ 0157U APC (APC regulator of WNT signaling pathway) (eg, 0 CPT Assistant Jun 20: 12
familial adenomatosis polyposis [FAP)) mRNA sequence
0165U Peanut allergen-specific quantitative assessment of
analysis (List separately in addition to code for primary
multiple epitopes using enzyme-linked immunosorbent
procedure)
assay (ELISA). blood, individual epitope results and
probability of peanut allergy
(Use 0157U in conjunction with 81201) 0 CPT Changes: An Insider's View 2021
+ 0158U MLH1 (mutl homolog 7)(eg, hereditary non-polyposis

0 CPT Assistant Jun 20: 12
colorectal cancer. Lynch syndrome) mRNA sequence 0166U Liver disease, 10 biochemical assays (cx2-macroglobulin,
analysis (List separately in addition to code for primary haptoglobin, apolipoprotein A1, bilirubin, GGT. ALT. AST.
procedure) triglycerides, cholesterol. fasting glucose) and biometric
0 CPT Changes: An Insider's View2021 and demographic data, utilizing serum. algorithm
reported as scores for fibrosis, necroinflammatory
activity, and steatosis with a summary interpretation
+ 0159U MSH2 (mutS homolog 2) (eg, hereditary colon cancer, 0 CPT Changes: An Insider's View2021
Lynch syndrome) mRNA sequence analysis (List ~ CPT Assistant Jun 20:12
0167U Gonadotropin. chorionic (hCG). immunoassay with direct
optical observation, blood
(Use 0159U in conjunction with 81295) 0 CPT Changes: An Insider's View 2021
+ 0160U MSH6 (mutS homolog 6)(eg, hereditary colon cancer, 0 CPT Assistant Jun 20: 12
Lynch syndrome) mRNA sequence analysis (List (0168U has been deleted)
0169U NUDT15 (nudix hydrolase 15) and TPMT (thiopurine
S-methyltransferase)(eg, drug metabolism) gene
(Use 0160U in conjunction with 81298) analysis, common variants
+ 0161 U PMS2 (PMS1 homolog 2, mismatch repair system 0 CPT Changes: An Insider's View 2021
component) (eg, hereditary non-polyposis colorectal 0 CPT Assistant Jun 20:12
cancer. Lynch syndrome) mRNA sequence analysis (List
(Use 0161U in conjunction with 81317) 0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 • 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0
0 0 0
0 0 ° 0 0 0 0 0 0 0 0 0
0 00 0 0 0 0 00 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0
0
704 *
= Telemedicine '4 =Audio-only +=Add-on code ~=FDA approval pending #=Resequenced code ~=Modifier 51 exempt OOO=See p xix for details
0170U Neurology (autism spectrum disorder [ASD]), RNA, next- 1-3-N-acetylgalactosaminyltransferase and alpha
generation sequencing, saliva, algorithmic analysis. and 1-3-galactosyltransferase)gene. including subtyping, 7
results reported as predictive probability of ASD exons
diagnosis @ CPT Changes: An Insider's View 2021
0181U Red cell antigen (Colton blood group) genotyping (CO),
@ CPT Assistant Jun 20:12
gene analysis, AOP1 (aquaporin 1[Colton blood group])
0171U Targeted genomic sequence analysis panel. acute exon 1
myeloid leukemia, myelodysplastic syndrome, and @ CPT Changes: An Insider's View 2021
myeloproliferative neoplasms, DNA analysis, 23 genes,
0182U Red cell antigen (Cromer blood group) genotyping
interrogation for sequence variants, rearrangements and
(CROM), gene analysis, CD55 (CD55 molecule [Cromer
minimal residual disease, reported as presence/absence
blood yroup]) exons 1-1 o-
0183U Red cell antigen (Diego blood group) genotyping (DI),

0172U Oncology (solid tumor as indicated by the label). somatic
gene analysis, SLC4A 1(solute carrier family 4 member 1
mutation analysis of BRCA 1(BRCA1, DNA repair
[Diego blood group]) exon 19
associated), BRCA2 (BHCA2, DNA repair associated) and
analysis of homologous recombination deficiency
pathways, DNA, formalin-fixed paraffin-embedded 0184U Red cell antigen (Dombrock blood group) genotyping (DO).
tissue, algorithm quantifying tumor genomic instability gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock
score blood group]) exon 2
@ CPT Changes: An Insider's View 2021 @ CPT Changes: An Insider's View2021
0173U Psychiatry (ie, depression, anxiety), genomic analysis 0185U Red cell antigen (H blood group) genotyping (FUT1 ). gene
panel, includes variant analysis of 14 genes analysis, FUT1 (fucosyltransferase 1[H blood group])
@ CPT Changes: An Insider's View2021 exon 4
0174U Oncology (solid tumor). mass spectrometric 30 protein
targets, formalin-fixed paraffin-embedded tissue, 0186U Red cell antigen (H blood group) r,enotyping (FUT2), gene
prognostic and predictive algorithm reported as likely, analysis. FUT2 (fucosyltransferase 2) exon 2
unlikely, or uncertain benefit of 39 chemotherapy and @ CPT Changes: An Insider's View2021
targeted therapeutic oncology agents
0187U Red cell antigen (Duffy blood group) genotyping (FY),
gene analysis. ACKRI (atypical chemokine receptor 1
0175U Psychiatry (eg, depression. anxiety), genomic analysis [Duffy blood group]) exons 1-2
panel. variant analysis of 15 genes @ CPT Changes: An Insider's View 2021
0188U Red cell antigen (Gerbich blood group) genotyping (GE),
0176U Cytolethal distending toxin B(CdtB) and vinculin lgG gene analysis. GYPC (glycophorin C[Gerbich blood
antibodies by immunoassay (ie, ELISA) group]) exors 1-4
0 CPT Changes: An Insider's View2021 @ CPT Changes: An Insider's View 2021
0177U Oncology (breast cancer), DNA, PIK3CA 0189U Red cell antigen (MNS blood group) genotyping (GYPA),
(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic gene analysis, GYPA (glycophorin A [MNS blood group])
subunit alpha) gene analysis of 11 gene variants utilizing introns 1, 5, exon 2
plasma, reported as PIK3CA gene mutation status @ CPT Changes: An Insider's View 2021
0190U Red cell antigen (MNS blood group) genotyping (GYPB),
0178U Peanut allergen-specific quantitative assessment of gene analysis, GYPB (glycophorin B[MNS blood group])
multiple epitopes using enzyme-linked immunosorbent introns 1, 5, pseudoexon 3
assay (ELISA), blood, report of minimum eliciting @ CPT Changes: An Insider's View 2021
exposure for a clinical reaction
0191U Red cell antigen (Indian blood group) genotyping (IN).
gene analysis, CD44 (CD44 molecule [Indian blood group])
0179U Oncology (non-small cell lung cancer), cell-free DNA, exons 2, 3, 6
targeted sequence analysis of 23 genes (single @ CPT Changes: An Insider's View 2021
nucleotide variations, insertions and deletions, fusions
without prior knowledge of partner/breakpoint, copy
0 0 0 0 0
number variations), with report of significant mutation(s) 0 0 0 0
0 0 0 0
0 0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0 0
0
0
0
0 0 0 0 0 0 0
0180U Red cell antigen (ABO blood group) genotyping (ABO), 0
0
0
0
0 0 0
0
0
0
0
0 0 0
0
0
0
0
0 0
gene analysis Sanger/chain termination/conventional 0 0 0
0 0
0 0 0 0 0
0 0
0 0 0 !I 0 .
sequencing, ABO (ABO, alpha 0
00
0
0 0
00
0
0 0
00
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0 0
0 0 0 0 0
"-=Revised code • = New code .,.. •=Contains new or revised text *=Duplicate Pl.A test ti=Category IPLA American Medical Association 705
0192U Red cell antigen (Kidd blood group) genotyping (JK). gene 0203U Autoimmune (inflammatory bowel disease), mRNA. gene
analysis. SLC14A 1(solute carrier family 14 member 1 expression profiling by quantitative RT-PCR. 17 genes (15
[Kidd blood group]) gene promoter. exon 9 target and 2 reference genes), whole blood, reported as a
0 CPT Changes: An Insider's View2021 continuous risk score and classification of inflammatory
bowel disease aggressiveness
0193U Red cell antigen (JR blood group) genotyping (JR). gene
analysis. ABCG2 (ATP binding cassette subfamily G
member 2 [Junior blood group]) exons 2-26 0204U Oncology (thyroid), mRNA. gene expression analysis of
0 CPT Changes: An Insider's View 2021 593 genes (including BRAF, RAS, RET. PAXB, and NTRK)
for sequence variants and rearrangements, utilizing fine
0194U Red cell antigen (Kell blood group) genotyping (KELI. gene
needle aspirate, reported as detected or not detected
analysis. KEL (Kell metallo-endopeptidase [Kell blood
group]) exon 8
0 CPT Changes: An Insider's v;ew 2021 0205U Ophthalmology (age-related macular degeneration).
analysis of 3 gene variants (2 CFHgene. 1 ARMS2gene).
0195U KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon
using PCR and MALDl-TOF. buccal swab, reported as
131 positive or negative for neovascular age-related macular-
degeneration risk associated with zinc supplements
0196U Red cell antigen (Lutheran blood group) genotyping (LUI. 0 CPT Changes: An Insider's View 2021
gene analysis, BCAM (basal cell adhesion molecule
0206U Neurology (Alzheimer disease); cell aggregation using
[Lutheran blood group]) exon 3
morphometric imaging and protein kinase C-epsilon
(PKGe) concentration in response to amylospheroid
0197U Red cell antigen (Landsteiner-Wiener blood group) treatment by ELISA. cultured skin fibroblasts, each
genotyping (LW), gene analysis, ICAM4 (intercellular reported as positive or negative for Alzheimer disease
adhesion molecule 4 [Landsteiner-Wiener blood group]) 0 CPTChanges: An Insider's View2021
exon 1
+ 0207U quantitative imaging of phosphorylatsd ERK1 and
ERK2 in response to ~radykinin treatment by in situ
0198U Red cell antigen (RH blood group) genotyping (RHO and immunofluorescence, using cultured skin fibroblasts.
RHCE). gene analysis Sanger/chain termination/ reported as a probability index for Alzheimer disease
conventional sequencing, RHO (Rh blood group Dantigen) (List separately in addition to code for primary
exons 1-10 and RHCE (Rh blood group CcEe antigens) procedure)
exon 5 0 CPT Changes: An Insider's View2021
(Use 0207U in conjunction with 0206U)
0199U Red cell antigen (Scianna blood group) genotyping (SC).
.,.(0208U has been deleted)~
gene analysis, ERMAP (erythroblast membrane
associated protein [Scianna blood group]) exons 4, 12 0209U Cytogenomic constitutional (genome-wide) analysis.
0 CPT Changes: An Insider's View 2021 interrogation of genomic regions for copy number.
structural changes and areas of homozygosity for
0200U Red cell antigen (Kx blood group) genotyping (XK), gene chromosomal abnormalities
analysis, XK (X-linked Kx blood group) exons 1-3
0 CPT Changes: An lnside('s View 2021
0210U Syphilis test. non-treponemal antibody, immunoassay,
0201U Red cell antigen (Yt blood group) genotyping (YT), gene quantitative (APR)
analysis. ACHE (acetylcholinesterase [Cartwright blood
group]) exon 2
0 CPT Changes: An Insider's View2021 0211U Oncology (pan-tumor), DNA and RNA by next-generation
*0202U Infectious disease (bacterial or viral respiratory tract

infection). pathogen-specific nucleic acid (DNA or RNA).
sequencing, utilizing formalin-fixed paraffin-embedded
tissue, interpretative report for single nucleotide variants,
copy number alterations. tumor mutational burden. and
22 targets including severe acute respiratory syndrome microsatellite instability. with therapy association
coronavirus 2 (SARS-CoV-2). qualitative RT-PCR,
nasopharyngeal swab. each pathogen reported as
detected or not detected


0 0 0 0
see 0223U. See Appendix 0 or the most current listing on 0 0 0
0 0 0 0
0 0 0 0 0 0
the AMA CPT website to determine appropriate code 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
assignment) 0
0 0 0 0 0 0 0 0 D 0 0 0
0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 00 0 0 0 00 0
0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0
0 0
0 0
706 *=Telemedicine '4=Audio-only +=Add-on code t4t'=FDAapprovalpending #=Resequenced code ~=Modifier51 exempt O O O = Seepxixfordetails
0212U Rare diseases (constitutional/heritable disorders), whole 0219U Infectious agent (human immunodeficiency virus),
genome and mitochondrial DNA sequence analysis. targeted viral next-generation sequence analysis {ie,
including small sequence changes, deletions, duplications, protease [PR). reverse transcriptase [Rn. integrase [INnl.
short tandem repeat gene expansions, and variants in non- algorithm reported as prediction of antiviral drug
uniquely mappable regions, blood or saliva, identification susceptibility
and categorization of genetic variants, proband 0 CPT Changes: An Insider's View2021
0 CPT Changes: An Insider's View 2021 '
0220U Oncology (breast cancer). image analysis with artificial
(Do not report 0212U in conjunction with 81425) intelligence assessment of 12 histologic and
immunohistochemical features. reported as a recurrence
0213U Rare diseases (constitutional/heritable disorders), whole
score
genome and mitochondrial DNA sequence analysis,
including small sequence changes, deletions,
duplications. short tandem repeat gene expansions, and 0221U Red cell antigen (ABO blood group) genotyping (ABO).
variants in non-uniquely mappable regions, blood or gene analysis. next-generation sequencing, ABO (ABO,
saliva, identification and categorization of genetic alpha 7-3-N-acetylgalactosaminyltransferase and alpha
variants, each comparator genome (eg, parent, sibling) 7-3-galactosyltransferase) gene
(Do not report 0213U in i:onjunction with 81426) 0222U Red cell antigen (RH blood group) genotyping (RHO and
RHCE). gene analysis. next-generation sequencing, RH
0214U Rare diseases (constitutional/heritable disorders), whole
proximal promoter, exons 1-10. portions of intrans 2-3
exome and mitochondrial DNA sequence analysis,
including small sequence changes, deletions, duplications, 0 CPT Changes: An Insider's View2021
short tandem repeat gene expansions, and variants in non-

uniquely mappable regions, blood or saliva, identification
*0223U Infectious disease (bacterial or viral respiratory tract
infection\, pathogen-specific nucleic acid (DNA or RNA).
and categorization of genetic variants, proband 22 targets including severe acute respiratory syndrome
0 CPT Changes: An Insider's View 2021 coronavirus 2 (SARS-CoV-2), qualitative RT-PCR.
nasopharyngeal swab. each pathogen reported as
(Do not report 0214U in conjunction wi!h 81415)
0215U Rare diseases (constitutional/heritable disorders), whole 0 CPT Changes: An Insider's View 2022
exome and mitochondrial DNA sequence analysis,
including small sequence changes, deletions, (For additional PLA code with identical clinical descriptor.
see 0202U. See Appendix 0 or the most current listing on
duplications. short tandem repeat gene expansions, and
the AMA CPT website to determine appropriate code
variants in non-uniquely mappable regions, blood or
assignment)
saliva, identification and categorization of genetic
variants, each comparator exome (eg, parent, sibling) 0224U Antibody, severe acute respiratory syndrome coronavirus
0 CPT Changes: An Insider's View 2021 2 (SARS-CoV-2) (coronavirus disease [COVID-19]).
includes titer(s). when performed
(Do not report 0215U in conjunction with 81416)
0216U Neurology (inherited ataxias), genomic DNA sequence
(Do not report 0224U in conjunction with 86769)
analysis of 12 common genes including small sequence
changes, deletions, duplications, short tandem repeat 0225U Infectious disease (bacterial or viral respiratory tract
gene expansions, and variants in non-uniquely mappable infection) pathogen-specific DNA and RNA. 21 targets.
regions, blood or saliva, identification and categorization including severe acute respiratory syndrome coronavirus
of genetic variants 2 (SARS-CoV-2). amplified probe technique. including
0 CPT Changes: An Insider's View 2021 multiplex reverse transcription for RNA targets. each
analyte reported as detected or not detected
0217U Neurology (inherited ataxias), genomic DNA sequence
analysis of 51 genes including small sequence changes, 0 CPT Changes: An Insider's View 2022
deletions, duplications, short tandem repeat gene 0226U Surrogate viral neutralization test (sVNT). severe acute
expansions, and variants in non-uniquely mappable respiratory syndrome coronavirus 2 (SARS-CoV-2)
regions, blood or saliva, identification and categorization (coronavirus disease [COVID-19)), ELISA, plasma, serum
of genetic variants 0 CPT Changes: An Insider's View 2022
021BU Neurology (muscular dystrophy), DMD gene sequence

analysis, including small sequence changes, deletions,
0 0 0 0 0
duplications, and variants in non-uniquely mappable 0
0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
regions, blood or saliva, identification and 0 0 0 0
characterization of genetic variants

0
0 0
0
0
0 0 0
0 0
0
0 • 0 0
0 0
0 0 0 0 0 0 0
0 0 0 0 O I 0 0 0 0
0
0 0
0 0
0
0 0 0
0 0
0 0
0
0 0 0
00 0 00 0 00
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
A=Revised code • = New code llJJ> <Ill = Contains new or revised text H=Duplicate PLA test ti =Category IPLA American Medical Association
0227U Drug assay, presumptive, 30 or more drugs or 0236U SMNT (survival of motor neuron 1, telomeric) and SMN2
metabolites, urine, liquid chromatography with tandem (survival of motor neuron 2. centromeric) (eg, spinal
mass spectrometry (LC-MS/MS) using multiple reaction muscular atrophy) full gene analysis, including small
monitoring (MAM). with drug or metabolite description. sequence changes in exonic and intronic regions.
includes sample validation duplications. deletions. and mobile element insertions
0228U Oncology (prostate). multianalyte molecular profile by 0237U Cardiac ion channelopathies (eg, 8rugada syndrome, long
phOtometric detection of macromolecules adsorbed on OT syndrome, short OT syndrome, catecholaminergic
nanosponge array slides with machine learning, utilizing polymorphic ventricular tachycardia). genomic sequence
first morning voided urine. algorithm reported as analysis panel including ANK2. CAS02, CAV3, KCNET,
likelihood of prostate cancer KCNE2. KCNH2, KCNJ2, KCNOT, RYR2, and SCN5A.
0 CPT Changes: An Insider's View 2022 including small sequence changes in exonic and intronic
regions. deletions, duplications. mobile element
A 0229U BCAT1 (Branched chain amino acid transaminase 1) and
insertions, and variants in non-uniquely mappable
IKZFT (IKAROS family zinc finger T)(eg, colorectal cancer)
regions
promoter methylation analysis
0238U Oncology (Lynch syndrome). genomic DNA sequence

0230U AR (androgen receptor) (eg, spinal and bu Ibar muscular
analysis of MLHT, MSH2. MSH6, PMS2, and EPCAM.
atrophy, Kennedy disease. X chromosome inactivation},
including small sequence changes in exonic and intronic
full sequence analysis, including small sequence changes
regions. deletions, duplications. mobile element
in exonic and intronic regions. deletions, duplications.
insertions. and variants in non-uniquely mappable
short tandem repeat (STA) expansions, mobile element
regions
insertions, and variants in non-uniquely mappable
regions
0 CPT Changes: An Insider's View 2022 0239U Targeted genomic sequence analysis panel. solid organ
neoplasm. cell-free DNA. analysis of 311 or more genes,
0231U CACNA TA (calcium voltage-gated channel subunit alpha
interrogation for sequence variants. including
TA)(eg, spinocerebellar ataxia), full gene analysis,
substitutions. insertions. deletions, select
rearrangements, and copy number variations
regions. deletions. duplications, short tandem repeat
(STA) gene expansions, mobile element insertions, and
variants in non-uniquely mappable regions 0240U Infectious disease (viral respiratory tract infection),
0 CPT Changes: An Insider's View 2022 pathogen-specific RNA. 3 targets (severe acute
respiratory syndrome coronavirus 2 [SARS-CoV-2).
0232U CSTB (cystatin B)(eg, progressive myoclonic epilepsy
influenza A, influenza 8), upper respiratory specimen.
type 1A. Unverricht-Lundborg disease). full gene analysis.
each pathogen reported as detected or not detected
regions, deletions. duplications, short tandem repeat
(STA) expansions. mobile element insertions. and 0241U Infectious disease (viral respiratory tract infection),
variants in non-uniquely mappable regions pathogen-specific RNA, 4 targets (severe acute
0 CPT Changes: An Insider's View 2022 respiratory syndrome coronavirus 2 [SARS-CoV-2),
influenza A. influenza 8, respiratory syncytial virus [RSV]).
0233U FXN (frataxin) (eg, Friedreich ataxia), gene analysis,
upper respiratory specimen, each pathogen reported as
regions, deletions. duplications, short tandem repeat
(STA) expansions. mobile element insertions. and
variants in non-uniquely mappable regions 0242U Targeted genomic sequence analysis panel. solid organ
0 CPT Changes: An Insider's View2022 neoplasm, cell-free circulating DNA analysis of 55-74
genes. interrogation for sequence variants. gene copy
0234U MECP2 (methyl CpG binding protein 2) (eg, Rett
number amplifications, and gene rearrangements
syndrome). full gene analysis, including small sequence
changes in exonic and intronic regions, deletions,
duplications. mobile element insertions. and variants in

non-uniquely mappable regions
0235U PTEN (phosphatase and tensin homolog) (eg, Cowden 0 0 0 0 0

syndrome. PTEN hamartoma tumor syndrome). full gene 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0 0 0
analysis, including small sequence changes in exonic and 0 0
0
0
O• 0 0
0 0
0
0
0 0 0
0
intronic regions. deletions. duplications, mobile element 0
0 0 0 0
0
0
0 0 0 0
0
0
0 0
insertions. and variants in non-uniquely mappable 0 0
0
0 0
0
0 0 0
0 0 0
0
0
0 0
regions 0
00 0 0
00 0 0
0
0 0
0
0 0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0 0 0
708 *= Telemedicine ~=Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code ISl =Modifier 51 exempt 0 0 0 =Seep xix for details
0243U Obstetrics (preeclampsia), biochemical assay of 0253U Reproductive medicine (endometrial receptivity analysis).
placental-growth factor, time-resolved fluorescence RNA gene expression profile, 238 genes by next-
immunoassay, maternal serum, predictive algorithm generation sequencing, endometrial tissue, predictive
reported as a risk score for preeclampsia algorithm reported as endometrial window of
0 CPT Changes: An Insider's View 2022 implantation (eg, pre-receptive. receptive, post-receptive)
0244U Oncology (solid organ). DNA, comprehensive genomic
profiling, 257 genes, interrogation for single-nucleotide 0254U Reproductive medicine (preimplantation genetic
variants. insertions/deletions, copy number alterations, assessment), analysis of 24 chromosomes using
gene rearrangements, tumor-mutational burden and embryonic DNA genomic sequence analysis for
microsatellite instability, utilizing formalin-fixed paraffin- aneuploidy, and a mitochondrial ONA score in euploid
embedded tumor tissue embryos. results reported as normal (euploidy).
0 CPT Changes: An Insider's View 2022 monosomy, trisomy, or partial deletion/duplication,
mosaicism, and segmental aneuploidy, per embryo tested
0245U Oncology (thyroid), mutation analysis of 10 genes and 37
RNA fusions and expression of 4 mRNA markers using
0 CPT Changes: An lns;der's View2022
next-generation sequencing. fine needle aspirate, report 0255U Andrology (infertility), sperm-capacitation assessment of
includes associated risk of malignancy expressed as a ganglioside GM1 distribution patterns. fluorescence
percentage microscopy, fresh or frozen specimen, reported as
0 CPT Changes: An Insider's View 2022 percentage of capacitated sperm and probability of
generating a pregnancy score
0246U Red blood cell antigen typing, DNA. genotyping of at
least 16 blood groups with phenotype prediction of at
least 51 red blood cell antigens 0256U Trimethylamine/trimethylamine N-oxide (TMA/TMAO)

0 CPT Changes: An Insider's View 2022 profile, tandem mass spectrometry (MS/MS), urine, with
algorithmic analysis and interpretive report
0247U Obstetrics (preterm birth), insulin-like growth factor-
binding protein 4 (IBP4). sex hormone-binding globulin
(SHBG), quantitative measurement by LC-MS/MS, 0257U Very long chain acyl-coenzyme A (CoA) dehydrogenase
utilizing maternal serum. combined with clinical data, (VLCAD). leukocyte enzyme activity, whole blood
reported as predictive-risk stratification for spontaneous 0 CPT Changes: An Insider's View 2022
preterm birth
0258U Autoimmune (psoriasis), mRNA, next-generation
sequencing, gene expression profiling of 50-100 genes.
0248U Oncology (brain), spheroid cell culture in a 30 skin-surface collection using adhesive patch, algorithm
microenvironment, 12 drug panel, tumor-response reported as likelihood of response to psoriasis biologics
prediction for each drug 0 CPT Changes: An Insider's View 2022
0259U Nephrology (chronic kidney disease), nuclear magnetic
0249U Oncology (breast). semiquantitative analysis of 32 resonance spectroscopy measurement of myo-inositol.
phosphoproteins and protein analytes, includes laser valine, and creatinine, algorithmically combined with
capture microdissection, with algorithmic analysis and cystatin C(by immunoassay) and demographic data to
interpretative report determine estimated glomerular filtration rate (GFR),
0 CPT Changes: An Insider's View2022 serum, quantitative
0250U Oncology (solid organ neoplasm). targeted genomic
sequence ONA analysis of 505 genes. interrogation for *0260U Rare diseases (constitutional/heritable disorders).
somatic alterations (SNVs [single nucleotide variant). identification of copy number variations. inversions,
small insertions and deletions. one amplification, and insertions. translocations, and other structural variants by
four translocations). microsatellite instability and tumor- optical genome mapping
mutation burden 0 CPT Changes: An Insider's View 2022
0251U Hepcidin-25. enzyme-linked immunosorbent assay see 0264U. See Appendix 0 or the most current listing on
(ELISA). serum or plasma the AMA CPT website to determine appropriate code
0 CPT Changes: An Insider's View2022 assignment)
0252U Fetal aneuploidy short tandem-repeat comparative
analysis, fetal DNA from products of conception. reported
as normal (euploidy). monosomy, trisomy, or partial 0
0 0
0
0
0
0
0
0
0
0 0
0 0 0 0
deletion/duplication. mosaicism. and segmental 0
0
0
0
0 0
0
0 0
0 0 0 0 0 0 •
aneuploidy 0 0 0 0 0 0
0 0 0 0 0
0 0
0
0
0 0 0
0 0 0
0
0
0 0 0
0 0 ° 0 0 0 0 0 0
0 0 0 0 0
0 00 00 0 00
0 0 0 0 0 0
0 0 0 0 0 0
0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0
0 0 0 0
0
A= Revised code •=New code • •=Contains new or revised text *=Duplicate PlA test ti= Category IPlA American Medical Association 709
0261U Oncology (colorectal cancer). image analysis with 0270U Hematology (congenital coagulation disorders). genomic
artificial intelligence assessment of 4 histologic and sequence analysis of 20 genes. blood, buccal swab. or
immunohistochemical features (CD3 and COB within amniotic fluid
tumor-stroma border and tumor core), tissue. reported as 0 CPT Changes: An Insider's View2022
immune response and recurrence-risk score
0271 U Hematology (congenital neutropenia). genomic sequence
analysis of 23 genes. blood, buccal swab, or amniotic
0262U Oncology (solid tumor). gene expression profiling by real- fluid
time RT-PCR of 7 gene pathways (ER. AR, P/3K. MAPK, 0 CPT Changes: An Insider's View2022
HH, TGFB, Notch), formalin-fixed paraffin-embedded
0272U Hematology (genetic bleeding disorders), genomic
(FFPE). algorithm reported as gene pathway activity score
sequence analysis of 51 genes, blood, buccal swab. or
amniotic fluid, comprehensive
0263U Neurology (autism spectrum disorder [ASD]). quantitative 0 CPT Changes: An Insider's Vie'W 2022
measurements of 16 central carbon metabolites (ie,
0273U Hematology (genetic hyperfibrinolysis, delayed bleeding),
a-ketoglutarate, alanine, lactate, phenylalanine,
analysis of 9 genes (F13A 1, F138, FGA. FGB, FGG,
pyruvate, succinate. carnitine, citrate. fumarate.
SERPINA 1, SERPINE1, SERP/NF2 by next-generation
hypoxanthine, inosine. malate, S-sulfocysteine. taurine,
sequencing, and PLAU by array comparative genomic
urate. and xanthine), liquid chromatography tandem mass
hybridization). blood, buccal swab, or amniotic fluid
spectrometry (LC-MS/MS), plasma. algorithmic analysis
with result reported as negative or positive (with
metabolic subtypes of ASD) 0274U Hematology (genetic platelet disorders), genomic

0 CPT Changes: An Insider's View2022 sequence analysis of 43 genes, blood. buccal swab, or
*0264U Rare diseases (constitutional/heritable disorders),
amniotic fluid
identification of copy number variations, inversions,
insertions, translocations, and other structural variants by 0275U Hematology (heparin-induced thrombocytopenia), platelet
optical genome mapping antibody reactivity by flow cytometry, serum
(For additional PLA code with identical clinical descriptor. .A. 0276U Hematology (inherited thrombocytopenia), genomic
see 0260U. See Appendix 0 or the most current listing on sequence analysis of 42 genes. blood, buccal swab. or
the AMA CPT website to determine appropriate code amniotic fluid
assignment) 0 CPT Changes: An Insider's View 2022, 2023
0265U Rare constitutional and other heritable disorders, whole 0277U Hematology (genetic platelet function disorder). genomic
genome and mitochondrial DNA sequence analysis, sequence analysis of 31 genes. blood, buccal swab. or
blood, frozen and formalin-fixed paraffin-embedded amniotic fluid
(FFPE) tissue. saliva. buccal swabs or cell lines, 0 CPT Changes: An Insider's View2022
identification of single nucleotide and copy number
variants 0278U Hematology (genetic thrombosis), genomic sequence
analysis of 12 genes, blood. buccal swab, or amniotic fluid
0266U Unexplained constitutional or other heritable disorders or
syndromes. tissue-specific gene expression by whole- 0279U Hematology (von Willebrand disease [VWD]). von
transcriptome and next-generation sequencing, blood, Willebrand factor (VWF) and collagen Ill binding by
formalin-fixed paraffin-embedded (FFPE) tissue or fresh enzyme-linked immunosorbent assays (ELISA). plasma,
frozen tissue, reported as presence or absence of splicing report of collagen Ill binding
or expression changes 0 CPT Changes: An Insider's View 2022
0 CPT Changes: An Insider's View 2022 0280U Hematology (von Willebrand disease [VWD]). von
0267U Rare constitutional and other heritable disorders. Willebrand factor (VWF) and collagen IV binding by
identification of copy number variations, inversions, enzyme-linked immunosorbent assays (ELISA). plasma,
insertions. translocations. and other structural variants by report of collagen IV binding
optical genome mapping and whole genome sequencing 0 CPT Changes: An lns;der's View 2022
0268U Hematology (atypical hemolytic uremic syndrome

[aHUS]). genomic sequence analysis of 15 genes, blood, 0 0 0 0 0
buccal swab, or amniotic fluid 0
0
0
0
0
0
0
0
0
0
0
0
0
0

0 0
0 0
0 0 0
0 0
0 0
0 0
0 0 0
0 0
0 0 0 0 0
0269U Hematology (autosomal dominant congenital 0 0 0 0 0
0
0 0 0 0 0
0
thrombocytopenia), genomic sequence analysis of 14
0 0 0 0 0 0 0 0 0 0
0 0 ° 0 0
0 00 0 00
genes. blood, buccal swab, or amniotic fluid 0 0 0 0 0 0 0 0 0 0 0

0
0
0
0 0 0
0
0 0 0
0
0
0
0 0 0
0
0
0 0 0
710 *= Telemedicine '4 =Audio-only +=Add-on code ,¥'=FDA approval pending #=Resequenced code IS)= Modifier 51 exempt 0 0 0 = See pxix for details
CPT 2023 Pathology and Laboratory I Proprietary Laboratory Analyses 02s1u--aao1U
0281U Hematology (von Willebrand disease [VWD]), von • 0293U Psychiatry (suicidal ideation). mRNA. gene expression
Willebrand propeptide, enzyme-linked immunosorbent profiling by RNA sequencing of 54 genes. whole blood,
assays (ELISA), plasma, diagnostic report of von algorithm reported as predictive risk score
Willebrand factor (VWF) propeptide antigen level 0 CPT Changes: An Insider's View 2023
• 0294U Longevity and mortality risk, mRNA, gene expression
0282U Red blood cell antigen typing, DNA, genotyping of 12 profiling by RNA sequencing of 18 genes, whole blood,
blood group system genes to predict 44 red blood cell algorithm reported as predictive risk score
antigen phenotypes 0 CPT Changes: An Insider's View 2023
• 0295U Oncology (breast ductal carcinoma in situ). protein
0283U von Willebrand factor (VWF). type 28, platelet-binding expression profiling by immunohistochemistry of 7
evaluation, radioimmunoassay, plasma proteins (COX2. FOXA 1. HER2, Ki-67, p16, PR. SIAH2),
0 CPT Changes: An Insider's View 2022 with 4 clinicopathologic factors (size, age, margin status.
palpability), utilizing formalin-fixed paraffin-embedded
0284U von Willebrand factor (VWF), type 2N, factor VIII and
(FFPE) tissue, algorithm reported as a recurrence risk
VWF binding evaluation, enzyme-linked immunosorbent
score
assays (ELISA), plasma
• 0296U Oncology (oral and/or oropharyngeal cancer), gene

e 0285U Oncology, response to radiation, cell-free DNA,
expression profiling by RNA sequencing of at least 20
quantitative branched chain DNA amplification, plasma,
molecular features (eg, human and/or microbial mRNA),
reported as a radiation toxicity score
saliva, algorithm reported as positive or negative for
signature associated with malignancy
e 0286U CEP72 (centrosoma/ protein. 72-KDaJ, NUDT15 (nudix 0 CPT Changes: An Insider's View 2023
hydrolase 15) and TPMT (thiopurine S-methyltransferase)
• 0297U Oncology (pan tumor), whole genome sequencing of
(eg, drug metabolism) gene analysis, common variants
paired malignant and normal DNA specimens, fresh or
formalin-fixed paraffin-embedded (FFPE) tissue. blood or
• 0287U Oncology (thyroid), DNA and mRNA. next-generation bone marrow, comparative sequence analyses and
sequencing analysis of 112 genes, fine needle aspirate or variant identification
formalin-fixed paraffin-embedded (FFPE) tissue, 0 CPT Changes: An Insider's View2023
algorithmic prediction of cancer recurrence, reported as a
• 0298U Oncology (pan tumor), whole transcriptome sequencing of
categorical risk result (low, intermediate, high)
paired malignant and normal RNA specimens. fresh or
formalin-fixed paraffin-embedded (FFPE) tissue, blood or
• 0288U Oncology (lung). mRNA. quantitative PCR analysis of 11 bone marrow, comparative sequence analyses and
genes (BAGI, BRCA 1. CDC6, CDK2AP1, ERBB3. FUT3, expression level and chimeric transcript identification
IL 11, LCK, RND3. SH3BGR, WNT3A) and 3 reference 0 CPT Changes: An Insider's View 2023
genes (ESD. TBP, YAP1 ). formalin-fixed paraffin-
• 0299U Oncology (pan tumor), whole genome optical genome
embedded (FFPE) tumor tissue, algorithmic interpretation
mapping of paired malignant and normal DNA
reported as a recurrence risk score
specimens, fresh frozen tissue, blood, or bone marrow.
comparative structural variant identification
• 0289U Neurology (Alzheimer disease), mRNA. gene expression 0 CPT Changes: An Insider's View2023
profiling by RNA sequencing of 24 genes, whole blood.
• 0300U Oncology (pan tumor). whole genome sequencing and
algorithm reported as predictive risk score
optical genome mapping of paired malignant and normal
DNA specimens. fresh tissue, blood, or bone marrow,
• 0290U Pain management, mRNA. gene expression profiling by comparative sequence analyses and variant identification
RNA sequencing of 36 genes, whole blood. algorithm 0 CPT Changes: An Insider's View 2023
reported as predictive risk score
• 0301U Infectious agent detection by nucleic acid (DNA or RNA),
Bartonella henselae and Bartonella quintana, droplet
• 0291U Psychiatry (mood disorders), mRNA, gene expression digital PCR (ddPCR);
profiling by RNA sequencing of 144 genes. whole blood, 0 CPT Changes: An Insider's View2023
algorithm reported as predictive risk score
• 0292U Psychiatry (stress disorders). mRNA, gene expression 0

0
0 0
0
0
0
0
0 0
0
0
0
0
0
0 0 0 0 0 0 0
profiling by RNA sequencing of 72 genes. whole blood. 0 0
0 0
0 0
0 0
0
0 0 0 0 0 0 0
0 0
algorithm reported as predictive risk score 0
0
0
0
0
0
0 0 0
0
0
0 0
0
0 0
0
0
0
0
0
0
0 0
0
0 0
0
0
0
0
0
0
0 0
0 0 0 0
00 0 00 0 00
0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0
0 0 0 0
0 0 0 0 0
•=Revised code •=New code Iii> <Ill =Contains new or revised text H= Duplicate PLA test ti =Category I PLA American Medical Association 711
• 0302U following liquid enrichment and indirect immunofluorescence, serum. or plasma and
0 CPT Changes: An Insider's View 2023 whole blood, individual components reported along with
an algorithmic SLE-likelihood assessment
• 0303U Hematology, red blood cell (RBC) adhesion to endothelial/
subendothelial adhesion molecules. functional
assessment, whole blood, with algorithmic analysis and • 0313U Oncology (pancreas). DNA and mRNA next-generation
result reported as an RBC adhesion index; hypoxic sequencing analysis of 74 genes and analysis of CEA
O CPT Changes: An Insider's View 2023 (CEACAM5) gene expression. pancreatic cyst fluid.
algorithm reported as a categorical result (ie. negative,
• 0304U normoxic
low probability of neoplasia or positive. high probability
of neoplasia)
• 0305U Hematology, red blood cell (RBC) functionality and 0 CPT Changes: An Insider's View 2023
deformity as a function of shear stress, whole blood.
• 0314U Oncology (cutaneous melanoma). mRNA gene expression
reported as a maximum elongation index
profiling by RT-PCR of 35 genes (32 content dnd 3
housekeeping). utilizing formalin-fixed paraffin-
e 0306U Oncology (minimal residual disease [MRD]). next- embedded (FFPE) tissue. algorithm reported as a
generation targeted sequencing analysis. cell-free DNA, categorical result (ie. benign, intermediate, malignant)
initial (baseline) assessment to determine a patient- 0 CPT Changes: An Insider's View2023
specific panel for future comparisons to evaluate for MRD
• 0315U Oncology (cutaneous squamous cell carcinoma). mRNA
gene expression profiling by RT-PCR of 40 genes (34
•(Do not report 0306U in conjunction with 0307U)~ content and 6 housekeeping). utilizing formalin-fixed
paraffin-embedded (FFPE) tissue. algorithm reported as a
• 0307U Oncology (minimal residual disease [MRD)). next- categorical risk result (ie, Class 1, Class 2A, Class 281
generation targeted sequencing analysis of a patient-
specific panel. cell-free DNA. subsequent assessment
with comparison to previously analyzed patient • 0316U Borrelia burgdorferi (Lyme disease). OspA protein
specimens to evaluate for MRD evaluation, urine
•(Do not report 0307U in conjunction with 0306U)~ • 0317U Oncology (lung cancer). four-probe FISH (3q29. 3p22.1.
1Oq22.3, 1Deen) assay, whole blood, predictive algorithm-
• 0308U Cardiology (coronary artery disease [CAD]), analysis of 3
generated evaluation reported as decreased or increased
proteins (high sensitivity [hs) troponin. adiponectin, and
risk for lung cancer
kidney injury molecule-1 [KIM-1 J). plasma. algorithm
reported as a risk score for obstructive CAD
0 CPT Changes: An Insider's View 2023 • 0318U Pediatrics (congenital epigenetic disorders). whole
genome methylation analysis by microarray for 50 or
e 0309U Cardiology (cardiovascular disease). analysis of 4
more genes, blood
proteins (NT-proBNP. osteopontin. tissue inhibitor of
metalloproteinase-1 [TIMP-1 ). and kidney injury
molecule-1 [KIM-1 )). plasma. algorithm reported as a risk • 0319U Nephrology (renal transplant). RNA expression by select
score for major adverse cardiac event transcriptome sequencing, using pretransplant peripheral
0 CPT Changes: An Insider's View 2023 blood, algorithm reported as a risk score for early acute
rejection
• 0310U Pediatrics (vasculitis, Kawasaki disease [KO]). analysis of
3 biomarkers (NTproBNP. C-reactive protein, and T-uptake).
plasma. algorithm reported as a risk score for KO • 0320U Nephrology (renal transplant), RNA expression by select
0 CPT Changes: An Insider's View2023 transcriptome sequencing, using posttransplant
peripheral blood, algorithm reported as a risk score for
• 0311U Infectious disease (bacterial). quantitative antimicrobial
acute cellular rejection
susceptibility reported as phenotypic minimum inhibitory
concentration (MIC}--based antimicrobial susceptibility
for each organism identified

•(Do not report 0311 U in conjunction with 87076, 87077.

0086U)~
e 0312U Autoimmune diseases (eg, systemic lupus erythematosus 0

0 0
0
0
0
0
0 0
0
0
0
0 0 0 0
ISLE)). analysis of 8 lgG autoantibodies and 2 cell-bound 0 0
0
0 0 0 0 0 0
0 0 0 0 0 0 • 0 0 0
complement activation products using enzyme-linked
0 0 0 0 0 0 0 0 0 0 0 0
immunosorbent immunoassay (ELISA). flow cytometry 0
0
0
0
0 0 0
0 0 ° 0 0 0 0
0 0 ° 0 0
0 00 0 0 0 00 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0
712 *= Telemedicine '4 =Audio-only +=Add-on code J( =FDA approval pending #=Resequenced code &=Modifier 51 exempt O O O =See pxix for details
• 03Z1U Infectious agent detection by nucleic acid (ONA or RNA), • 0331U Oncology (hematolymphoid neoplasia). optical genome
genitourinary pathogens. identification of 20 bacterial mapping for copy number alterations and gene
and fungal organisms and identification of 16 associated rearrangements utilizing DNA from blood or bone
antibiotic-resistance genes. multiplex amplified probe marrow. report of clinically significant alterations
technique 0 CPT Changes: :An Insider's View 2023
• 0332U Oncology (pan-tumor), genetic profiling of 8 DNA-
• OJZZU Neurology (autism spectrum disorder [ASO]). quantitative regulatory (epigenetic) markers by quantitative
measurements of 14 acyl carnitines and microbiome- polymerase chain reaction (qPCR). whole blood, reported
derived metabolites. liquid chromatography with tandem as a high or low probability of responding to immune
mass spectrometry (LC-MS/MS). plasma, results reported checkpoint-inhibitor therapy
as negative or positive for risk of metabolic subtypes 0 CPT Changes: An Insider's View2023
associated with ASO
• 0333U Oncology (liver), surveillance for hepatoceiiular
0 C!T Changes.· An Insider's View 2023
carcinoma (HCC) in high-risk patients, analysis of
e 03Z3U Infectious agent detection by nucleic acid (ONA and methylation patterns on circulating cell-free DNA (cfDNA)
RNA), central nervous system pathogen, metagenomic plus measurement of serum of AFP/AFP-L3 and
next-generation sequencing, cerebrospinal fluid (CSF), oncoprotein des-gamma-carboxy-prothrombin (DCP),
identification of pathogenic bacteria, viruses, parasites, algorithm reported as normal or abnormal result
or fungi 0 CPT Changes: An Insider's View 2023
0 CPT Changes. An Insider's View 2023
• 0334U Oncology (solid organ). targeted genomic sequence
• 03Z4U Oncology (ovarian). spheroid cell culture, 4-drug panel analysis. formalin-fixed paraffin-embedded (FFPE) tumor
(carboplatin. doxorubicin, gemcitabine, paclitaxel), tumor tissue, DNA analysis. 84 or more genes. interrogation for
chemotherapy response prediction for each drug sequence variants, gene copy number amplifications.
0 CPT Changes: An Insider's View2023 gene rearrangements, microsatellite instability and tumor
mutational burden
• 03Z5U Oncology (ovarian). spheroid cell culture. poly (AOP-ribose)
polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib.
velparib). tumor response prediction for each drug • 0335U Rare diseases (constitutional/heritable disorders). whole
0 CPT Changes: An Insider's View 2023 genome sequence analysis, including small sequence
changes. copy number variants, deletions, duplications.
• 03Z6U Targeted genomic sequence analysis panel, solid organ
mobile element insertions, uniparental disomy (UPD).
neoplasm, cell-free circulating ONA analysis of 83 or
inversions, aneuploidy, mitochondrial genome sequence
more genes. interrogation for sequence variants. gene
analysis with heteroplasmy and large deletions, short
copy number amplifications. gene rearrangements,
tandem repeat (STR) gene expansions, fetal sample,
microsatellite instability and tumor mutational burden
identification and categorization of genetic variants
• 03Z7U Fetal aneuploidy (trisomy 13, 18, and 21 ). DNA sequence
"'(Do not report 0335U in conjunction with 81425,
analysis of selected regions using maternal plasma,
0212U)<lll
algorithm reported as a risk score for each trisorr.y,
includes sex reporting, if performed • 0336U Rare diseases (constitutional/heritable disorders), whole
0 CPT Changes: An Insider's View 2023 genome sequence analysis. including small sequence
changes, copy number variants, deletions. duplications.
• 03Z8U Drug assay, definitive, 120 or more drugs and
mobile element insertions. uniparental disomy (UPD),
metabolites, urine, quantitative liquid chromatography
inversions, aneuploidy, mitochondrial genome sequence
with tandem mass spectrometry (LC-MS/MS), includes
analysis with heteroplasmy and large deletions, short
specimen validity and algorithmic analysis describing
tandem repeat (STR) gene expansions, blood or saliva,
drug or metabolite and presence or absence of risks for a
identification and categorization of genetic variants. each
significant patient-adverse event, per date of service
comparator genome (eg, parent)
• 03Z9U Oncology (neoplasia), exome and transcriptome sequence "'(Do not report 0336U in conjunction with 81426,
analysis for sequence variants, gene copy number 0213U)<lll
amplifications and deletions. gene rearrangements,
microsatellite instability and tumor mutational burden
utilizing DNA and RNA from tumor with DNA from normal
blood or saliva for subtraction, report of clinically 0 0 0 0 0
significant mutation(s) with therapy associations 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0 0
0
0
0
0 0
0
0
0 0
0
0
0
0 0
0
0
0 0
0 0 0 0 0 0
0
• 0330U Infectious agent detection by nucleic acid (DNA or RNA). 0 0 0 0
0
0 0 0 0
0
0
0 0 0 0 0 0 0 0 0 0 0 0
vaginal pathogen panel, identification of 27 organisms, 0 0 0 0
amplified probe technique. vaginal swab b oo

0 0 0
0
0
0
00
0 0 0 • 0
0
00

0 0
0
0
0
0
0
0
0
0
0 0
0
0
0
0
0 0
0
0
0 0
A = Revised code • = New code .,. <Ill = Contains new or revised text H=Duplicate PLA test t~=Category IPLA American Medical Association 713
• 0337U Oncology (plasma cell disorders and myeloma), • 0346U Beta amyloid, A&40 and A&42 by liquid chromatography
circulating plasma cell immunologic selection, with tandem mass spectrometry (LC-MS/MS), ratio.
identification, morphological characterization, and plasma
enumeration of plasma cells based on differential CD138. 0 CPT Char1;;P,;;: An Insider's View 2023
CD38, CD19, and CD45 protein biomarker expression.
• 0347U Drug 111etabolism or processing (multiple conditions),
peripheral blood
whole blood or buccal specimen, DNA analysis, 16 gene
report, with variant analysis and reported phenotypes
• 0338U Oncology (solid tumor). circulating tumor cell selection, 0 CPT Changes: An Insider's View2023
identification. morphological characterization, detection
• 0348U Drug metabolism or processing (multiple conditions).
and enumeration based on differential EpCAM.
whole blood or buccal specimen. DNA analysis, 25 gene
cytokeratins 8. 18, and 19, and CD45 protein biomarkers,
and quantification of HER2 protein biomarker-expressing
cells, peripheral blood 0 CPT Changes: An Insider's View 2023
0 CPT Changes: An Insider's View 2023 • 0349U Drug metabolism or processing (multiple conditions),
whole blood or buccal specimen: DNA analysis, 27 gene
• 0339U Oncology (prostate). mRNA expression profiling of HOXC6
report, with variant analysis. including reported
and DU<T, reverse transcription polymerase chain
phenotypes and impacted gene-drug interactions
reaction (RT-PCR). first-void urine following digital rectal
examination. algorithm reported as probability of high- 0 CPT Changes: An Insider's View 2023
grade cancer • 0350U Drug metabolism or processing (multiple conditions).

0 CPT Changes: An Insider's View 2023 whole blood or buccal specimen, DNA analysis, 27 gene
• 0340U Oncology (pan-cancer), analysis of minimal residual
disease (MAD) from plasma, with assays personalized to 0 CPT Changes: An Insider's View 2023
each patient based on prior next-generation sequencing • 0351U Infectious disease (bacterial or viral). biochemical assays,
of the patient's tumor and germ line DNA, reported as tumor necrosis factor-related apoptosis-inducing ligand
absence or presence of MAD, with disease-burden (TRAIL). interferon gamma-induced protein-10 (IP-1 O). and
correlation, if appropriate C-reactive protein, serum, algorithm reported as
0 CPT Changes: An Insider~ View2023 likelihood of bacterial infection
• 0341U Fetal aneuploidy DNA sequencing comparative analysis,
fetal DNA from products of conception, reported as • 0352U Infectious disease (bacterial vaginosis and vaginitis).
normal (euploidy), monosomy, trisomy, or partial deletion/ multiplex amplified probe technique, for detection of
duplication. mosaicism, and segmental aneuploid bacterial vaginosis-associated bacteria (BVAB-2,
0 CPT Changes: An Insider's View 2023 Atopobium vaginae, and Megasphera type 1). algorithm
reported as detected or not detected and separate ·
• 0342U Oncology (pancreatic cancer). multiplex immunoassay of
detection of Candida species (C. albicans, C. tropicalis, C.
C5. C4. cystatin C. factor B. osteoprotegerin (OPG).
parapsilosis, C. dubliniensis). Candida glabrata/Candida
gelsolin. IGFBP3. CA125 and multiplex
krusei, and trichomonas vaginalis, vaginal-fluid
electrochemiluminescent immunoassay (ECLIA) for CA 19-
specimen, each result reported as detected or not
9, serum, diagnostic algorithm reported qualitatively as
detected
positive. negative, or borderline
• 0353U Infectious agent detection by nucleic acid (DNA).

• 0343U Oncology (prostate), exosome-based analysis of 442
Chlamydia trachomatis and Neisseria gonorrhoeae,
small noncoding RNAs (sncRNAs) by quantitative reverse
multiplex amplified probe technique, urine. vaginal,
transcription polymerase chain reaction (RT-qPCR), urine.
pharyngeal, or rectal, each pathogen reported as
reported as molecular evidence of no-, low-,
intermediate- or high-risk of prostate cancer
• 0354U Human papilloma virus (HPV), high-risk types (ie. 16, 18,
• 0344U Hepatology (nonalcoholic fatty liver disease [NAFLD)),
31, 33, 45, 52 and 58) qualitative mRNA expression of
semiquantitative evaluation of 28 lipid markers by liquid
E6/E7 by quantitative polymerase chain reaction (qPCR)
chromatography with tandem mass spectrometry (LC-
MS/MS). serum, reported as at-risk for nonalcoholic
steatohepatitis (NASH) or not NASH

0 0 0 0 0
e 0345U Psychiatry (eg, depression, anxiety, attention deficit 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
hyperactivity disorder [ADHD]), genomic analysis panel, 0
0 0
0 0
0 0 0
0 0
0 0
0 0
0 0 0
0 0
0
variant analysis of 15 genes, including deletion/ 0 0 0 0 0 00 0 0 0 0 0 0 0 0
duplication analysis of CYP2D6 0 0 0 0 0 0 oo oo Poo 0
0
0

0 0 0 0 0
0 00
0 0 0 0 0 0
0 0
0 0 0
0 0
0
. 0 0
0
0 0 0
0
0
0 0 0
0
0 0
714 *= Telemedicine ~ = Audio-only +=Add-on code ,¥= FDA approval pending #=Resequenced code (9 =Modifier 51 exempt 0 0 0 =See pxix for details

2023 CPT Book

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2023 CPT Book

Uploaded by

Copyright:

Available Formats

Pathology and Laboratory Guidelines

Services in Pathology and Laboratory ...................................................•.. 595

Pathology and Laboratory

American Medical Association 571

; 1111•~ ... I • I I ~ t I "

American Medical Association 573

BSCL2 Berardinelli-Seip congenital lipodystrophy, hereditary

American Medical Association 575

Ch22013 Cytogenomic N/A N/A 81405

Molecular Patholog Gene Table, continued

American Medical Association 577

Molecular Patholog ' Gene Table, continued

F8 F8 Coagulation factor VIII Hemophilia A 81403. 81406,

American Medical Association 579

Ewing san:oma/peripheral neuroectodermal tumor, alveolar

FSHM01A FSHMOlA acioscapulohumeral muscular dystrophy 1A Facioscapulohumeral muscular dystrophy 404

GCDH GCDH Glutaryf-coa dehydrogenase I ~ Jut ricacidemia type 1 81406

Molecular Patholo ~Y Gene Table, continued '

American Medical Association 581

Neonatal alloimmune thrombocytopenia (NAITJ. post-

Molecular Patholo IV Gene Table, continued

' . . .... 1,.-; -.. .• ''" .•

American Medical Association 583

Molecular.~ath.~~oE~: ~!~le, continued . _-. .

Molecular Patholo Gene Table, continued

MPL proto-oncogene, thrombopoietin receptor

Myeloproliferative disorder, inherited bone marrow failure

syndromes llBMFS) 81441

American Medical Association 585

Molecular Patholo n Gene Table, continued

'Y•I , ..... _ '.c :,.-,_,. :!;1J~ ~~·~_,._, .•

NOP NOP Norrie disease (pseudogliomal Norrie disease B1403. B1404

American Medical Association 587

Molecular Patholo ~Y Gene Table, continued

Phosphate regulating endopeptidase homolog,

Solid organ or hematolymphoid neoplasm

Gene Table, continued

PROP! PROPl PROP paired-like ho bo 1 Combined pituita hormone deficient 81

American Medical Association 589

SGCE SGCE Sarcoglycan, epsilon Myoclonic dystonia 81405, 81406

American Medical Association 591

. "'. ·""'{~·; . . . . ~~ :~/ !~ .. . '~""' ,, .

American Medical Association 593

Gene Table, continued

Services in Pathology and 89398 Unlisted reproductive medicine laboratory procedure

Unlisted Service or Procedure

Pathology and Lalloratory

Glucose (82947) Calcium, total (82310)

Chloride (82435) Urea nitrogen (BUN) (84520)

@ CPT Changes: An Insider's View 2000. 2008, 2009 0 0 0

80055 Obstetric panel 80061 Lipid panel

Drug Assay associated metabolites, if performed. A presumptive

(continued on page 601)

DEFINITIONS AND ACRONYM CONVERSION LISTING

DEFINITIONS AND ACRONYM CONVERSION LISTING

Drug Testing Definition

DEFINITIONS AND ACRONYM CONVERSION LISTING

DEFINITIONS AND ACRONYM CONVERSION LISTING

(continued from page 598)

# 80307 by instrument chemistry analyzers (eg, utilizing # 80321 Alcohol biomarkers; 1 or 2

Definitive methods include, but are not limited to, gas 0

immunoassays (eg, IA, EIA, ELISA, RIA, EMIT, FPIA)

0 CPT Assistant Apr 15:5 # 80346 Benzodiazepines; 1-12